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Colorectal cancer (CRC), including cancer of the colon and rectum, is a major public 
health concern for many countries worldwide. With an estimated 1.8 million new 
cases each year globally, it is the third most common malignancy in men and women 
combined.1 Although CRC was primarily occurring in developed countries, incidence 
is rising rapidly in countries undergoing economic development, which can be 
explained by changes in diet and lifestyle.2 Due to these changes in diet and lifestyle, 
and the increasing life expectancy, it is expected that CRC incidence will keep on 
increasing, with an estimated 2.2 million new cases globally in 2030.2 The majority of 
studies presented in this thesis focus on the US. In the US, approximately 148 thousand 
individuals are projected to be diagnosed with CRC in 2020, accounting for 8.3% of all 
cancer diagnoses.3 Approximately 4.2% of the population will be diagnosed with CRC at 
some point during their lifetime. The incidence and mortality of CRC increases with age 























































Figure 1.1: Colorectal cancer incidence and mortality rates per 100,000 individuals in the 
United States (2012-2016) by 5-year age groups.5
Colorectal cancer mortality and survival
CRC is not only a major cause of morbidity, but also of mortality. It is estimated that 
approximately 52 thousand individuals will die of CRC in the US in 2020. Off all cancer 
types, CRC is second only to lung cancer in terms of the numbers of cancer deaths 
in men and women combined.3 Survival of CRC strongly depends on the stage of 
diagnosis (Figure 1.2A), which is determined by the Tumor-Node-Metastasis (TNM) 
classification.6 In stage 0, the cancer cells have only invaded the mucosa (inner lining) of 
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1the colon or rectum, and is therefore also called carcinoma in situ. In stage 1, the cancer cells also invaded the muscular layer of the colon or rectum. In stage 2, the cancer has 
grown passed the colon wall. When the cancer has invaded the local lymph nodes or has 
spread to other organs in the body such as the liver or lungs, it is classified as a stage 3 or 
stage 4 cancer, respectively. Symptomatically, the majority of CRCs are detected in stage 
3 or 4 (Figure 1.2B). The later the disease is diagnosed, the more difficult it is to treat 
the disease. In the US, the 5-year relative survival of CRC ranges from 88% for stage 1 
cancers to 13% for stage 4 cancers.5




















Figure 1.2: Colorectal survival by stage, and stage distribution upon diagnosis. A: 5-year 
relative survival by stage of colorectal cancer diagnosis in the United States, 2007-2013.7 
B: Stage distribution by symptom-detected and screen-detected colorectal cancers in the 
Netherlands, 2015, ages 60-75 years.8
 
Trends in colorectal cancer incidence and mortality
There is an alarming global increase in CRC incidence observed in individuals below 
age 50 years.9-14 Although overall CRC incidence and mortality has declined for several 
decades in the US,15 CRC incidence increased by over 25% since the mid-1990s in 
individuals below age 50 years.15-21 Physicians have been called to look out for symptoms 
to enhance earlier diagnosis, but actual trends suggest that there is currently a shift 
toward later stage at diagnosis in those aged 40 through 49 compared to the 1990s.22 
Age-period-cohort modeling suggests that the increase in CRC cases observed in young 
adults is primarily driven by a cohort effect, where age-specific CRC risk for successive 
generations has been increasing compared to those born in the 1940s (Figure 1.3).16 
This implies that increasing incidence is not restricted to the young ages, but is carried 
forward with contemporary birth cohorts as they age. Compared with US citizens born 
in 1950, those born in 1990 have 2.4 times the risk to develop colon cancer, and 4.3 times 
the risk to develop rectal cancer (Figure 1.3).16 Interestingly, for unknown reasons, 
the increase is stronger in rectal than in colon cancers in the US,16 whereas in most of 
Europe, the increase is stronger in colon than in rectal cancers.12 What is causing the 
troubling rise in CRC among young adults is currently unknown, which is therefore 












































Figure 1.3: Incidence rate ratios by birth cohort compared to the 1935 birth cohort for colon 
and rectal cancer in the Unites States, obtained by age-period-cohort modeling.16
Risk factors for colorectal cancer
Risk factors for CRC can be divided into non-modifiable risk factors, modifiable 
risk factors and medical conditions (Table 1.1). In addition to age, important non-
modifiable risk factors are sex, race/ethnicity, and family history. CRC incidence rates 
are approximately 30% higher in men compared to women, and rates in blacks are 
20% higher than in whites and 50% higher than in Asians.23 Underlying causes for the 
discrepancies in incidence rates by sex and ethnicity are not fully understood, but the 
discrepancies can be partly explained by a different exposure to modifiable risk factors. 
Alcohol consumption, obesity, red- and processed meat consumption, and smoking are 
modifiable risk factors that increase CRC risk. On the other hand, physical activity, 
aspirin and dairy- and milk consumption decrease CRC risk. Medical conditions that 
increase the risk of CRC are inflammatory bowel disease and diabetes, which have 
relative risks of 1.7 and 1.3, respectively.23
Familial colorectal cancer
Up to 30% of CRC cases have relatives that are affected by the disease. Only about 5% 
of all CRC cases have a hereditary cancer syndrome, caused by a well-characterized 
germline mutation in a high-penetrance gene.35 Asymptomatic individuals with a 
hereditary cancer syndrome can be identified through a process called cascade testing: 
when a pathogenic germline mutation is identified in a CRC case, genetic testing can 
be extended to his/her relatives. Lynch syndrome, also called Hereditary Nonpolyposis 
Colorectal Cancer, is caused by a germline mutation in one of the mismatch repair genes 
(MLH1, MSH2, MSH6, PMS2 or EPCAM). It is the most common familial syndrome, 
accounting for approximately 3% of all CRC cases.36 Individuals with Lynch syndrome 
have an approximate 35% risk of developing CRC before the age of 70 years.37 Another 
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1hereditary syndrome is Familial Adenomatous Polyposis (FAP), which is characterized by germline mutations of the tumor suppressor gene APC. Patients with FAP typically 
present with hundreds to thousands adenomas, resulting in a lifetime risk to develop 
CRC of nearly 100%. It accounts for less than 1% of all CRC cases. Other, even more 
rare familial syndromes are familial CRC type X, MutYH-associated polyposis, Peutz-
Jeghers syndrome, juvenile polyposis syndrome and PTEN hamartomatous syndrome.35 
Serrated polyposis syndrome, previously considered to be uncommon, is now known 
to be the most common polyposis syndrome.38 However, the majority of patients have 
no family history of CRC. Patients present with numerous serrated polyps, which is 
the basis of their diagnosis as no genetic mutations have been identified.38 Even family 
members of individuals diagnosed with CRC that do not have one of these syndromes 
have an increased risk to develop CRC, for whom risk depends on the number and the 
age of the affected relatives (Table 1.1). 
Table 1.1: Risk factors for colorectal cancer.23
Risk factor Relative risk Source
Non-modifiable risk factors
     Age Age specific (Figure 1.1) USCSWG 5
     Sex ACS 23
          Women 1
          Men 1.3
     Race ACS 23
         Whites 1
         Blacks 1.2
         Asians 0.8
     Family history
          1 first-degree relative 2.2 Butterworth et al. 24
          Relative with diagnoses < age 45 3.9 Johns et al. 25
          ≥2 relatives 4.0 Butterworth et al. 24
Modifiable risk factors 
     Alcohol consumption (daily average) Bagnardi et al. 26
          2-3 drinks 1.2
          >3 drinks 1.4
     Obesity (body mass index ≥30 kg/m2) 1.3 Ma et al. 27
     Red meat consumption (100g/day) 1.2 Chan et al. 28
     Processed meat consumption (50g/day) 1.2 Chan et al. 28
     Smoking (ever vs. never) 1.2 Botteri et al. 29
     Physical activity 0.7 Boyle et al. 30
     Dairy consumption (400g/day) 0.8 Aune et al. 31
     Milk consumption (200g/day) 0.9 Aune et al. 31
     Aspirin usage (>75mg/day) 0.8 Rothwell et al. 32
Medical conditions
     Inflammatory bowel disease 1.7 Lutgens et al. 33
     Diabetes 1.3 Tsilidis et al. 34




Most CRCs originate from benign precursor lesions in the inner lining of the colon or 
rectum. Two carcinogenic pathways have been distinguished: the adenoma-carcinoma 
sequence and the serrated pathway. These multistep processes differ in histological, 
morphological and genetic changes that occur during carcinoma genesis (Figure 1.4). In 
the conventional pathway, which gives rise to the large majority of the CRCs, the benign 
precursor lesion is an adenomatous polyp, also called an adenoma. Approximately 30-
50% of individuals develop one or more adenomas throughout their life, of which the 
large majority remains benign. However, when a small adenoma progresses, it grows 
in size and malignant potential. An adenoma that is larger than 10 mm in size has 
high-grade dysplasia or has a ≥ 25% villous histology component is called an advanced 
adenoma. Subsequently, these advanced adenomas can progress into Stage 1 to Stage 4 
CRCs by acquiring several somatic mutations.39 It has been estimated that the average 
time from adenoma onset to clinical diagnosis of the cancer is approximately 20 years.40 
The second pathway, the serrated pathway, may account for up to one-third of all 
CRCs.41 Sessile serrated lesions (which can progress to cancer), can originate directly 
from normal mucosa or originate via a precursor lesion called the hyperplastic polyp. 
The hyperplastic polyp is characterized histologically by a serrated (or saw-toothed) 
appearance of the crypt epithelium.41 These lesions tend to have a flatter shape 
than conventional adenomas, and have a mucus cap, making them harder to detect 
endoscopically. There is great uncertainty regarding the progression risk of sessile 
serrated lesions. They were barely reported before the 4th WHO classification of tumors 
was released in 2010.42 Consequently, the natural history of sessile serrated lesions 
remains largely to be discovered. Initially, they were believed to have a larger malignant 
potential compared to adenomatous polyp.43-45 However, reports of increased risk may 
be due to the misclassification of sessile serrated lesions and the higher endoscopic miss 
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Figure 1.4: Schematic overview of the colorectal carcinogenic pathways, 39,41,49 adapted from 
Keum et al.50 
APC, KRAS, TP53, BRAF, MLH1 - somatic mutations; CIMP - CPG island methylator phenotype; 





With screening, an apparently healthy, asymptomatic population is systematically tested 
for disease or for risk factors associated with the disease. The aim of screening is to detect 
the disease in an earlier stage, providing the opportunity to act earlier. As survival for 
cancers is often better when diagnosed in an earlier stage, screening is a suitable method 
to decrease cancer morbidity and mortality. CRC is a very good candidate for screening 
due to its occurrence of a benign precursor lesion, the relative long period between 
disease onset and malignancy,40 and its good prognosis when diagnosed in an early 
stage (Figure 1.2A). CRC screening decreases CRC mortality in two ways: it improves 
the survival of CRC cases by earlier diagnosis, and it can prevent CRC cases by the 
removal of adenomas (CRC precursor lesions). Evidence for the effectiveness of CRC 
screening comes from studies showing a CRC stage shift (Figure 1.2B),8 numerous 
clinical trials,51-62 and observational studies.63-66 
Colorectal cancer screening tests
Many different CRC screening tests have been developed. They can be divided into three 
groups. The first group consists of the direct visualization tests, namely colonoscopy, 
flexible sigmoidoscopy, computed tomographic colonography (CTC) and capsule 
endoscopy. All these visualization tests require cleansing of the colorectum by taking 
medication that empties the bowel. When this bowel preparation is successful, the inside 
of the colon and the rectum can be examined. A colonoscopy is a procedure that enables 
visual inspection of the inside of the colon using a flexible tube with a small camera at 
its tip. Individuals are usually sedated when undergoing this procedure. Most lesions 
detected can be removed immediately, but large lesions require surgical removal.67 A 
flexible sigmoidoscopy resembles a colonoscopy, but only examines the lower part of 
the colon (rectum and sigmoid). Sedation is less frequently used as with colonoscopy, 
and it requires less heavy bowel preparation.68 With a CTC, the colon and rectum are 
examined using a low dose CT scan.69 Capsule endoscopy is a recently developed CRC 
screening test, in which a capsule, the size of the vitamin pill, is swallowed.70 The capsule 
contains two cameras, which capture images when travelling through the digestive tract. 
These images are wirelessly transmitted to a computer and reviewed by an examiner. 
The second group are the stool-based tests. This group consists of the guaiac-based fecal 
occult blood test (gFOBT), the fecal immunochemical test (FIT) and the multitarget 
stool DNA (FIT-DNA) test. All these tests aim to detect small amounts of blood in the 
stool that are not visible to the naked eye, which can be an early sign of CRC. All these 
tests are non-invasive and can be performed at home. For the gFOBT test, participants 
have to smear multiple small amounts of stool on a card, collected from multiple bowel 
movements.56 For the FIT, a mascara stick-like probe is used to scrape the stool surface 
of a single bowel movement, which is than inserted back into the sampling bottle and 
send to a laboratory for analysis. A benefit of the FIT compared to the gFOBT is that it 
can quantify the amount of blood detected in the stool, allowing health care providers to 
select a cut-off based on the desired balance between test sensitivity and specificity.71 The 
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FIT-DNA test does not only detect blood in the stool, but also detects DNA markers of 
colorectal neoplasia.72 It requires participants to collect an entire stool sample at home, 
and send it to the laboratory for evaluation.
The third group are the liquid biopsies. The methylated SEPT9 DNA plasma assay is 
the only test in this group that has been FDA approved, but it can only be used for 
individuals that are not willing to do any of the tests described above. It evaluates 
whether there is DNA in the blood plasma in which the SEPT9 gene promoter has been 
methylated, which is a biomarker for CRC. Furthermore, a urine-based test is being 
developed, which analyses metabolomics biomarkers by using liquid chromatography-
mass spectrometry.73
All CRC screening tests have different trade-offs in terms of test accuracy, burden 
and cost. All positive non-colonoscopy tests must be followed by a colonoscopy for 
diagnosis and lesion removal. Screening is not simply having individuals take a test, 
but involves a multistep process of identifying eligible individuals, testing individuals, 
giving individuals a diagnostic follow-up if needed, and giving individuals the proper 
treatment and/or surveillance.74 All these steps are essential components of a successful 
screening program. 
The downside of colorectal cancer screening
Similar to any other cancer screening program, CRC screening does not solely have 
positive effects. In addition to the costs, CRC screening comes with significant harms 
and burdens. Harms of CRC screening are, for example, the detection of lesions that 
would have never been diagnosed without screening (= overdiagnosis). Furthermore, 
colonoscopy can result in substantial complications, such as major bleeding.75 Although 
fatal complications of colonoscopy are rare,75 they cannot be ignored. No single CRC 
screening test is perfect, resulting in false-positives (unnecessary follow-up, anxiety and 
stress), and false-negatives (false reassurance, potentially delaying clinical diagnosis). 
Although the burden of CRC screening depends on which screening test is being used, 
no CRC screening test is without any discomfort or disgust. Particularly the bowel 
preparation needed for the direct visualization test is a substantial burden for individuals, 
as well as the procedures themselves. In addition, CRC screening is a financial burden, 
not just to the health care system, but potentially also to the individual. Although CRC 
screening is recommended by expert panels,76-78 it is essential that every individual 
makes an informed decision regarding CRC screening.79
Guidelines for colorectal cancer screening in the United States
CRC screening was introduced in the US almost four decades ago, even before the first 
randomized controlled trials demonstrated its effectiveness. The US has opportunistic 
CRC screening, which implies that the opportunity for screening results from an 
individual’s request or health care providers who choose to recommend it.80 In contrast, 
other countries such as the Netherlands, have implemented organized screening 
programs, in which invitations are send out directly from central registries.71 In countries 
with an organized screening program, the decision about who should be screened and 
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1which screening test should be used is made on a national or regional level. In the US, it is the responsibility of the physician to discuss CRC screening options with their patients. 
Several organizations, such as the US Preventive Services Task Force (USPSTF), the US 
Multi-Society Task Force (USMSTF) and the American Cancer Society (ACS), make 
recommendations about CRC screening that intend to guide physicians.76,78,81 Although 
these recommendations largely align, there are some differences (Table 1.2). An im-
portant difference is the recommend ages at which screening is supposed to commence. 
Although all three organizations strongly recommend screening between ages 50 and 
75 years, the USMSTF and the ACS recommend screening from ages 45 to 50 years for 
African Americans and for all races/ethnicities, respectively. Furthermore, the USMSTF 
ranked the recommended screening strategies, whereas the other organization did not. 
Table 1.2: Overview of US colorectal cancer screening recommendations issued by the US 
Preventive Services Task Force, US Multi-society Task Force and American Cancer Society. 
US Preventive Services 
Task Force







Ages (years) 50 to 75 Blacks: 45 to 75
Others: 50 to 75
Strong: 50 to 75 




























Source Bibbins-Domingo et al.76 Rex et al. 81 Wolf et al. 78
CTC - computed tomographic colonography; FIT - fecal immunochemical test; FIT-DNA - 
multitarget stool DNA test; HS-gFOBT - high-sensitivity guaiac-based fecal occult blood test; 
SIG - flexible sigmoidoscopy 
 
Colorectal cancer screening utilization in the United States
As there is no central registry in the US to monitor CRC screening, national CRC 
screening parameters are based on self-reported estimates from surveys. The Behavioral 
Risk Factor Surveillance Survey (BRFSS) estimated that 67.3% of the population 
between ages 50 to 75 years is currently up to date with CRC screening, and 74% have 
ever participated in screening.82 Estimates from the National Health interview Survey 
are approximately 8 percentage point lower, reflecting the uncertainty in what true 
participation rates are.83 It is noteworthy that screening participation rates vary greatly 
by state – the reported percentage up to date ranges from 58.5% in New Mexico to 
75.9% in Maine in BRFSS data.82 Among the individuals up to date with CRC screening 
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in 2015, 96% reported receiving an endoscopy within the last 10 years, whereas 12% 
reported having received a FIT or gFOBT in the past year.15 Although these data are not 
test-specific, it is known that sigmoidoscopy use has dropped to 2.5% for individuals ages 
50 and above, and gFOBT has largely been replaced by FIT.23 Therefore, colonoscopy is 
by far the most common CRC screening test in the US, followed by FIT.23
Once a first CRC screening test is done, continued adherence to the recommended test 
after a specified interval is necessary to achieve the full benefit of a screening strategy. 
Very little information is available about screening participation over multiple rounds 
of screening in the US. Furthermore, there are no national estimates of adherence to 
diagnostic colonoscopy follow-up and compliance to surveillance guidelines. A recent 
international systematic review reported an adherence rate to follow-up diagnostic 
colonoscopy of 80.4%;84 US estimates of adherence to surveillance colonoscopies 
range from 60% to 85% .85-87 In 2014, a large national collaboration of more than 1,700 
public, private, and voluntary organizations called the National colorectal cancer 
roundtable launched the “80% by 2018” initiative, which aimed to increase CRC 
screening participation to 80% in 2018.88 They now updated their goal to “80% in Every 
Community” and continue working to reduce barriers to screening.
Microsimulation modeling to inform colorectal cancer screening 
policies
The need for modeling
Randomized controlled trials (RCTs) are considered the highest level of evidence,89 
and are crucial for evaluating the effectiveness of CRC screening. However, not every 
question regarding CRC screening policies can be addressed by RCTs, because of five 
reasons. First, RCTs are very expensive and time-consuming studies. This is why, for 
several of the CRC screening tests described above, a RCT demonstrating long-term 
reductions in CRC incidence and mortality has not been performed. Second, RCTs can 
only evaluate a few intervention strategies at the same time, as the number of individuals 
needed in each arm to reach statistical significance is substantial. Third, RCTs usually 
have a limited follow-up time. Therefore, they do not provide evidence for lifetime 
benefits, harms and costs of CRC screening, which are needed to determine the cost-
effectiveness of a screening program.90,91 Fourth, RCTs are performed within a specific 
context. Important parameters that drive the effectiveness of screening programs can 
be very different from setting to setting. For example, approximately 60% in the US 
are screened by means of a colonoscopy, whereas in a Dutch clinical trial only 22% of 
individuals were willing to participate in colonoscopy screening.92 This implies than 
RCTs performed in a specific setting may not be representative for another setting. 
Finally, RCTs cannot directly be used to predict the health care resources needed on a 
national level. Capacity estimates are essential when planning the implementation of a 
CRC screening program or when changing an existing CRC program.
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1To address these issues, mathematical models have been developed. These models can be used to extrapolate results from RCTs to new time periods, populations or regions. 
The lifetime benefits, harms and burden of hundreds of screening strategies can 
be analyzed within a short timeframe. Therefore, models are a useful tool to inform 
screening policies.93
The Microsimulation Screening Analysis – Colon model
One of the mathematical models developed to guide CRC screening policies is the 
Microsimulation Screening Analysis Colon model (MISCAN-Colon). MISCAN-Colon 
was developed in 1998 by the department of Public Health of the Erasmus University 
Medical Center in Rotterdam, the Netherlands.94 It was partly based on earlier versions 
of MISCAN that were generated for other cancers.95 It has been used to inform CRC 
screening policies in multiple countries, among which the Netherlands and the US.93,96-99 
Figure 1.5 illustrates the model inputs, modules and outputs; a detailed description of 
the model can be found in the Model Appendix. 
Figure 1.5: Overview of the Microsimulation Screening Analysis Colon model. The MISCAN-
colon model consists of the demography -, natural history - and screening module, which 
require country-specific model inputs. By comparing a scenario with screening to a scenario 
without screening, the effects of screening can be quantified. 
CRC - colorectal cancer; MISCAN-Colon - microsimulation screening analysis colon; (QA)LYG - 
(quality-adjusted) life-years gained 
 
In short, a hypothetical cohort of individuals is generated by the model resembling 
a real target population in terms of the life expectancy and occurrence of CRC. The 
lives of these hypothetical individuals are simulated one by one, hence the term 
microsimulation. The simulated individuals move subsequently through the three 
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different model modules (Figure 1.5). In the demography module, individuals get a 
date of birth and a date of death in the absence of CRC, based on the birth tables and 
life tables entered in the model. In the natural history module, individuals can develop 
one or multiple adenomas, which may or may not progress to cancer. When individuals 
develop CRC, a date of death by CRC is generated based on CRC survival rates entered 
in the model. Only if the date of CRC death generated in the natural history module is 
earlier than the date of death generated in the demography module, individuals die of 
the disease instead of from competing conditions. In the screening module, individuals 
are offered screening, which may or may not detect adenomas and CRC depending on 
the assumed screening ages, participation, and test characteristics. We run the model 
twice with the same individuals; once in the presence of screening and once in the 
absence screening. By comparing all individual life histories of both simulations, the 
benefits, harms and burdens of CRC screening can be quantified on a population level.
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1Research and outline of this thesis
The aim of this thesis is to advise CRC screening programs using microsimulation 
modeling. The remainder of this thesis is divided in three parts. In Part I, optimal CRC 
screening strategies are determined, given recent trends in CRC incidence. In Part 
II, the cost-effectiveness of several interventions that aim to improve CRC screening 
participation is explored. Part III focusses on the cost-effectiveness of screening for, and 
subsequently clinical management of, individuals diagnosed with Lynch syndrome. The 
research questions addressed in each of these parts are listed below.
Part I. Informing screening guidelines
Does the optimal screening strategy for the general population change when 
incorporating contemporary trends in CRC incidence? (Chapter 2)
What is the potential benefit and burden from earlier screening for black men and 
women versus whites? (Chapter 3)
How do the rising CRC incidence and the increasing CRC treatment costs impact 
the optimal screening strategy from a cost-effectiveness perspective? (Chapter 4)
Part II. Interventions to improve adherence
Under what circumstances is waiving all coinsurance for CRC screening in 
Medicare beneficiaries cost-effective? (Chapter 5)
For individuals who are unwilling to undergo FIT or colonoscopy screening, which 
screening strategy is a cost-effective alternative? (Chapter 6)
What are the optimal screening strategies for women willing to obtain some, but 
not all, US Preventive Services Task Force (USPSTF)-recommended screenings? 
(Chapter 7)
Would it be cost-effective to include the FIT kit in the screening invitation letter in 
France? (Chapter 8)
Part III. Screening and subsequent steps for Lynch syndrome patients
Is it cost-effective to screen CRC cases for Lynch syndrome, and what is the optimal 
surveillance interval for first-degree relatives identified through cascade testing? 
(Chapter 9)
What are the optimal age thresholds for offering prophylactic hysterectomy to 
asymptomatic women identified with Lynch syndrome from a cost-effectiveness 
perspective? (Chapter 10)
The thesis directly informs screening programs in the US (Chapters 2-7, 10), France 
(Chapter 8) and Canada (Chapter 9), but is informative for policy makers across the 
globe. It ends with a general discussion (Chapter 11) in which the above research 
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In 2016, the Microsimulation Screening Analysis‐Colon (MISCAN‐Colon) model 
was used to inform the US Preventive Services Task Force colorectal cancer (CRC) 
screening guidelines. In this study, 1 of 2 microsimulation analyses to inform the update 
of the American Cancer Society CRC screening guideline, the authors re‐evaluated the 
optimal screening strategies in light of the increase in CRC diagnosed in young adults.
Methods
The authors adjusted the MISCAN‐Colon model to reflect the higher CRC incidence in 
young adults, who were assumed to carry forward escalated disease risk as they age. Life‐
years gained (LYG; benefit), the number of colonoscopies (COL; burden) and the ratios 
of incremental burden to benefit (efficiency ratio [ER] = ΔCOL/ΔLYG) were projected 
for different screening strategies. Strategies differed with respect to test modality, ages to 
start (40 years, 45 years, and 50 years) and ages to stop (75 years, 80 years, and 85 years) 
screening, and screening intervals (depending on screening modality). The authors then 
determined the model‐recommended strategies in a similar way as was done for the US 
Preventive Services Task Force, using ER thresholds in accordance with the previously 
accepted ER of 39.
Results
Because of the higher CRC incidence, model‐predicted LYG from screening increased 
compared with the previous analyses. Consequently, the balance of burden to benefit of 
screening improved and now 10‐yearly colonoscopy screening starting at age 45 years 
resulted in an ER of 32. Other recommended strategies included fecal immunochemical 
testing annually, flexible sigmoidoscopy screening every 5 years, and computed 
tomographic colonography every 5 years.
Conclusions
This decision‐analysis suggests that in light of the increase in CRC incidence among 
young adults, screening may be offered earlier than has previously been recommended.




It is estimated that in 2018, > 50,000 colorectal cancer (CRC) deaths will occur in the 
United States,100 making CRC the second most common cause of cancer death in men 
and women combined.15 CRC death often can be prevented by CRC screening,51 which 
is recommended from ages 50 years to 75 years by the US Preventive Services Task Force 
(USPSTF) and the American Cancer Society (ACS).76,101 For the population as a whole, 
CRC incidence and mortality have been declining for several decades, much of which is 
attributed to an increase in CRC screening uptake.15 However, in adults aged <50 years 
among whom screening currently is not routinely recommended for those at average 
risk, CRC incidence has been increasing since the mid‐1990s.16-21 Based on national 
data, CRC now is the most commonly diagnosed cancer and the most common cause of 
cancer death in American men aged <50 years.39,40
In the recently updated USPSTF guidelines,76 screening was recommended to begin 
at age 50 years, despite the fact that 2 of 3 colorectal microsimulation models of the 
Cancer Intervention and Surveillance Modeling Network (CISNET) suggested that 
starting screening at age 45 years provided a more favorable balance between the 
benefits and burden of screening compared with starting at age 50 years.96 As described 
in the USPSTF recommendation statement, reasons for not lowering the recommended 
age to start screening were the lack of agreement between all 3 CISNET models and the 
limited empirical data related to screening before age 50 years.76 However, accumulating 
evidence has demonstrated a persistent increase in CRC incidence in adults aged <50 
years.15,16 Although the elevated background risk likely will be carried forward with these 
generations as they age due to the cohort effect, 6 it is unlikely that it will be observed in 
CRC incidence data for those aged ≥55 years because it is counteracted by the increased 
uptake of screening in those ages.
The CISNET microsimulation models that were used to inform the 2016 USPSTF CRC 
screening guidelines were calibrated to CRC incidence rates from the Surveillance, 
Epidemiology, and End Results (SEER) program registries during 1975 through 1979.96 
This time frame was chosen because there was little CRC screening in this period. 
As a result, these models did not account for the recent increase in CRC incidence 
in individuals aged <50 years. Therefore, at the request of the ACS, we re‐evaluated 
the optimal age to start screening, age to stop screening, and the screening interval 
incorporating contemporary trends in young adults to inform the update of the ACS 
CRC screening guideline.
Materials and methods
We used the Microsimulation Screening Analysis‐Colon (MISCAN‐Colon) model 
to evaluate the optimal age to start screening, age to stop screening, and screening 
interval. First, we adjusted the model to reflect the increased CRC incidence in more 
recent birth cohorts. Second, the benefits and harms of the different screening strategies 
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were predicted. Third, the balance between the benefits and the burden of screening 
was used to select model‐recommended strategies. The methods used for these steps 
are described in the section below. Analyses were similar to those performed to inform 
USPSTF guideline recommendations (see Supplementary Table A2.1 for a summary 
of all differences).96
MISCAN‐Colon
The MISCAN‐Colon model used in this study was developed by the Department of 
Public Health within Erasmus University Medical Center in Rotterdam, the Netherlands, 
and has been described in detail elsewhere (Model Appendix).102,103 It is part of 
CISNET, a consortium of cancer decision modelers sponsored by the National Cancer 
Institute (NCI). In brief, the model generates, with random variation, the individual life 
histories for a large cohort to simulate the US population in terms of life expectancy 
and cancer risk. Each simulated person ages over time and may develop ≥1 adenomas 
that can progress from small (≤5 mm) to medium (6‐9 mm) to large (≥10 mm) in size. 
Some adenomas develop into preclinical cancer, which may progress through stages 
I to IV. During each disease transition point, CRC may be diagnosed because of 
symptoms. Survival after clinical diagnosis is determined by the stage at diagnosis, the 
location of the cancer, and the person’s age. Some simulated life histories are altered 
by screening through the detection and removal of adenomas or diagnosing CRC in 
an earlier stage, resulting in a better prognosis. Screening also results in high rates of 
detection and removal (overtreatment) of polyps, the majority of which would not 
progress to invasive disease, and may result in fatal complications from colonoscopy 
with polypectomy,102,104,105 all of which are considered in the model.
Model incorporation of increase in CRC incidence
The original MISCAN‐Colon model was calibrated to CRC incidence in 1975‐1979. 
To incorporate the increased CRC incidence in recent birth cohorts, we adjusted the 
model based on the observed increase since that period as estimated by Siegel et al.16 
Age‐period‐cohort modeling of SEER data performed by Siegel et al revealed that the 
increase in CRC incidence currently is confined to ages <55 years and primarily is the 
result of a strong birth cohort effect that began in those born in the 1950s. Consequently, 
these and subsequent generations will carry forward escalated disease risk as they age.16 
Affected cohorts are only now reaching the age to initiate screening, which will likely 
somewhat counteract the trend. In our analyses, we simulated a cohort of adults aged 40 
years in 2015, and assumed that this cohort had a 1.591‐fold increased CRC incidence 
across all ages compared with the original model. This incidence multiplier was based 
on the incidence rate ratio (IRR) for CRC of the 1935 birth cohort (those aged 40 years 
in 1975) compared with the 1975 birth cohort (those aged 40 years in 2015).106 In 
accordance with the data, we assumed that the increase in CRC incidence was mostly 
confined to an increase in tumors in the rectum and the distal colon.16 In the base 
case analysis, we assumed that the increase in CRC incidence was caused by a higher 
prevalence of adenomas. In a sensitivity analysis, we explored how our results differed 
with the alternative assumption of stable adenoma prevalence, but faster progression to 
malignancy.




Six screening modalities were evaluated: 1) colonoscopy; 2) fecal immunochemical 
testing (FIT); 3) high‐sensitivity guaiac‐based fecal occult blood testing (HSgFOBT); 
4) multitarget stool DNA testing (FIT‐DNA); 5) flexible sigmoidoscopy (SIG); and 6) 
computed tomographic colonography (CTC). Multiple ages to begin and stop screening 
and multiple screening intervals were evaluated for each modality (Table 2.1). Test 
characteristics are described by Knudsen et al,96 and are presented in Supplementary 
Table A2.2. A 40‐year‐old US cohort free of CRC was simulated, thereby only 
evaluating the effect of the different screening strategies in a population of individuals 
to whom the screening guidelines for average‐risk individuals apply. These 40‐year‐olds 
were assumed to have a 100% adherence to screening, follow‐up, and surveillance.107
The benefit of screening was measured by the number of life‐years gained (LYG) from 
the screening strategy, and corrected for life‐years lost due to screening complications. 
The number of required colonoscopies was used as a measure of the aggregate burden 
of screening, and included colonoscopies for screening, follow‐up, surveillance, and the 
diagnosis of symptomatic cancer. Because this measure of burden does not capture the 
burden of other screening modalities, direct comparisons of the benefit and burden 
across screening strategies were limited to those with similar noncolonoscopy burden. 
Therefore, only the stool‐based tests were grouped, which resulted in 4 classes of 
screening modalities: 1) colonoscopy; 2) stool‐based modalities (FIT, HSgFOBT, and 
FIT‐DNA); 3) SIG; and 4) CTC. 
Table 2.1: Screening strategies evaluated by the microsimulation model 















No screening   1 (1)
Colonoscopy 40,45,50 75,80,85 5,10,15 27 (20)
Stool-based tests
Fecal immunochemical test 40,45,50 75,80,85 1,2,3 27 (27)
High-sensitivity guaiac-based 
fecal occult blood test 
40,45,50 75,80,85 1,2,3 27 (27)
Multitarget stool DNA test 40,45,50 75,80,85 1,3,5 27 (27)
Flexible sigmoidoscopy 40,45,50 75,80,85 5,10 18 (15)
Computed tomographic 
colonography
40,45,50 75,80,85 5,10 18 (15)
Total       145 (132)
a The number of unique strategies excluded the strategies that overlap (eg, COL every 10 years 
from ages 50-80 years and from ages 50-85 years both include colonoscopies at age 50, 60, 70, 
and 80 years, and thus are not unique strategies).
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Efficient and near‐efficient screening strategies
The LYG and colonoscopy burden were plotted for each screening strategy by class of 
screening modalities. Strategies providing the largest incremental increase in LYG per 
additional colonoscopy were connected, thereby composing the efficient frontier. All 
strategies on the efficient frontier were considered efficient screening options,108 whereas 
others fell below the frontier and were dominated. Weakly dominated strategies that had 
LYG within 98% of the efficient frontier were defined as near-efficient; other strategies 
below the efficient frontier were considered inefficient. For efficient and near-efficient 
strategies, the incremental number of colonoscopies (ΔCOL), the incremental number 
of LYG (ΔLYG), and the efficiency ratio (ER) (ΔCOL/ΔLYG) relative to the next less 
effective efficient strategy were calculated.
Model‐recommended screening strategies
A predefined algorithm was used to select model-recommended screening strategies 
(Figure 2.1).96 First, the efficient frontier for the colonoscopy strategies was generated 
(step 1), after which a benchmark colonoscopy screening strategy was selected that 1) 
was an efficient or near-efficient colonoscopy screening strategy, 2) had LYG no less 
than the previously recommended colonoscopy every 10 years from ages 50 to 75 
years, and 3) had an efficiency ratio (ER = ΔCOL/ΔLYG) of ≤ 40, 45, or 50 incremental 
colonoscopies per LYG (step 2). We decided to evaluate different ER thresholds in liaison 
with recommendations for cost-effectiveness analysis, for which it is recommended to 
evaluate multiple willingness-to-pay thresholds.109 We analyzed ER thresholds of 40, 45, 
and 50, in accordance with the efficiency ratio for the MISCAN-Colon model in the 
USPSTF analyses, in which 39 was considered an acceptable number of colonoscopies per 
LYG and 114 was not, suggesting the threshold of an acceptable number of colonoscopies 
per LYG was in-between those values.96 Next, the start age and stop age of screening 
were fixed at those of the colonoscopy benchmark strategy (step 3), because different 
start ages and stop ages for different screening modalities are not easy to implement 
in practice because this may complicate the communication between physicians and 
patients. Simplifying a regimen has been shown to be an important intervention to 
increase patient adherence,110 and therefore recommending different start ages or stop 
ages for the different screening modalities may result in lower participation. For the 
noncolonoscopy screening modalities, within-class efficient frontiers were created, 
with the same start age and stop age as the benchmark colonoscopy strategy (step 4), 
and selected were 1) efficient or near-efficient strategies that 2) had at least 90% of the 
LYG compared with the benchmark colonoscopy strategy and 3) had ERs lower than 
the benchmark colonoscopy strategy (step 5). Among all strategies within a class of 
screening modality fulfilling all the above criteria, only the most effective strategies were 
recommended by the model (step 6).




Fix start age and stop age 
based on benchmark
Step 1
Create efficient frontier by 




a. In or near the efficient 
    frontier 
b. LYG => current 
    recommendation





a. In or near the efficient
    frontier
b. LYG => 90% of 
    benchmark
c. ER < benchmark
Model
 recommendation





including strategies with 
the same start age and 
stop age as the benchmark 
Step 6
Select most effective 
strategy per class 
Figure 2.1: Algorithm used to select model-recommended strategies. LYG indicates life-years 
gained (current recommendation is colonoscopy screening from ages 50 to 75 years every 10 
years); ER, efficiency ratio. The ER is calculated as and is an incremental burden-to-benefits 
ratio. Threshold ERs of 40, 45, and 50 colonoscopies per LYG were evaluated. The stool-based 
strategies (fecal immunochemical test, high-sensitivity guaiac-based fecal occult blood test, 
and multitarget stool DNA test) were combined into 1 class because they have a similar 
noncolonoscopy burden. 
CTC - computed tomographic colonography; SIG - flexible sigmoidoscopy.
Assumptions evaluated in the sensitivity analyses
Three major assumptions were made that potentially influenced the results, which 
therefore were explored in the sensitivity analyses. First, as mentioned above, we 
assumed that the increase in CRC incidence was caused by an increase in adenoma 
onset in our primary analyses. Therefore, we explored faster adenoma progression to 
malignancy in a sensitivity analysis. Second, we assumed that the 1975 birth cohort 
will carry forward the increased CRC incidence as they age. Therefore, we increased 
incidence only <age 50 years in a sensitivity analysis. Third, we used an IRR of 1.591 
because this is applicable to the 1975 birth cohort. Incidence rate ratios of 1.2, 1.3… 
2.3 and 2.4 were explored in a sensitivity analysis, with higher ratios being potentially 
informative for more recent birth cohorts.
Results
A total of 132 unique screening strategies were evaluated (Table 2.1). The CRC deaths 
averted per 1000 40-year-olds ranged from 25 for triennial HSgFOBT from ages 50 to 
75 years to 40 for colonoscopy every 5 years from ages 40 to 85 years (Supplementary 
Table A2.3). The lifetime number of colonoscopies per 1000 40-year-olds, used as 
a measure of burden, ranged from 1433 for triennial FIT screening from ages 50 to 
75 years to 8671 for colonoscopy every 5 years from ages 40 to 85 years, whereas the 
number of LYG compared with no screening, used to measure benefit, ranged from 284 
for triennial HSgFOBT from ages 50 to 75 years to 475 for colonoscopy every 5 years 
from ages 40 to 85 years (see Supplemenatry Table A2.3).
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Efficient and near‐efficient screening strategies
The LYG compared with the number of colonoscopies required and the efficient frontier 
for the colonoscopy strategies are presented in Figure 2.2. Nine efficient and 5 near-
efficient (LYG within 98% of the efficient frontier) colonoscopy strategies were identified, 
in which the ERs (incremental burden-to-benefits ratios) for the colonoscopy strategies 
ranged from 11 colonoscopies per LYG for screening every 15 years from ages 50 to 
75 years to 569 for colonoscopy screening every 5 years from ages 40 to 85 years (see 
Supplementary Table A2.4). The current colonoscopy screening recommendation 
(screening every 10 years from ages 50-75 years) was 1 of the 9 efficient strategies 
and had an ER of 23. The plots of the other screening modalities can be found in 
Supplementary Figures A2.1 to A2.3. Twenty-two of 25 stool-based strategies in or 
near the efficient frontier were FIT strategies, demonstrating that FIT screening largely 
dominated the other stool-based strategies (Supplementary Figure A2.1). 
 
Figure 2.2: Lifetime number of colonoscopies and life-years gained (LYG) for colonoscopy 
screening strategies.
Model‐recommended strategies
The colonoscopy strategy recommended by the model was screening every 10 years from 
ages 45 to 75 years with an ER of 32 incremental colonoscopies per LYG (Table 2.2). 
This strategy was selected because it was on the efficient frontier and had the highest 
number of LYG among the strategies with ERs <40 and 45. Compared with the current 
recommendation (screening every 10 years from ages 50-75 years), this strategy resulted 
in 25 (+6.2%) additional LYG accompanied by an increase in 810 (+17%) colonoscopies 
per 1000 40-year-olds. 
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Table 2.2: Outcomes for screening strategies with similar age to start and age to stop 
screening as the selected benchmark colonoscopy strategy
Modality, and  
Age to Start/ 
Age to End/ 
Interval, Years



































































































































COL 45/75/10e 0 0 0 5646 429 23 37 32 - - Yes
Stool tests
FIT 45/75/3 8038 0 0 1619 310 11 27 5 Yes No  
FIT 45/75/2 10,973 0 0 1994 352 13 30 9 Yes No  
HSgFOBT 45/75/3 7405 0 0 2024 310 13 27 Dom. - No
FIT-DNA 45/75/5 4949 0 0 2157 333 14 29 Dom. - No  
HSgFOBT 45/75/2 9776 0 0 2516 354 15 30 Dom. - No  
FIT-DNA 45/75/3 6644 0 0 2640 376 16 32 Dom - No  
FIT 45/75/1 17,835 0 0 2698 403 16 34 14 Yes Yes  Yes
HSgFOBT 45/75/1 14,366 0 0 3364 403 18 34 Dom. - Yes  
FIT-DNA 45/75/1 12,019 0 0 3851 426 19 36 50 No Yes  
Flexible sigmoidoscopy 
SIG 45/75/10 0 2691 0 3314 373 19 33 9 Yes No  
SIG 45/75/5 0 3865 0 3761 403 20 35 15 Yes Yes Yes 
CT colonography
CTC 45/75/10 0 0 3045 2106 322 14 29 6 Yes No  
CTC 45/75/5 0 0 4630 2666 390 16 34 8 Yes Yes Yes
COL - colonoscopy; Dom. - Dominated; FIT - Fecal immunochemical test; HSgFOBT - High-
sensitivity guaiac-based fecal occult blood test; FIT-DNA - Multitarget stool DNA test; SIG - 
Flexible sigmoidoscopy; CTC - Computed tomographic colonography; LYG - Life-years gained; 
CRC - Colorectal cancer; ER - Efficiency ratio
a In the absence of screening, the model predicted 45 CRC Deaths.  
b calculated as                                                        . It is an incremental burden-to-benefits ratio.
c A strategy can only be recommended by the model if it has an efficiency ratio lower than 
the efficiency ratio of the benchmark strategy (colonoscopy every 10 years from ages 45 to 
75 years). 
d A strategy is recommended by the model if it is an efficient or a near-efficient strategy with 
a lower burden-to-benefits ratio and at least 90% of the LYG compared to the benchmark 
strategy (colonoscopy screening every 10 years from ages 45 to 75 years).
e This strategy was selected by the model when an efficiency ratio threshold of 40 or 45 
incremental colonoscopies per LYG was applied.
incremental colonoscopies w.r.t. previous efficient strategy
incremental LYG w.r.t. previous efficient strategy
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Class-specific efficient frontiers for strategies other than colonoscopy were created, 
including only those strategies with the same start age and stop age as the benchmark 
colonoscopy strategy (Table 2.2). Per screening class, 1 screening strategy was in or 
near the efficient frontier, had an ER smaller than the benchmark colonoscopy strategy, 
and had at least 90% of the LYG from the benchmark strategy, thereby fulfilling the 
criteria to be recommended by the model. In addition to colonoscopy screening every 
10 years, our model recommended FIT screening annually, SIG every 5 years, and CTC 
every 5 years from ages 45 to 75 years (Table 2.2).
With an ER threshold of 50, screening was recommended from ages 40 to 75 years by 
colonoscopy every 10 years, FIT every year, SIG every 5 years, and CTC every 5 years 
(Supplemenatry Table A2.5). Irrespective of the ER threshold, no HSgFOBT and 
FIT-DNA strategies were recommended. HSgFOBT strategies were not on the efficient 
frontier and for the few efficient FIT-DNA strategies that were, the ER was higher than 
the colonoscopy benchmark.
Table 2.3: Model-recommended colonoscopy strategies under alternative model assumptions 
evaluated in the sensitivity analyses
Recommended colonoscopy strategies  
(start age / end age / interval)
Scenario ER < 40 ER < 45 ER < 50
Base casea 45/75/10 45/75/10 40/75/10
Faster adenoma progression 40/75/10 40/75/10 40/75/10
Higher incidence only below age 50 50/75/10b 40/75/10 40/75/10





















































Colonoscopy strategies are described by: Age to start screening/Age to stop screening/
screening interval. Efficiency Ratio (ER) thresholds of 40, 45 and 50 colonoscopies per life-year 
gained were evaluated. 
a In our Base-Case analyses, we assumed an Incidence Rate Ratio of 1.591 and we assumed that 
the higher incidence was caused by an increase in adenoma onset instead of faster adenoma 
progression. Furthermore, we assumed that the current generation of 40-year-olds will carry 
forward escalated disease risk as they age.
b 50-75-10 had an ER of 40.7; it was the strategy with the lowest ER among the strategies that 
met the LYG criterion. 




As shown in Table 2.3, alternative assumptions that were explored in the sensitivity 
analyses influenced the model recommendations. First, when the increased CRC 
incidence was incorporated as faster adenoma progression to malignancy rather than 
higher adenoma onset, the model suggested to start screening at age 40 years for all ER 
thresholds. Second, if the assumed higher CRC incidence was confined to ages <50 years, 
colonoscopy screening every 10 years from ages 50 to 75 years resulted in the lowest ER: 
40.7. The model recommended starting screening at age 40 years by colonoscopy every 10 
years with ER thresholds of 45 and 50. Finally, model-recommended strategies depended 
on the level of increase in CRC incidence. The start age for colonoscopy decreased as 
IRRs increased. With an ER threshold of 45, the optimal age to start screening remained 
at age 50 years for IRRs < 1.3, whereas the optimal age to start screening was decreased 
to age 40 years with an IRR of ≥1.7. The first and second alternative assumption did not 
influence the stopping age nor the screening interval, but stopping age and/or interval 
were influenced by some of the more extreme IRRs.
Discussion
The results of the current analyses suggest that screening initiation at age 45 years has a 
favorable balance between screening benefits and burden based on the increase in CRC 
incidence in young adults. For current 40-year-olds, the model recommends screening 
every 10 years with colonoscopy, every year with FIT, every 5 years with SIG, or every 5 
years with CTC from ages 45 to 75 years. The model-recommended start age depended 
on the ER threshold that was applied; when 50 colonoscopies per LYG was used as a 
threshold, the model recommended starting screening at age 40 years.
The results of the current study were sensitive for alternative assumptions regarding the 
magnitude and etiology of the increase in CRC incidence in young adults; however, the 
model recommended starting screening before age 50 years, often even at age 40 years, 
in the majority of alternative scenarios. Thus, the model recommendation of screening 
initiation at age 45 years appears robust and may even be conservative. Close monitoring 
of the developments in CRC incidence is required to inform future guidelines because 
incidence is increasing with each subsequent birth cohort.16
To our knowledge, the current study is the first study that incorporates the recent increase 
in CRC incidence, especially for rectal and distal colon cancer, in a decision-analytic 
modeling approach to assess CRC screening. Our estimated benefits of screening, 
which resulted in decreased incremental burden-to-benefit ratios, were much higher 
compared with the analysis performed to inform the USPSTF guidelines.96 For example, 
the LYG and ERs for screening every 10 years by colonoscopy from ages 50 to 75 years 
were 248 and 39 for the USPSTF analysis, versus 404 and 23 in this analysis. In addition, 
in contrast to the analysis performed for the USPSTF, SIG screening every 5 years was 
recommended by the model. This likely can be attributed to the higher percentage of 
tumors in the rectum and the distal colon. The only other difference between the current 
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model and the one used for USPSTF was the update of the lifetable from 2009 to 2012, 
which did not meaningfully influence findings (data not shown).
The ER of colonoscopy screening every 10 years from ages 45 to 75 years in our analysis 
was 32, a lower ratio of incremental burden to benefit than the ER of the model-
recommended colonoscopy strategy in the USPSTF analysis. In contrast to the USPSTF 
analysis, this analysis to inform the ACS was only performed by 1 of the 3 CISNET 
models. However, the other 2 CISNET models already suggested that starting screening 
at age 45 years was preferred in the analysis for the USPSTF, in which the higher risk was 
not incorporated, albeit with a 15-year interval for colonoscopy screening.96
Decision models are a useful tool with which to inform screening guidelines because they 
can extrapolate evidence and predict long-term outcomes of numerous screening strategies. 
Decision modeling is an important component within the context of all scientific evidence 
that is taken into consideration when screening guidelines are evaluated. Since the USPSTF 
recommendations, compelling empirical data from Siegel et al 16 have demonstrated that 
the increase in CRC incidence is primarily the result of a strong birth cohort effect, which 
fueled debate regarding the age of screening initiation. This debate triggered reanalysis 
of the optimal age to begin and end screening and the screening interval that CISNET 
models performed earlier for the USPSTF. Taken together, empirical data and modeling 
now suggest that screening should be started at an earlier age for those at average risk of 
disease. Our model recommendation to start screening at age 45 years instead of age 50 
years is driven solely by the assumed increase in CRC disease burden. A study by Murphy 
et al suggested that the increase in CRC incidence in younger ages is likely caused by an 
increase in colonoscopy use rather than an increase in disease burden, based in part on 
stable CRC mortality rates.111 It is important to note that Murphy et al presented mortality 
data from 1992 through 2013 and did not systematically quantify recent trends. Race-
specific examination of CRC mortality from 1970 to 2014 among individuals aged 20 to 
49 years by Siegel et al demonstrated that although CRC mortality is decreasing in blacks, 
it actually is increasing in whites. Moreover, the trend is consistent with a cohort effect, 
with the increase beginning in 1995 for individuals aged 30 to 39 years and in 2005 for 
individuals aged 40 to 49 years, a decade later than the uptick in incidence for each age 
group.112 Therefore, because the increase in incidence is accompanied by an increase in 
mortality, higher colonoscopy use in individuals aged <50 years does not appear to be the 
main driver of the increase in CRC incidence in young adults.
The current study has several limitations. First, it is not known whether the increase in 
CRC incidence is caused by an increase in the number of adenomas, a faster adenoma 
progression to malignancy, or some combination of the 2. We found that under both 
assumption of a higher adenoma onset as well as faster adenoma progression, screening 
initiation before age 50 years was optimal and therefore also would be expected for the 
combination of assumptions. Future research is needed to determine the cause and 
carcinogenic pathway of the increase in CRC. Second, it is not certain that the current 
40-year-olds will carry forward the same escalated disease risk as they age. Therefore, 
we evaluated the extreme, namely that they would return to levels for 1975-1979 levels, 
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in a sensitivity analysis. Although this impacted the predicted benefits of screening, this 
only further lowered the recommended starting age to 40 years when an ER threshold of 
45 incremental colonoscopies per LYG was applied. Third, we used the number of LYG 
and the number of colonoscopies to measure the benefits and the burden, respectively. 
Therefore, the burden of tests other than colonoscopies was not considered, which made 
direct comparison of all strategies not possible. Fourth, to the best of our knowledge, there 
is no commonly accepted threshold for the incremental number of colonoscopies per LYG. 
For the USPSTF analysis, 39 was considered an acceptable ratio for our model.96 Because 
it is recommended to evaluate multiple willingness-to-pay thresholds,109 we evaluated ER 
thresholds of 40, 45, and 50. Although these thresholds are subjective and do influence 
our model recommendations, the ER for screening initiation at age 45 years was 32 in this 
analysis, and therefore was superior to the ER accepted by the USPSTF.96 Fifth, similar to 
the assumptions in our analysis for the USPSTF,96 we assumed perfect adherence to all 
screening, diagnostic follow-up, and surveillance tests for the purpose of comparing the 
performance of individual tests under ideal assumptions. Therefore, the model predicted the 
maximum achievable benefit for all screening strategies. In reality, the current percentage 
of being up to date with screening is 61.1%,113 and the adherence to diagnostic follow-
up and surveillance is approximately 80%.55,114This suggests that the model-predicted 
benefits will not be achieved. However, guidelines are optimally based on the full potential 
of benefit that would accrue under complete adherence to recommendations because 
assuming realistic adherence might result in recommending more frequent screenings 
as the model then compensates for the substantial percentage of the population that does 
not participate in every recommended screening. For individuals who do adhere to the 
recommendations, this actually would result in overscreening associated with unnecessary 
burden. Furthermore, public health organizations will always seek to increase adherence 
to recommendations. Sixth, the lack of empirical data regarding the performance of CRC 
screening tests in adults aged 45 to 49 years means that we assumed that these tests would 
perform equally well in this age group compared with adults aged 50 to 54 years. In fact, 
apart from a lower prevalence of disease, there is little reason to expect that performance 
would differ. In the case of visual tests, lesions of interest should have similar visibility. 
Tests for occult blood have been shown to perform differently by age, but the difference 
in characteristics is small at younger ages. Harms associated with colonoscopy should be 
lower given the observation that harms increase with increasing age. Finally, we did not 
tailor recommendations to population characteristics, whereas further personalization of 
screening may improve the balance of burden to benefit. In the accompanying article, 
Meester et al 98 have demonstrated that when incidence is updated in race- and sex-specific 
analyses, screening is recommended from age 45 years for all race and gender combinations.
A well-established decision-analytic modeling approach that incorporates the increase 
in CRC incidence among those of younger ages suggests that screening from ages 45 
to 75 years is recommended for the current generation of 40-year-olds. Colonoscopy 
screening every 10 years, annual FIT screening, SIG screening every 5 years, and CTC 
screening every 5 years are screening strategies with similar benefits and acceptable 
colonoscopy burdens. If the gradual increase in CRC incidence in more recent birth co-





Supplementary Figure A2.1: Lifetime number of colonoscopies and life-years gained for 
stool-based screening strategies.
 
Supplementary Figure A2.2: Lifetime number of colonoscopies and life-years gained for 
flexible sigmoidoscopy screening strategies.




Supplementary Figure A2.3: Lifetime number of colonoscopies and life-years gained for 
computed tomographic colonography strategies.
Supplementary Table A2.1: Summary of differences between this analysis and our previous 
analysis for the US Preventive Services Task Force.
ACS analysis USPSTF analysis
Data source, life 
expectancy
2013 U.S. lifetables 2009 U.S. lifetables
Data source, CRC risk Elevated risk based on trends 
in incidence under age 40
SEER 1975-1979
Data source, CRC location SEER 1975 birth cohort SEER 1975-1979
Evaluated tests Single test strategies only Single- and hybrid test 
strategies
Evaluated start ages Start ages 40, 45 and 50 Start ages 45, 50 and 55




Re-assessed for classes of 
screening modality other 
than colonoscopy after se-
lecting age to start and stop
Assessed among start ages 
50 and 55 and stop ages 75, 
80 and 85 for all screening 
modalities





An acceptance threshold 
of maximum 40, 45 or 50 
colonoscopies per LYG was 
applied for colonoscopy-
based screening strategies
No specified acceptance 
threshold was applied, but 
the number effectively 
accepted by the Task Force 














adenomas ≤5 mm, %
75 0 e 0 e 0 e 75
Sensitivity for 
adenomas 6–9 mm, %
85 11.4 4.29 22 85 57
Sensitivity for 
adenomas ≥10 mm, %
95 15.9 14.7 28.4 95 84
Sensitivity for CRC, % 95 88.6/62.6 f 85.9/56.8 f 96.7/86.4 f 95 84
Specificity, % 86 b 96.4 92.5 89.8 87 b 88 g
Reach, % 95 c 100 100 100 76 c 100
Risk of fatal 
complications, %
0.01 d 0 0 0 0 d 0
CTC - computed tomographic colonography; FIT - fecal immunochemical test ; FIT-DNA - 
multitarget stool DNA test; SIG - flexible sigmoidoscopy; HSgFOBT - high-sensitivity guaiac-
based fecal occult blood test. a It was assumed that the same test characteristics for screening 
colonoscopies applied to colonoscopies for diagnostic follow-up or for surveillance. 
b The lack of specificity with endoscopy reflects the detection of nonadenomatous polyps, 
which, in the case of flexible sigmoidoscopy, may lead to unnecessary diagnostic colonoscopy, 
and in the case of colonoscopy, leads to unnecessary polypectomy, which is associated with 
an increased risk of colonoscopy complications.
c   95% of the colonoscopies reached the end of the colorectum (cecum); for the remainder 5% 
the endpoint was distributed between the cecum and rectum. With flexible sigmoidoscopy, 
76% reached the end the sigmoid colon; 14% had an endpoint between the beginning and 
the end of the sigmoid colon; 12% had an endpoint between the beginning and end of the 
descending colon.
d Case fatality was derived by combining the overall perforation rate from Warren and col-
leagues with mortality given perforation (0.0519) in Gatto and colleagues. Flexible sigmoid-
oscopy was modeled without biopsy or polypectomy of detected lesions, and was therefore 
assumed to have 0 mortality risk. 
e It was assumed that 1–5 mm adenomas do not bleed and therefore cannot cause a positive 
stool test. 
f  “Short” before clinical diagnosis / “Long” before clinical diagnosis.
g  The lack of specificity with CTC reflects the detection of 6-mm nonadenomatous lesions, 
artifacts, stool, and adenomas smaller than the 6-mm threshold for referral to colonoscopy 
that are measured as ≥6 mm. 
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Supplementary Table A2.3: Lifetime number of screening tests, life-years gained, CRC Cases 















No Screening        - - - - - 108 - 108 45
COL 40 75 5 0 0 0 8330 473 30 6
COL 40 75 10 0 0 0 6083 438 37 8
COL 40 75 15 0 0 0 5226 406 41 10
COL 40 80 5 0 0 0 8544 475 30 5
COL 40 80 10 0 0 0 6345 443 35 7
COL 40 80 15 0 0 0 5226 406 41 10
COL 40 85 5 0 0 0 8671 475 30 5
COL 40 85 10 0 0 0 6345 443 35 7
COL 40 85 15 0 0 0 5418 408 41 9
COL 45 75 5 0 0 0 7277 457 32 6
COL 45 75 10 0 0 0 5646 429 36 8
COL 45 75 15 0 0 0 4923 400 41 10
COL 45 80 5 0 0 0 7492 459 31 6
COL 45 80 10 0 0 0 5646 429 36 8
COL 45 80 15 0 0 0 4923 400 41 10
COL 45 85 5 0 0 0 7619 459 31 6
COL 45 85 10 0 0 0 5806 430 36 8
COL 45 85 15 0 0 0 4923 400 41 10
COL 50 75 5 0 0 0 6234 429 34 7
COL 50 75 10 0 0 0 4836 404 39 9
COL 50 75 15 0 0 0 4183 376 45 12
COL 50 80 5 0 0 0 6449 431 33 7
COL 50 80 10 0 0 0 5098 409 38 8
COL 50 80 15 0 0 0 4502 384 43 10
COL 50 85 5 0 0 0 6576 431 33 7
COL 50 85 10 0 0 0 5098 409 38 8
COL 50 85 15 0 0 0 4502 384 43 10
FIT 40 75 1 21262 0 0 2942 417 52 11
FIT 40 75 2 12800 0 0 2139 363 66 15
FIT 40 75 3 9162 0 0 1704 314 74 19
FIT 40 80 1 22578 0 0 3040 427 50 9
FIT 40 80 2 13843 0 0 2242 378 64 13
FIT 40 80 3 9971 0 0 1802 332 73 17
FIT 40 85 1 23492 0 0 3101 431 50 8
FIT 40 85 2 14331 0 0 2285 382 64 12
FIT 40 85 3 10504 0 0 1858 338 73 15
FIT 45 75 1 17835 0 0 2698 403 54 11
FIT 45 75 2 10973 0 0 1994 352 67 16
FIT 45 75 3 8038 0 0 1619 310 75 19
FIT 45 80 1 19157 0 0 2797 413 52 10


















FIT 45 80 3 8434 0 0 1665 318 74 17
FIT 45 85 1 20074 0 0 2858 417 51 9
FIT 45 85 2 12407 0 0 2129 368 65 13
FIT 45 85 3 9016 0 0 1728 325 74 16
FIT 50 75 1 14610 0 0 2402 377 56 12
FIT 50 75 2 8839 0 0 1762 325 69 17
FIT 50 75 3 6522 0 0 1433 284 77 20
FIT 50 80 1 15948 0 0 2504 387 54 11
FIT 50 80 2 9900 0 0 1870 341 67 14
FIT 50 80 3 7298 0 0 1529 300 76 18
FIT 50 85 1 16872 0 0 2567 391 54 10
FIT 50 85 2 10394 0 0 1915 345 67 13
FIT 50 85 3 7580 0 0 1560 303 76 17
HSgFOBT 40 75 1 17001 0 0 3714 418 49 10
HSgFOBT 40 75 2 11348 0 0 2749 366 62 15
HSgFOBT 40 75 3 8410 0 0 2174 317 71 19
HSgFOBT 40 80 1 17955 0 0 3827 426 48 9
HSgFOBT 40 80 2 12213 0 0 2869 379 61 13
HSgFOBT 40 80 3 9121 0 0 2288 332 70 16
HSgFOBT 40 85 1 18610 0 0 3898 429 47 8
HSgFOBT 40 85 2 12612 0 0 2920 382 61 12
HSgFOBT 40 85 3 9585 0 0 2354 337 70 15
HSgFOBT 45 75 1 14366 0 0 3364 403 51 11
HSgFOBT 45 75 2 9776 0 0 2516 354 63 15
HSgFOBT 45 75 3 7405 0 0 2024 310 72 18
HSgFOBT 45 80 1 15326 0 0 3479 411 49 10
HSgFOBT 45 80 2 10357 0 0 2598 362 62 13
HSgFOBT 45 80 3 7754 0 0 2078 318 72 17
HSgFOBT 45 85 1 15983 0 0 3550 414 49 9
HSgFOBT 45 85 2 10960 0 0 2676 367 62 12
HSgFOBT 45 85 3 8263 0 0 2152 324 72 16
HSgFOBT 50 75 1 11925 0 0 2956 377 53 12
HSgFOBT 50 75 2 7965 0 0 2181 327 67 16
HSgFOBT 50 75 3 6061 0 0 1755 284 75 20
HSgFOBT 50 80 1 12899 0 0 3073 385 52 11
HSgFOBT 50 80 2 8853 0 0 2309 340 65 14
HSgFOBT 50 80 3 6749 0 0 1867 298 74 18
HSgFOBT 50 85 1 13563 0 0 3146 388 52 10
HSgFOBT 50 85 2 9260 0 0 2362 344 65 13
HSgFOBT 50 85 3 6996 0 0 1903 301 74 17
FIT-DNA 40 75 1 14326 0 0 4235 441 41 9
FIT-DNA 40 75 3 7608 0 0 2818 383 57 13
FIT-DNA 40 75 5 5793 0 0 2332 345 66 16
FIT-DNA 40 80 1 15086 0 0 4351 447 40 8
FIT-DNA 40 80 3 8193 0 0 2941 396 55 11
table continues

















FIT-DNA 40 80 5 6113 0 0 2406 353 65 14
FIT-DNA 40 85 1 15609 0 0 4426 449 39 7
FIT-DNA 40 85 3 8572 0 0 3011 400 55 10
FIT-DNA 40 85 5 6324 0 0 2450 356 65 14
FIT-DNA 45 75 1 12019 0 0 3851 426 42 9
FIT-DNA 45 75 3 6644 0 0 2640 376 57 13
FIT-DNA 45 75 5 4949 0 0 2157 333 67 16
FIT-DNA 45 80 1 12780 0 0 3968 432 41 8
FIT-DNA 45 80 3 6930 0 0 2698 382 56 12
FIT-DNA 45 80 5 5271 0 0 2231 342 66 15
FIT-DNA 45 85 1 13302 0 0 4042 434 40 8
FIT-DNA 45 85 3 7344 0 0 2776 387 56 11
FIT-DNA 45 85 5 5483 0 0 2276 344 66 14
FIT-DNA 50 75 1 9887 0 0 3409 401 45 10
FIT-DNA 50 75 3 5422 0 0 2331 350 60 15
FIT-DNA 50 75 5 4147 0 0 1937 312 69 17
FIT-DNA 50 80 1 10659 0 0 3528 407 43 9
FIT-DNA 50 80 3 5982 0 0 2449 361 58 13
FIT-DNA 50 80 5 4473 0 0 2014 321 68 16
FIT-DNA 50 85 1 11184 0 0 3603 409 43 9
FIT-DNA 50 85 3 6182 0 0 2487 363 58 12
FIT-DNA 50 85 5 4686 0 0 2059 323 68 15
SIG 40 75 5 0 4631 0 4012 413 40 10
SIG 40 75 10 0 2992 0 3396 378 46 12
SIG 40 80 5 0 4837 0 4088 416 39 9
SIG 40 80 10 0 3260 0 3529 384 45 11
SIG 40 85 5 0 4967 0 4122 417 39 9
SIG 40 85 10 0 3260 0 3529 384 45 11
SIG 45 75 5 0 3865 0 3761 403 41 10
SIG 45 75 10 0 2691 0 3314 373 46 12
SIG 45 80 5 0 4070 0 3837 405 40 10
SIG 45 80 10 0 2691 0 3314 373 46 12
SIG 45 85 5 0 4201 0 3871 406 40 9
SIG 45 85 10 0 2866 0 3384 374 46 12
SIG 50 75 5 0 3181 0 3426 380 43 11
SIG 50 75 10 0 2119 0 2986 352 49 13
SIG 50 80 5 0 3388 0 3503 383 42 10
SIG 50 80 10 0 2388 0 3120 358 47 12
SIG 50 85 5 0 3519 0 3537 383 42 10
SIG 50 85 10 0 2388 0 3120 358 47 12
CTC 40 75 5 0 0 5458 2856 402 49 11
CTC 40 75 10 0 0 3311 2134 322 63 18
CTC 40 80 5 0 0 5742 2931 409 47 10
CTC 40 80 10 0 0 3675 2265 337 60 15


















CTC 40 85 10 0 0 3675 2265 337 60 15
CTC 45 75 5 0 0 4630 2666 390 50 12
CTC 45 75 10 0 0 3045 2106 322 62 17
CTC 45 80 5 0 0 4915 2742 397 48 10
CTC 45 80 10 0 0 3045 2106 322 62 17
CTC 45 85 5 0 0 5102 2788 399 48 10
CTC 45 85 10 0 0 3286 2185 327 61 15
CTC 50 75 5 0 0 3850 2430 368 52 13
CTC 50 75 10 0 0 2374 1873 300 65 19
CTC 50 80 5 0 0 4137 2507 375 50 11
CTC 50 80 10 0 0 2741 2006 315 62 16
CTC 50 85 5 0 0 4325 2553 377 49 11
CTC 50 85 10 0 0 2741 2006 315 62 16
COL - Colonoscopy; FIT - Fecal immunochemical test; HSgFOBT - High-sensitivity guaiac-
based fecal occult blood test; SIG - Flexible sigmoidoscopy; CTC - Computed tomographic 
colonography; LYG - Life-years gained; CRC - Colorectal cancer
a Total number of colonoscopies performed per 1000 40-year olds, including diagnostic 
colonoscopies and potential surveillance colonoscopies after adenoma removal.
b  This includes the number of deaths due to fatal complications.
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Supplementary Table A2.4: Lifetime number of screening tests and life-years gained per 
1000 40-year-olds for all efficient and near-efficient screening strategies within each class.a
Modality, and  
age to start, 











COL 50-75-15 0 0 0 4183 376 34 11  
COL 50-80-15 0 0 0 4502 384 35 40 *
COL 50-75-10 0 0 0 4836 404 36 23  
COL 50-80-10 0 0 0 5098 409 37 60 *
COL 45-75-10 0 0 0 5646 429 37 32  
COL 45-85-10 0 0 0 5806 430 38 156 *
COL 40-75-10 0 0 0 6083 438 37 48  
COL 40-80-10 0 0 0 6345 443 38 59  
COL 45-75-5 0 0 0 7277 457 39 66  
COL 45-80-5 0 0 0 7492 459 39 113 *
COL 45-85-5 0 0 0 7619 459 40 162 *
COL 40-75-5 0 0 0 8330 473 40 66  
COL 40-80-5 0 0 0 8544 475 40 117  
COL 40-85-5 0 0 0 8671 475 40 569  
FIT 50-75-3 6522 0 0 1433 284 25 5  
FIT 50-80-3 7298 0 0 1529 300 28 6  
FIT 50-85-3 7580 0 0 1560 303 28 10 *
FIT 45-75-3 8038 0 0 1619 310 27 9 *
FIT 45-80-3 8434 0 0 1665 318 28 8  
FIT 45-85-3 9016 0 0 1728 325 29 9  
FIT 50-75-2 8839 0 0 1762 325 28 1935 *
FIT 40-80-3 9971 0 0 1802 332 29 12 *
FIT 40-85-3 10504 0 0 1858 338 30 11 *
FIT 50-80-2 9900 0 0 1870 341 31 9  
FIT 50-85-2 10394 0 0 1915 345 32 11 *
FIT 45-75-2 10973 0 0 1994 352 30 11 *
FIT 45-80-2 11672 0 0 2064 362 32 9  
FIT 45-85-2 12407 0 0 2129 368 33 11  
FIT 40-80-2 13843 0 0 2242 378 32 11 *
FIT 40-85-2 14331 0 0 2285 382 33 11  
FIT 45-75-1 17835 0 0 2698 403 34 19 *
FIT 45-80-1 19157 0 0 2797 413 36 16  
FIT 45-85-1 20074 0 0 2858 417 36 17 *
FIT 40-75-1 21262 0 0 2942 417 34 35 *
FIT 40-80-1 22578 0 0 3040 427 36 17  
FIT 40-85-1 23492 0 0 3101 431 37 18  
FIT-DNA 40-75-1 14326 0 0 4235 441 37 115 *
FIT-DNA 40-80-1 15086 0 0 4351 447 38 79 *
FIT-DNA 40-85-1 15609 0 0 4426 449 38 75  




Modality, and  
age to start, 











SIG 50-80-10 0 2388 0 3120 358 33 21 *
SIG 45-75-10 0 2691 0 3314 373 33 16 *
SIG 45-85-10 0 2866 0 3384 374 34 18 *
SIG 40-75-10 0 2992 0 3396 378 33 16 *
SIG 50-75-5 0 3181 0 3426 380 34 16 *
SIG 50-80-5 0 3388 0 3503 383 35 17 *
SIG 40-80-10 0 3260 0 3529 384 34 17 *
SIG 45-75-5 0 3865 0 3761 403 35 15  
SIG 45-80-5 0 4070 0 3837 405 36 27 *
SIG 45-85-5 0 4201 0 3871 406 36 33 *
SIG 40-75-5 0 4631 0 4012 413 36 23  
SIG 40-80-5 0 4837 0 4088 416 36 26  
SIG 40-85-5 0 4967 0 4122 417 36 67  
CTC 50-75-10 0 0 2374 1873 300 27 6  
CTC 50-80-10 0 0 2741 2006 315 30 8 *
CTC 45-75-10 0 0 3045 2106 322 29 10 *
CTC 50-75-5 0 0 3850 2430 368 33 8  
CTC 50-80-5 0 0 4137 2507 375 34 11 *
CTC 50-85-5 0 0 4325 2553 377 35 14 *
CTC 45-75-5 0 0 4630 2666 390 34 11  
CTC 45-80-5 0 0 4915 2742 397 35 11  
CTC 45-85-5 0 0 5102 2788 399 35 26 *
CTC 40-75-5 0 0 5458 2856 402 34 23 *
CTC 40-80-5 0 0 5742 2931 409 35 16  
CTC 40-85-5 0 0 5928 2977 411 36 25  
COL - Colonoscopy; FIT - Fecal immunochemical test; HSgFOBT - High-sensitivity guaiac-
based fecal occult blood test; SIG - Flexible sigmoidoscopy; CTC - Computed tomographic 
colonography; LYG - Life-years gained; CRC - Colorectal cancer, ER - Efficiency ratio
a Strategies are ordered by class and by number of colonoscopies.
b Total number of colonoscopies performed per 1000 40-year-olds, including diagnostic 
colonoscopies and potential surveillance colonoscopies after adenoma removal.
c ER=                                                      . It is an incremental burden-to-benefits ratio.
d Strategies within 2% from the efficiency frontier within each class of screening modalities 
(colonoscopy, stool-based, flexible sigmoidoscopy, and CT colonography). All other listed 
strategies are on the efficiency frontier.
incremental colonoscopies w.r.t. previous efficient strategy
incremental LYG w.r.t. previous efficient strategy
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Supplementary Table A2.5: Outcomes per 1000 40-year-olds for screening strategies with 
similar age to start and age to stop screening as the selected benchmark colonoscopy strategy.
Modality, and  
age to start/ 
age to end/ 
interval, years


































































































































Colonoscopy                    
COL 40/75/10e 0 0 0 6083 438 22 37 48 - - Yes
Stool tests      
FIT 40/75/3 9162 0 0 1704 314 11 26 5 Yes No
FIT 40/75/2 12,800 0 0 2139 363 13 30 9 Yes No
HSgFOBT 40/75/3 8410 0 0 2174 317 13 27 Dom. - No
FIT-DNA 40/75/5 5793 0 0 2332 345 14 30 Dom. - No
HSgFOBT 40/75/2 11,348 0 0 2749 366 15 31 Dom. - No
FIT-DNA 40/75/3 7608 0 0 2818 383 15 32 Dom - No
FIT 40/75/1 21,262 0 0 2942 417 16 34 15 Yes Yes Yes
HSgFOBT 40/75/1 17,001 0 0 3714 418 18 35 Dom. - Yes
FIT-DNA 40/75/1 14,326 0 0 4235 441 19 37 56 No Yes
Flexible sigmoidoscopy   
SIG 40/75/10 0 2992 0 3396 378 18 33 9 Yes No
SIG 40/75/5 0 4631 0 4012 413 20 36 17 Yes Yes Yes
CT colonography      
CTC 40/75/10 0 0 3311 2134 322 13 27 6 Yes No
CTC 40/75/5 0 0 5458 2856 402 16 34 9 Yes Yes Yes
COL -Colonoscopy; Dom. - Dominated; FIT - Fecal immunochemical test; HSgFOBT - High-
sensitivity guaiac-based fecal occult blood test; FIT-DNA - Multitarget stool DNA test; SIG - 
Flexible sigmoidoscopy; CTC - Computed tomographic colonography; LYG - Life-years gained; 
CRC - Colorectal cancer; ER - Efficiency ratio
a In the absence of screening, the model predicted 45 CRC Deaths.  
b calculated as                                                      . It is an incremental burden-to-benefits ratio.
c A strategy can only be recommended by the model if it has an efficiency ratio lower than the 
efficiency ratio of the benchmark strategy (colonoscopy every 10 years from ages 40 to 75 years). 
d A strategy is recommended by the model if it is an efficient or a near-efficient strategy 
with a lower burden-to-benefits ratio and at least 90% of the LYG compared to the 
benchmark strategy (colonoscopy screening every 10 years from ages 40 to 75 years). 
e This strategy was selected by the model when an efficiency ratio threshold of 50 incremental 
colonoscopies per LYG was applied.
incremental colonoscopies w.r.t. previous efficient strategy
incremental LYG w.r.t. previous efficient strategy

Chapter 3 
Optimizing colorectal cancer screening by race and 
sex: Microsimulation analysis II to inform the American 
Cancer Society colorectal cancer screening guideline
Reinier G.S. Meester, Elisabeth F.P. Peterse, Amy B. Knudsen, Anne C. de Weerdt, 
Jennifer C. Chen, Anna P. Lietz, Andrea Dwyer, Dennis J. Ahnen, Rebecca L. Siegel, 
Robert A. Smith, Ann G. Zauber & Iris Lansdorp-Vogelaar





Colorectal cancer (CRC) risk varies by race and sex. This study, 1 of 2 microsimulation 
analyses to inform the 2018 American Cancer Society CRC screening guideline, 
explored the influence of race and sex on optimal CRC screening strategies.
Methods
Two Cancer Intervention and Surveillance Modeling Network microsimulation models, 
informed by US incidence data, were used to evaluate a variety of screening methods, ages 
to start and stop, and intervals for 4 demographic subgroups (black and white males and 
females) under 2 scenarios for the projected lifetime CRC risk for 40-year-olds: 1) assuming 
that risk had remained stable since the early screening era and 2) assuming that risk had 
increased proportionally to observed incidence trends under the age of 40 years. Model-
based screening recommendations were based on the predicted level of benefit (life-years 
gained) and burden (required number of colonoscopies), the incremental burden-to-
benefit ratio, and the relative efficiency in comparison with strategies with similar burdens. 
Results
When lifetime CRC risk was assumed to be stable over time, the models differed in 
the recommended age to start screening for whites (45 vs 50 years) but consistently 
recommended screening from the age of 45 years for blacks. When CRC risk was 
assumed to be increased, the models recommended starting at the age of 45 years, 
regardless of race and sex. Strategies recommended under both scenarios included 
colonoscopy every 10 or 15 years, annual fecal immunochemical testing, and computed 
tomographic colonography every 5 years through the age of 75 years.
Conclusions
Microsimulation modeling suggests that CRC screening should be considered from the 
age of 45 years for blacks and for whites if the lifetime risk has increased proportionally 
to the incidence for younger adults. 




Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United 
States.15 Screening can prevent death from CRC and has been promoted by multiple 
organizations since 1980.115,116 Recommendations for screening have evolved over 
the years, with the emergence of new screening technologies, new evidence on the 
performance of various screening methods, and evidence of differential risk across 
population subgroups.
It has been well documented that individuals with African ancestry have higher rates 
of CRC incidence and mortality than individuals of other races or ethnicities in the 
United States and that men are at higher risk than women.15 Similarly, longevity varies 
by race and sex.117 These differences in cause-specific and other-cause mortality could 
influence the optimal start age, duration, and intensity of screening.118 A higher risk of 
CRC may justify a more intensive screening approach, whereas a high risk of other-
cause morbidity and mortality may reduce the benefit from screening at older ages.
There are differences in the current US guidelines for the age to start CRC screening in 
African Americans. Currently, the American College of Gastroenterology and the US 
Multi-Society Task Force recommend that African Americans begin screening at the age 
of 45 years, whereas those of other races should begin at the age of 50 years, regardless 
of sex. 119,120 The US Preventive Services Task Force (USPSTF) updated its screening 
recommendations for the US general population in 2016.76  Although it acknowledged 
that black and Alaska Native individuals have higher CRC incidence and mortality rates 
than the general population and that microsimulation analyses indicated that there may 
be some merit to starting screening at the age of 45 years rather than 50 years even for 
the general population, it concluded that the current evidence best supports a starting 
age of 50 years for all individuals at average risk.
To inform the update of its 2008 CRC screening guideline,101 the American Cancer 
Society requested a decision-analytic modeling analysis to further explore the question 
of optimal CRC screening strategies by race and sex. An accompanying article by 
Peterse et al 99 shows that based on increasing CRC rates in young birth cohorts, 
modeling supports earlier screening for the whole population. However, as explained 
in that article, there is controversy around the mechanism for that increase, with some 
arguing that it is a detection bias attributable to early uptake of screening rather than a 
true increase in risk.111 In this article, we explore the potential benefit and burden from 
earlier screening for black men and women versus whites, and we consider 2 scenarios 
for current background CRC risk: one based on original models informed by data from 
a period before screening was widely adopted that assumed stable risk and another 




Four US demographic subgroups were distinguished: white females, black females, 
white males, and black males. There were insufficient data to include other races or to 
distinguish Hispanic ethnicity. Two independently developed microsimulation models 
for CRC were used to evaluate a large number of possible screening strategies with 
various screening modalities, ages to begin, ages to end, and screening intervals for 
each subgroup. Models were developed within the National Cancer Institute–funded 
Cancer Intervention and Surveillance Modeling Network. Apart from the distinction 
of race- and sex-specific population subgroups and scenarios considered for current 
CRC risk, the analyses were similar to those performed to inform USPSTF guideline 
recommendations (see Supplementary Table A3.1 for a summary of all differences).96,97
Model description
The Microsimulation Screening Analysis–Colon (MISCAN-Colon) and the Simulation 
Model of Colorectal Cancer (SimCRC) have been described extensively in other 
studies 121 and in the Cancer Intervention and Surveillance Modeling Network model 
registry.122 Each model consists of 3 components, which are used to simulate individual 
life histories from birth to death under alternative CRC screening strategies (Model 
Appendix). First, the demography component determines each simulated person’s 
date of birth and death in the absence of CRC. Second, the natural history component 
is used to simulate the potential development of CRC and reductions in the overall 
years of life. The natural history of CRC is assumed to follow the adenoma-carcinoma 
sequence (Supplementary Figure A3.1). Simulated individuals may develop 1 or 
more adenomas. An adenoma may grow in size and develop into CRC, which then 
may transition through stages I to IV without symptoms or be clinically diagnosed at 
any stage. Depending on the varying rates of CRC progression and survival, simulated 
individuals may die of either other causes or clinically diagnosed CRC. The third 
component, the model’s screening component, allows a simulated person’s life trajectory 
to be altered because of the detection of preclinical CRC or the detection and removal 
of an adenoma.
The demography component was informed by all-cause mortality rates from the 2013 
US life tables by race and sex.117 For the natural history component, the age-specific 
adenoma onset was based on the prevalence and multiplicity of adenomas as observed 
in autopsy studies.123-132 Race- and sex-specific CRC incidence by age, stage, and 
localization was calibrated to data from the Surveillance, Epidemiology, and End Results 
Program (SEER) from the period before screening was widely adopted 133: SimCRC was 
calibrated to 1975-1979 data, a period devoid of screening, and MISCAN-Colon was 
calibrated to 1990-1994 data, a period with limited screening but more pronounced 
racial disparities in CRC risk (see Supplementary Figure A3.2 for a comparison of 
incidence by period). Race- and sex-specific CRC survival in both models was based on 
recent SEER data.134 The screening component was informed by data on the sensitivity 
and specificity of the test performed and, for endoscopic tests, the proportion visualizing 
the complete colon or rectum (Table 3.1).
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The models have been validated against the mortality reductions of the UK Flexible 
Sigmoidoscopy Screening (UKFSS) trial of once-only sigmoidoscopy.135 The MISCAN-
Colon model has also been successfully validated to the Norwegian CRC Prevention 
(NORCCAP) Trial136 and Screening for COlon and REctum (SCORE) Trial.61
 
Study population
For each of the 4 population subgroups described previously, the models simulated 
outcomes for 40-year-old individuals without a prior CRC diagnosis.
Scenarios for background risk
Two scenarios were considered for the projected lifetime risk of CRC in 40-year-
olds in the absence of screening. In the first scenario, the conventional scenario in 
microsimulation models for CRC screening, 96,97 age-specific risks of CRC were assumed 
to have remained at the level observed before screening was widely adopted in the 
United States. In the second scenario, age-specific CRC risks for all ages older than 40 
years were assumed to have increased proportionally to observed trends in incidence for 
individuals younger than 40 years old. 16 Hence, the assumed relative increase in lifetime 
risk across models was 1.80 to 1.90 for white females, 1.24 to 1.27 for black females, 2.07 
to 2.13 for white males, and 1.41 to 1.56 for black males. The increase was assumed to 
have arisen from an increased rate of adenoma onset, primarily in the rectum and distal 
colon. More details on the background and methodology for these assumptions are in 
the article by Peterse et al.99
 
Screening strategies
Six screening modalities were evaluated: colonoscopy, fecal immunochemical testing 
(FIT) with a positivity cutoff at hemoglobin levels ≥ 20 μg/g of stool, high-sensitivity 
guaiac-based fecal occult blood testing (HSgFOBT), multitarget stool DNA testing (fecal 
immunochemical testing with a DNA stool test [FIT-DNA]), flexible sigmoidoscopy 
(SIG), and computed tomographic colonography (CTC). For each modality, multiple 
ages to begin and end screening and multiple screening intervals were evaluated for 
a total of 132 unique strategies for each population subgroup or 528 across all race 
and sex combinations (Table 3.2). In all evaluated strategies, individuals in whom 
adenomas were detected and removed received colonoscopy surveillance through the 
age of 85 years. It was assumed that there was 100% adherence to all procedures to avoid 
compensation of lower adherence rates by shorter recommended screening intervals. 
As a result, predicted outcomes from the model reflect the potential lifetime benefits 


















































































Specificity, % 86 c 96.4 92.5 89.8 87 c 88 h
Proportion 
completed, %
95 d 100 100 100 76 d 100
Risk of fatal 
complications, 
%
0.01 e 0 0 0 0 e 0
CTC - computed tomographic colonography; FIT - fecal immunochemical test with a positivity 
cutoff of ≥100 ng of hemoglobin (Hb) per mL of buffer (≥20 μg Hb/g of feces); FIT-DNA - 
multitarget stool DNA test (fecal immunochemical test with a DNA stool test); HSgFOBT - 
high-sensitivity guaiac-based fecal occult blood test; SIG - flexible sigmoidoscopy.
a Ranges evaluated in sensitivity analysis are presented in brackets behind base-case 
characteristics.
b It was assumed that the same test characteristics for screening colonoscopies applied to 
colonoscopies for diagnostic follow-up or for surveillance.
c The lack of specificity with endoscopy reflects the detection of nonadenomatous polyps, 
which, in the case of sigmoidoscopy, may lead to unnecessary diagnostic colonoscopy, and 
in the case of colonoscopy, leads to unnecessary polypectomy, which is associated with an 
increased risk of colonoscopy complications.
d With colonoscopy 95% reached the end of the colorectum (cecum); for the remainder 5% 
the endpoint was distributed between the cecum and rectum. With SIG 76% reached the end 
the sigmoid colon; 14% had an endpoint between the beginning and the end of the sigmoid 
colon; 12% had an endpoint between the beginning and end of the descending colon. 
e Case fatality was derived by combining the overall perforation rate from Warren and colleagues 
with mortality given perforation (0.0519) in Gatto and colleagues.104,105 Sigmoidoscopy was 
modeled without biopsy or polypectomy of detected lesions, and was therefore assumed to 
have 0 mortality risk. 
f For individuals with 1–5 mm adenomas, it was assumed that the sensitivity is equal to the 
positivity rate in individuals without adenomas. The sensitivity for individuals with 6–9 mm 
adenomas was such that the weighted average sensitivity for individuals with 1–9 mm
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adenomas equals that for nonadvanced adenomas. 
g Sensitivity for individuals with advanced adenomas (ie, adenomas ≥10 mm or adenomas 
with advanced histology). Sensitivity was not reported for the subset of individuals with ≥10 
mm adenomas.
h It was assumed that 1–5 mm adenomas do not bleed and therefore cannot cause a positive 
stool test. It was also assumed that HSgFOBT can be positive because of bleeding from other 
causes, the probability of which is equal to positivity rate in individuals without adenomas. 
i The lack of specificity with CTC reflects the detection of ≥6-mm nonadenomatous lesions, 
artifacts, stool, and adenomas smaller than the 6-mm threshold for referral to colonoscopy 
that are measured as ≥6 mm.
Table 3.2: Screening strategies evaluated by the model for each race and sex subgroup a
Screening modality Age to begin 
screening, y







No screening 45,50,55 75,80,85   1
Stool-based screening
FIT 45,50,55 75,80,85 1,2,3 27 (27)
HSgFOBT 45,50,55 75,80,85 1,2,3 27 (27)
FIT-DNA 45,50,55 75,80,85 1,3,5 27 (27)
SIG screening 45,50,55 75,80,85 5,10 18 (15)
CTC screening 45,50,55 75,80,85 5,10 18 (15)
Colonoscopy screening 45,50,55 75,80,85 5,10,15 27 (20)
Total number of (unique) 
screening strategies 
evaluated in the model
      145 (132)
CTC - computed tomographic colonography; FIT - fecal immunochemical test; FIT-DNA - 
multitarget stool DNA test; HSgFOBT - high-sensitivity guaiac-based fecal occult blood test; 
SIG - flexible sigmoidoscopy.
a Strategies were similar to those evaluated in an analysis for the US Preventive Services 
Task Force.96  Combinations of SIG with stool-based screening were not considered here. 
b  The number of unique strategies excludes the strategies that result in the same screening 
regimen (eg, COL every 10 years from ages 50-80 years and from ages 50-85 years both include 
colonoscopies at age 50, 60, 70, and 80 years, and thus are not unique strategies).
Main outcomes
The benefit or effectiveness of screening was measured by the number of life-years 
gained (LYG) from the screening strategy; this accounted for life-years lost because of 
fatal screening complications. The primary fatal complication is perforation of the colon, 
which occurs at a rate less than 1 per 1000 colonoscopies; approximately 5% of these 
cases result in death.137,138 The number of required colonoscopies was used as a measure 
of the aggregate burden of screening, and it included colonoscopies for screening, 
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follow-up, surveillance, and the diagnosis of symptomatic cancer. We controlled for the 
burden of tests other than colonoscopy by grouping and comparing tests with similar 
noncolonoscopy burdens. This resulted in 4 classes of screening modalities: colonoscopy, 
stool-based modalities, SIG, and CTC.
Efficient and near‐efficient screening strategies
Efficient strategies were identified via the plotting of LYG with respect to the number of 
required colonoscopies. A strategy was considered efficient when it provided the largest 
incremental increase in LYG per additional colonoscopy performed in comparison 
with the next less colonoscopy-intensive screening strategy within the same class of 
screening modalities. The line connecting all efficient strategies is the efficient frontier. 
Near-efficient strategies were defined as strategies just below the efficient frontier that 
provided at least 98% of the maximum incremental benefit per additional colonoscopy 
performed in comparison with the next less effective strategy on the efficient frontier. 
For efficient and near-efficient screening strategies, the incremental number of 
colonoscopies (ΔCOL), the incremental number of life-years gained (ΔLYG), and the 
burden-to-benefit ratio (or efficiency ratio [ER]: ΔCOL/ΔLYG) in comparison with the 
next less effective strategy on the efficient frontier were calculated.
Model recommendations
Model-recommendable strategies fulfilled 3 main criteria: efficiency within their class of 
screening modality, comparable overall benefit as measured by LYG, and an acceptable 
balance of burden and benefit (see Figure 3.1).96 First, an optimal colonoscopy screening 
strategy was selected. This was an efficient or near-efficient colonoscopy screening 
strategy required to provide at least as many LYG as the current general population 
recommendation of screening colonoscopy (every 10 years between 50 and 75 years) and 
to have a burden-to-benefit ratio of no more than 50 additional colonoscopies per LYG. 
This threshold was similar to the accepted balance in USPSTF model recommendations 
across models 96 and was judged to be an acceptable balance for this analysis by the 
American Cancer Society. The most effective colonoscopy strategy (defined by most 
LYG) meeting these requirements was recommended. Second, for each alternative class 
of screening modalities, all strategies with the same ages to begin and end screening 
as the optimal colonoscopy strategy (benchmark strategy) were identified, and within-
class efficiency was re-assessed. Model-recommendable strategies were efficient or 
near-efficient strategies with at least 90% of the LYG of the benchmark colonoscopy 
strategy and with a burden-to-benefit ratio lower than the benchmark. Again, the most 
effective strategies within each class meeting the requirements were considered model-
recommendable. It was possible to have no recommendable strategy within a class of 
screening modalities.
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Figure 3.1: Illustration of the selection algorithm for model-recommendable strategies.Each 
dot represents the hypothetical outcomes for a single screening strategy. The bold line is the 
efficient frontier connecting efficient strategies (not plotted as separate dots). Dashed lines 
represent thresholds imposed by the decision algorithm: the efficiency criterion ensures that 
recommended strategies are efficient in terms of the yield in LYG for any level of colonoscopy 
requirement; the benefit criterion ensures that LYG do not lag far behind a selected reference 
strategy; the burden-to-benefit criterion ensures that the incremental number of required 
colonoscopies per LYG does not exceed a predefined number. The shaded area encompasses 
strategies fulfilling all three decision criteria. The model-recommended strategy is the strategy 
within this area with the highest predicted LYG. 
Sensitivity analysis
In sensitivity analyses, 3 alternative scenarios were evaluated. First, we evaluated best-
case and worst-case scenarios for the sensitivity of each evaluated screening modality, 
including potential follow-up or surveillance colonoscopy, to reflect uncertainty in the 
estimates of the diagnostic performance of each modality (Table 3.1). Second, we 
varied the minimum acceptance threshold for LYG to 75% instead of 90% for alternative 
screening strategies in comparison with colonoscopy screening. Third, we lowered the 
acceptance threshold for burden to benefit from 50 additional colonoscopies per LYG to 
40. For each alternative scenario, model recommendations were re-assessed.
Results
In the absence of screening, the model-predicted life expectancy and CRC risk among 
40-year-olds varied by race and sex. Life expectancy from the age of 40 years ranged from 
35.3 to 42.3 years in the scenario of stable CRC risk and was lowest for black males and 
highest for white females (Supplementary Table A3.2). In the conservative scenario 
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of stable background CRC risk, the predicted lifetime CRC risk ranged from 59.3 to 70.7 
per 1000 adults across population subgroups in MISCAN-Colon and from 58.7 to 78.6 
per 1000 adults in SimCRC. In the scenario of increased CRC risk, predicted lifetime 
risk across population subgroups increased to 76.7 to 149.0 in MISCAN-Colon and to 
79.9 to 162.5 in SimCRC. The predicted risk was highest for white males, but the rank 
order for other demographic subgroups differed across models and scenarios and in 
comparison with life-years lost to CRC; this reflected differences in incidence by age in 
the data used to inform each model (Supplementary Figure A3.2).
Screening benefit and burden
Screening was predicted to result in clinically significant LYG in comparison with 
no screening by both models, regardless of the population subgroup and scenario 
for CRC risk. In the scenario of stable age-specific CRC risk, predicted LYG across 
models, strategies, and population subgroups ranged from 117 to 348 per 1000 adults 
(Supplementary Tables A3.3-A3.6). The burden of screening, as measured by 
the lifetime number of required colonoscopies, varied from fewer than 800 per 1000 
adults for triennial FIT during the ages of 55 to 75 years to almost 8000 per 1000 
adults for colonoscopy every 5 years during the ages of 45 to 85 years. The predicted 
benefit of screening varied across population subgroups and was higher in SimCRC 
than MISCAN-Colon. In MISCAN-Colon, black females had the highest benefit from 
any of the screening strategies (range, 159-306 LYG per 1000 adults), white females 
had the lowest benefit (117-223 LYG), and white males and black males had similar 
intermediate benefits (141-258 and 149-284 LYG, respectively). In SimCRC, in contrast, 
black females and white males had the highest benefit from screening (175-348 and 194-
334 LYG per 1000 40-year-olds, respectively), white females had somewhat fewer LYG 
(168-307 LYG), and black males had the lowest benefit from screening (142-272 LYG). 
In general, the lifetime number of colonoscopies required for screening was somewhat 
lower for black males and females because of their lower life expectancy in comparison 
with their white counterparts.
In the scenario with increased age-specific CRC risk, the predicted benefit from 
screening was substantially higher than that in the scenario of stable risk, with LYG 
ranging from 203 to 556 per 1000 adults in MISCAN-Colon and from 211 to 673 per 
1000 adults in SimCRC; the maximum benefit from screening thus exceeded 0.5 LYG 
per individual in both models (Supplementary Tables A3.3-A3.6). The required 
number of colonoscopies was only moderately higher for most colonoscopy-based 
strategies in comparison with the scenario of stable risk and ranged from 684 to 8024 
per 1000 adults across models, strategies, and population subgroups.
Efficient and near‐efficient strategies
The set of strategies constituting the efficient frontier was similar across demographic 
subgroups and scenarios for CRC risk but differed between models (Figure 3.2, 
Supplementary Figure A3.3 and Supplementary Tables A3.3-A3.6). In general, 
the predicted LYG range across evaluated strategies was smaller in MISCAN-Colon 
than SimCRC, and this resulted in a wider set of strategies considered near-efficient. 
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The incremental burden-to-benefit ratio across models and population subgroups 
ranged from 6.0 to 2032.9 from the least to most resource-intensive colonoscopy-
based screening strategy in the scenario of stable CRC risk. The biggest increase in 
LYG per additional screening colonoscopy was derived from lowering the starting age 
for screening, with lower resulting ERs for blacks versus whites in MISCAN-Colon. 
The previously recommended strategy of colonoscopy every 10 years between the 
ages of 50 and 75 years was among the efficient strategies for all population subgroups 
in MISCAN-Colon (range of ERs, 37.7-43.2) but was less efficient in SimCRC than 
colonoscopy every 15 years between the ages of 45 and 75 years (range of ERs, 24.4-
31.6). For strategies other than colonoscopy-based screening, the range of ERs across 
models, strategies, and population subgroups was smaller (2.0-149.8). Among the stool-
based testing strategies, FIT screening was more efficient than most HSgFOBT and FIT-
DNA strategies, regardless of race and sex.
Compared with the scenario of stable CRC risk, the scenario of increased CRC risk was 
predicted to result in lower ERs because of increased LYG from screening; a smaller 
total ER range across models, evaluated strategies, and population subgroups (0.1-
992.8); and a further expanded set of near-efficient strategies in MISCAN-Colon.
Model‐recommendable strategies
In the scenario of stable age-specific CRC risk, the 2 models differed in their recommended 
ages to start screening and their recommended colonoscopy screening intervals. Among 
all colonoscopy strategies deemed efficient or near-efficient in MISCAN-Colon, the 
optimal (most effective) strategy meeting both the imposed benefit and incremental 
burden-to-benefit criteria (ie, providing sufficient LYG and having an ER < 50) was 
colonoscopy every 10 years from the ages of 50 to 75 years for white males and females 
and colonoscopy every 10 years from the ages of 45 to 75 years for black males and 
females (Table 3.3 and Supplementary Table A3.7). In SimCRC, colonoscopy 
screening every 15 years from the ages of 45 to 75 years was model-recommendable, 
regardless of race or sex. Among other screening strategies with the same start and stop 
ages, recommended strategies by both models included FIT every year and CTC every 
5 years. From the stool-based screening modalities, HSgFOBT and FIT-DNA were not 
model-recommendable because of their inefficiency from higher false-positive rates 
and, in the case of FIT-DNA, also because of an unfavorable balance of burden and 
benefit (a minimum of 63.3 additional colonoscopies per LYG for annual FIT-DNA vs 
annual FIT). SIG was not model-recommendable because of a failure to provide at least 
90% of the benefit of colonoscopy screening.
With assumed increased age-specific CRC risk, both models recommended screening 
between the ages of 45 and 75 years for all 4 demographic subgroups, with colonoscopy 
recommended every 10 years, FIT annually, SIG every 5 years, and CTC every 5 years, 
except for white males, for whom MISCAN-Colon recommended only colonoscopy 
every 5 years. SIG every 5 years was added to the list of model-recommendable strategies 
for other population subgroups because of its higher comparative effectiveness with 
more assumed distal tumors.
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Figure 3.2: Lifetime number of colonoscopies and LYG for colonoscopy screening strategies 
under 2 scenarios for CRC risk by model and demographic subgroup. Colors reflect the 
screening interval (blue, 15 years; pink, 10 years; green, 5 years), symbols reflect the starting 
age (diamonds, 55 years; circles, 50 years; squares, 45 years), and the filling of the symbols 
reflects the end age (empty, 75 years; crossed, 80 years; and full, 85 years). Efficient and near-
efficient strategies are labeled, with efficiency assessed among all evaluated colonoscopy-
based screening strategies. In the stable-risk scenario, the risk within each age-, race-, and 
sex-specific demographic subgroup was assumed to have remained stable over time since 
the early screening phase in the United States (1975-1979 for SimCRC and 1990-1994 for 
MISCAN). In the increased-risk scenario, the CRC risk was increased proportionally to observed 
trends in CRC incidence among adults younger than 40 years. Estimated incidence rate ratios 
were 1.80 to 1.90 for white females (range across models), 1.24 to 1.27 for black females, 2.07 
to 2.13 for white males, and 1.41 to 1.56 for black males. 
CRC - colorectal cancer; LYG - life-years gained; MISCAN - Microsimulation Screening Analysis; 
SimCRC - Simulation Model of Colorectal Cancer.
Sensitivity analysis
Model recommendations were influenced by alternative assumptions for test 
performance, the minimum acceptable percentage of LYG for alternative strategies in 
comparison with colonoscopy screening, and a more stringent acceptance threshold for 
the burden-to-benefit ratio (Supplementary Tables A3.8-A3.11). Most notably, under 
worst-case performance assumptions, MISCAN-Colon no longer recommended CTC or 
SIG screening (Supplementary Table A3.9); with a 75% acceptance threshold for LYG 
rather than 90% in comparison with colonoscopy screening, both MISCAN-Colon and 
SimCRC included SIG in the set of model-recommendable strategies, regardless of the 
scenario for background risk (Supplementary Table A3.10); and with a burden-to-
benefit threshold of a maximum of 40 additional colonoscopies per LYG rather than 50, 
MISCAN-Colon no longer recommended earlier screening for blacks in the stable CRC 
risk scenario (Supplementary Table A3.11).
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Table 3.3: Model-recommendable strategies for two scenarios of CRC risk a










Scenario 1: Stable CRC risk b
MISCAN COL  50-75-10 45-75-10 50-75-10 45-75-10
Stool FIT 50-75-1 FIT 45-75-1 FIT 50-75-1 FIT 45-75-1
SIG - - - -
CTC 50-75-5 45-75-5  50-75-5  45-75-5
SimCRC COL 45-75-15 45-75-15 45-75-15 45-75-15
Stool FIT 45-75-1 FIT 45-75-1 FIT 45-75-1 FIT 45-75-1
SIG - - - -
  CTC 45-75-5 45-75-5 45-75-5 45-75-5
Scenario 2: Increased CRC risk c
MISCAN COL  45-75-10 45-75-10 45-75-5 45-75-10
Stool FIT 45-75-1 FIT 45-75-1 - FIT 45-75-1
SIG 45-75-5 45-75-5 - 45-75-5
CTC  45-75-5 45-75-5 - 45-75-5
SimCRC COL 45-75-10 45-75-10 45-75-10 45-75-10
Stool FIT 45-75-1 FIT 45-75-1 FIT 45-75-1 FIT 45-75-1
SIG 45‐75-5 45‐75-5 45‐75-5 45‐75-5
  CTC 45-75-5 45-75-5 45-75-5 45-75-5
- = no model-recommendable strategy within this class; COL - colonoscopy; CTC - computed 
tomographic colonography; FIT - fecal immunochemical test; SIG - sigmoidoscopy.
a Numbers in each field of the table successively represent recommended age to start 
screening, age to stop, and interval, all in years. For the class of stool-based screening 
modalities, the model-recommendable modality is also included, i.e. FIT. 
b Risk within each age-, race-, and sex-specific demographic subgroup was assumed to have 
remained stable over time since the early screening period in the U.S. 
c CRC risk was increased proportional to observed trends in CRC incidence among adults 
under 40 years old. Estimated incidence rate ratios were 1.77-1.90 for white females (range 
across models), 1.27-1.30 for black females, 2.01-2.13 for white males, and 1.41-1.55 for black 
males.
Discussion
The results from this modeling study suggest that CRC screening should be considered 
from the age of 45 years in average-risk black Americans. The recommended age to begin 
screening among whites varied across models, with one model suggesting that screening 
should begin at the age of 50 years in a scenario of stable age-specific CRC risk and with the 
other suggesting that screening should begin at the age of 45 years. If lifetime risk increases 
proportionally to trends observed at younger ages, both models support recommending 
screening from the age of 45 years for all population subgroups. Within blacks and whites, 
recommendable strategies generally did not differ for men and women. Although men 
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are at higher risk for CRC than women, the higher potential benefit from screening is 
partly offset by their lower life expectancy. Model-recommendable strategies generally 
included colonoscopy screening every 10 or 15 years, FIT screening every year, and CTC 
every 5 years through the age of 75 years. SIG was not consistently model-recommendable 
because of its inability to meet the minimum benefit criterion, and HSgFOBT and FIT-
DNA were not recommendable because of inefficiency.
Model-based recommendations were dependent on assumptions for CRC risk. The models 
used in this study were calibrated to data from a period in which guideline-adherent 
screening was uncommon to avoid serious contamination from either prevention of 
disease or an earlier diagnosis. By making this assumption, the models implicitly assumed 
that the current underlying age-specific risk of CRC in the absence of screening would 
be the same as that observed in the prescreening era. However, SEER data indicate that 
incidence has risen for every subsequent generation born since the 1950s,16 and this 
suggests that the projected underlying lifetime risk for current 40- to 50-year-olds may be 
elevated in comparison with earlier birth cohorts. To reflect this uncertainty, we considered 
2 scenarios for lifetime CRC risk: one in which age-, race-, and sex-specific risks were 
assumed to remain stable over time and another in which risks increased proportionally 
to trends observed in young-onset cases. As we showed, screening should be considered 
as early as the age of 45 years in both white and black men and women if the lifetime risk 
is increasing. This stems from converging risks in white and black adults younger than 
40 years 139,140 and is consistent with the recommendation in an accompanying article by 
Peterse et al.99 The article by Peterse et al. discusses the potential increase in disease risk in 
more detail, including possible causal mechanisms other than increased adenoma onset.
There were some discrepancies in screening recommendations across the 2 models. 
Under the first scenario of no increase in age-, race-, and sex-specific CRC risk over time, 
MISCAN-Colon recommended screening for black adults from the age of 45 years and 
for white adults from the age of 50 years, both at 10-year intervals for colonoscopy. In 
contrast, SimCRC recommended both white and black adults begin screening at the age 
of 45 years with longer recommended colonoscopy intervals of 15 years. These differences 
reflect the differences in the dwell time of adenomas (ie, the time from adenoma onset 
to symptom-detected cancer in the absence of screening among individuals with a 
CRC diagnosis)40 and were observed in previous analyses for the USPSTF.96 SimCRC 
has longer adenoma dwell times, and this suggests that screening can be deferred 
longer after a negative previous screening result. In addition, models were calibrated 
to different time periods from the early-screening era (1975-1979 for SimCRC and 
1990-1994 for MISCAN-Colon). Although there may have been some screening during 
the more recent period used to inform MISCAN-Colon, this was to a large extent low-
sensitivity guaiac-based fecal occult blood testing with limited presumed influence on 
CRC incidence.141 CRC incidence was similar in blacks and whites until the mid-1980s, 
but it has since been higher among blacks than whites for screening-eligible ages140; 
this may partly explain why MISCAN-Colon recommended differential screening by 
race. Although colonoscopy every 15 years between the ages of 45 and 75 years was 
not considered efficient in MISCAN-Colon for white adults in the stable-risk scenario, 
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the colonoscopy requirement and the predicted number of LYG were close to those for 
colonoscopy every 10 years from the age of 50 to 75 years. This suggests that the former 
strategy might be considered an option if uniformity in starting ages across demographic 
population subgroups were desired. To date, younger recommended start ages for 
screening black individuals by some organizations 119,120 have not led to higher screening 
rates among blacks in comparison with whites aged 45 to 49 years according to National 
Health Interview Survey data.142 Conversely, there is no evidence that race-specific 
recommendations negatively affect screening uptake among whites aged 50 to 54 years.
The cancer registry data used to inform the models in this study did not allow the 
simulation of races/ethnicities other than black and white. Although recommendations 
depend on patterns in risk across a person’s lifetime and on other-cause mortality, we 
expect that model recommendations for other races/ethnicities except Alaskan Natives 
would be closer to those for whites than those for blacks because of the relatively similar 
observed CRC mortality risks.15
To our knowledge, this is the first time that race and sex differences have been 
formally considered for model-based screening recommendations. The approach and 
conclusions from the first stable age-specific risk scenario in this study were similar to 
a study performed by Lansdorp-Vogelaar et al.143 Our model-recommended strategies 
differ from the 2016 USPSTF screening recommendations, which suggested offering 
screening from the ages of 50 to 75 years to all adults at average risk.76 Consistent with 
2009 American College of Gastroenterology 119 and 2017 US Multi-Society Task Force 
guidelines,120 our models recommend 45 years as the preferred starting age for blacks. 
Previous modeling studies have suggested that personalizing the age to stop screening 
may result in more efficient use of resources and help to reduce potential harms from 
screening.144 However, tailoring screening recommendations to different subgroups may 
complicate the promotion of screening in the primary care setting, and this may hamper 
guideline-consistent adherence. More research is needed to assess the performance of 
personalized screening programs before wide application in practice.
There are some general limitations to the approach of this study for selecting model-
recommendable screening strategies. First, we predicted the potential benefit of screening 
under the assumption of 100% adherence to provide the best possible recommendation 
for patients who adhere to screening. In practice, some forms of screening may be less 
acceptable to people than others,145 and preferences may vary by setting, race, and sex 
and over time.146-148 These preferences are an important determinant of the success of 
any screening approach and should be considered in practice. A test that is predicted 
to have higher performance in the model in comparison with other tests under the 
assumption of full adherence may have lower population-based performance because 
of lower acceptance. Second, to measure the burden of screening, we used the required 
number of colonoscopies. This ruled out a direct comparison of all strategies because 
the burden from tests other than colonoscopy was not explicitly considered. In practice, 
the potential burden from the primary screening method, such as low-dose radiation 
exposure in CTC, should also be considered when one is recommending any of the 
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evaluated strategies. Finally, there are no objective or widely accepted standards 
for the decision criteria applied in this study to narrow down the set of potentially 
recommendable screening strategies. We used similar acceptance thresholds for the 
degree of efficiency (proximity to the efficient frontier), minimum number of LYG, 
and maximum number of colonoscopies per LYG as applied in analyses performed for 
the USPSTF.96 As we showed in sensitivity analyses, sigmoidoscopy may be added to 
recommended screening modalities with a more relaxed benefit criterion of at least 75% 
of LYG in comparison with colonoscopy-based screening. Earlier ages to start screening 
may not be acceptable with more stringent burden-to-benefit thresholds.
In conclusion, using an established decision-analytic modeling approach, we suggest 
that screening for CRC should be considered between the ages 45 and 75 years for 
black adults in the United States and also for whites, particularly if lifetime risks have 
increased similarly to trends observed under the age of 40 years. Colonoscopy every 10 
to 15 years, FIT every year, and CTC every 5 years were predicted to generate similar 
overall LYG with an acceptable colonoscopy burden. Our findings differ from previous 
model recommendations for the USPSTF, in which no distinction was made between 
blacks and whites, but are consistent with recent recommendations by the US Multi-
Society Task Force.120 In recommending any particular screening strategy, policymakers 
and physicians should consider patient preferences.




















detection and removal of 
adenoma through screening
early detection
of cancer through screening
Supplementary Figure A3.1: Natural history of CRC and the effects of screening as simulated 
by MISCAN-Colon and SimCRC. The opportunity to intervene in the natural history through 
screening is noted in italic. Screening can either remove an adenoma, thus moving a person 
to the “no lesion” state, or diagnose a preclinical cancer, which, if detected at an earlier stage, 


























































































Supplementary Figure A3.2: CRC incidence by age, race and sex in the surveillance 
epidemiology end results program (SEER) for the period 1975-1979 vs 1990-1994.
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Supplementary Figure A3.3: Lifetime number of colonoscopies and LYG for stool-based (A), 
sigmoidoscopy (B) and CTC (C) screening strategies under a scenario of stable CRC risk, by 
model and demographic subgroup a 
A: Colors reflect the screening test (pink=FIT; purple=HSgFOBT; turquoise=FIT-DNA), symbols 
reflect the starting age (diamond=55; circle=50; square=45 years), fill reflects end age 
(empty=75; cross=80; full=85 years). Efficient and near-efficient* strategies are labelled, with 
efficiency assessed among all evaluated stool-based screening strategies.
B: Colors reflect the screening interval (pink=10; green=5 years), symbols reflect the starting 
age (diamond=55; circle=50; square=45 years), fill reflects end age (empty=75; cross=80; 
full=85 years). Efficient and near-efficient* strategies are labelled, with efficiency assessed 
among all evaluated SIG-based screening strategies.
C: Colors reflect the screening interval (pink=10; green=5 years), symbols reflect the starting 
age (diamond=55; circle=50; square=45 years), fill reflects end age (empty=75; cross=80; 
full=85 years). Efficient and near-efficient* strategies are labelled, with efficiency assessed 
among all evaluated CTC-based screening strategies.
a Risk within each age-, race-, and sex-specific demographic subgroup was assumed to have 
remained stable over time since the early screening phase in the U.S. (1975-1979 for SimCRC; 




Supplementary Table A3.1: Summary of differences of this analysis compared with a 
previous analysis for the US preventive services task force. 
ACS analysis USPSTF analysis
Desion models MISCAN-Colon and SimCRC MISCAN-Colon, SimCRC, and 
CRC-Spin
Simulated population Race- and sex-specific 
40-year-old adults at average 
risk of CRC
All 40-year-old adults at 
average risk of CRC
Data source, life expectancy 2013 U.S. lifetables 2009 U.S. lifetables




Evaluated scenarios Stable and increased age-
specific risk based on trends 
in incidence under age 40, 
including a shift to more distal 
localization
Stable age-specific risk
Evaluated strategies Single-test strategies only Single- and hybrid test 
strategies




Reassessed for classes of 
screening modality other than 
colonoscopy after selecting 
age to start and stop
Assessed among start ages 
50 and 55 and stop ages 75, 
80, and 85 for all screening 
modalities






screening strategies, an 
acceptance threshold for 
the incremental number of 
colonoscopies per LYG of 
maximum 50 was applied 
For colonoscopy-based 
screening strategies, an 
acceptance threshold of 
less than or equal to the 
incremental number of 
colonoscopies per LYG for 
the strategy recommended 
by the USPSTF in 2008, 
namely colonoscopy every 
10 years from ages 50 to 75, 
was applied; this number 
ranged  from 39-65 across 
the three models included in 
that study
ACS - American Cancer Society; LYG - life-year gained; SEER - Surveillance Epidemiology and 
End Results Program; USPSTF - US Preventive Services Task Force.
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Supplementary Table A3.2: Simulated life expectancy and lifetime CRC risk in the absence of 









 Scenario 1: Stable CRC risk a
MISCAN-Colon        
Life expectancy, years 42.3 40.0 38.5 35.3
Lifetime CRC incidence b 59.3 59.9 70.7 62.0
Lifetime CRC mortality b 21.9 28.4 27.2 29.6
LY lost to CRC b 278 387 322 365
SimCRC
Life expectancy, years 42.3 40.0 38.4 35.3
Lifetime CRC incidence b 66.5 64.4 78.6 58.7
Lifetime CRC mortality b 25.7 30.0 31.0 27.0
LY lost to CRC b 335 387 366 307
Scenario 2: Increased CRC risk c
MISCAN-Colon        
Life expectancy, years 42.1 39.9 38.1 35.1
Lifetime CRC incidence b 112.6 76.7 149.0 88.0
Lifetime CRC mortality b 42.9 36.8 59.0 42.5
LY lost to CRC b 539 497 696 518
SimCRC
Life expectancy, years 42.1 39.9 38.1 35.1
Lifetime CRC incidence b 119.5 79.9 162.5 91.7
Lifetime CRC mortality b 45.4 37.6 64.6 43.2
LY lost to CRC b 541 490 739 510
LY - life-years. 
a Risk within each age-, race-, and sex-specific demographic subgroup was assumed to have 
remained stable over time since the early screening period in the U.S. (1975-1979 for SimCRC; 
1990-1994 for MISCAN). 
b   CRC outcomes, per 1000 40-year-olds.
c CRC risk was increased proportional to observed trends in CRC incidence among adults 
under 40 years old. Estimated incidence rate ratios were 1.80-1.90 for white females (range 




Supplementary Table A3.3: Lifetime number of colonoscopies and LYG for all evaluated 
screening strategies under two scenarios for CRC risk, by model, in white females a


































































































































MISCAN - Scenario 1: Stable CRC risk
WF No screening 0 0 0 59 0 0 0 - -
WF COL 55-75, 15 0 0 0 3028 166 33 15 0% 17.9
WF COL 55-80, 15 0 0 0 3028 166 33 15 0% 17.9
WF COL 55-85, 15 0 0 0 3397 168 33 16 -4.7% Dom.
WF COL 50-75, 15 0 0 0 3223 172 32 15 0% 30.8
WF COL 50-80, 15 0 0 0 3758 180 34 16 -2.9% Dom.
WF COL 50-85, 15 0 0 0 3758 180 34 16 -2.9% Dom.
WF COL 45-75, 15 0 0 0 4045 187 35 16 -2.5% Dom.
WF COL 45-80, 15 0 0 0 4045 187 35 16 -2.5% Dom.
WF COL 45-85, 15 0 0 0 4045 187 35 16 -2.5% Dom.
WF COL 55-75, 10 0 0 0 3743 178 36 17 -3.3% Dom.
WF COL 55-80, 10 0 0 0 3743 178 36 17 -3.3% Dom.
WF COL 55-85, 10 0 0 0 4081 180 36 17 -6.6% Dom.
WF COL 50-75, 10 0 0 0 4067 192 36 17 0% 43.2
WF COL 50-80, 10 0 0 0 4551 196 38 18 -1.2% 116.5*
WF COL 50-85, 10 0 0 0 4551 196 38 18 -1.2% 116.5*
WF COL 45-75, 10 0 0 0 4927 204 38 18 0% 74.4
WF COL 45-80, 10 0 0 0 4927 204 38 18 0% 74.4
WF COL 45-85, 10 0 0 0 5265 205 38 18 -0.7% 297.2*
WF COL 55-75, 5 0 0 0 5142 190 39 18 -7.2% Dom.
WF COL 55-80, 5 0 0 0 5578 192 39 18 -7.8% Dom.
WF COL 55-85, 5 0 0 0 5880 193 40 18 -8.7% Dom.
WF COL 50-75, 5 0 0 0 6175 209 40 18 -1.9% 231.7*
WF COL 50-80, 5 0 0 0 6611 211 41 19 -2.6% Dom.
WF COL 50-85, 5 0 0 0 6913 211 41 19 -3.4% Dom.
WF COL 45-75, 5 0 0 0 7219 221 41 19 0% 131.9
WF COL 45-80, 5 0 0 0 7655 223 42 19 0% 237.0
WF COL 45-85, 5 0 0 0 7957 223 42 19 0% 908.9
WF FIT 55-75, 3 5566 0 0 737 118 13 10 0% 5.8
WF FIT 55-80, 3 6683 0 0 826 130 15 12 0% 7.5
WF FIT 55-85, 3 7494 0 0 884 134 15 13 -1.3% Dom.
WF FIT 50-75, 3 7173 0 0 880 134 15 11 -1.0% 12.5*
WF FIT 50-80, 3 8236 0 0 962 144 16 13 0% 9.5
WF FIT 50-85, 3 8654 0 0 991 146 16 13 -0.1% 13.1*
WF FIT 45-75, 3 8806 0 0 1004 145 16 12 -1.3% Dom.
WF FIT 45-80, 3 9347 0 0 1044 151 17 13 -0.1% 12.4*
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MISCAN - Scenario 1: Stable CRC risk
WF FIT 45-85, 3 10206 0 0 1105 156 17 14 0% 12.0
WF FIT 55-75, 2 8188 0 0 971 140 18 12 -3.1% Dom.
WF FIT 55-80, 2 9206 0 0 1041 147 19 14 -2.1% Dom.
WF FIT 55-85, 2 10371 0 0 1115 152 19 14 -3.0% Dom.
WF FIT 50-75, 2 9907 0 0 1115 154 19 13 -1.7% Dom.
WF FIT 50-80, 2 11420 0 0 1216 164 21 14 0% 13.5
WF FIT 50-85, 2 12193 0 0 1265 167 21 15 -0.1% 16.7*
WF FIT 45-75, 2 12244 0 0 1277 165 20 14 -1.5% Dom.
WF FIT 45-80, 2 13249 0 0 1344 172 21 15 0% 16.1
WF FIT 45-85, 2 14402 0 0 1415 176 22 16 0% 16.3
WF FIT 55-75, 1 13579 0 0 1379 162 24 14 -6.8% Dom.
WF FIT 55-80, 1 15655 0 0 1496 170 26 16 -5.4% Dom.
WF FIT 55-85, 1 17232 0 0 1580 173 27 16 -5.5% Dom.
WF FIT 50-75, 1 16959 0 0 1620 179 26 15 -2.8% Dom.
WF FIT 50-80, 1 19018 0 0 1734 187 28 16 -1.2% 30.8*
WF FIT 50-85, 1 20587 0 0 1816 190 28 17 -1.4% 30.3*
WF FIT 45-75, 1 20462 0 0 1834 190 27 16 -1.5% 30.5*
WF FIT 45-80, 1 22513 0 0 1947 197 29 17 0% 25.1
WF FIT 45-85, 1 24077 0 0 2028 200 29 17 0% 28.6
WF FIT-DNA 55-75, 5 3821 0 0 1109 134 18 12 -14.3% Dom.
WF FIT-DNA 55-80, 5 4304 0 0 1191 140 19 13 -13.9% Dom.
WF FIT-DNA 55-85, 5 4652 0 0 1247 142 19 14 -14.6% Dom.
WF FIT-DNA 50-75, 5 4652 0 0 1286 147 20 13 -12.5% Dom.
WF FIT-DNA 50-80, 5 5131 0 0 1367 153 20 14 -11.7% Dom.
WF FIT-DNA 50-85, 5 5477 0 0 1421 155 20 14 -12.2% Dom.
WF FIT-DNA 45-75, 5 5508 0 0 1441 157 21 13 -11.5% Dom.
WF FIT-DNA 45-80, 5 5985 0 0 1520 162 21 14 -10.0% Dom.
WF FIT-DNA 45-85, 5 6330 0 0 1574 164 21 15 -10.0% Dom.
WF FIT-DNA 55-75, 3 4807 0 0 1322 148 22 13 -13.4% Dom.
WF FIT-DNA 55-80, 3 5701 0 0 1466 157 24 15 -11.7% Dom.
WF FIT-DNA 55-85, 3 6344 0 0 1561 161 24 15 -11.8% Dom.
WF FIT-DNA 50-75, 3 6138 0 0 1581 165 24 14 -9.8% Dom.
WF FIT-DNA 50-80, 3 6984 0 0 1714 173 26 15 -8.0% Dom.
WF FIT-DNA 50-85, 3 7315 0 0 1762 175 26 16 -8.1% Dom.
WF FIT-DNA 45-75, 3 7498 0 0 1813 178 25 15 -7.5% Dom.
WF FIT-DNA 45-80, 3 7929 0 0 1879 182 26 15 -6.6% Dom.
WF FIT-DNA 45-85, 3 8610 0 0 1979 186 27 16 -6.4% Dom.
WF FIT-DNA 55-75, 1 9625 0 0 2167 175 31 16 -13.2% Dom.
WF FIT-DNA 55-80, 1 10928 0 0 2339 180 33 17 -11.2% Dom.
WF FIT-DNA 55-85, 1 11936 0 0 2466 182 33 17 -10.7% Dom.
WF FIT-DNA 50-75, 1 11871 0 0 2548 191 33 16 -6.2% Dom.
WF FIT-DNA 50-80, 1 13195 0 0 2721 196 34 17 -4.3% Dom.
WF FIT-DNA 50-85, 1 14190 0 0 2846 198 35 18 -3.8% Dom.
WF FIT-DNA 45-75, 1 14257 0 0 2903 202 34 17 -2.2% Dom.
WF FIT-DNA 45-80, 1 15567 0 0 3074 207 35 18 -0.4% 159.6*
WF FIT-DNA 45-85, 1 16561 0 0 3198 209 36 18 0% 140.2




MISCAN - Scenario 1: Stable CRC risk
WF HSgFOBT 55-80, 3 6198 0 0 1105 128 16 12 -17.7% Dom.
WF HSgFOBT 55-85, 3 6925 0 0 1187 132 16 13 -18.4% Dom.
WF HSgFOBT 50-75, 3 6637 0 0 1199 134 17 11 -17.5% Dom.
WF HSgFOBT 50-80, 3 7590 0 0 1312 143 17 13 -15.8% Dom.
WF HSgFOBT 50-85, 3 7964 0 0 1353 145 17 13 -15.8% Dom.
WF HSgFOBT 45-75, 3 8104 0 0 1393 146 18 12 -16.7% Dom.
WF HSgFOBT 45-80, 3 8589 0 0 1449 150 18 13 -15.4% Dom.
WF HSgFOBT 45-85, 3 9356 0 0 1533 155 18 14 -14.4% Dom.
WF HSgFOBT 55-75, 2 7408 0 0 1309 140 19 13 -17.4% Dom.
WF HSgFOBT 55-80, 2 8287 0 0 1407 147 20 14 -16.6% Dom.
WF HSgFOBT 55-85, 2 9284 0 0 1511 151 20 14 -16.4% Dom.
WF HSgFOBT 50-75, 2 8900 0 0 1530 155 21 13 -14.5% Dom.
WF HSgFOBT 50-80, 2 10199 0 0 1673 164 22 15 -12.2% Dom.
WF HSgFOBT 50-85, 2 10859 0 0 1741 166 22 15 -12.2% Dom.
WF HSgFOBT 45-75, 2 10924 0 0 1783 167 22 14 -12.7% Dom.
WF HSgFOBT 45-80, 2 11786 0 0 1877 172 23 15 -11.4% Dom.
WF HSgFOBT 45-85, 2 12768 0 0 1978 176 23 16 -11.3% Dom.
WF HSgFOBT 55-75, 1 11197 0 0 1835 162 26 15 -15.8% Dom.
WF HSgFOBT 55-80, 1 12775 0 0 1994 169 27 16 -15.2% Dom.
WF HSgFOBT 55-85, 1 13974 0 0 2108 171 28 16 -14.7% Dom.
WF HSgFOBT 50-75, 1 13803 0 0 2179 180 28 15 -10.8% Dom.
WF HSgFOBT 50-80, 1 15376 0 0 2335 186 29 16 -8.2% Dom.
WF HSgFOBT 50-85, 1 16565 0 0 2447 188 30 17 -7.5% Dom.
WF HSgFOBT 45-75, 1 16527 0 0 2496 190 29 16 -6.5% Dom.
WF HSgFOBT 45-80, 1 18091 0 0 2649 196 30 17 -4.1% Dom.
WF HSgFOBT 45-85, 1 19275 0 0 2760 199 31 17 -3.4% Dom.
WF SIG 55-75, 10 0 2367 0 1453 129 26 12 0% 10.8
WF SIG 55-80, 10 0 2367 0 1453 129 26 12 0% 10.8
WF SIG 55-85, 10 0 2724 0 1546 131 26 13 -4.9% Dom.
WF SIG 50-75, 10 0 2537 0 1534 137 26 12 0% 10.5
WF SIG 50-80, 10 0 3031 0 1679 142 27 13 -1.0% 26.6*
WF SIG 50-85, 10 0 3031 0 1679 142 27 13 -1.0% 26.6*
WF SIG 45-75, 10 0 3284 0 1753 146 27 13 -0.5% 22.9*
WF SIG 45-80, 10 0 3284 0 1753 146 27 13 -0.5% 22.9*
WF SIG 45-85, 10 0 3640 0 1844 148 28 14 -2.4% Dom.
WF SIG 55-75, 5 0 3454 0 1738 144 29 14 -1.5% 27.3*
WF SIG 55-80, 5 0 3867 0 1835 147 30 14 -2.8% Dom.
WF SIG 55-85, 5 0 4161 0 1895 147 30 14 -4.1% Dom.
WF SIG 50-75, 5 0 4220 0 1978 158 30 14 0% 21.1
WF SIG 50-80, 5 0 4631 0 2074 160 31 15 -1.0% 37.1*
WF SIG 50-85, 5 0 4924 0 2133 161 31 15 -2.1% Dom.
WF SIG 45-75, 5 0 5025 0 2183 167 31 15 0% 23.1
WF SIG 45-80, 5 0 5435 0 2279 169 32 15 0% 36.5
WF SIG 45-85, 5 0 5727 0 2338 170 32 15 0% 92.2
WF CTC 55-75, 10 0 0 2448 1095 132 22 12 0% 7.8
WF CTC 55-80, 10 0 0 2448 1095 132 22 12 0% 7.8
WF CTC 55-85, 10 0 0 2837 1182 136 22 13 -4.0% Dom.
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WF CTC 50-75, 10 0 0 2614 1141 138 21 12 0% 7.9
WF CTC 50-80, 10 0 0 3148 1267 149 24 14 0% 12.1
WF CTC 50-85, 10 0 0 3148 1267 149 24 14 0% 12.1
WF CTC 45-75, 10 0 0 3394 1320 150 23 13 -1.9% 45.6*
WF CTC 45-80, 10 0 0 3394 1320 150 23 13 -1.9% 45.6*
WF CTC 45-85, 10 0 0 3781 1406 153 24 14 -3.9% Dom.
WF CTC 55-75, 5 0 0 3657 1397 159 27 14 0.0% 12.8*
WF CTC 55-80, 5 0 0 4110 1485 164 29 15 -1.1% 14.3*
WF CTC 55-85, 5 0 0 4437 1545 165 30 16 -2.9% Dom.
WF CTC 50-75, 5 0 0 4466 1592 174 29 15 0% 12.8
WF CTC 50-80, 5 0 0 4917 1679 179 30 16 -0.2% 17.4*
WF CTC 50-85, 5 0 0 5242 1739 181 31 16 -1.4% 22.4*
WF CTC 45-75, 5 0 0 5305 1762 184 30 15 0% 16.2
WF CTC 45-80, 5 0 0 5754 1849 189 31 16 0% 18.0
WF CTC 45-85, 5 0 0 6079 1908 191 32 17 0% 38.8
MISCAN - Scenario 2: Increased CRC risk
WF No screening 0 0 0 113 0 0 0 - -
WF COL 55-75, 15 0 0 0 3950 328 65 31 0% 11.7
WF COL 55-80, 15 0 0 0 3950 328 65 31 0% 11.7
WF COL 55-85, 15 0 0 0 4184 331 65 32 -2.5% Dom.
WF COL 50-75, 15 0 0 0 4266 343 64 30 0% 20.5
WF COL 50-80, 15 0 0 0 4652 355 68 33 -1.8% 34.0*
WF COL 50-85, 15 0 0 0 4652 355 68 33 -1.8% 34.0*
WF COL 45-75, 15 0 0 0 5038 366 68 33 -3.1% Dom.
WF COL 45-80, 15 0 0 0 5038 366 68 33 -3.1% Dom.
WF COL 45-85, 15 0 0 0 5038 366 68 33 -3.1% Dom.
WF COL 55-75, 10 0 0 0 4515 349 70 33 -1.5% 40.5*
WF COL 55-80, 10 0 0 0 4515 349 70 33 -1.5% 40.5*
WF COL 55-85, 10 0 0 0 4703 351 70 33 -3.4% Dom.
WF COL 50-75, 10 0 0 0 5004 377 71 34 0% 21.9
WF COL 50-80, 10 0 0 0 5310 383 73 35 -0.4% 48.4*
WF COL 50-85, 10 0 0 0 5310 383 73 35 -0.4% 48.4*
WF COL 45-75, 10 0 0 0 5823 398 74 35 0% 39.4
WF COL 45-80, 10 0 0 0 5823 398 74 35 0% 39.4
WF COL 45-85, 10 0 0 0 6011 399 75 35 -0.4% 119.7*
WF COL 55-75, 5 0 0 0 5503 370 74 34 -5.2% Dom.
WF COL 55-80, 5 0 0 0 5740 372 76 35 -6.0% Dom.
WF COL 55-85, 5 0 0 0 5880 372 76 35 -6.6% Dom.
WF COL 50-75, 5 0 0 0 6539 407 78 36 -0.9% 79.7*
WF COL 50-80, 5 0 0 0 6775 409 79 36 -1.3% 82.7*
WF COL 50-85, 5 0 0 0 6916 410 79 37 -1.8% 91.5*
WF COL 45-75, 5 0 0 0 7585 429 80 37 0% 56.1
WF COL 45-80, 5 0 0 0 7821 432 81 37 0% 93.0
WF COL 45-85, 5 0 0 0 7962 432 81 37 0% 328.0
WF FIT 55-75, 3 5302 0 0 1195 227 27 20 0% 4.8
WF FIT 55-80, 3 6248 0 0 1317 249 30 24 0% 5.6




MISCAN - Scenario 2: Increased CRC risk
WF FIT 50-75, 3 6815 0 0 1407 259 30 22 -1.2% 9.2*
WF FIT 50-80, 3 7700 0 0 1516 278 32 25 0% 6.9
WF FIT 50-85, 3 8031 0 0 1553 282 32 26 0.0% 8.8*
WF FIT 45-75, 3 8367 0 0 1583 281 32 24 -1.6% Dom.
WF FIT 45-80, 3 8818 0 0 1635 291 34 25 -0.2% 9.2*
WF FIT 45-85, 3 9500 0 0 1711 300 34 27 0% 8.8
WF FIT 55-75, 2 7623 0 0 1532 271 36 25 -3.1% Dom.
WF FIT 55-80, 2 8444 0 0 1620 284 38 27 -1.9% 16.3*
WF FIT 55-85, 2 9328 0 0 1706 292 38 28 -2.3% Dom.
WF FIT 50-75, 2 9268 0 0 1742 298 38 25 -1.8% Dom.
WF FIT 50-80, 2 10477 0 0 1867 317 41 28 0% 9.0
WF FIT 50-85, 2 11058 0 0 1922 323 41 30 0.0% 10.6*
WF FIT 45-75, 2 11456 0 0 1964 322 41 27 -1.5% Dom.
WF FIT 45-80, 2 12254 0 0 2046 334 43 29 -0.1% 10.6*
WF FIT 45-85, 2 13118 0 0 2127 342 43 30 0% 10.5
WF FIT 55-75, 1 12302 0 0 2082 316 49 28 -6.6% Dom.
WF FIT 55-80, 1 13860 0 0 2209 330 52 31 -5.1% Dom.
WF FIT 55-85, 1 14960 0 0 2290 335 53 32 -5.0% Dom.
WF FIT 50-75, 1 15404 0 0 2411 350 52 30 -2.7% Dom.
WF FIT 50-80, 1 16931 0 0 2532 364 55 32 -1.1% 18.9*
WF FIT 50-85, 1 18014 0 0 2611 369 56 33 -1.0% 18.2*
WF FIT 45-75, 1 18692 0 0 2690 371 54 31 -1.6% 19.3*
WF FIT 45-80, 1 20204 0 0 2808 385 57 33 -0.1% 16.1*
WF FIT 45-85, 1 21280 0 0 2885 390 58 34 0% 16.0
WF FIT-DNA 55-75, 5 3570 0 0 1690 259 36 24 -13.1% Dom.
WF FIT-DNA 55-80, 5 3951 0 0 1785 269 38 26 -12.6% Dom.
WF FIT-DNA 55-85, 5 4209 0 0 1844 273 38 27 -13.3% Dom.
WF FIT-DNA 50-75, 5 4347 0 0 1938 287 39 25 -11.6% Dom.
WF FIT-DNA 50-80, 5 4721 0 0 2029 297 41 27 -10.8% Dom.
WF FIT-DNA 50-85, 5 4976 0 0 2086 301 41 28 -11.2% Dom.
WF FIT-DNA 45-75, 5 5161 0 0 2145 303 41 26 -11.7% Dom.
WF FIT-DNA 45-80, 5 5532 0 0 2234 314 42 28 -10.1% Dom.
WF FIT-DNA 45-85, 5 5784 0 0 2290 317 42 29 -10.1% Dom.
WF FIT-DNA 55-75, 3 4475 0 0 1989 287 44 26 -12.8% Dom.
WF FIT-DNA 55-80, 3 5169 0 0 2148 305 47 29 -11.3% Dom.
WF FIT-DNA 55-85, 3 5628 0 0 2241 311 48 30 -11.1% Dom.
WF FIT-DNA 50-75, 3 5684 0 0 2337 322 48 28 -9.3% Dom.
WF FIT-DNA 50-80, 3 6325 0 0 2478 337 51 30 -7.4% Dom.
WF FIT-DNA 50-85, 3 6561 0 0 2525 340 51 31 -7.3% Dom.
WF FIT-DNA 45-75, 3 6941 0 0 2633 345 50 29 -7.8% Dom.
WF FIT-DNA 45-80, 3 7268 0 0 2703 353 52 30 -6.8% Dom.
WF FIT-DNA 45-85, 3 7754 0 0 2800 360 53 32 -6.4% Dom.
WF FIT-DNA 55-75, 1 8442 0 0 3003 341 61 31 -12.8% Dom.
WF FIT-DNA 55-80, 1 9319 0 0 3149 350 64 33 -11.1% Dom.
WF FIT-DNA 55-85, 1 9936 0 0 3244 353 65 33 -10.6% Dom.
WF FIT-DNA 50-75, 1 10441 0 0 3478 375 65 33 -5.7% Dom.
WF FIT-DNA 50-80, 1 11320 0 0 3622 383 67 34 -4.1% Dom.
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WF FIT-DNA 50-85, 1 11927 0 0 3715 386 68 35 -3.7% Dom.
WF FIT-DNA 45-75, 1 12627 0 0 3902 395 66 33 -2.0% 178.8*
WF FIT-DNA 45-80, 1 13492 0 0 4043 404 69 35 -0.4% 82.8*
WF FIT-DNA 45-85, 1 14096 0 0 4135 407 70 35 0% 74.0
WF HSgFOBT 55-75, 3 4968 0 0 1466 227 29 20 -16.2% Dom.
WF HSgFOBT 55-80, 3 5814 0 0 1611 247 32 24 -14.5% Dom.
WF HSgFOBT 55-85, 3 6382 0 0 1698 254 31 25 -14.9% Dom.
WF HSgFOBT 50-75, 3 6317 0 0 1763 260 33 23 -14.9% Dom.
WF HSgFOBT 50-80, 3 7098 0 0 1892 277 35 25 -13.3% Dom.
WF HSgFOBT 50-85, 3 7387 0 0 1936 281 35 26 -13.3% Dom.
WF HSgFOBT 45-75, 3 7695 0 0 2019 283 36 24 -14.8% Dom.
WF HSgFOBT 45-80, 3 8091 0 0 2082 291 37 25 -13.8% Dom.
WF HSgFOBT 45-85, 3 8686 0 0 2171 300 37 27 -13.1% Dom.
WF HSgFOBT 55-75, 2 6922 0 0 1896 271 38 25 -15.2% Dom.
WF HSgFOBT 55-80, 2 7615 0 0 2002 283 40 27 -14.3% Dom.
WF HSgFOBT 55-85, 2 8347 0 0 2104 290 41 28 -14.6% Dom.
WF HSgFOBT 50-75, 2 8325 0 0 2203 301 42 26 -13.3% Dom.
WF HSgFOBT 50-80, 2 9334 0 0 2353 318 44 29 -10.9% Dom.
WF HSgFOBT 50-85, 2 9811 0 0 2417 322 45 30 -10.7% Dom.
WF HSgFOBT 45-75, 2 10188 0 0 2526 325 45 28 -11.4% Dom.
WF HSgFOBT 45-80, 2 10851 0 0 2623 336 46 29 -10.0% Dom.
WF HSgFOBT 45-85, 2 11557 0 0 2718 343 47 31 -9.6% Dom.
WF HSgFOBT 55-75, 1 10189 0 0 2569 317 52 29 -14.3% Dom.
WF HSgFOBT 55-80, 1 11322 0 0 2717 328 54 31 -13.4% Dom.
WF HSgFOBT 55-85, 1 12110 0 0 2810 332 55 32 -13.7% Dom.
WF HSgFOBT 50-75, 1 12523 0 0 3012 351 56 31 -10.3% Dom.
WF HSgFOBT 50-80, 1 13634 0 0 3153 362 58 32 -8.0% Dom.
WF HSgFOBT 50-85, 1 14407 0 0 3243 366 59 33 -7.3% Dom.
WF HSgFOBT 45-75, 1 15026 0 0 3402 372 58 31 -6.1% Dom.
WF HSgFOBT 45-80, 1 16121 0 0 3539 383 60 33 -4.0% Dom.
WF HSgFOBT 45-85, 1 16886 0 0 3628 387 61 34 -3.3% Dom.
WF SIG 55-75, 10 0 1985 0 2935 310 62 30 0% 9.1
WF SIG 55-80, 10 0 1985 0 2935 310 62 30 0% 9.1
WF SIG 55-85, 10 0 2181 0 3034 312 62 30 -2.6% Dom.
WF SIG 50-75, 10 0 2198 0 3132 331 62 30 0% 9.4
WF SIG 50-80, 10 0 2492 0 3307 339 65 32 -0.7% 20.4*
WF SIG 50-85, 10 0 2492 0 3307 339 65 32 -0.7% 20.4*
WF SIG 45-75, 10 0 2795 0 3466 350 65 31 -0.5% 17.0*
WF SIG 45-80, 10 0 2795 0 3466 350 65 31 -0.5% 17.0*
WF SIG 45-85, 10 0 2989 0 3564 353 66 32 -1.5% 19.7*
WF SIG 55-75, 5 0 2673 0 3229 331 66 31 -1.9% Dom.
WF SIG 55-80, 5 0 2894 0 3327 334 67 32 -2.6% Dom.
WF SIG 55-85, 5 0 3035 0 3376 335 67 32 -3.2% Dom.
WF SIG 50-75, 5 0 3300 0 3618 362 69 33 0% 15.7
WF SIG 50-80, 5 0 3520 0 3715 366 70 33 -0.4% 25.0*
WF SIG 50-85, 5 0 3661 0 3763 366 70 34 -0.9% 31.1*




MISCAN - Scenario 2: Increased CRC risk
WF SIG 45-80, 5 0 4224 0 4026 383 72 34 0% 25.1
WF SIG 45-85, 5 0 4365 0 4075 384 72 34 0% 60.2
WF CTC 55-75, 10 0 0 2275 1761 258 43 24 0% 6.4
WF CTC 55-80, 10 0 0 2275 1761 258 43 24 0% 6.4
WF CTC 55-85, 10 0 0 2567 1863 264 45 26 -2.8% Dom.
WF CTC 50-75, 10 0 0 2471 1838 269 42 23 0% 7.2
WF CTC 50-80, 10 0 0 2894 1996 288 46 27 -0.3% 8.2*
WF CTC 50-85, 10 0 0 2894 1996 288 46 27 -0.3% 8.2*
WF CTC 45-75, 10 0 0 3178 2074 291 46 26 -2.7% Dom.
WF CTC 45-80, 10 0 0 3178 2074 291 46 26 -2.7% Dom.
WF CTC 45-85, 10 0 0 3467 2174 297 47 27 -4.7% Dom.
WF CTC 55-75, 5 0 0 3309 2162 310 54 29 0% 7.8
WF CTC 55-80, 5 0 0 3644 2259 319 57 30 -0.5% 10.4*
WF CTC 55-85, 5 0 0 3870 2319 322 58 31 -1.7% 13.0*
WF CTC 50-75, 5 0 0 4058 2431 340 57 30 0% 8.9
WF CTC 50-80, 5 0 0 4389 2525 349 60 32 0% 10.5
WF CTC 50-85, 5 0 0 4613 2584 352 61 32 -0.6% 22.1*
WF CTC 45-75, 5 0 0 4853 2652 358 58 31 -0.4% 14.1*
WF CTC 45-80, 5 0 0 5182 2745 367 61 32 0% 12.2
WF CTC 45-85, 5 0 0 5405 2803 370 62 33 0% 22.3
SimCRC - Scenario 1: Stable CRC risk
WF No screening 0 0 0 66 0 0 0 - -
WF COL 55-75, 15 0 0 0 3001 229 48 21 0% 12.8
WF COL 55-80, 15 0 0 0 3001 229 48 21 0% 12.8
WF COL 55-85, 15 0 0 0 3384 230 48 21 -12.1% Dom.
WF COL 50-75, 15 0 0 0 3178 255 50 21 0% 6.6
WF COL 50-80, 15 0 0 0 3745 261 52 22 -4.5% Dom.
WF COL 50-85, 15 0 0 0 3745 261 52 22 -4.5% Dom.
WF COL 45-75, 15 0 0 0 4062 283 55 23 0% 31.6
WF COL 45-80, 15 0 0 0 4062 283 55 23 0% 31.6
WF COL 45-85, 15 0 0 0 4062 283 55 23 0% 31.6
WF COL 55-75, 10 0 0 0 3746 239 51 22 -12.6% Dom.
WF COL 55-80, 10 0 0 0 3746 239 51 22 -12.6% Dom.
WF COL 55-85, 10 0 0 0 4080 240 51 22 -15.5% Dom.
WF COL 50-75, 10 0 0 0 4062 270 54 23 -4.7% Dom.
WF COL 50-80, 10 0 0 0 4555 273 55 23 -6.3% Dom.
WF COL 50-85, 10 0 0 0 4555 273 55 23 -6.3% Dom.
WF COL 45-75, 10 0 0 0 4952 297 58 24 0% 64.8
WF COL 45-80, 10 0 0 0 4952 297 58 24 0% 64.8
WF COL 45-85, 10 0 0 0 5286 298 58 24 -0.2% 511.6*
WF COL 55-75, 5 0 0 0 5172 246 53 22 -17.5% Dom.
WF COL 55-80, 5 0 0 0 5592 247 54 22 -17.7% Dom.
WF COL 55-85, 5 0 0 0 5881 247 54 22 -18.0% Dom.
WF COL 50-75, 5 0 0 0 6217 280 58 24 -7.2% Dom.
WF COL 50-80, 5 0 0 0 6637 281 58 24 -7.5% Dom.
WF COL 50-85, 5 0 0 0 6925 281 58 24 -7.8% Dom.
WF COL 45-75, 5 0 0 0 7272 306 61 24 0% 248.3
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WF COL 45-80, 5 0 0 0 7692 307 61 25 0% 597.2
WF COL 45-85, 5 0 0 0 7980 307 61 25 0% 1998.2
WF FIT 55-75, 3 5618 0 0 760 176 24 15 0% 3.9
WF FIT 55-80, 3 6735 0 0 863 188 26 17 -4.8% Dom.
WF FIT 55-85, 3 7460 0 0 928 191 26 18 -9.0% Dom.
WF FIT 50-75, 3 7252 0 0 915 208 28 17 0% 4.8
WF FIT 50-80, 3 8207 0 0 1003 217 30 18 -3.1% Dom.
WF FIT 50-85, 3 8728 0 0 1048 220 30 19 -5.3% Dom.
WF FIT 45-75, 3 8777 0 0 1046 232 31 18 0% 5.4
WF FIT 45-80, 3 9458 0 0 1104 239 32 19 0% 9.0
WF FIT 45-85, 3 10289 0 0 1176 243 32 20 -0.5% 16.2*
WF FIT 55-75, 2 8126 0 0 1003 200 30 17 -10.6% Dom.
WF FIT 55-80, 2 9124 0 0 1085 207 32 18 -12.5% Dom.
WF FIT 55-85, 2 10249 0 0 1173 211 32 19 -13.7% Dom.
WF FIT 50-75, 2 9840 0 0 1154 230 34 18 -5.3% Dom.
WF FIT 50-80, 2 11322 0 0 1272 239 36 20 -5.1% Dom.
WF FIT 50-85, 2 12069 0 0 1330 241 36 21 -5.9% Dom.
WF FIT 45-75, 2 12158 0 0 1333 257 38 20 0% 12.5
WF FIT 45-80, 2 13143 0 0 1412 263 39 21 0% 12.9
WF FIT 45-85, 2 14258 0 0 1498 266 39 22 0% 24.2
WF FIT 55-75, 1 13408 0 0 1428 221 39 19 -16.0% Dom.
WF FIT 55-80, 1 15410 0 0 1563 227 41 20 -15.6% Dom.
WF FIT 55-85, 1 16903 0 0 1658 229 41 21 -15.9% Dom.
WF FIT 50-75, 1 16764 0 0 1680 254 44 21 -6.8% Dom.
WF FIT 50-80, 1 18753 0 0 1811 260 45 22 -6.5% Dom.
WF FIT 50-85, 1 20240 0 0 1905 262 46 22 -6.9% Dom.
WF FIT 45-75, 1 20234 0 0 1911 281 47 22 -0.2% 28.5*
WF FIT 45-80, 1 22216 0 0 2041 286 48 23 0% 27.7
WF FIT 45-85, 1 23698 0 0 2134 288 49 23 0% 53.5
WF FIT-DNA 55-75, 5 3809 0 0 1133 191 30 17 -20.6% Dom.
WF FIT-DNA 55-80, 5 4285 0 0 1227 197 31 18 -20.8% Dom.
WF FIT-DNA 55-85, 5 4624 0 0 1291 198 31 18 -21.7% Dom.
WF FIT-DNA 50-75, 5 4638 0 0 1318 221 34 18 -13.6% Dom.
WF FIT-DNA 50-80, 5 5111 0 0 1410 226 35 19 -14.0% Dom.
WF FIT-DNA 50-85, 5 5449 0 0 1474 228 35 20 -14.2% Dom.
WF FIT-DNA 45-75, 5 5489 0 0 1486 243 37 19 -8.6% Dom.
WF FIT-DNA 45-80, 5 5960 0 0 1577 248 38 20 -7.8% Dom.
WF FIT-DNA 45-85, 5 6297 0 0 1640 250 38 20 -8.0% Dom.
WF FIT-DNA 55-75, 3 4965 0 0 1372 210 36 18 -19.1% Dom.
WF FIT-DNA 55-80, 3 5851 0 0 1533 218 38 20 -18.6% Dom.
WF FIT-DNA 55-85, 3 6349 0 0 1619 220 38 20 -18.8% Dom.
WF FIT-DNA 50-75, 3 6335 0 0 1651 245 41 20 -10.1% Dom.
WF FIT-DNA 50-80, 3 6999 0 0 1771 250 42 21 -9.5% Dom.
WF FIT-DNA 50-85, 3 7529 0 0 1859 252 42 21 -9.8% Dom.
WF FIT-DNA 45-75, 3 7510 0 0 1869 269 44 21 -3.9% Dom.
WF FIT-DNA 45-80, 3 8214 0 0 1990 274 45 22 -3.5% Dom.




SimCRC - Scenario 1: Stable CRC risk
WF FIT-DNA 55-75, 1 9509 0 0 2190 232 46 21 -19.4% Dom.
WF FIT-DNA 55-80, 1 10771 0 0 2376 236 47 21 -18.6% Dom.
WF FIT-DNA 55-85, 1 11726 0 0 2510 237 48 22 -18.5% Dom.
WF FIT-DNA 50-75, 1 11755 0 0 2576 265 50 22 -8.8% Dom.
WF FIT-DNA 50-80, 1 13042 0 0 2764 269 52 23 -8.0% Dom.
WF FIT-DNA 50-85, 1 13987 0 0 2897 270 52 23 -7.9% Dom.
WF FIT-DNA 45-75, 1 14124 0 0 2946 291 53 23 -0.7% 239.9*
WF FIT-DNA 45-80, 1 15396 0 0 3132 294 55 24 0.0% 153.1*
WF FIT-DNA 45-85, 1 16340 0 0 3264 295 55 24 0% 149.8
WF HSgFOBT 55-75, 3 5303 0 0 1022 176 26 15 -22.9% Dom.
WF HSgFOBT 55-80, 3 6312 0 0 1157 187 27 17 -23.2% Dom.
WF HSgFOBT 55-85, 3 6912 0 0 1235 190 28 18 -23.8% Dom.
WF HSgFOBT 50-75, 3 6794 0 0 1249 209 30 17 -16.5% Dom.
WF HSgFOBT 50-80, 3 7584 0 0 1355 217 32 18 -16.1% Dom.
WF HSgFOBT 50-85, 3 8135 0 0 1423 219 32 19 -16.7% Dom.
WF HSgFOBT 45-75, 3 8097 0 0 1434 233 33 18 -11.8% Dom.
WF HSgFOBT 45-80, 3 8821 0 0 1525 239 34 19 -10.6% Dom.
WF HSgFOBT 45-85, 3 9533 0 0 1615 243 35 20 -10.3% Dom.
WF HSgFOBT 55-75, 2 7342 0 0 1337 200 32 18 -22.1% Dom.
WF HSgFOBT 55-80, 2 8205 0 0 1444 206 33 19 -21.9% Dom.
WF HSgFOBT 55-85, 2 9173 0 0 1559 210 34 19 -22.0% Dom.
WF HSgFOBT 50-75, 2 8835 0 0 1559 231 36 19 -14.1% Dom.
WF HSgFOBT 50-80, 2 10114 0 0 1715 239 38 20 -12.9% Dom.
WF HSgFOBT 50-85, 2 10756 0 0 1790 241 38 21 -13.0% Dom.
WF HSgFOBT 45-75, 2 10852 0 0 1824 258 40 20 -7.2% Dom.
WF HSgFOBT 45-80, 2 11701 0 0 1928 263 41 21 -6.6% Dom.
WF HSgFOBT 45-85, 2 12658 0 0 2039 266 41 22 -6.8% Dom.
WF HSgFOBT 55-75, 1 11066 0 0 1857 222 40 20 -20.6% Dom.
WF HSgFOBT 55-80, 1 12609 0 0 2029 227 42 20 -20.6% Dom.
WF HSgFOBT 55-85, 1 13763 0 0 2151 228 42 21 -20.7% Dom.
WF HSgFOBT 50-75, 1 13679 0 0 2204 255 45 21 -11.5% Dom.
WF HSgFOBT 50-80, 1 15223 0 0 2373 260 47 22 -10.2% Dom.
WF HSgFOBT 50-85, 1 16369 0 0 2493 261 47 22 -9.9% Dom.
WF HSgFOBT 45-75, 1 16396 0 0 2530 282 49 22 -3.1% Dom.
WF HSgFOBT 45-80, 1 17931 0 0 2698 286 50 23 -1.9% Dom.
WF HSgFOBT 45-85, 1 19074 0 0 2818 288 50 23 -1.7% Dom.
WF SIG 55-75, 10 0 2431 0 1214 168 35 15 0% 6.8
WF SIG 55-80, 10 0 2431 0 1214 168 35 15 0% 6.8
WF SIG 55-85, 10 0 2805 0 1317 170 35 16 -12.4% Dom.
WF SIG 50-75, 10 0 2595 0 1277 190 37 16 0% 2.9
WF SIG 50-80, 10 0 3115 0 1429 195 39 17 -5.1% Dom.
WF SIG 50-85, 10 0 3115 0 1429 195 39 17 -5.1% Dom.
WF SIG 45-75, 10 0 3359 0 1510 214 41 17 0% 9.7
WF SIG 45-80, 10 0 3359 0 1510 214 41 17 0% 9.7
WF SIG 45-85, 10 0 3732 0 1612 216 41 18 -1.9% 64.1*
WF SIG 55-75, 5 0 3583 0 1530 187 40 17 -13.1% Dom.
WF SIG 55-80, 5 0 4013 0 1633 189 40 18 -14.3% Dom.
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WF SIG 55-85, 5 0 4318 0 1702 190 41 18 -15.5% Dom.
WF SIG 50-75, 5 0 4369 0 1761 216 44 19 -5.1% Dom.
WF SIG 50-80, 5 0 4796 0 1864 219 44 19 -6.5% Dom.
WF SIG 50-85, 5 0 5099 0 1932 219 45 19 -7.7% Dom.
WF SIG 45-75, 5 0 5179 0 1973 240 46 20 0% 17.8
WF SIG 45-80, 5 0 5604 0 2074 242 47 20 0% 45.7
WF SIG 45-85, 5 0 5907 0 2142 243 47 20 0% 108.9
WF CTC 55-75, 10 0 0 2407 1323 209 42 19 0% 6.0
WF CTC 55-80, 10 0 0 2407 1323 209 42 19 0% 6.0
WF CTC 55-85, 10 0 0 2769 1440 211 42 20 -12.6% Dom.
WF CTC 50-75, 10 0 0 2578 1371 234 44 19 0% 2.0
WF CTC 50-80, 10 0 0 3085 1540 240 46 21 -5.2% Dom.
WF CTC 50-85, 10 0 0 3085 1540 240 46 21 -5.2% Dom.
WF CTC 45-75, 10 0 0 3336 1608 261 48 21 0% 8.6
WF CTC 45-80, 10 0 0 3336 1608 261 48 21 0% 8.6
WF CTC 45-85, 10 0 0 3696 1723 263 48 22 -1.6% 60.8*
WF CTC 55-75, 5 0 0 3548 1626 226 47 20 -13.8% Dom.
WF CTC 55-80, 5 0 0 3966 1733 228 48 21 -14.7% Dom.
WF CTC 55-85, 5 0 0 4260 1804 229 48 21 -15.6% Dom.
WF CTC 50-75, 5 0 0 4341 1848 259 51 22 -5.4% Dom.
WF CTC 50-80, 5 0 0 4757 1954 261 52 22 -6.4% Dom.
WF CTC 50-85, 5 0 0 5051 2025 262 52 22 -7.4% Dom.
WF CTC 45-75, 5 0 0 5163 2045 284 53 23 0% 19.0
WF CTC 45-80, 5 0 0 5579 2150 287 55 23 0% 44.3
WF CTC 45-85, 5 0 0 5872 2221 287 55 23 0% 109.8
SimCRC - Scenario 2: Increased CRC risk
WF No screening 0 0 0 120 0 0 0 - -
WF COL 55-75, 15 0 0 0 3181 370 82 35 0% 8.3
WF COL 55-80, 15 0 0 0 3181 370 82 35 0% 8.3
WF COL 55-85, 15 0 0 0 3540 375 84 36 -8.1% Dom.
WF COL 50-75, 15 0 0 0 3300 396 80 34 0% 4.7
WF COL 50-80, 15 0 0 0 3889 414 88 38 -2.6% Dom.
WF COL 50-85, 15 0 0 0 3889 414 88 38 -2.6% Dom.
WF COL 45-75, 15 0 0 0 4218 442 91 39 0% 19.9
WF COL 45-80, 15 0 0 0 4218 442 91 39 0% 19.9
WF COL 45-85, 15 0 0 0 4218 442 91 39 0% 19.9
WF COL 55-75, 10 0 0 0 3943 397 90 38 -7.3% Dom.
WF COL 55-80, 10 0 0 0 3943 397 90 38 -7.3% Dom.
WF COL 55-85, 10 0 0 0 4228 399 91 39 -9.8% Dom.
WF COL 50-75, 10 0 0 0 4254 434 92 38 -2.2% Dom.
WF COL 50-80, 10 0 0 0 4723 442 97 40 -3.6% Dom.
WF COL 50-85, 10 0 0 0 4723 442 97 40 -3.6% Dom.
WF COL 45-75, 10 0 0 0 5138 473 99 41 0% 29.4
WF COL 45-80, 10 0 0 0 5138 473 99 41 0% 29.4
WF COL 45-85, 10 0 0 0 5424 475 100 41 -0.1% 142.9*
WF COL 55-75, 5 0 0 0 5343 413 96 39 -13.0% Dom.




SimCRC - Scenario 2: Increased CRC risk
WF COL 55-85, 5 0 0 0 5914 416 98 40 -13.4% Dom.
WF COL 50-75, 5 0 0 0 6393 461 101 41 -5.0% Dom.
WF COL 50-80, 5 0 0 0 6745 463 103 42 -5.2% Dom.
WF COL 50-85, 5 0 0 0 6964 463 104 42 -5.5% Dom.
WF COL 45-75, 5 0 0 0 7453 495 105 42 0% 106.6
WF COL 45-80, 5 0 0 0 7805 497 107 43 0% 146.4
WF COL 45-85, 5 0 0 0 8024 498 107 43 0% 472.9
WF FIT 55-75, 3 5566 0 0 871 271 39 23 0% 2.8
WF FIT 55-80, 3 6627 0 0 1002 299 43 28 -3.1% Dom.
WF FIT 55-85, 3 7289 0 0 1084 308 44 30 -6.7% Dom.
WF FIT 50-75, 3 7200 0 0 1027 316 45 26 0% 3.5
WF FIT 50-80, 3 8106 0 0 1140 338 48 30 -1.9% 5.1*
WF FIT 50-85, 3 8582 0 0 1196 345 49 31 -3.5% Dom.
WF FIT 45-75, 3 8732 0 0 1155 348 48 28 0% 3.9
WF FIT 45-80, 3 9380 0 0 1229 364 51 30 0% 4.8
WF FIT 45-85, 3 10143 0 0 1322 375 52 33 -0.4% 8.3*
WF FIT 55-75, 2 8025 0 0 1140 318 50 28 -7.8% Dom.
WF FIT 55-80, 2 8961 0 0 1244 335 54 31 -8.5% Dom.
WF FIT 55-85, 2 9972 0 0 1353 345 55 33 -9.5% Dom.
WF FIT 50-75, 2 9766 0 0 1279 354 54 29 -4.5% Dom.
WF FIT 50-80, 2 11159 0 0 1430 379 59 33 -3.4% Dom.
WF FIT 50-85, 2 11831 0 0 1501 385 60 35 -4.2% Dom.
WF FIT 45-75, 2 12090 0 0 1459 393 59 32 -0.6% 7.9*
WF FIT 45-80, 2 13017 0 0 1560 410 63 34 0% 7.3
WF FIT 45-85, 2 14022 0 0 1666 419 64 36 0% 11.2
WF FIT 55-75, 1 13210 0 0 1595 360 66 33 -12.8% Dom.
WF FIT 55-80, 1 15050 0 0 1759 376 71 35 -11.5% Dom.
WF FIT 55-85, 1 16349 0 0 1869 381 72 37 -11.7% Dom.
WF FIT 50-75, 1 16603 0 0 1840 405 72 35 -5.8% Dom.
WF FIT 50-80, 1 18435 0 0 2002 421 76 37 -4.4% Dom.
WF FIT 50-85, 1 19730 0 0 2111 426 78 39 -4.7% Dom.
WF FIT 45-75, 1 20115 0 0 2064 439 76 36 -1.3% 20.1*
WF FIT 45-80, 1 21941 0 0 2225 455 81 39 0% 15.6
WF FIT 45-85, 1 23235 0 0 2333 460 82 40 0% 20.2
WF FIT-DNA 55-75, 5 3770 0 0 1267 300 50 27 -18.7% Dom.
WF FIT-DNA 55-80, 5 4216 0 0 1380 314 53 30 -18.4% Dom.
WF FIT-DNA 55-85, 5 4519 0 0 1456 319 53 31 -19.4% Dom.
WF FIT-DNA 50-75, 5 4607 0 0 1446 340 55 29 -13.8% Dom.
WF FIT-DNA 50-80, 5 5050 0 0 1557 353 58 32 -13.8% Dom.
WF FIT-DNA 50-85, 5 5353 0 0 1632 357 58 33 -14.1% Dom.
WF FIT-DNA 45-75, 5 5466 0 0 1607 368 59 30 -10.9% Dom.
WF FIT-DNA 45-80, 5 5908 0 0 1718 381 62 33 -9.7% Dom.
WF FIT-DNA 45-85, 5 6210 0 0 1792 386 62 34 -9.6% Dom.
WF FIT-DNA 55-75, 3 4916 0 0 1516 334 59 30 -17.1% Dom.
WF FIT-DNA 55-80, 3 5745 0 0 1710 356 65 34 -15.6% Dom.
WF FIT-DNA 55-85, 3 6187 0 0 1809 361 66 35 -15.6% Dom.
WF FIT-DNA 50-75, 3 6293 0 0 1796 383 66 33 -10.4% Dom.
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WF FIT-DNA 50-80, 3 6913 0 0 1940 398 70 35 -8.8% Dom.
WF FIT-DNA 50-85, 3 7385 0 0 2041 404 72 37 -8.8% Dom.
WF FIT-DNA 45-75, 3 7484 0 0 2003 414 70 34 -6.1% Dom.
WF FIT-DNA 45-80, 3 8144 0 0 2150 430 74 36 -4.5% Dom.
WF FIT-DNA 45-85, 3 8679 0 0 2268 437 76 38 -4.4% Dom.
WF FIT-DNA 55-75, 1 9367 0 0 2380 381 79 35 -17.3% Dom.
WF FIT-DNA 55-80, 1 10505 0 0 2587 392 83 37 -15.4% Dom.
WF FIT-DNA 55-85, 1 11311 0 0 2724 395 84 38 -15.0% Dom.
WF FIT-DNA 50-75, 1 11653 0 0 2757 426 84 37 -8.4% Dom.
WF FIT-DNA 50-80, 1 12814 0 0 2968 438 89 39 -6.5% Dom.
WF FIT-DNA 50-85, 1 13612 0 0 3104 441 90 40 -6.2% Dom.
WF FIT-DNA 45-75, 1 14057 0 0 3120 460 88 38 -2.1% Dom.
WF FIT-DNA 45-80, 1 15206 0 0 3328 471 93 40 -0.3% 90.1*
WF FIT-DNA 45-85, 1 16003 0 0 3464 474 94 41 0% 79.4
WF HSgFOBT 55-75, 3 5256 0 0 1136 273 42 24 -20.6% Dom.
WF HSgFOBT 55-80, 3 6215 0 0 1295 299 47 28 -20.0% Dom.
WF HSgFOBT 55-85, 3 6764 0 0 1384 306 47 30 -20.5% Dom.
WF HSgFOBT 50-75, 3 6751 0 0 1361 319 48 27 -16.5% Dom.
WF HSgFOBT 50-80, 3 7502 0 0 1486 338 52 30 -15.3% Dom.
WF HSgFOBT 50-85, 3 8005 0 0 1564 345 53 31 -15.8% Dom.
WF HSgFOBT 45-75, 3 8066 0 0 1539 350 52 28 -13.9% Dom.
WF HSgFOBT 45-80, 3 8756 0 0 1646 367 55 31 -12.2% Dom.
WF HSgFOBT 45-85, 3 9411 0 0 1751 376 56 33 -11.4% Dom.
WF HSgFOBT 55-75, 2 7259 0 0 1475 319 54 29 -19.8% Dom.
WF HSgFOBT 55-80, 2 8070 0 0 1600 334 57 31 -19.1% Dom.
WF HSgFOBT 55-85, 2 8941 0 0 1728 343 58 33 -18.9% Dom.
WF HSgFOBT 50-75, 2 8779 0 0 1684 357 58 30 -15.0% Dom.
WF HSgFOBT 50-80, 2 9986 0 0 1866 379 63 34 -12.3% Dom.
WF HSgFOBT 50-85, 2 10564 0 0 1950 384 64 35 -12.1% Dom.
WF HSgFOBT 45-75, 2 10808 0 0 1945 396 63 32 -9.4% Dom.
WF HSgFOBT 45-80, 2 11610 0 0 2067 411 67 35 -7.7% Dom.
WF HSgFOBT 45-85, 2 12474 0 0 2192 419 68 37 -7.5% Dom.
WF HSgFOBT 55-75, 1 10925 0 0 2021 360 68 33 -18.4% Dom.
WF HSgFOBT 55-80, 1 12351 0 0 2214 375 73 36 -17.4% Dom.
WF HSgFOBT 55-85, 1 13357 0 0 2342 380 74 37 -17.5% Dom.
WF HSgFOBT 50-75, 1 13579 0 0 2358 406 75 35 -11.7% Dom.
WF HSgFOBT 50-80, 1 15008 0 0 2550 421 79 38 -9.1% Dom.
WF HSgFOBT 50-85, 1 16010 0 0 2677 425 80 39 -8.4% Dom.
WF HSgFOBT 45-75, 1 16337 0 0 2676 440 79 36 -5.2% Dom.
WF HSgFOBT 45-80, 1 17759 0 0 2866 454 83 39 -2.7% Dom.
WF HSgFOBT 45-85, 1 18759 0 0 2994 459 84 40 -2.0% Dom.
WF SIG 55-75, 10 0 2334 0 1783 347 77 33 0% 4.8
WF SIG 55-80, 10 0 2334 0 1783 347 77 33 0% 4.8
WF SIG 55-85, 10 0 2629 0 1924 351 78 34 -10.2% Dom.
WF SIG 50-75, 10 0 2530 0 1808 375 77 33 0% 0.9
WF SIG 50-80, 10 0 2971 0 2040 389 83 36 -4.5% Dom.




SimCRC - Scenario 2: Increased CRC risk
WF SIG 45-75, 10 0 3257 0 2103 416 85 36 0% 7.2
WF SIG 45-80, 10 0 3257 0 2103 416 85 36 0% 7.2
WF SIG 45-85, 10 0 3551 0 2243 420 86 37 -1.3% 37.4*
WF SIG 55-75, 5 0 3352 0 2108 370 83 35 -11.1% Dom.
WF SIG 55-80, 5 0 3690 0 2240 375 86 36 -11.6% Dom.
WF SIG 55-85, 5 0 3913 0 2319 377 86 37 -12.4% Dom.
WF SIG 50-75, 5 0 4129 0 2352 413 88 37 -4.5% Dom.
WF SIG 50-80, 5 0 4465 0 2483 418 91 38 -5.1% Dom.
WF SIG 50-85, 5 0 4688 0 2562 419 92 39 -5.9% Dom.
WF SIG 45-75, 5 0 4937 0 2567 446 92 38 0% 15.5
WF SIG 45-80, 5 0 5274 0 2698 451 95 39 0% 25.0
WF SIG 45-85, 5 0 5496 0 2777 453 95 40 0% 59.7
WF CTC 55-75, 10 0 0 2386 1507 338 71 32 0% 4.1
WF CTC 55-80, 10 0 0 2386 1507 338 71 32 0% 4.1
WF CTC 55-85, 10 0 0 2707 1656 343 73 34 -10.8% Dom.
WF CTC 50-75, 10 0 0 2574 1510 361 70 31 0% 0.1
WF CTC 50-80, 10 0 0 3049 1738 379 77 35 -4.6% Dom.
WF CTC 50-85, 10 0 0 3049 1738 379 77 35 -4.6% Dom.
WF CTC 45-75, 10 0 0 3325 1780 405 79 35 0% 6.2
WF CTC 45-80, 10 0 0 3325 1780 405 79 35 0% 6.2
WF CTC 45-85, 10 0 0 3646 1927 410 81 36 -2.1% Dom.
WF CTC 55-75, 5 0 0 3500 1841 373 81 35 -9.2% Dom.
WF CTC 55-80, 5 0 0 3874 1976 380 84 37 -10.3% Dom.
WF CTC 55-85, 5 0 0 4121 2060 382 85 37 -11.5% Dom.
WF CTC 50-75, 5 0 0 4302 2057 416 86 37 -3.5% Dom.
WF CTC 50-80, 5 0 0 4675 2192 423 89 38 -4.6% Dom.
WF CTC 50-85, 5 0 0 4922 2275 425 90 39 -5.7% Dom.
WF CTC 45-75, 5 0 0 5134 2248 449 89 38 0% 10.4
WF CTC 45-80, 5 0 0 5507 2382 457 93 40 0% 18.2
WF CTC 45-85, 5 0 0 5754 2465 459 94 40 0% 45.7
COL - colonoscopy; CRC - colorectal cancer; CTC - computed tomographic colonography; 
Dom. - dominated strategy; ER - efficiency ratio; FIT - fecal immunochemical test; FIT-DNA - 
multitarget stool DNA test; HSgFOBT - high-sensitivity guaiac-based fecal occult blood test; 
LYG - life-years gained; SIG - flexible sigmoidoscopy; WF - white female.
a Both models evaluated two scenarios for CRC risk: one in which age-specific risks were 
assumed to have remained stable since the early screening period in the U.S. (1975-1979 
for SimCRC; 1990-1994 for MISCAN), and one in which risks were assumed to have increased 
proportional to observed trends among adults under age 40 years. Strategies for each model 
and scenario are ordered successively by screening modality, interval ( ), end age ( ), and 
start age ( ).
b Total number of colonoscopies performed per 1000 40-year-olds, including diagnostic 
colonoscopies and potential surveillance colonoscopies after adenoma removal. The number 
of screening-related complications ranged from 3.5 to 27.6 per 1000 40-year-olds across 
models, scenarios, and strategies.
c Including deaths from complications of screening.
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d The difference in LYG compared to (combinations of ) adjacent strategies on the efficient 
frontier. Near-efficient strategies have a loss in LYG of less than 2% before rounding. For the 
least intensive screening strategy evaluated within each class of screening modality, the 
difference was zero by definition.
e Efficiency ratio = incremental number of colonoscopies/LYG with respect to the next less 
effective strategy on the efficient frontier, a burden-to-benefit ratio. Only calculated for 
efficient and near-efficient strategies (marked with an asterisk*), i.e. strategies within 2% from 
the efficient frontier among all evaluated strategies within a class of screening modalities 
(colonoscopy, stool-based, sigmoidoscopy, and CTC). 
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Supplementary Table A3.4: Lifetime number of colonoscopies and LYG for all evaluated 
screening strategies under two scenarios for CRC risk, by model, in black females a
































































































































MISCAN - Scenario 1: Stable CRC risk
BF No screening 0 0 0 60 0 0 0 - -
BF COL 55-75, 15 0 0 0 3037 227 34 20 0% 13.1
BF COL 55-80, 15 0 0 0 3037 227 34 20 0% 13.1
BF COL 55-85, 15 0 0 0 3322 228 34 21 -7.1% Dom.
BF COL 50-75, 15 0 0 0 3327 246 35 21 0% 15.0
BF COL 50-80, 15 0 0 0 3746 251 36 22 -2.3% Dom.
BF COL 50-85, 15 0 0 0 3746 251 36 22 -2.3% Dom.
BF COL 45-75, 15 0 0 0 4101 266 37 22 -0.4% Dom.
BF COL 45-80, 15 0 0 0 4101 266 37 22 -0.4% Dom.
BF COL 45-85, 15 0 0 0 4101 266 37 22 -0.4% Dom.
BF COL 55-75, 10 0 0 0 3646 239 36 21 -6.2% Dom.
BF COL 55-80, 10 0 0 0 3646 239 36 21 -6.2% Dom.
BF COL 55-85, 10 0 0 0 3908 240 37 22 -8.4% Dom.
BF COL 50-75, 10 0 0 0 4060 266 38 22 0% 37.7
BF COL 50-80, 10 0 0 0 4439 268 39 23 -2.2% Dom.
BF COL 50-85, 10 0 0 0 4439 268 39 23 -2.2% Dom.
BF COL 45-75, 10 0 0 0 4894 285 40 23 0% 43.4
BF COL 45-80, 10 0 0 0 4894 285 40 23 0% 43.4
BF COL 45-85, 10 0 0 0 5155 286 40 23 -0.6% 348.0*
BF COL 55-75, 5 0 0 0 4864 251 39 22 -11.5% Dom.
BF COL 55-80, 5 0 0 0 5209 252 39 22 -12.3% Dom.
BF COL 55-85, 5 0 0 0 5454 253 39 23 -13.0% Dom.
BF COL 50-75, 5 0 0 0 5888 283 41 24 -3.9% Dom.
BF COL 50-80, 5 0 0 0 6234 284 42 24 -4.6% Dom.
BF COL 50-85, 5 0 0 0 6479 284 42 24 -5.3% Dom.
BF COL 45-75, 5 0 0 0 6930 304 43 24 0% 104.0
BF COL 45-80, 5 0 0 0 7276 305 44 25 0% 370.5
BF COL 45-85, 5 0 0 0 7520 306 44 25 0% 950.9
BF FIT 55-75, 3 5191 0 0 825 161 15 14 0% 4.8
BF FIT 55-80, 3 6137 0 0 906 172 16 16 -0.8% 7.1*
BF FIT 55-85, 3 6798 0 0 955 176 16 16 -3.0% Dom.
BF FIT 50-75, 3 6726 0 0 991 187 17 15 0% 6.3
BF FIT 50-80, 3 7618 0 0 1063 196 18 17 0.0% 7.8*
BF FIT 50-85, 3 7959 0 0 1088 198 18 17 -0.6% 8.7*
BF FIT 45-75, 3 8297 0 0 1136 205 19 16 -0.2% 7.9*
BF FIT 45-80, 3 8752 0 0 1171 210 19 17 0% 7.8
BF FIT 45-85, 3 9454 0 0 1222 214 19 18 -0.3% 11.9*
table continues
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MISCAN - Scenario 1: Stable CRC risk
BF FIT 55-75, 2 7554 0 0 1063 188 19 16 -4.2% Dom.
BF FIT 55-80, 2 8406 0 0 1124 194 20 18 -4.7% Dom.
BF FIT 55-85, 2 9351 0 0 1185 198 20 18 -6.2% Dom.
BF FIT 50-75, 2 9240 0 0 1237 213 22 18 -1.3% Dom.
BF FIT 50-80, 2 10503 0 0 1324 223 23 19 -0.7% 11.9*
BF FIT 50-85, 2 11128 0 0 1364 225 23 19 -1.4% 12.7*
BF FIT 45-75, 2 11477 0 0 1422 233 23 19 -0.3% 10.8*
BF FIT 45-80, 2 12314 0 0 1480 239 24 19 0% 10.5
BF FIT 45-85, 2 13246 0 0 1538 243 24 20 0% 16.7
BF FIT 55-75, 1 12431 0 0 1469 217 26 19 -9.0% Dom.
BF FIT 55-80, 1 14150 0 0 1567 223 27 20 -8.5% Dom.
BF FIT 55-85, 1 15418 0 0 1633 226 28 20 -9.0% Dom.
BF FIT 50-75, 1 15658 0 0 1743 246 29 20 -3.1% Dom.
BF FIT 50-80, 1 17357 0 0 1837 252 30 21 -2.7% Dom.
BF FIT 50-85, 1 18615 0 0 1902 255 30 22 -3.1% Dom.
BF FIT 45-75, 1 19041 0 0 1988 267 30 21 -0.4% 18.8*
BF FIT 45-80, 1 20731 0 0 2080 273 31 22 0% 18.0
BF FIT 45-85, 1 21984 0 0 2144 275 32 22 0% 28.8
BF FIT-DNA 55-75, 5 3535 0 0 1192 181 20 16 -14.6% Dom.
BF FIT-DNA 55-80, 5 3935 0 0 1261 186 20 17 -14.9% Dom.
BF FIT-DNA 55-85, 5 4214 0 0 1306 188 20 17 -15.8% Dom.
BF FIT-DNA 50-75, 5 4336 0 0 1397 205 22 17 -11.4% Dom.
BF FIT-DNA 50-80, 5 4731 0 0 1464 210 22 18 -11.7% Dom.
BF FIT-DNA 50-85, 5 5008 0 0 1508 212 22 19 -12.2% Dom.
BF FIT-DNA 45-75, 5 5168 0 0 1578 221 23 18 -9.8% Dom.
BF FIT-DNA 45-80, 5 5561 0 0 1644 226 24 19 -9.3% Dom.
BF FIT-DNA 45-85, 5 5836 0 0 1687 227 23 19 -9.5% Dom.
BF FIT-DNA 55-75, 3 4457 0 0 1412 200 24 17 -14.3% Dom.
BF FIT-DNA 55-80, 3 5203 0 0 1533 208 25 19 -14.0% Dom.
BF FIT-DNA 55-85, 3 5719 0 0 1609 211 25 19 -14.4% Dom.
BF FIT-DNA 50-75, 3 5716 0 0 1700 230 27 19 -8.7% Dom.
BF FIT-DNA 50-80, 3 6415 0 0 1810 237 28 20 -8.1% Dom.
BF FIT-DNA 50-85, 3 6681 0 0 1848 238 28 20 -8.3% Dom.
BF FIT-DNA 45-75, 3 7012 0 0 1960 250 28 20 -6.2% Dom.
BF FIT-DNA 45-80, 3 7369 0 0 2014 253 29 21 -5.9% Dom.
BF FIT-DNA 45-85, 3 7917 0 0 2093 256 29 21 -6.2% Dom.
BF FIT-DNA 55-75, 1 8771 0 0 2215 233 32 20 -15.4% Dom.
BF FIT-DNA 55-80, 1 9839 0 0 2352 237 33 21 -14.4% Dom.
BF FIT-DNA 55-85, 1 10642 0 0 2451 239 34 21 -14.3% Dom.
BF FIT-DNA 50-75, 1 10898 0 0 2632 263 35 22 -6.2% Dom.
BF FIT-DNA 50-80, 1 11980 0 0 2770 267 36 22 -5.3% Dom.
BF FIT-DNA 50-85, 1 12773 0 0 2866 269 36 23 -5.2% Dom.
BF FIT-DNA 45-75, 1 13174 0 0 3023 283 37 23 -0.8% 112.0*
BF FIT-DNA 45-80, 1 14243 0 0 3158 287 38 23 0.0% 87.2*
BF FIT-DNA 45-85, 1 15035 0 0 3254 288 38 23 0% 86.5
BF HSgFOBT 55-75, 3 4861 0 0 1043 159 16 14 -17.9% Dom.




MISCAN - Scenario 1: Stable CRC risk
BF HSgFOBT 55-85, 3 6309 0 0 1218 173 16 16 -19.3% Dom.
BF HSgFOBT 50-75, 3 6243 0 0 1283 186 18 16 -15.8% Dom.
BF HSgFOBT 50-80, 3 7042 0 0 1380 194 19 17 -15.4% Dom.
BF HSgFOBT 50-85, 3 7347 0 0 1414 196 19 17 -15.8% Dom.
BF HSgFOBT 45-75, 3 7649 0 0 1502 205 20 17 -15.0% Dom.
BF HSgFOBT 45-80, 3 8056 0 0 1550 209 20 17 -14.1% Dom.
BF HSgFOBT 45-85, 3 8681 0 0 1619 213 20 18 -13.9% Dom.
BF HSgFOBT 55-75, 2 6865 0 0 1363 187 20 17 -18.0% Dom.
BF HSgFOBT 55-80, 2 7600 0 0 1447 193 21 18 -18.2% Dom.
BF HSgFOBT 55-85, 2 8409 0 0 1531 197 21 18 -18.9% Dom.
BF HSgFOBT 50-75, 2 8325 0 0 1619 213 23 18 -13.7% Dom.
BF HSgFOBT 50-80, 2 9408 0 0 1738 222 24 19 -12.7% Dom.
BF HSgFOBT 50-85, 2 9941 0 0 1793 224 24 20 -12.9% Dom.
BF HSgFOBT 45-75, 2 10252 0 0 1899 234 25 19 -10.9% Dom.
BF HSgFOBT 45-80, 2 10967 0 0 1977 239 25 20 -10.4% Dom.
BF HSgFOBT 45-85, 2 11759 0 0 2058 242 25 20 -10.7% Dom.
BF HSgFOBT 55-75, 1 10314 0 0 1880 217 27 19 -17.3% Dom.
BF HSgFOBT 55-80, 1 11617 0 0 2009 222 28 20 -17.4% Dom.
BF HSgFOBT 55-85, 1 12578 0 0 2099 224 28 20 -18.1% Dom.
BF HSgFOBT 50-75, 1 12793 0 0 2259 246 30 21 -10.9% Dom.
BF HSgFOBT 50-80, 1 14086 0 0 2385 251 31 21 -9.5% Dom.
BF HSgFOBT 50-85, 1 15037 0 0 2473 253 31 22 -9.2% Dom.
BF HSgFOBT 45-75, 1 15400 0 0 2611 266 32 21 -5.0% Dom.
BF HSgFOBT 45-80, 1 16681 0 0 2735 271 33 22 -3.8% Dom.
BF HSgFOBT 45-85, 1 17627 0 0 2822 273 33 22 -3.5% Dom.
BF SIG 55-75, 10 0 2181 0 1527 176 27 16 0% 8.3
BF SIG 55-80, 10 0 2181 0 1527 176 27 16 0% 8.3
BF SIG 55-85, 10 0 2471 0 1593 177 27 17 -3.9% Dom.
BF SIG 50-75, 10 0 2377 0 1669 194 28 17 0% 8.0
BF SIG 50-80, 10 0 2786 0 1772 198 29 17 -1.2% 26.0*
BF SIG 50-85, 10 0 2786 0 1772 198 29 17 -1.2% 26.0*
BF SIG 45-75, 10 0 3060 0 1905 208 30 18 -0.4% 17.3*
BF SIG 45-80, 10 0 3060 0 1905 208 30 18 -0.4% 17.3*
BF SIG 45-85, 10 0 3348 0 1969 209 30 18 -1.7% 20.3*
BF SIG 55-75, 5 0 3162 0 1801 195 30 18 -3.7% Dom.
BF SIG 55-80, 5 0 3504 0 1869 196 30 18 -4.8% Dom.
BF SIG 55-85, 5 0 3745 0 1914 197 30 18 -5.8% Dom.
BF SIG 50-75, 5 0 3884 0 2085 219 32 19 -0.4% 17.0*
BF SIG 50-80, 5 0 4223 0 2152 220 32 19 -1.5% 18.4*
BF SIG 50-85, 5 0 4463 0 2197 221 32 19 -2.4% Dom.
BF SIG 45-75, 5 0 4650 0 2333 235 33 20 0% 16.4
BF SIG 45-80, 5 0 4988 0 2399 236 34 20 0% 40.0
BF SIG 45-85, 5 0 5226 0 2443 237 34 20 0% 87.2
BF CTC 55-75, 10 0 0 2259 1218 183 24 17 0% 6.3
BF CTC 55-80, 10 0 0 2259 1218 183 24 17 0% 6.3
BF CTC 55-85, 10 0 0 2570 1288 186 24 17 -5.3% Dom.
BF CTC 50-75, 10 0 0 2460 1301 199 24 17 0% 5.4
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BF CTC 50-80, 10 0 0 2900 1407 208 26 18 -0.6% 11.5*
BF CTC 50-85, 10 0 0 2900 1407 208 26 18 -0.6% 11.5*
BF CTC 45-75, 10 0 0 3179 1490 215 26 18 -1.1% 11.5*
BF CTC 45-80, 10 0 0 3179 1490 215 26 18 -1.1% 11.5*
BF CTC 45-85, 10 0 0 3488 1559 218 27 19 -2.8% Dom.
BF CTC 55-75, 5 0 0 3347 1512 216 29 19 -1.7% 12.3*
BF CTC 55-80, 5 0 0 3717 1584 220 30 20 -3.0% Dom.
BF CTC 55-85, 5 0 0 3977 1631 221 31 20 -4.4% Dom.
BF CTC 50-75, 5 0 0 4122 1739 242 31 20 0% 10.1
BF CTC 50-80, 5 0 0 4490 1810 246 32 21 -0.9% 17.5*
BF CTC 50-85, 5 0 0 4748 1856 248 33 21 -2.0% 22.4*
BF CTC 45-75, 5 0 0 4935 1937 260 33 21 0% 11.4
BF CTC 45-80, 5 0 0 5301 2007 264 34 22 0% 17.6
BF CTC 45-85, 5 0 0 5559 2053 265 34 22 0% 39.7
MISCAN - Scenario 2: Increased CRC risk
BF No screening 0 0 0 77 0 0 0 - -
BF COL 55-75, 15 0 0 0 3375 292 44 26 0% 11.3
BF COL 55-80, 15 0 0 0 3375 292 44 26 0% 11.3
BF COL 55-85, 15 0 0 0 3614 294 45 27 -5.0% Dom.
BF COL 50-75, 15 0 0 0 3723 317 46 27 0% 13.8
BF COL 50-80, 15 0 0 0 4085 324 47 28 -1.9% 56.4*
BF COL 50-85, 15 0 0 0 4085 324 47 28 -1.9% 56.4*
BF COL 45-75, 15 0 0 0 4485 342 48 29 -0.5% 136.4*
BF COL 45-80, 15 0 0 0 4485 342 48 29 -0.5% 136.4*
BF COL 45-85, 15 0 0 0 4485 342 48 29 -0.5% 136.4*
BF COL 55-75, 10 0 0 0 3925 307 47 28 -5.4% Dom.
BF COL 55-80, 10 0 0 0 3925 307 47 28 -5.4% Dom.
BF COL 55-85, 10 0 0 0 4136 308 47 28 -7.2% Dom.
BF COL 50-75, 10 0 0 0 4405 342 50 29 0% 28.2
BF COL 50-80, 10 0 0 0 4721 345 50 30 -1.7% 89.4*
BF COL 50-85, 10 0 0 0 4721 345 50 30 -1.7% 89.4*
BF COL 45-75, 10 0 0 0 5231 366 52 30 0% 33.2
BF COL 45-80, 10 0 0 0 5231 366 52 30 0% 33.2
BF COL 45-85, 10 0 0 0 5442 367 52 30 -0.5% 233.4*
BF COL 55-75, 5 0 0 0 4982 323 50 29 -10.1% Dom.
BF COL 55-80, 5 0 0 0 5258 324 50 29 -11.7% Dom.
BF COL 55-85, 5 0 0 0 5450 324 50 29 -12.3% Dom.
BF COL 50-75, 5 0 0 0 6008 363 54 31 -3.6% Dom.
BF COL 50-80, 5 0 0 0 6284 365 54 31 -4.2% Dom.
BF COL 50-85, 5 0 0 0 6476 365 54 31 -4.8% Dom.
BF COL 45-75, 5 0 0 0 7050 391 56 32 0% 74.1
BF COL 45-80, 5 0 0 0 7326 392 56 32 0% 249.5
BF COL 45-85, 5 0 0 0 7518 392 56 32 0% 550.7
BF FIT 55-75, 3 5082 0 0 1000 205 20 18 0% 4.5
BF FIT 55-80, 3 5965 0 0 1091 219 21 20 -0.4% 6.4*
BF FIT 55-85, 3 6569 0 0 1145 224 21 21 -2.2% Dom.




MISCAN - Scenario 1: Stable CRC risk
BF FIT 50-80, 3 7403 0 0 1276 250 23 22 0% 6.8
BF FIT 50-85, 3 7714 0 0 1303 252 23 22 -0.5% 10.9*
BF FIT 45-75, 3 8114 0 0 1363 261 24 21 -0.3% 7.4*
BF FIT 45-80, 3 8535 0 0 1402 267 25 22 0% 7.0
BF FIT 45-85, 3 9175 0 0 1458 273 25 23 -0.2% 10.1*
BF FIT 55-75, 2 7324 0 0 1276 240 25 21 -3.8% Dom.
BF FIT 55-80, 2 8104 0 0 1343 248 26 23 -4.1% Dom.
BF FIT 55-85, 2 8952 0 0 1406 253 26 24 -5.5% Dom.
BF FIT 50-75, 2 8974 0 0 1480 272 28 23 -1.5% Dom.
BF FIT 50-80, 2 10125 0 0 1574 284 29 24 -0.7% 10.3*
BF FIT 50-85, 2 10684 0 0 1615 287 29 25 -1.2% 10.9*
BF FIT 45-75, 2 11148 0 0 1691 297 30 24 -0.4% 9.6*
BF FIT 45-80, 2 11909 0 0 1752 305 31 25 0% 9.3
BF FIT 45-85, 2 12741 0 0 1812 310 31 26 0% 13.6
BF FIT 55-75, 1 11915 0 0 1732 278 34 24 -8.3% Dom.
BF FIT 55-80, 1 13448 0 0 1831 287 35 26 -7.8% Dom.
BF FIT 55-85, 1 14552 0 0 1895 289 36 26 -8.1% Dom.
BF FIT 50-75, 1 15021 0 0 2044 316 37 26 -2.7% Dom.
BF FIT 50-80, 1 16529 0 0 2138 324 39 28 -2.0% Dom.
BF FIT 50-85, 1 17621 0 0 2201 327 39 28 -2.4% Dom.
BF FIT 45-75, 1 18305 0 0 2319 341 39 27 -0.5% 16.1*
BF FIT 45-80, 1 19800 0 0 2411 349 41 28 0% 15.2
BF FIT 45-85, 1 20885 0 0 2472 352 41 29 0% 22.5
BF FIT-DNA 55-75, 5 3435 0 0 1411 231 26 21 -14.0% Dom.
BF FIT-DNA 55-80, 5 3798 0 0 1484 238 26 22 -14.0% Dom.
BF FIT-DNA 55-85, 5 4046 0 0 1530 240 26 23 -14.7% Dom.
BF FIT-DNA 50-75, 5 4211 0 0 1648 261 28 22 -11.1% Dom.
BF FIT-DNA 50-80, 5 4569 0 0 1718 268 29 23 -11.2% Dom.
BF FIT-DNA 50-85, 5 4814 0 0 1762 270 29 24 -11.8% Dom.
BF FIT-DNA 45-75, 5 5024 0 0 1853 282 30 23 -9.8% Dom.
BF FIT-DNA 45-80, 5 5379 0 0 1921 288 31 24 -9.1% Dom.
BF FIT-DNA 45-85, 5 5623 0 0 1964 290 31 25 -9.3% Dom.
BF FIT-DNA 55-75, 3 4321 0 0 1663 256 31 23 -13.4% Dom.
BF FIT-DNA 55-80, 3 4994 0 0 1787 267 33 24 -13.2% Dom.
BF FIT-DNA 55-85, 3 5447 0 0 1861 270 33 25 -13.6% Dom.
BF FIT-DNA 50-75, 3 5529 0 0 1989 294 34 25 -8.5% Dom.
BF FIT-DNA 50-80, 3 6153 0 0 2099 303 36 26 -7.8% Dom.
BF FIT-DNA 50-85, 3 6386 0 0 2136 304 36 26 -8.0% Dom.
BF FIT-DNA 45-75, 3 6780 0 0 2278 319 37 26 -6.2% Dom.
BF FIT-DNA 45-80, 3 7098 0 0 2333 324 37 27 -5.7% Dom.
BF FIT-DNA 45-85, 3 7578 0 0 2409 328 38 27 -6.0% Dom.
BF FIT-DNA 55-75, 1 8299 0 0 2522 300 42 27 -14.9% Dom.
BF FIT-DNA 55-80, 1 9215 0 0 2649 305 43 27 -14.0% Dom.
BF FIT-DNA 55-85, 1 9886 0 0 2736 306 44 28 -13.9% Dom.
BF FIT-DNA 50-75, 1 10319 0 0 2980 338 46 28 -6.0% Dom.
BF FIT-DNA 50-80, 1 11242 0 0 3105 343 47 29 -5.2% Dom.
BF FIT-DNA 50-85, 1 11903 0 0 3190 344 47 29 -5.1% Dom.
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BF FIT-DNA 45-75, 1 12503 0 0 3403 363 48 29 -0.8% 81.6*
BF FIT-DNA 45-80, 1 13413 0 0 3526 368 49 30 0.0% 65.0*
BF FIT-DNA 45-85, 1 14072 0 0 3610 369 49 30 0% 64.4
BF HSgFOBT 55-75, 3 4771 0 0 1222 203 20 18 -16.2% Dom.
BF HSgFOBT 55-80, 3 5566 0 0 1336 216 21 20 -16.3% Dom.
BF HSgFOBT 55-85, 3 6105 0 0 1405 220 21 21 -17.7% Dom.
BF HSgFOBT 50-75, 3 6111 0 0 1497 237 24 20 -14.8% Dom.
BF HSgFOBT 50-80, 3 6848 0 0 1598 248 25 22 -14.2% Dom.
BF HSgFOBT 50-85, 3 7123 0 0 1633 250 24 22 -14.5% Dom.
BF HSgFOBT 45-75, 3 7479 0 0 1745 261 26 21 -14.1% Dom.
BF HSgFOBT 45-80, 3 7853 0 0 1794 267 26 22 -13.4% Dom.
BF HSgFOBT 45-85, 3 8418 0 0 1864 272 26 23 -13.1% Dom.
BF HSgFOBT 55-75, 2 6672 0 0 1580 239 26 21 -16.6% Dom.
BF HSgFOBT 55-80, 2 7340 0 0 1665 247 27 23 -16.6% Dom.
BF HSgFOBT 55-85, 2 8058 0 0 1748 251 27 24 -17.7% Dom.
BF HSgFOBT 50-75, 2 8090 0 0 1873 272 30 23 -13.1% Dom.
BF HSgFOBT 50-80, 2 9067 0 0 1993 283 31 25 -11.9% Dom.
BF HSgFOBT 50-85, 2 9537 0 0 2046 286 31 25 -12.1% Dom.
BF HSgFOBT 45-75, 2 9948 0 0 2185 300 32 24 -10.3% Dom.
BF HSgFOBT 45-80, 2 10591 0 0 2263 306 33 25 -9.7% Dom.
BF HSgFOBT 45-85, 2 11287 0 0 2340 310 33 26 -9.9% Dom.
BF HSgFOBT 55-75, 1 9915 0 0 2149 278 35 25 -16.2% Dom.
BF HSgFOBT 55-80, 1 11058 0 0 2273 285 37 26 -16.1% Dom.
BF HSgFOBT 55-85, 1 11879 0 0 2354 287 37 26 -16.8% Dom.
BF HSgFOBT 50-75, 1 12277 0 0 2571 316 39 27 -10.6% Dom.
BF HSgFOBT 50-80, 1 13403 0 0 2689 323 40 28 -9.1% Dom.
BF HSgFOBT 50-85, 1 14211 0 0 2769 325 41 28 -8.9% Dom.
BF HSgFOBT 45-75, 1 14780 0 0 2957 342 41 28 -4.8% Dom.
BF HSgFOBT 45-80, 1 15894 0 0 3073 348 42 29 -3.6% Dom.
BF HSgFOBT 45-85, 1 16695 0 0 3151 350 43 29 -3.3% Dom.
BF SIG 55-75, 10 0 1998 0 2222 267 41 24 0% 8.0
BF SIG 55-80, 10 0 1998 0 2222 267 41 24 0% 8.0
BF SIG 55-85, 10 0 2223 0 2287 268 41 25 -2.6% Dom.
BF SIG 50-75, 10 0 2202 0 2441 294 42 25 0% 7.9
BF SIG 50-80, 10 0 2527 0 2549 299 43 26 -0.8% 22.4*
BF SIG 50-85, 10 0 2527 0 2549 299 43 26 -0.8% 22.4*
BF SIG 45-75, 10 0 2812 0 2743 314 45 26 0% 15.1
BF SIG 45-80, 10 0 2812 0 2743 314 45 26 0% 15.1
BF SIG 45-85, 10 0 3035 0 2806 315 45 27 -0.8% 49.3*
BF SIG 55-75, 5 0 2784 0 2483 285 44 26 -4.1% Dom.
BF SIG 55-80, 5 0 3047 0 2547 287 44 26 -4.9% Dom.
BF SIG 55-85, 5 0 3230 0 2588 287 44 26 -5.5% Dom.
BF SIG 50-75, 5 0 3429 0 2850 319 47 27 -0.6% 22.6*
BF SIG 50-80, 5 0 3690 0 2913 321 47 28 -1.2% 25.6*
BF SIG 50-85, 5 0 3872 0 2953 321 47 28 -1.8% 29.2*
BF SIG 45-75, 5 0 4134 0 3161 340 48 28 0% 16.0




MISCAN - Scenario 1: Stable CRC risk
BF SIG 45-85, 5 0 4576 0 3263 343 49 29 0% 73.3
BF CTC 55-75, 10 0 0 2190 1473 235 31 21 0% 5.9
BF CTC 55-80, 10 0 0 2190 1473 235 31 21 0% 5.9
BF CTC 55-85, 10 0 0 2467 1547 239 32 22 -4.1% Dom.
BF CTC 50-75, 10 0 0 2400 1574 254 31 21 0% 5.5
BF CTC 50-80, 10 0 0 2800 1689 266 33 23 -0.5% 9.5*
BF CTC 50-85, 10 0 0 2800 1689 266 33 23 -0.5% 9.5*
BF CTC 45-75, 10 0 0 3090 1786 274 34 23 -1.4% 10.3*
BF CTC 45-80, 10 0 0 3090 1786 274 34 23 -1.4% 10.3*
BF CTC 45-85, 10 0 0 3365 1858 278 34 24 -3.0% Dom.
BF CTC 55-75, 5 0 0 3207 1802 277 38 25 -1.2% 9.9*
BF CTC 55-80, 5 0 0 3536 1875 282 39 26 -2.2% Dom.
BF CTC 55-85, 5 0 0 3762 1921 284 40 26 -3.5% Dom.
BF CTC 50-75, 5 0 0 3955 2062 310 41 26 0% 8.6
BF CTC 50-80, 5 0 0 4281 2133 316 42 27 -0.6% 13.6*
BF CTC 50-85, 5 0 0 4505 2178 317 43 27 -1.5% 17.4*
BF CTC 45-75, 5 0 0 4748 2284 333 42 27 0% 10.0
BF CTC 45-80, 5 0 0 5072 2354 338 44 28 0% 13.6
BF CTC 45-85, 5 0 0 5295 2399 339 44 28 0% 30.6
SimCRC - Scenario 1: Stable CRC risk
BF No screening 0 0 0 64 0 0 0 - -
BF COL 55-75, 15 0 0 0 2815 250 46 23 0% 11.0
BF COL 55-80, 15 0 0 0 2815 250 46 23 0% 11.0
BF COL 55-85, 15 0 0 0 3141 251 47 23 -12.9% Dom.
BF COL 50-75, 15 0 0 0 3017 283 48 24 0% 6.0
BF COL 50-80, 15 0 0 0 3512 289 51 25 -4.7% Dom.
BF COL 50-85, 15 0 0 0 3512 289 51 25 -4.7% Dom.
BF COL 45-75, 15 0 0 0 3845 317 53 26 0% 24.4
BF COL 45-80, 15 0 0 0 3845 317 53 26 0% 24.4
BF COL 45-85, 15 0 0 0 3845 317 53 26 0% 24.4
BF COL 55-75, 10 0 0 0 3503 262 49 24 -13.7% Dom.
BF COL 55-80, 10 0 0 0 3503 262 49 24 -13.7% Dom.
BF COL 55-85, 10 0 0 0 3789 262 50 24 -16.6% Dom.
BF COL 50-75, 10 0 0 0 3849 300 52 26 -5.3% Dom.
BF COL 50-80, 10 0 0 0 4280 303 54 26 -6.9% Dom.
BF COL 50-85, 10 0 0 0 4280 303 54 26 -6.9% Dom.
BF COL 45-75, 10 0 0 0 4701 334 56 27 0% 50.4
BF COL 45-80, 10 0 0 0 4701 334 56 27 0% 50.4
BF COL 45-85, 10 0 0 0 4987 335 57 28 -0.3% 380.6*
BF COL 55-75, 5 0 0 0 4855 270 51 25 -19.2% Dom.
BF COL 55-80, 5 0 0 0 5224 271 52 25 -19.5% Dom.
BF COL 55-85, 5 0 0 0 5470 271 52 25 -19.8% Dom.
BF COL 50-75, 5 0 0 0 5888 313 56 27 -8.0% Dom.
BF COL 50-80, 5 0 0 0 6257 314 56 27 -8.3% Dom.
BF COL 50-85, 5 0 0 0 6503 314 56 27 -8.6% Dom.
BF COL 45-75, 5 0 0 0 6939 347 59 28 0% 179.2
BF COL 45-80, 5 0 0 0 7307 347 59 28 0% 433.8
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BF COL 45-85, 5 0 0 0 7554 348 59 28 0% 1225.4
BF FIT 55-75, 3 5347 0 0 703 175 23 15 0% 3.7
BF FIT 55-80, 3 6340 0 0 793 187 25 17 -5.3% Dom.
BF FIT 55-85, 3 6964 0 0 849 191 25 18 -9.7% Dom.
BF FIT 50-75, 3 6947 0 0 852 212 27 18 0% 4.0
BF FIT 50-80, 3 7794 0 0 929 221 28 19 -3.7% Dom.
BF FIT 50-85, 3 8243 0 0 966 223 29 20 -6.1% Dom.
BF FIT 45-75, 3 8461 0 0 978 241 30 19 0% 4.4
BF FIT 45-80, 3 9066 0 0 1029 247 31 20 0.0% 8.2*
BF FIT 45-85, 3 9784 0 0 1091 251 31 21 -1.3% 10.5*
BF FIT 55-75, 2 7713 0 0 927 206 29 18 -10.0% Dom.
BF FIT 55-80, 2 8598 0 0 999 213 30 20 -12.5% Dom.
BF FIT 55-85, 2 9570 0 0 1074 217 31 20 -14.2% Dom.
BF FIT 50-75, 2 9438 0 0 1075 241 33 20 -4.7% Dom.
BF FIT 50-80, 2 10754 0 0 1179 251 35 22 -5.7% Dom.
BF FIT 50-85, 2 11398 0 0 1229 253 35 22 -6.9% Dom.
BF FIT 45-75, 2 11722 0 0 1249 274 36 22 0% 8.1
BF FIT 45-80, 2 12597 0 0 1318 280 37 23 0% 11.1
BF FIT 45-85, 2 13561 0 0 1392 284 38 24 -0.3% 19.7*
BF FIT 55-75, 1 12744 0 0 1324 237 37 21 -15.5% Dom.
BF FIT 55-80, 1 14522 0 0 1442 243 39 22 -15.6% Dom.
BF FIT 55-85, 1 15812 0 0 1524 246 40 23 -16.3% Dom.
BF FIT 50-75, 1 16076 0 0 1569 278 42 23 -6.2% Dom.
BF FIT 50-80, 1 17843 0 0 1685 284 44 24 -6.6% Dom.
BF FIT 50-85, 1 19127 0 0 1766 286 44 25 -7.4% Dom.
BF FIT 45-75, 1 19536 0 0 1797 311 45 25 0% 15.7
BF FIT 45-80, 1 21297 0 0 1912 317 47 26 0% 20.2
BF FIT 45-85, 1 22578 0 0 1992 319 47 26 0% 40.3
BF FIT-DNA 55-75, 5 3613 0 0 1047 193 29 18 -22.6% Dom.
BF FIT-DNA 55-80, 5 4031 0 0 1128 198 30 19 -23.6% Dom.
BF FIT-DNA 55-85, 5 4321 0 0 1183 200 30 19 -24.9% Dom.
BF FIT-DNA 50-75, 5 4438 0 0 1227 228 33 19 -16.2% Dom.
BF FIT-DNA 50-80, 5 4853 0 0 1307 233 34 20 -16.7% Dom.
BF FIT-DNA 50-85, 5 5141 0 0 1361 234 34 21 -17.2% Dom.
BF FIT-DNA 45-75, 5 5288 0 0 1392 255 36 21 -10.5% Dom.
BF FIT-DNA 45-80, 5 5702 0 0 1471 260 37 22 -10.4% Dom.
BF FIT-DNA 45-85, 5 5989 0 0 1525 262 37 22 -10.8% Dom.
BF FIT-DNA 55-75, 3 4730 0 0 1274 220 34 20 -20.5% Dom.
BF FIT-DNA 55-80, 3 5518 0 0 1416 228 36 21 -20.5% Dom.
BF FIT-DNA 55-85, 3 5947 0 0 1490 230 37 22 -21.0% Dom.
BF FIT-DNA 50-75, 3 6077 0 0 1544 261 39 22 -11.4% Dom.
BF FIT-DNA 50-80, 3 6665 0 0 1649 267 41 23 -11.4% Dom.
BF FIT-DNA 50-85, 3 7124 0 0 1725 269 41 24 -12.1% Dom.
BF FIT-DNA 45-75, 3 7257 0 0 1759 292 42 23 -5.5% Dom.
BF FIT-DNA 45-80, 3 7883 0 0 1866 297 44 24 -5.4% Dom.
BF FIT-DNA 45-85, 3 8399 0 0 1954 300 44 25 -5.5% Dom.




SimCRC - Scenario 1: Stable CRC risk
BF FIT-DNA 55-80, 1 10183 0 0 2206 257 45 24 -20.1% Dom.
BF FIT-DNA 55-85, 1 11008 0 0 2322 258 46 24 -20.1% Dom.
BF FIT-DNA 50-75, 1 11299 0 0 2422 294 48 25 -9.3% Dom.
BF FIT-DNA 50-80, 1 12442 0 0 2588 298 50 26 -8.7% Dom.
BF FIT-DNA 50-85, 1 13259 0 0 2703 299 50 26 -8.7% Dom.
BF FIT-DNA 45-75, 1 13664 0 0 2789 327 52 26 -0.5% 99.5*
BF FIT-DNA 45-80, 1 14795 0 0 2953 330 53 27 0% 82.9
BF FIT-DNA 45-85, 1 15610 0 0 3067 331 53 27 0% 94.9
BF HSgFOBT 55-75, 3 5049 0 0 949 176 24 16 -24.8% Dom.
BF HSgFOBT 55-80, 3 5945 0 0 1068 187 26 17 -25.9% Dom.
BF HSgFOBT 55-85, 3 6462 0 0 1134 190 27 18 -27.0% Dom.
BF HSgFOBT 50-75, 3 6511 0 0 1167 214 29 18 -18.8% Dom.
BF HSgFOBT 50-80, 3 7211 0 0 1260 222 30 19 -19.3% Dom.
BF HSgFOBT 50-85, 3 7687 0 0 1318 225 31 20 -19.9% Dom.
BF HSgFOBT 45-75, 3 7815 0 0 1349 243 32 19 -13.9% Dom.
BF HSgFOBT 45-80, 3 8458 0 0 1428 249 33 20 -13.3% Dom.
BF HSgFOBT 45-85, 3 9073 0 0 1506 253 33 21 -13.4% Dom.
BF HSgFOBT 55-75, 2 6975 0 0 1240 207 31 19 -24.3% Dom.
BF HSgFOBT 55-80, 2 7741 0 0 1335 213 32 20 -24.4% Dom.
BF HSgFOBT 55-85, 2 8578 0 0 1433 216 32 21 -24.8% Dom.
BF HSgFOBT 50-75, 2 8481 0 0 1459 243 35 20 -16.0% Dom.
BF HSgFOBT 50-80, 2 9617 0 0 1597 252 37 22 -15.6% Dom.
BF HSgFOBT 50-85, 2 10171 0 0 1661 254 37 22 -16.1% Dom.
BF HSgFOBT 45-75, 2 10472 0 0 1717 277 38 22 -9.5% Dom.
BF HSgFOBT 45-80, 2 11226 0 0 1808 282 40 23 -9.4% Dom.
BF HSgFOBT 45-85, 2 12052 0 0 1904 285 40 24 -9.7% Dom.
BF HSgFOBT 55-75, 1 10533 0 0 1728 238 39 22 -22.5% Dom.
BF HSgFOBT 55-80, 1 11905 0 0 1879 243 40 23 -22.9% Dom.
BF HSgFOBT 55-85, 1 12901 0 0 1985 245 41 23 -23.1% Dom.
BF HSgFOBT 50-75, 1 13136 0 0 2068 279 44 24 -12.7% Dom.
BF HSgFOBT 50-80, 1 14507 0 0 2217 284 45 25 -11.6% Dom.
BF HSgFOBT 50-85, 1 15498 0 0 2321 286 45 25 -11.4% Dom.
BF HSgFOBT 45-75, 1 15850 0 0 2391 312 47 25 -3.6% Dom.
BF HSgFOBT 45-80, 1 17214 0 0 2539 317 48 26 -2.6% Dom.
BF HSgFOBT 45-85, 1 18201 0 0 2642 318 49 26 -2.4% Dom.
BF SIG 55-75, 10 0 2303 0 1122 177 33 17 0% 6.0
BF SIG 55-80, 10 0 2303 0 1122 177 33 17 0% 6.0
BF SIG 55-85, 10 0 2623 0 1210 178 33 17 -12.7% Dom.
BF SIG 50-75, 10 0 2500 0 1193 202 35 17 0% 2.8
BF SIG 50-80, 10 0 2957 0 1326 207 37 18 -5.3% Dom.
BF SIG 50-85, 10 0 2957 0 1326 207 37 18 -5.3% Dom.
BF SIG 45-75, 10 0 3231 0 1412 230 38 19 0% 7.9
BF SIG 45-80, 10 0 3231 0 1412 230 38 19 0% 7.9
BF SIG 45-85, 10 0 3548 0 1499 231 39 20 -1.9% 53.4*
BF SIG 55-75, 5 0 3401 0 1417 198 37 19 -14.1% Dom.
BF SIG 55-80, 5 0 3778 0 1507 200 38 19 -15.4% Dom.
BF SIG 55-85, 5 0 4038 0 1566 201 39 19 -16.5% Dom.
table continues
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SimCRC - Scenario 1: Stable CRC risk
BF SIG 50-75, 5 0 4182 0 1643 232 41 20 -5.5% Dom.
BF SIG 50-80, 5 0 4557 0 1732 235 42 21 -6.9% Dom.
BF SIG 50-85, 5 0 4815 0 1790 236 42 21 -8.1% Dom.
BF SIG 45-75, 5 0 4992 0 1852 261 44 22 0% 14.2
BF SIG 45-80, 5 0 5365 0 1940 263 45 22 0% 37.9
BF SIG 45-85, 5 0 5623 0 1998 264 45 22 0% 86.5
BF CTC 55-75, 10 0 0 2283 1220 225 40 21 0% 5.1
BF CTC 55-80, 10 0 0 2283 1220 225 40 21 0% 5.1
BF CTC 55-85, 10 0 0 2592 1319 227 41 21 -12.9% Dom.
BF CTC 50-75, 10 0 0 2485 1278 255 42 22 0% 2.0
BF CTC 50-80, 10 0 0 2930 1424 262 45 23 -5.5% Dom.
BF CTC 50-85, 10 0 0 2930 1424 262 45 23 -5.5% Dom.
BF CTC 45-75, 10 0 0 3211 1499 288 46 24 0% 6.7
BF CTC 45-80, 10 0 0 3211 1499 288 46 24 0% 6.7
BF CTC 45-85, 10 0 0 3518 1597 290 47 24 -1.6% 48.0*
BF CTC 55-75, 5 0 0 3370 1504 246 45 23 -14.8% Dom.
BF CTC 55-80, 5 0 0 3738 1597 248 46 23 -15.7% Dom.
BF CTC 55-85, 5 0 0 3989 1658 249 46 23 -16.7% Dom.
BF CTC 50-75, 5 0 0 4159 1721 286 49 25 -5.7% Dom.
BF CTC 50-80, 5 0 0 4525 1813 289 50 25 -6.8% Dom.
BF CTC 50-85, 5 0 0 4776 1874 290 50 25 -7.8% Dom.
BF CTC 45-75, 5 0 0 4980 1916 317 52 26 0% 14.3
BF CTC 45-80, 5 0 0 5345 2007 320 53 26 0% 35.4
BF CTC 45-85, 5 0 0 5596 2068 320 53 27 0% 83.4
SimCRC - Scenario 2: Increased CRC risk
BF No screening 0 0 0 80 0 0 0 - -
BF COL 55-75, 15 0 0 0 2733 306 54 28 0% 8.7
BF COL 55-80, 15 0 0 0 2733 306 54 28 0% 8.7
BF COL 55-85, 15 0 0 0 3067 308 55 28 -12.9% Dom.
BF COL 50-75, 15 0 0 0 2923 346 56 28 0% 4.7
BF COL 50-80, 15 0 0 0 3429 356 60 30 -4.7% Dom.
BF COL 50-85, 15 0 0 0 3429 356 60 30 -4.7% Dom.
BF COL 45-75, 15 0 0 0 3755 391 63 32 0% 18.7
BF COL 45-80, 15 0 0 0 3755 391 63 32 0% 18.7
BF COL 45-85, 15 0 0 0 3755 391 63 32 0% 18.7
BF COL 55-75, 10 0 0 0 3434 325 59 30 -13.2% Dom.
BF COL 55-80, 10 0 0 0 3434 325 59 30 -13.2% Dom.
BF COL 55-85, 10 0 0 0 3727 326 60 30 -16.3% Dom.
BF COL 50-75, 10 0 0 0 3768 372 62 31 -4.9% Dom.
BF COL 50-80, 10 0 0 0 4212 377 65 32 -6.7% Dom.
BF COL 50-85, 10 0 0 0 4212 377 65 32 -6.7% Dom.
BF COL 45-75, 10 0 0 0 4623 416 67 33 0% 34.8
BF COL 45-80, 10 0 0 0 4623 416 67 33 0% 34.8
BF COL 45-85, 10 0 0 0 4917 417 68 34 -0.3% 223.5*
BF COL 55-75, 5 0 0 0 4821 338 62 31 -19.1% Dom.
BF COL 55-80, 5 0 0 0 5202 339 63 31 -19.4% Dom.




SimCRC - Scenario 2: Increased CRC risk
BF COL 50-75, 5 0 0 0 5859 392 68 33 -8.0% Dom.
BF COL 50-80, 5 0 0 0 6239 394 69 34 -8.3% Dom.
BF COL 50-85, 5 0 0 0 6493 394 69 34 -8.6% Dom.
BF COL 45-75, 5 0 0 0 6913 435 71 35 0% 121.6
BF COL 45-80, 5 0 0 0 7293 436 72 35 0% 241.7
BF COL 45-85, 5 0 0 0 7547 437 73 35 0% 687.9
BF FIT 55-75, 3 5338 0 0 684 211 26 18 0% 2.9
BF FIT 55-80, 3 6332 0 0 771 227 28 20 -5.4% Dom.
BF FIT 55-85, 3 6954 0 0 825 231 28 21 -9.9% Dom.
BF FIT 50-75, 3 6946 0 0 827 258 31 21 0% 3.1
BF FIT 50-80, 3 7791 0 0 901 270 32 23 -3.6% Dom.
BF FIT 50-85, 3 8242 0 0 939 273 33 23 -6.1% Dom.
BF FIT 45-75, 3 8465 0 0 949 294 34 23 0% 3.4
BF FIT 45-80, 3 9073 0 0 998 302 35 24 0% 6.0
BF FIT 45-85, 3 9792 0 0 1059 308 36 25 -1.3% 10.2*
BF FIT 55-75, 2 7711 0 0 896 251 33 22 -9.9% Dom.
BF FIT 55-80, 2 8599 0 0 967 260 35 23 -12.4% Dom.
BF FIT 55-85, 2 9576 0 0 1041 265 35 25 -14.1% Dom.
BF FIT 50-75, 2 9448 0 0 1038 294 38 24 -4.6% Dom.
BF FIT 50-80, 2 10772 0 0 1140 307 40 26 -5.5% Dom.
BF FIT 50-85, 2 11420 0 0 1189 311 40 27 -6.7% Dom.
BF FIT 45-75, 2 11747 0 0 1207 336 42 26 0% 6.1
BF FIT 45-80, 2 12627 0 0 1276 345 43 27 0% 7.9
BF FIT 45-85, 2 13597 0 0 1348 350 44 29 -0.3% 14.2*
BF FIT 55-75, 1 12784 0 0 1275 291 43 26 -15.5% Dom.
BF FIT 55-80, 1 14585 0 0 1393 300 46 27 -15.4% Dom.
BF FIT 55-85, 1 15893 0 0 1474 303 46 28 -16.2% Dom.
BF FIT 50-75, 1 16149 0 0 1513 343 49 28 -6.1% Dom.
BF FIT 50-80, 1 17941 0 0 1629 352 51 30 -6.3% Dom.
BF FIT 50-85, 1 19244 0 0 1710 355 52 30 -7.2% Dom.
BF FIT 45-75, 1 19641 0 0 1735 384 53 30 0% 11.6
BF FIT 45-80, 1 21428 0 0 1850 393 55 31 0% 13.4
BF FIT 45-85, 1 22729 0 0 1930 396 56 32 0% 26.3
BF FIT-DNA 55-75, 5 3614 0 0 1012 235 33 21 -22.9% Dom.
BF FIT-DNA 55-80, 5 4034 0 0 1092 242 34 22 -23.9% Dom.
BF FIT-DNA 55-85, 5 4325 0 0 1146 244 35 23 -25.2% Dom.
BF FIT-DNA 50-75, 5 4445 0 0 1185 277 38 23 -16.6% Dom.
BF FIT-DNA 50-80, 5 4863 0 0 1264 284 39 24 -17.2% Dom.
BF FIT-DNA 50-85, 5 5153 0 0 1317 286 39 25 -17.8% Dom.
BF FIT-DNA 45-75, 5 5301 0 0 1347 312 41 25 -11.1% Dom.
BF FIT-DNA 45-80, 5 5717 0 0 1424 319 42 26 -10.9% Dom.
BF FIT-DNA 45-85, 5 6006 0 0 1478 321 42 26 -11.4% Dom.
BF FIT-DNA 55-75, 3 4739 0 0 1229 268 39 24 -21.0% Dom.
BF FIT-DNA 55-80, 3 5535 0 0 1370 279 42 25 -20.8% Dom.
BF FIT-DNA 55-85, 3 5968 0 0 1444 282 43 26 -21.4% Dom.
BF FIT-DNA 50-75, 3 6098 0 0 1492 320 45 26 -11.9% Dom.
BF FIT-DNA 50-80, 3 6693 0 0 1596 328 47 28 -11.8% Dom.
table continues
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SimCRC - Scenario 2: Increased CRC risk
BF FIT-DNA 50-85, 3 7158 0 0 1672 332 48 28 -12.5% Dom.
BF FIT-DNA 45-75, 3 7288 0 0 1700 359 49 28 -5.9% Dom.
BF FIT-DNA 45-80, 3 7923 0 0 1807 367 51 29 -5.7% Dom.
BF FIT-DNA 45-85, 3 8446 0 0 1896 371 52 30 -6.0% Dom.
BF FIT-DNA 55-75, 1 9131 0 0 1976 312 52 28 -21.4% Dom.
BF FIT-DNA 55-80, 1 10277 0 0 2142 318 54 29 -20.4% Dom.
BF FIT-DNA 55-85, 1 11120 0 0 2260 320 55 29 -20.3% Dom.
BF FIT-DNA 50-75, 1 11400 0 0 2348 364 57 30 -9.6% Dom.
BF FIT-DNA 50-80, 1 12569 0 0 2517 370 59 31 -8.7% Dom.
BF FIT-DNA 50-85, 1 13404 0 0 2634 372 60 32 -8.7% Dom.
BF FIT-DNA 45-75, 1 13792 0 0 2709 406 61 32 -0.8% 79.9*
BF FIT-DNA 45-80, 1 14948 0 0 2876 412 63 33 0.0% 60.9*
BF FIT-DNA 45-85, 1 15782 0 0 2993 414 64 33 0% 60.6
BF HSgFOBT 55-75, 3 5041 0 0 924 213 28 19 -25.7% Dom.
BF HSgFOBT 55-80, 3 5939 0 0 1041 227 30 21 -26.5% Dom.
BF HSgFOBT 55-85, 3 6455 0 0 1106 231 30 22 -27.7% Dom.
BF HSgFOBT 50-75, 3 6512 0 0 1135 261 33 21 -19.7% Dom.
BF HSgFOBT 50-80, 3 7213 0 0 1226 271 35 23 -20.0% Dom.
BF HSgFOBT 50-85, 3 7692 0 0 1284 274 35 24 -20.6% Dom.
BF HSgFOBT 45-75, 3 7822 0 0 1311 297 37 23 -14.5% Dom.
BF HSgFOBT 45-80, 3 8471 0 0 1390 306 38 24 -13.8% Dom.
BF HSgFOBT 45-85, 3 9088 0 0 1466 311 39 26 -14.0% Dom.
BF HSgFOBT 55-75, 2 6972 0 0 1204 252 35 22 -24.9% Dom.
BF HSgFOBT 55-80, 2 7743 0 0 1298 261 37 24 -24.8% Dom.
BF HSgFOBT 55-85, 2 8585 0 0 1396 265 38 25 -25.3% Dom.
BF HSgFOBT 50-75, 2 8493 0 0 1415 297 40 24 -16.7% Dom.
BF HSgFOBT 50-80, 2 9639 0 0 1551 309 42 26 -16.2% Dom.
BF HSgFOBT 50-85, 2 10198 0 0 1616 312 43 27 -16.6% Dom.
BF HSgFOBT 45-75, 2 10500 0 0 1666 340 44 27 -10.2% Dom.
BF HSgFOBT 45-80, 2 11261 0 0 1757 348 46 28 -10.0% Dom.
BF HSgFOBT 45-85, 2 12096 0 0 1853 352 47 29 -10.4% Dom.
BF HSgFOBT 55-75, 1 10562 0 0 1675 292 45 26 -22.9% Dom.
BF HSgFOBT 55-80, 1 11954 0 0 1826 300 47 27 -23.3% Dom.
BF HSgFOBT 55-85, 1 12967 0 0 1933 303 48 28 -23.6% Dom.
BF HSgFOBT 50-75, 1 13198 0 0 2005 344 51 29 -13.4% Dom.
BF HSgFOBT 50-80, 1 14592 0 0 2156 352 53 30 -12.0% Dom.
BF HSgFOBT 50-85, 1 15600 0 0 2261 354 54 30 -11.7% Dom.
BF HSgFOBT 45-75, 1 15942 0 0 2322 386 55 30 -4.2% Dom.
BF HSgFOBT 45-80, 1 17331 0 0 2471 393 57 32 -2.9% Dom.
BF HSgFOBT 45-85, 1 18336 0 0 2576 396 58 32 -2.7% Dom.
BF SIG 55-75, 10 0 2256 0 1336 272 48 25 0% 4.6
BF SIG 55-80, 10 0 2256 0 1336 272 48 25 0% 4.6
BF SIG 55-85, 10 0 2554 0 1434 274 49 26 -12.4% Dom.
BF SIG 50-75, 10 0 2460 0 1415 310 51 26 0% 2.1
BF SIG 50-80, 10 0 2891 0 1564 317 53 27 -5.4% Dom.
BF SIG 50-85, 10 0 2891 0 1564 317 53 27 -5.4% Dom.




SimCRC - Scenario 2: Increased CRC risk
BF SIG 45-80, 10 0 3174 0 1657 351 56 29 0% 5.9
BF SIG 45-85, 10 0 3471 0 1754 353 57 29 -1.3% 45.8*
BF SIG 55-75, 5 0 3288 0 1611 292 52 27 -15.0% Dom.
BF SIG 55-80, 5 0 3640 0 1706 295 54 27 -16.8% Dom.
BF SIG 55-85, 5 0 3881 0 1768 296 54 28 -17.6% Dom.
BF SIG 50-75, 5 0 4059 0 1851 340 58 29 -6.6% Dom.
BF SIG 50-80, 5 0 4410 0 1945 343 59 30 -7.4% Dom.
BF SIG 50-85, 5 0 4650 0 2006 344 59 30 -8.2% Dom.
BF SIG 45-75, 5 0 4862 0 2068 379 61 31 0% 14.6
BF SIG 45-80, 5 0 5212 0 2162 382 62 31 0% 32.1
BF SIG 45-85, 5 0 5452 0 2223 383 63 31 0% 78.9
BF CTC 55-75, 10 0 0 2293 1153 275 47 25 0% 3.9
BF CTC 55-80, 10 0 0 2293 1153 275 47 25 0% 3.9
BF CTC 55-85, 10 0 0 2606 1251 278 48 26 -12.9% Dom.
BF CTC 50-75, 10 0 0 2495 1209 311 49 26 0% 1.6
BF CTC 50-80, 10 0 0 2947 1353 320 52 28 -5.6% Dom.
BF CTC 50-85, 10 0 0 2947 1353 320 52 28 -5.6% Dom.
BF CTC 45-75, 10 0 0 3228 1425 354 54 28 0% 5.0
BF CTC 45-80, 10 0 0 3228 1425 354 54 28 0% 5.0
BF CTC 45-85, 10 0 0 3540 1522 357 55 29 -1.8% 32.7*
BF CTC 55-75, 5 0 0 3399 1428 303 53 27 -14.3% Dom.
BF CTC 55-80, 5 0 0 3773 1521 308 55 28 -15.4% Dom.
BF CTC 55-85, 5 0 0 4030 1582 309 55 29 -16.5% Dom.
BF CTC 50-75, 5 0 0 4196 1639 354 58 30 -5.7% Dom.
BF CTC 50-80, 5 0 0 4570 1731 358 60 31 -6.9% Dom.
BF CTC 50-85, 5 0 0 4826 1793 359 60 31 -8.1% Dom.
BF CTC 45-75, 5 0 0 5024 1829 394 62 31 0% 10.0
BF CTC 45-80, 5 0 0 5398 1921 398 63 32 0% 22.7
BF CTC 45-85, 5 0 0 5654 1982 399 64 33 0% 54.7
BF - black female; COL - colonoscopy; CRC - colorectal cancer; CTC - computed tomographic 
colonography; Dom. - dominated strategy; ER - efficiency ratio; FIT - fecal immunochemical 
test; FIT-DNA - multitarget stool DNA test; HSgFOBT - high-sensitivity guaiac-based fecal 
occult blood test; LYG - life-years gained; SIG - flexible sigmoidoscopy.
a Both models evaluated two scenarios for CRC risk: one in which age-specific risks were 
assumed to have remained stable since the early screening period in the U.S. (1975-1979 
for SimCRC; 1990-1994 for MISCAN), and one in which risks were assumed to have increased 
proportional to observed trends among adults under age 40 years. Strategies for each model 
and scenario are ordered successively by screening modality, interval ( ), end age ( ), and 
start age ( ).
b Total number of colonoscopies performed per 1000 40-year-olds, including diagnostic 
colonoscopies and potential surveillance colonoscopies after adenoma removal. The number 
of screening-related complications ranged from 1.6 to 18.9 per 1000 40-year-olds across 
models, scenarios, and strategies.
c Including deaths from complications of screening.
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d The difference in LYG compared to (combinations of ) adjacent strategies on the efficient 
frontier. Near-efficient strategies have a loss in LYG of less than 2% before rounding. For the 
least intensive screening strategy evaluated within each class of screening modality, the 
difference was zero by definition.
e Efficiency ratio = incremental number of colonoscopies/LYG with respect to the next less 
effective strategy on the efficient frontier, a burden-to-benefit ratio. Only calculated for 
efficient and near-efficient strategies (marked with an asterisk*), i.e. strategies within 2% from 
the efficient frontier among all evaluated strategies within a class of screening modalities 
(colonoscopy, stool-based, sigmoidoscopy, and CTC). 
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Supplementary Table A3.5: Lifetime number of colonoscopies and LYG for all evaluated 
screening strategies under two scenarios for CRC risk, by model, in white males a
































































































































MISCAN - Scenario 1: Stable CRC risk
WM No screening 0 0 0 71 0 0 0 - -
WM COL 55-75, 15 0 0 0 3001 197 39 20 0% 14.8
WM COL 55-80, 15 0 0 0 3001 197 39 20 0% 14.8
WM COL 55-85, 15 0 0 0 3240 198 39 20 -3.8% Dom.
WM COL 50-75, 15 0 0 0 3264 207 39 20 0% 26.4
WM COL 50-80, 15 0 0 0 3657 212 41 21 -2.3% Dom.
WM COL 50-85, 15 0 0 0 3657 212 41 21 -2.3% Dom.
WM COL 45-75, 15 0 0 0 3979 218 41 21 -3.4% Dom.
WM COL 45-80, 15 0 0 0 3979 218 41 21 -3.4% Dom.
WM COL 45-85, 15 0 0 0 3979 218 41 21 -3.4% Dom.
WM COL 55-75, 10 0 0 0 3598 209 42 21 -3.3% Dom.
WM COL 55-80, 10 0 0 0 3598 209 42 21 -3.3% Dom.
WM COL 55-85, 10 0 0 0 3813 210 42 21 -5.4% Dom.
WM COL 50-75, 10 0 0 0 4007 227 43 21 0% 38.6
WM COL 50-80, 10 0 0 0 4357 230 44 22 -0.8% 116.6*
WM COL 50-85, 10 0 0 0 4357 230 44 22 -0.8% 116.6*
WM COL 45-75, 10 0 0 0 4797 238 45 22 0% 72.0
WM COL 45-80, 10 0 0 0 4797 238 45 22 0% 72.0
WM COL 45-85, 10 0 0 0 5012 238 45 22 -0.6% 351.8*
WM COL 55-75, 5 0 0 0 4786 221 45 22 -7.1% Dom.
WM COL 55-80, 5 0 0 0 5098 222 45 22 -7.6% Dom.
WM COL 55-85, 5 0 0 0 5285 222 45 22 -8.3% Dom.
WM COL 50-75, 5 0 0 0 5807 243 47 23 -1.5% 181.2*
WM COL 50-80, 5 0 0 0 6119 244 48 23 -2.1% Dom.
WM COL 50-85, 5 0 0 0 6305 245 48 23 -2.8% Dom.
WM COL 45-75, 5 0 0 0 6844 257 48 23 0% 108.1
WM COL 45-80, 5 0 0 0 7157 258 49 24 0% 225.9
WM COL 45-85, 5 0 0 0 7343 258 49 24 0% 1902.6
WM FIT 55-75, 3 5146 0 0 796 142 16 14 0% 5.1
WM FIT 55-80, 3 6037 0 0 876 153 17 15 0% 7.6
WM FIT 55-85, 3 6615 0 0 922 156 17 16 -1.5% 13.3*
WM FIT 50-75, 3 6689 0 0 947 162 18 15 0% 7.9
WM FIT 50-80, 3 7524 0 0 1019 171 19 17 0% 8.0
WM FIT 50-85, 3 7824 0 0 1042 172 19 17 -0.2% 12.9*
WM FIT 45-75, 3 8274 0 0 1074 173 20 16 -1.4% 21.1*
WM FIT 45-80, 3 8702 0 0 1109 178 20 16 -0.5% 12.5*
WM FIT 45-85, 3 9327 0 0 1158 182 19 17 -0.6% 12.2*
table continues
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MISCAN - Scenario 1: Stable CRC risk
WM FIT 55-75, 2 7481 0 0 1030 167 21 16 -3.0% Dom.
WM FIT 55-80, 2 8279 0 0 1091 173 22 17 -2.4% Dom.
WM FIT 55-85, 2 9107 0 0 1148 176 22 18 -3.2% Dom.
WM FIT 50-75, 2 9204 0 0 1188 185 23 17 -0.7% 12.0*
WM FIT 50-80, 2 10388 0 0 1275 194 24 19 0% 11.0
WM FIT 50-85, 2 10936 0 0 1312 196 24 19 -0.2% 16.5*
WM FIT 45-75, 2 11465 0 0 1354 197 25 18 -1.0% 22.1*
WM FIT 45-80, 2 12251 0 0 1412 203 25 19 0% 14.4
WM FIT 45-85, 2 13070 0 0 1466 207 25 20 0% 16.0
WM FIT 55-75, 1 12335 0 0 1437 192 29 19 -6.2% Dom.
WM FIT 55-80, 1 13936 0 0 1534 199 31 20 -5.3% Dom.
WM FIT 55-85, 1 15040 0 0 1595 201 31 20 -5.5% Dom.
WM FIT 50-75, 1 15619 0 0 1693 214 32 20 -1.3% 29.7*
WM FIT 50-80, 1 17205 0 0 1787 221 33 21 -0.5% 23.0*
WM FIT 50-85, 1 18301 0 0 1847 223 33 21 -0.7% 23.6*
WM FIT 45-75, 1 19081 0 0 1915 226 33 20 -0.8% 23.5*
WM FIT 45-80, 1 20659 0 0 2008 232 34 21 0% 21.4
WM FIT 45-85, 1 21751 0 0 2067 234 34 22 0% 28.6
WM FIT-DNA 55-75, 5 3495 0 0 1152 158 22 16 -13.3% Dom.
WM FIT-DNA 55-80, 5 3861 0 0 1220 164 22 17 -13.4% Dom.
WM FIT-DNA 55-85, 5 4096 0 0 1259 165 22 17 -14.3% Dom.
WM FIT-DNA 50-75, 5 4308 0 0 1340 176 24 17 -11.3% Dom.
WM FIT-DNA 50-80, 5 4670 0 0 1405 181 24 18 -10.8% Dom.
WM FIT-DNA 50-85, 5 4904 0 0 1444 182 24 18 -11.3% Dom.
WM FIT-DNA 45-75, 5 5156 0 0 1499 185 25 17 -11.3% Dom.
WM FIT-DNA 45-80, 5 5517 0 0 1563 190 25 18 -10.2% Dom.
WM FIT-DNA 45-85, 5 5750 0 0 1602 191 25 18 -10.3% Dom.
WM FIT-DNA 55-75, 3 4427 0 0 1380 176 26 17 -12.4% Dom.
WM FIT-DNA 55-80, 3 5129 0 0 1501 185 28 19 -11.4% Dom.
WM FIT-DNA 55-85, 3 5577 0 0 1570 187 28 19 -11.6% Dom.
WM FIT-DNA 50-75, 3 5701 0 0 1650 198 29 18 -8.0% Dom.
WM FIT-DNA 50-80, 3 6352 0 0 1759 205 30 20 -6.9% Dom.
WM FIT-DNA 50-85, 3 6585 0 0 1794 206 30 20 -7.0% Dom.
WM FIT-DNA 45-75, 3 7017 0 0 1885 210 31 19 -7.3% Dom.
WM FIT-DNA 45-80, 3 7352 0 0 1939 213 31 20 -6.8% Dom.
WM FIT-DNA 45-85, 3 7837 0 0 2014 216 31 20 -6.8% Dom.
WM FIT-DNA 55-75, 1 8705 0 0 2190 206 37 20 -12.3% Dom.
WM FIT-DNA 55-80, 1 9690 0 0 2324 210 38 21 -11.0% Dom.
WM FIT-DNA 55-85, 1 10380 0 0 2412 211 39 21 -10.8% Dom.
WM FIT-DNA 50-75, 1 10885 0 0 2589 227 40 21 -4.8% Dom.
WM FIT-DNA 50-80, 1 11884 0 0 2723 231 41 22 -3.6% Dom.
WM FIT-DNA 50-85, 1 12566 0 0 2809 232 41 22 -3.4% Dom.
WM FIT-DNA 45-75, 1 13234 0 0 2953 239 41 21 -1.3% 194.0*
WM FIT-DNA 45-80, 1 14221 0 0 3085 243 42 22 -0.2% 120.7*
WM FIT-DNA 45-85, 1 14903 0 0 3171 244 42 22 0% 114.8
WM HSgFOBT 55-75, 3 4813 0 0 1022 141 17 14 -17.7% Dom.




MISCAN - Scenario 1: Stable CRC risk
WM HSgFOBT 55-85, 3 6133 0 0 1188 154 18 16 -17.3% Dom.
WM HSgFOBT 50-75, 3 6201 0 0 1248 161 20 15 -15.8% Dom.
WM HSgFOBT 50-80, 3 6947 0 0 1342 169 20 17 -14.6% Dom.
WM HSgFOBT 50-85, 3 7215 0 0 1373 171 20 17 -14.7% Dom.
WM HSgFOBT 45-75, 3 7623 0 0 1445 173 21 16 -15.8% Dom.
WM HSgFOBT 45-80, 3 8005 0 0 1492 177 22 17 -14.8% Dom.
WM HSgFOBT 45-85, 3 8561 0 0 1557 181 21 17 -14.2% Dom.
WM HSgFOBT 55-75, 2 6788 0 0 1339 166 23 16 -16.3% Dom.
WM HSgFOBT 55-80, 2 7473 0 0 1420 172 23 17 -15.8% Dom.
WM HSgFOBT 55-85, 2 8179 0 0 1497 175 23 18 -16.0% Dom.
WM HSgFOBT 50-75, 2 8279 0 0 1580 185 25 17 -12.6% Dom.
WM HSgFOBT 50-80, 2 9290 0 0 1697 193 26 19 -11.1% Dom.
WM HSgFOBT 50-85, 2 9755 0 0 1747 195 26 19 -11.1% Dom.
WM HSgFOBT 45-75, 2 10234 0 0 1837 198 27 18 -11.7% Dom.
WM HSgFOBT 45-80, 2 10904 0 0 1914 203 27 19 -10.8% Dom.
WM HSgFOBT 45-85, 2 11597 0 0 1987 206 27 20 -10.9% Dom.
WM HSgFOBT 55-75, 1 10212 0 0 1858 192 31 19 -14.6% Dom.
WM HSgFOBT 55-80, 1 11419 0 0 1984 197 32 20 -14.5% Dom.
WM HSgFOBT 55-85, 1 12250 0 0 2064 199 32 20 -14.9% Dom.
WM HSgFOBT 50-75, 1 12737 0 0 2221 214 34 20 -9.0% Dom.
WM HSgFOBT 50-80, 1 13937 0 0 2343 219 35 21 -7.3% Dom.
WM HSgFOBT 50-85, 1 14760 0 0 2422 221 35 21 -6.9% Dom.
WM HSgFOBT 45-75, 1 15423 0 0 2545 225 35 20 -5.4% Dom.
WM HSgFOBT 45-80, 1 16615 0 0 2666 230 36 21 -3.7% Dom.
WM HSgFOBT 45-85, 1 17436 0 0 2744 232 36 22 -3.3% Dom.
WM SIG 55-75, 10 0 2103 0 1695 171 34 17 0% 9.5
WM SIG 55-80, 10 0 2103 0 1695 171 34 17 0% 9.5
WM SIG 55-85, 10 0 2331 0 1757 172 34 18 -3.0% Dom.
WM SIG 50-75, 10 0 2328 0 1822 183 35 18 0% 10.0
WM SIG 50-80, 10 0 2681 0 1944 188 36 19 -0.9% 29.2*
WM SIG 50-85, 10 0 2681 0 1944 188 36 19 -0.9% 29.2*
WM SIG 45-75, 10 0 2997 0 2034 191 36 18 -1.4% 27.9*
WM SIG 45-80, 10 0 2997 0 2034 191 36 18 -1.4% 27.9*
WM SIG 45-85, 10 0 3225 0 2096 192 36 19 -2.4% Dom.
WM SIG 55-75, 5 0 3012 0 1957 185 37 19 -2.4% Dom.
WM SIG 55-80, 5 0 3303 0 2037 187 38 19 -3.3% Dom.
WM SIG 55-85, 5 0 3486 0 2072 188 38 19 -4.0% Dom.
WM SIG 50-75, 5 0 3737 0 2231 203 39 20 0% 20.6
WM SIG 50-80, 5 0 4026 0 2310 205 40 20 -0.6% 39.6*
WM SIG 50-85, 5 0 4209 0 2345 206 40 20 -1.1% 50.2*
WM SIG 45-75, 5 0 4522 0 2452 212 40 20 0% 24.8
WM SIG 45-80, 5 0 4810 0 2530 214 41 20 0% 39.7
WM SIG 45-85, 5 0 4993 0 2565 214 41 20 0% 131.0
WM CTC 55-75, 10 0 0 2234 1159 157 26 16 0% 6.9
WM CTC 55-80, 10 0 0 2234 1159 157 26 16 0% 6.9
WM CTC 55-85, 10 0 0 2498 1223 159 26 17 -3.8% Dom.
WM CTC 50-75, 10 0 0 2456 1223 166 26 15 0% 7.2
table continues
Modeling CRC Screening by Race and Sex
107
3
MISCAN - Scenario 1: Stable CRC risk
WM CTC 50-80, 10 0 0 2862 1329 175 28 17 -0.6% 12.0*
WM CTC 50-85, 10 0 0 2862 1329 175 28 17 -0.6% 12.0*
WM CTC 45-75, 10 0 0 3171 1393 176 28 17 -3.4% Dom.
WM CTC 45-80, 10 0 0 3171 1393 176 28 17 -3.4% Dom.
WM CTC 45-85, 10 0 0 3433 1456 178 28 17 -5.1% Dom.
WM CTC 55-75, 5 0 0 3320 1460 188 33 18 0% 10.7
WM CTC 55-80, 5 0 0 3659 1531 192 34 19 -1.1% 16.7*
WM CTC 55-85, 5 0 0 3877 1574 193 34 20 -2.5% Dom.
WM CTC 50-75, 5 0 0 4110 1667 207 35 19 0% 11.0
WM CTC 50-80, 5 0 0 4447 1737 211 36 20 0% 16.6
WM CTC 50-85, 5 0 0 4664 1779 212 36 20 -0.5% 41.7*
WM CTC 45-75, 5 0 0 4940 1842 216 36 20 -0.3% 21.6*
WM CTC 45-80, 5 0 0 5276 1911 220 37 21 0% 19.3
WM CTC 45-85, 5 0 0 5492 1953 221 37 21 0% 41.2
MISCAN - Scenario 2: Increased CRC risk
WM No screening 0 0 0 149 0 0 0 - -
WM COL 55-75, 15 0 0 0 4093 438 85 44 0% 9.0
WM COL 55-80, 15 0 0 0 4093 438 85 44 0% 9.0
WM COL 55-85, 15 0 0 0 4194 439 85 44 -1.0% 70.6*
WM COL 50-75, 15 0 0 0 4540 463 87 44 -0.2% 17.3*
WM COL 50-80, 15 0 0 0 4746 471 89 46 -1.3% 19.8*
WM COL 50-85, 15 0 0 0 4746 471 89 46 -1.3% 19.8*
WM COL 45-75, 15 0 0 0 5173 483 90 46 -3.4% Dom.
WM COL 45-80, 15 0 0 0 5173 483 90 46 -3.4% Dom.
WM COL 45-85, 15 0 0 0 5173 483 90 46 -3.4% Dom.
WM COL 55-75, 10 0 0 0 4478 458 90 46 -0.6% 18.9*
WM COL 55-80, 10 0 0 0 4478 458 90 46 -0.6% 18.9*
WM COL 55-85, 10 0 0 0 4553 459 90 46 -1.4% Dom.
WM COL 50-75, 10 0 0 0 5102 498 93 47 0% 16.7
WM COL 50-80, 10 0 0 0 5252 502 95 48 -0.1% 38.9*
WM COL 50-85, 10 0 0 0 5252 502 95 48 -0.1% 38.9*
WM COL 45-75, 10 0 0 0 5846 520 96 48 0% 33.5
WM COL 45-80, 10 0 0 0 5846 520 96 48 0% 33.5
WM COL 45-85, 10 0 0 0 5920 521 96 49 -0.2% 108.8*
WM COL 55-75, 5 0 0 0 5125 477 94 47 -4.4% Dom.
WM COL 55-80, 5 0 0 0 5231 478 95 48 -4.7% Dom.
WM COL 55-85, 5 0 0 0 5276 478 95 48 -4.9% Dom.
WM COL 50-75, 5 0 0 0 6146 526 100 50 -0.3% 48.5*
WM COL 50-80, 5 0 0 0 6251 528 100 50 -0.5% 52.3*
WM COL 50-85, 5 0 0 0 6297 528 100 50 -0.7% 57.5*
WM COL 45-75, 5 0 0 0 7182 554 102 51 0% 39.5
WM COL 45-80, 5 0 0 0 7288 556 103 51 0% 67.2
WM COL 45-85, 5 0 0 0 7334 556 103 51 0% 555.4
WM FIT 55-75, 3 4750 0 0 1416 311 37 30 0% 4.1
WM FIT 55-80, 3 5418 0 0 1531 333 39 34 0% 5.2
WM FIT 55-85, 3 5804 0 0 1589 339 38 36 -0.9% 8.8*




MISCAN - Scenario 2: Increased CRC risk
WM FIT 50-80, 3 6771 0 0 1760 372 43 36 0% 5.9
WM FIT 50-85, 3 6970 0 0 1790 375 43 37 -0.1% 8.5*
WM FIT 45-75, 3 7643 0 0 1853 378 45 35 -1.6% 15.0*
WM FIT 45-80, 3 7953 0 0 1902 387 45 36 -0.7% 9.0*
WM FIT 45-85, 3 8371 0 0 1964 395 45 38 -0.7% 8.6*
WM FIT 55-75, 2 6661 0 0 1774 364 48 36 -2.5% Dom.
WM FIT 55-80, 2 7209 0 0 1852 377 50 38 -1.8% 17.8*
WM FIT 55-85, 2 7721 0 0 1916 383 50 40 -2.2% Dom.
WM FIT 50-75, 2 8277 0 0 2027 402 53 37 -1.0% 8.6*
WM FIT 50-80, 2 9079 0 0 2137 421 55 41 0% 7.6
WM FIT 50-85, 2 9412 0 0 2177 425 55 42 -0.1% 9.8*
WM FIT 45-75, 2 10343 0 0 2270 431 56 39 -0.9% 12.8*
WM FIT 45-80, 2 10870 0 0 2341 443 57 41 0% 9.3
WM FIT 45-85, 2 11365 0 0 2401 449 57 43 0% 9.5
WM FIT 55-75, 1 10514 0 0 2348 420 65 41 -5.2% Dom.
WM FIT 55-80, 1 11486 0 0 2448 433 68 43 -4.5% Dom.
WM FIT 55-85, 1 12073 0 0 2501 436 68 44 -4.5% Dom.
WM FIT 50-75, 1 13419 0 0 2724 468 71 43 -1.4% 17.1*
WM FIT 50-80, 1 14362 0 0 2818 480 73 46 -0.5% 13.7*
WM FIT 50-85, 1 14937 0 0 2869 483 74 46 -0.6% 13.8*
WM FIT 45-75, 1 16592 0 0 3033 495 74 45 -0.8% 13.8*
WM FIT 45-80, 1 17522 0 0 3125 506 76 47 0% 12.7
WM FIT 45-85, 1 18090 0 0 3174 510 77 47 0% 13.8
WM FIT-DNA 55-75, 5 3141 0 0 1904 347 49 35 -11.0% Dom.
WM FIT-DNA 55-80, 5 3385 0 0 1980 357 50 37 -10.7% Dom.
WM FIT-DNA 55-85, 5 3524 0 0 2019 360 49 38 -11.2% Dom.
WM FIT-DNA 50-75, 5 3880 0 0 2187 384 53 37 -10.0% Dom.
WM FIT-DNA 50-80, 5 4117 0 0 2260 393 54 39 -9.4% Dom.
WM FIT-DNA 50-85, 5 4254 0 0 2297 396 53 39 -9.7% Dom.
WM FIT-DNA 45-75, 5 4674 0 0 2413 405 56 38 -10.1% Dom.
WM FIT-DNA 45-80, 5 4908 0 0 2484 414 56 40 -9.1% Dom.
WM FIT-DNA 45-85, 5 5044 0 0 2521 416 56 40 -9.2% Dom.
WM FIT-DNA 55-75, 3 3948 0 0 2246 387 59 38 -10.6% Dom.
WM FIT-DNA 55-80, 3 4400 0 0 2375 403 62 41 -9.7% Dom.
WM FIT-DNA 55-85, 3 4648 0 0 2435 407 63 42 -9.9% Dom.
WM FIT-DNA 50-75, 3 5056 0 0 2635 434 65 41 -7.2% Dom.
WM FIT-DNA 50-80, 3 5459 0 0 2744 447 68 43 -6.1% Dom.
WM FIT-DNA 50-85, 3 5587 0 0 2775 449 68 44 -6.1% Dom.
WM FIT-DNA 45-75, 3 6240 0 0 2951 460 68 42 -6.6% Dom.
WM FIT-DNA 45-80, 3 6446 0 0 3005 466 70 43 -6.1% Dom.
WM FIT-DNA 45-85, 3 6716 0 0 3070 472 70 45 -6.0% Dom.
WM FIT-DNA 55-75, 1 7075 0 0 3227 451 81 44 -11.6% Dom.
WM FIT-DNA 55-80, 1 7565 0 0 3321 458 83 46 -10.6% Dom.
WM FIT-DNA 55-85, 1 7858 0 0 3371 459 84 46 -10.4% Dom.
WM FIT-DNA 50-75, 1 8916 0 0 3756 497 87 47 -4.3% Dom.
WM FIT-DNA 50-80, 1 9402 0 0 3848 503 88 48 -3.4% Dom.
WM FIT-DNA 50-85, 1 9687 0 0 3896 505 89 48 -3.3% Dom.
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WM FIT-DNA 45-75, 1 11006 0 0 4210 522 89 47 -1.0% 85.7*
WM FIT-DNA 45-80, 1 11484 0 0 4299 528 91 49 -0.2% 61.9*
WM FIT-DNA 45-85, 1 11768 0 0 4347 529 91 49 0% 58.9
WM HSgFOBT 55-75, 3 4485 0 0 1647 308 39 30 -12.6% Dom.
WM HSgFOBT 55-80, 3 5082 0 0 1773 328 41 34 -12.0% Dom.
WM HSgFOBT 55-85, 3 5419 0 0 1835 334 40 35 -12.3% Dom.
WM HSgFOBT 50-75, 3 5740 0 0 1983 353 45 33 -12.0% Dom.
WM HSgFOBT 50-80, 3 6271 0 0 2090 369 46 36 -10.9% Dom.
WM HSgFOBT 50-85, 3 6443 0 0 2121 372 46 37 -11.1% Dom.
WM HSgFOBT 45-75, 3 7045 0 0 2260 379 48 35 -12.8% Dom.
WM HSgFOBT 45-80, 3 7316 0 0 2312 387 49 37 -12.0% Dom.
WM HSgFOBT 45-85, 3 7676 0 0 2377 394 48 38 -11.7% Dom.
WM HSgFOBT 55-75, 2 6098 0 0 2085 363 51 36 -12.3% Dom.
WM HSgFOBT 55-80, 2 6555 0 0 2170 374 52 38 -11.8% Dom.
WM HSgFOBT 55-85, 2 6971 0 0 2238 380 52 40 -12.0% Dom.
WM HSgFOBT 50-75, 2 7465 0 0 2444 405 57 38 -10.6% Dom.
WM HSgFOBT 50-80, 2 8122 0 0 2562 420 58 41 -9.0% Dom.
WM HSgFOBT 50-85, 2 8389 0 0 2604 424 58 42 -8.9% Dom.
WM HSgFOBT 45-75, 2 9211 0 0 2792 434 60 40 -9.6% Dom.
WM HSgFOBT 45-80, 2 9639 0 0 2868 444 62 42 -8.7% Dom.
WM HSgFOBT 45-85, 2 10033 0 0 2930 449 61 43 -8.5% Dom.
WM HSgFOBT 55-75, 1 8811 0 0 2770 421 68 42 -12.0% Dom.
WM HSgFOBT 55-80, 1 9493 0 0 2873 430 70 43 -11.5% Dom.
WM HSgFOBT 55-85, 1 9895 0 0 2927 433 71 44 -11.7% Dom.
WM HSgFOBT 50-75, 1 10968 0 0 3269 468 75 44 -8.4% Dom.
WM HSgFOBT 50-80, 1 11624 0 0 3365 477 77 46 -6.9% Dom.
WM HSgFOBT 50-85, 1 12014 0 0 3416 480 77 46 -6.6% Dom.
WM HSgFOBT 45-75, 1 13359 0 0 3692 495 78 45 -4.5% Dom.
WM HSgFOBT 45-80, 1 14003 0 0 3786 504 80 47 -3.1% Dom.
WM HSgFOBT 45-85, 1 14387 0 0 3836 506 80 47 -2.8% Dom.
WM SIG 55-75, 10 0 1676 0 3228 408 80 42 0% 7.6
WM SIG 55-80, 10 0 1676 0 3228 408 80 42 0% 7.6
WM SIG 55-85, 10 0 1767 0 3280 409 80 42 -1.1% 41.4*
WM SIG 50-75, 10 0 1934 0 3513 439 82 42 0% 9.1
WM SIG 50-80, 10 0 2095 0 3637 446 84 44 -0.7% 19.0*
WM SIG 50-85, 10 0 2095 0 3637 446 84 44 -0.7% 19.0*
WM SIG 45-75, 10 0 2451 0 3825 457 85 44 -1.4% 17.4*
WM SIG 45-80, 10 0 2451 0 3825 457 85 44 -1.4% 17.4*
WM SIG 45-85, 10 0 2541 0 3876 458 85 44 -1.9% 18.9*
WM SIG 55-75, 5 0 2157 0 3504 432 85 44 -1.3% 11.2*
WM SIG 55-80, 5 0 2270 0 3571 435 86 44 -1.9% Dom.
WM SIG 55-85, 5 0 2328 0 3590 436 86 44 -2.1% Dom.
WM SIG 50-75, 5 0 2718 0 3959 474 89 46 0% 12.8
WM SIG 50-80, 5 0 2829 0 4024 477 90 46 -0.2% 22.6*
WM SIG 50-85, 5 0 2887 0 4043 477 90 46 -0.4% 26.2*
WM SIG 45-75, 5 0 3389 0 4302 494 91 46 0% 16.9




MISCAN - Scenario 2: Increased CRC risk
WM SIG 45-85, 5 0 3558 0 4385 497 92 47 0% 66.2
WM CTC 55-75, 10 0 0 1995 2033 345 58 35 0% 5.5
WM CTC 55-80, 10 0 0 1995 2033 345 58 35 0% 5.5
WM CTC 55-85, 10 0 0 2156 2105 350 58 36 -2.0% Dom.
WM CTC 50-75, 10 0 0 2255 2149 364 58 35 0% 6.2
WM CTC 50-80, 10 0 0 2526 2282 381 61 38 -1.0% 7.7*
WM CTC 50-85, 10 0 0 2526 2282 381 61 38 -1.0% 7.7*
WM CTC 45-75, 10 0 0 2875 2385 386 62 37 -3.9% Dom.
WM CTC 45-80, 10 0 0 2875 2385 386 62 37 -3.9% Dom.
WM CTC 45-85, 10 0 0 3033 2455 390 62 38 -5.4% Dom.
WM CTC 55-75, 5 0 0 2836 2449 412 72 41 0% 6.3
WM CTC 55-80, 5 0 0 3036 2522 420 74 43 -0.4% 9.5*
WM CTC 55-85, 5 0 0 3151 2560 421 75 43 -1.1% 11.7*
WM CTC 50-75, 5 0 0 3542 2757 452 76 43 0% 7.7
WM CTC 50-80, 5 0 0 3740 2828 459 78 44 0% 9.5
WM CTC 50-85, 5 0 0 3852 2864 461 79 45 -0.4% 22.3*
WM CTC 45-75, 5 0 0 4315 2999 474 78 44 -0.2% 11.8*
WM CTC 45-80, 5 0 0 4510 3069 481 80 45 0% 11.0
WM CTC 45-85, 5 0 0 4622 3105 483 81 46 0% 21.9
SimCRC - Scenario 1: Stable CRC risk
WM No screening 0 0 0 79 0 0 0 - -
WM COL 55-75, 15 0 0 0 3060 250 57 25 0% 11.9
WM COL 55-80, 15 0 0 0 3060 250 57 25 0% 11.9
WM COL 55-85, 15 0 0 0 3299 252 57 25 -9.5% Dom.
WM COL 50-75, 15 0 0 0 3301 278 59 25 0% 8.7
WM COL 50-80, 15 0 0 0 3719 283 61 27 -3.3% Dom.
WM COL 50-85, 15 0 0 0 3719 283 61 27 -3.3% Dom.
WM COL 45-75, 15 0 0 0 4098 307 64 27 0% 28.0
WM COL 45-80, 15 0 0 0 4098 307 64 27 0% 28.0
WM COL 45-85, 15 0 0 0 4098 307 64 27 0% 28.0
WM COL 55-75, 10 0 0 0 3685 261 60 26 -10.5% Dom.
WM COL 55-80, 10 0 0 0 3685 261 60 26 -10.5% Dom.
WM COL 55-85, 10 0 0 0 3883 262 60 26 -12.4% Dom.
WM COL 50-75, 10 0 0 0 4094 294 64 27 -4.0% Dom.
WM COL 50-80, 10 0 0 0 4436 297 65 28 -5.2% Dom.
WM COL 50-85, 10 0 0 0 4436 297 65 28 -5.2% Dom.
WM COL 45-75, 10 0 0 0 4918 322 68 29 0% 51.8
WM COL 45-80, 10 0 0 0 4918 322 68 29 0% 51.8
WM COL 45-85, 10 0 0 0 5116 323 68 29 -0.2% 385.3*
WM COL 55-75, 5 0 0 0 4884 269 63 27 -16.4% Dom.
WM COL 55-80, 5 0 0 0 5156 270 63 27 -16.7% Dom.
WM COL 55-85, 5 0 0 0 5316 270 63 27 -16.9% Dom.
WM COL 50-75, 5 0 0 0 5915 306 68 28 -6.7% Dom.
WM COL 50-80, 5 0 0 0 6187 306 68 28 -6.9% Dom.
WM COL 50-85, 5 0 0 0 6347 306 68 29 -7.1% Dom.
WM COL 45-75, 5 0 0 0 6963 333 71 29 0% 191.3
WM COL 45-80, 5 0 0 0 7235 334 71 30 0% 423.8
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WM COL 45-85, 5 0 0 0 7396 334 71 30 0% 1396.2
WM FIT 55-75, 3 5158 0 0 891 195 31 18 0% 4.2
WM FIT 55-80, 3 6025 0 0 996 207 34 21 -4.1% Dom.
WM FIT 55-85, 3 6522 0 0 1053 211 34 21 -7.5% Dom.
WM FIT 50-75, 3 6708 0 0 1067 231 36 21 0% 4.9
WM FIT 50-80, 3 7441 0 0 1155 240 38 22 -2.6% Dom.
WM FIT 50-85, 3 7799 0 0 1194 242 38 23 -4.3% Dom.
WM FIT 45-75, 3 8194 0 0 1213 256 40 22 0% 5.7
WM FIT 45-80, 3 8716 0 0 1270 262 41 23 0% 9.1
WM FIT 45-85, 3 9293 0 0 1335 267 41 24 -0.5% 15.9*
WM FIT 55-75, 2 7358 0 0 1153 223 39 21 -9.4% Dom.
WM FIT 55-80, 2 8113 0 0 1233 229 40 23 -11.4% Dom.
WM FIT 55-85, 2 8874 0 0 1307 232 41 23 -12.5% Dom.
WM FIT 50-75, 2 9061 0 0 1325 254 43 23 -4.8% Dom.
WM FIT 50-80, 2 10180 0 0 1440 263 45 24 -4.7% Dom.
WM FIT 50-85, 2 10684 0 0 1489 265 45 25 -5.4% Dom.
WM FIT 45-75, 2 11274 0 0 1522 283 47 24 0% 12.2
WM FIT 45-80, 2 12017 0 0 1598 289 48 25 0% 12.7
WM FIT 45-85, 2 12769 0 0 1670 292 48 26 0% 23.6
WM FIT 55-75, 1 12001 0 0 1594 245 48 24 -15.1% Dom.
WM FIT 55-80, 1 13468 0 0 1715 251 50 25 -14.7% Dom.
WM FIT 55-85, 1 14439 0 0 1789 252 50 25 -15.0% Dom.
WM FIT 50-75, 1 15221 0 0 1869 281 54 26 -6.2% Dom.
WM FIT 50-80, 1 16675 0 0 1987 286 55 27 -5.9% Dom.
WM FIT 50-85, 1 17640 0 0 2059 287 56 27 -6.2% Dom.
WM FIT 45-75, 1 18598 0 0 2119 308 57 27 -0.2% 28.1*
WM FIT 45-80, 1 20047 0 0 2235 313 59 28 0% 26.8
WM FIT 45-85, 1 21009 0 0 2307 315 59 28 0% 49.3
WM FIT-DNA 55-75, 5 3463 0 0 1264 212 39 21 -19.1% Dom.
WM FIT-DNA 55-80, 5 3813 0 0 1348 217 40 22 -19.4% Dom.
WM FIT-DNA 55-85, 5 4031 0 0 1398 218 39 22 -20.0% Dom.
WM FIT-DNA 50-75, 5 4267 0 0 1468 243 43 22 -12.6% Dom.
WM FIT-DNA 50-80, 5 4614 0 0 1550 248 44 23 -13.0% Dom.
WM FIT-DNA 50-85, 5 4830 0 0 1599 250 44 24 -13.6% Dom.
WM FIT-DNA 45-75, 5 5102 0 0 1652 268 46 23 -8.1% Dom.
WM FIT-DNA 45-80, 5 5446 0 0 1733 272 47 24 -7.5% Dom.
WM FIT-DNA 45-85, 5 5662 0 0 1781 274 47 25 -7.6% Dom.
WM FIT-DNA 55-75, 3 4513 0 0 1520 233 45 22 -17.6% Dom.
WM FIT-DNA 55-80, 3 5176 0 0 1666 241 47 24 -17.4% Dom.
WM FIT-DNA 55-85, 3 5505 0 0 1733 243 47 24 -17.6% Dom.
WM FIT-DNA 50-75, 3 5805 0 0 1820 270 50 25 -9.3% Dom.
WM FIT-DNA 50-80, 3 6297 0 0 1927 275 52 26 -8.8% Dom.
WM FIT-DNA 50-85, 3 6648 0 0 1995 277 52 26 -9.0% Dom.
WM FIT-DNA 45-75, 3 6966 0 0 2056 296 53 26 -3.6% Dom.
WM FIT-DNA 45-80, 3 7489 0 0 2163 301 55 27 -3.0% Dom.
WM FIT-DNA 45-85, 3 7885 0 0 2243 303 55 27 -3.3% Dom.




SimCRC - Scenario 1: Stable CRC risk
WM FIT-DNA 55-80, 1 9354 0 0 2469 259 57 26 -18.0% Dom.
WM FIT-DNA 55-85, 1 9954 0 0 2563 260 57 26 -17.9% Dom.
WM FIT-DNA 50-75, 1 10613 0 0 2726 291 60 27 -8.4% Dom.
WM FIT-DNA 50-80, 1 11528 0 0 2877 294 62 27 -7.7% Dom.
WM FIT-DNA 50-85, 1 12121 0 0 2970 295 62 28 -7.6% Dom.
WM FIT-DNA 45-75, 1 12911 0 0 3114 318 64 28 -0.7% 233.9*
WM FIT-DNA 45-80, 1 13816 0 0 3263 321 65 28 0.0% 144.7*
WM FIT-DNA 45-85, 1 14409 0 0 3355 322 65 29 0% 141.4
WM HSgFOBT 55-75, 3 4876 0 0 1130 194 33 19 -19.6% Dom.
WM HSgFOBT 55-80, 3 5658 0 0 1256 206 35 21 -21.2% Dom.
WM HSgFOBT 55-85, 3 6070 0 0 1320 208 35 21 -21.8% Dom.
WM HSgFOBT 50-75, 3 6291 0 0 1376 231 38 21 -14.9% Dom.
WM HSgFOBT 50-80, 3 6898 0 0 1474 239 40 22 -14.5% Dom.
WM HSgFOBT 50-85, 3 7275 0 0 1527 241 40 23 -15.0% Dom.
WM HSgFOBT 45-75, 3 7576 0 0 1578 256 42 22 -10.9% Dom.
WM HSgFOBT 45-80, 3 8129 0 0 1660 263 43 23 -9.9% Dom.
WM HSgFOBT 45-85, 3 8621 0 0 1733 266 43 24 -9.6% Dom.
WM HSgFOBT 55-75, 2 6673 0 0 1455 222 40 22 -20.0% Dom.
WM HSgFOBT 55-80, 2 7325 0 0 1551 228 42 23 -20.2% Dom.
WM HSgFOBT 55-85, 2 7977 0 0 1640 231 42 23 -20.7% Dom.
WM HSgFOBT 50-75, 2 8158 0 0 1700 255 45 23 -13.2% Dom.
WM HSgFOBT 50-80, 2 9122 0 0 1838 263 47 25 -11.9% Dom.
WM HSgFOBT 50-85, 2 9552 0 0 1896 265 47 25 -12.0% Dom.
WM HSgFOBT 45-75, 2 10082 0 0 1979 283 49 25 -6.7% Dom.
WM HSgFOBT 45-80, 2 10721 0 0 2071 289 50 26 -6.0% Dom.
WM HSgFOBT 45-85, 2 11363 0 0 2157 291 51 26 -6.1% Dom.
WM HSgFOBT 55-75, 1 9971 0 0 1978 245 50 24 -19.3% Dom.
WM HSgFOBT 55-80, 1 11100 0 0 2120 250 51 25 -19.2% Dom.
WM HSgFOBT 55-85, 1 11847 0 0 2208 251 51 25 -19.6% Dom.
WM HSgFOBT 50-75, 1 12485 0 0 2345 281 55 26 -10.8% Dom.
WM HSgFOBT 50-80, 1 13612 0 0 2485 285 56 27 -9.7% Dom.
WM HSgFOBT 50-85, 1 14354 0 0 2571 286 57 27 -9.5% Dom.
WM HSgFOBT 45-75, 1 15127 0 0 2689 308 58 27 -2.9% Dom.
WM HSgFOBT 45-80, 1 16247 0 0 2828 313 60 28 -1.8% Dom.
WM HSgFOBT 45-85, 1 16986 0 0 2914 314 60 28 -1.6% Dom.
WM SIG 55-75, 10 0 2202 0 1382 198 45 20 0% 6.6
WM SIG 55-80, 10 0 2202 0 1382 198 45 20 0% 6.6
WM SIG 55-85, 10 0 2444 0 1464 200 45 20 -9.9% Dom.
WM SIG 50-75, 10 0 2423 0 1468 222 47 21 0% 3.6
WM SIG 50-80, 10 0 2805 0 1608 228 49 22 -4.1% Dom.
WM SIG 50-85, 10 0 2805 0 1608 228 49 22 -4.1% Dom.
WM SIG 45-75, 10 0 3112 0 1711 248 51 22 0% 9.3
WM SIG 45-80, 10 0 3112 0 1711 248 51 22 0% 9.3
WM SIG 45-85, 10 0 3352 0 1791 250 52 23 -1.3% 58.5*
WM SIG 55-75, 5 0 3211 0 1703 218 50 22 -12.1% Dom.
WM SIG 55-80, 5 0 3516 0 1791 220 51 22 -13.1% Dom.
WM SIG 55-85, 5 0 3705 0 1841 220 51 23 -13.9% Dom.
table continues
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SimCRC - Scenario 1: Stable CRC risk
WM SIG 50-75, 5 0 3968 0 1957 250 55 24 -4.7% Dom.
WM SIG 50-80, 5 0 4270 0 2044 252 56 24 -5.7% Dom.
WM SIG 50-85, 5 0 4458 0 2093 253 56 24 -6.4% Dom.
WM SIG 45-75, 5 0 4760 0 2185 275 58 25 0% 17.7
WM SIG 45-80, 5 0 5061 0 2271 277 59 25 0% 42.4
WM SIG 45-85, 5 0 5248 0 2320 278 59 25 0% 99.2
WM CTC 55-75, 10 0 0 2170 1533 232 51 23 0% 6.3
WM CTC 55-80, 10 0 0 2170 1533 232 51 23 0% 6.3
WM CTC 55-85, 10 0 0 2397 1626 234 52 24 -10.4% Dom.
WM CTC 50-75, 10 0 0 2397 1605 259 53 24 0% 2.7
WM CTC 50-80, 10 0 0 2762 1763 265 56 25 -4.3% Dom.
WM CTC 50-85, 10 0 0 2762 1763 265 56 25 -4.3% Dom.
WM CTC 45-75, 10 0 0 3077 1854 287 58 26 0% 8.8
WM CTC 45-80, 10 0 0 3077 1854 287 58 26 0% 8.8
WM CTC 45-85, 10 0 0 3303 1946 288 58 26 -1.2% 61.6*
WM CTC 55-75, 5 0 0 3152 1840 250 56 25 -12.4% Dom.
WM CTC 55-80, 5 0 0 3441 1932 252 57 25 -13.4% Dom.
WM CTC 55-85, 5 0 0 3618 1984 253 57 25 -14.1% Dom.
WM CTC 50-75, 5 0 0 3913 2086 285 61 26 -4.8% Dom.
WM CTC 50-80, 5 0 0 4201 2177 287 62 27 -5.7% Dom.
WM CTC 50-85, 5 0 0 4377 2229 288 62 27 -6.4% Dom.
WM CTC 45-75, 5 0 0 4713 2303 312 64 27 0% 18.2
WM CTC 45-80, 5 0 0 5001 2393 314 65 28 0% 43.9
WM CTC 45-85, 5 0 0 5177 2444 314 65 28 0% 103.5
SimCRC - Scenario 2: Increased CRC risk
WM No screening 0 0 0 162 0 0 0 - -
WM COL 55-75, 15 0 0 0 3659 517 117 52 0% 6.8
WM COL 55-80, 15 0 0 0 3659 517 117 52 0% 6.8
WM COL 55-85, 15 0 0 0 3820 519 118 53 -4.7% Dom.
WM COL 50-75, 15 0 0 0 3964 566 120 53 0% 6.2
WM COL 50-80, 15 0 0 0 4301 577 124 55 -2.0% 31.9*
WM COL 50-85, 15 0 0 0 4301 577 124 55 -2.0% 31.9*
WM COL 45-75, 15 0 0 0 4744 617 129 57 0% 15.2
WM COL 45-80, 15 0 0 0 4744 617 129 57 0% 15.2
WM COL 45-85, 15 0 0 0 4744 617 129 57 0% 15.2
WM COL 55-75, 10 0 0 0 4197 539 124 55 -7.2% Dom.
WM COL 55-80, 10 0 0 0 4197 539 124 55 -7.2% Dom.
WM COL 55-85, 10 0 0 0 4310 540 124 55 -8.2% Dom.
WM COL 50-75, 10 0 0 0 4712 600 130 57 -2.4% Dom.
WM COL 50-80, 10 0 0 0 4946 605 132 58 -3.4% Dom.
WM COL 50-85, 10 0 0 0 4946 605 132 58 -3.4% Dom.
WM COL 45-75, 10 0 0 0 5513 650 137 59 0% 23.5
WM COL 45-80, 10 0 0 0 5513 650 137 59 0% 23.5
WM COL 45-85, 10 0 0 0 5627 651 137 59 -0.1% 148.3*
WM COL 55-75, 5 0 0 0 5143 554 128 56 -12.6% Dom.
WM COL 55-80, 5 0 0 0 5294 555 129 56 -13.3% Dom.




SimCRC - Scenario 2: Increased CRC risk
WM COL 50-75, 5 0 0 0 6186 623 137 59 -5.5% Dom.
WM COL 50-80, 5 0 0 0 6337 624 138 59 -5.6% Dom.
WM COL 50-85, 5 0 0 0 6414 624 138 59 -5.7% Dom.
WM COL 45-75, 5 0 0 0 7244 672 143 61 0% 79.1
WM COL 45-80, 5 0 0 0 7395 673 144 61 0% 152.6
WM COL 45-85, 5 0 0 0 7472 673 144 61 0% 427.6
WM FIT 55-75, 3 4854 0 0 1363 409 69 39 0% 2.9
WM FIT 55-80, 3 5553 0 0 1508 435 74 44 -3.4% Dom.
WM FIT 55-85, 3 5920 0 0 1579 442 74 46 -6.1% Dom.
WM FIT 50-75, 3 6326 0 0 1597 475 78 44 0% 3.5
WM FIT 50-80, 3 6911 0 0 1717 495 82 47 -2.1% Dom.
WM FIT 50-85, 3 7171 0 0 1764 499 82 48 -3.5% Dom.
WM FIT 45-75, 3 7768 0 0 1784 522 84 46 0% 4.0
WM FIT 45-80, 3 8180 0 0 1862 536 86 49 0% 5.7
WM FIT 45-85, 3 8607 0 0 1942 544 87 50 -0.4% 10.2*
WM FIT 55-75, 2 6779 0 0 1708 465 84 46 -7.7% Dom.
WM FIT 55-80, 2 7355 0 0 1810 478 87 48 -9.3% Dom.
WM FIT 55-85, 2 7886 0 0 1895 484 88 50 -10.4% Dom.
WM FIT 50-75, 2 8440 0 0 1928 523 92 48 -4.0% Dom.
WM FIT 50-80, 2 9295 0 0 2075 542 96 52 -3.7% Dom.
WM FIT 50-85, 2 9644 0 0 2130 545 97 52 -4.3% Dom.
WM FIT 45-75, 2 10548 0 0 2172 575 99 51 0.0% 7.9*
WM FIT 45-80, 2 11113 0 0 2270 588 101 53 0% 7.8
WM FIT 45-85, 2 11637 0 0 2352 593 102 55 0% 14.6
WM FIT 55-75, 1 10764 0 0 2237 510 102 50 -12.6% Dom.
WM FIT 55-80, 1 11803 0 0 2372 521 106 53 -12.4% Dom.
WM FIT 55-85, 1 12420 0 0 2443 524 107 53 -12.6% Dom.
WM FIT 50-75, 1 13806 0 0 2573 576 112 54 -5.2% Dom.
WM FIT 50-80, 1 14834 0 0 2704 586 115 56 -4.8% Dom.
WM FIT 50-85, 1 15447 0 0 2775 589 116 56 -5.1% Dom.
WM FIT 45-75, 1 17055 0 0 2867 625 118 56 -0.3% 16.3*
WM FIT 45-80, 1 18077 0 0 2997 635 121 58 0% 15.4
WM FIT 45-85, 1 18687 0 0 3067 638 122 58 0% 26.9
WM FIT-DNA 55-75, 5 3232 0 0 1799 443 83 44 -15.6% Dom.
WM FIT-DNA 55-80, 5 3498 0 0 1898 453 85 46 -16.2% Dom.
WM FIT-DNA 55-85, 5 3650 0 0 1950 455 85 47 -16.8% Dom.
WM FIT-DNA 50-75, 5 4004 0 0 2053 502 91 47 -10.4% Dom.
WM FIT-DNA 50-80, 5 4267 0 0 2149 511 93 49 -10.7% Dom.
WM FIT-DNA 50-85, 5 4417 0 0 2201 514 93 50 -11.3% Dom.
WM FIT-DNA 45-75, 5 4814 0 0 2272 544 96 49 -7.4% Dom.
WM FIT-DNA 45-80, 5 5076 0 0 2368 554 99 51 -6.9% Dom.
WM FIT-DNA 45-85, 5 5225 0 0 2419 556 99 52 -7.0% Dom.
WM FIT-DNA 55-75, 3 4161 0 0 2112 486 95 48 -14.4% Dom.
WM FIT-DNA 55-80, 3 4655 0 0 2278 502 100 51 -14.7% Dom.
WM FIT-DNA 55-85, 3 4876 0 0 2345 505 100 51 -14.9% Dom.
WM FIT-DNA 50-75, 3 5367 0 0 2475 554 105 52 -7.9% Dom.
WM FIT-DNA 50-80, 3 5732 0 0 2595 565 108 54 -7.3% Dom.
table continues
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SimCRC - Scenario 2: Increased CRC risk
WM FIT-DNA 50-85, 3 5965 0 0 2662 568 109 54 -7.4% Dom.
WM FIT-DNA 45-75, 3 6500 0 0 2753 599 111 53 -3.3% Dom.
WM FIT-DNA 45-80, 3 6884 0 0 2873 611 114 55 -2.7% Dom.
WM FIT-DNA 45-85, 3 7150 0 0 2953 614 115 56 -2.9% Dom.
WM FIT-DNA 55-75, 1 7459 0 0 2977 530 115 53 -16.3% Dom.
WM FIT-DNA 55-80, 1 8054 0 0 3115 537 118 54 -15.9% Dom.
WM FIT-DNA 55-85, 1 8405 0 0 3188 538 118 55 -15.8% Dom.
WM FIT-DNA 50-75, 1 9487 0 0 3443 596 124 56 -7.3% Dom.
WM FIT-DNA 50-80, 1 10092 0 0 3582 602 126 57 -6.6% Dom.
WM FIT-DNA 50-85, 1 10440 0 0 3654 604 127 57 -6.5% Dom.
WM FIT-DNA 45-75, 1 11686 0 0 3874 644 129 58 -0.8% 141.4*
WM FIT-DNA 45-80, 1 12284 0 0 4011 650 132 59 -0.1% 78.7*
WM FIT-DNA 45-85, 1 12631 0 0 4082 651 133 59 0% 75.8
WM HSgFOBT 55-75, 3 4602 0 0 1590 408 71 40 -13.9% Dom.
WM HSgFOBT 55-80, 3 5231 0 0 1743 431 76 44 -15.7% Dom.
WM HSgFOBT 55-85, 3 5537 0 0 1812 437 76 45 -17.1% Dom.
WM HSgFOBT 50-75, 3 5943 0 0 1894 475 81 44 -12.0% Dom.
WM HSgFOBT 50-80, 3 6430 0 0 2012 492 84 47 -11.4% Dom.
WM HSgFOBT 50-85, 3 6700 0 0 2068 496 85 48 -11.7% Dom.
WM HSgFOBT 45-75, 3 7199 0 0 2136 521 87 46 -8.8% Dom.
WM HSgFOBT 45-80, 3 7632 0 0 2232 534 90 49 -8.3% Dom.
WM HSgFOBT 45-85, 3 7995 0 0 2312 541 91 50 -8.4% Dom.
WM HSgFOBT 55-75, 2 6185 0 0 1986 463 86 46 -16.0% Dom.
WM HSgFOBT 55-80, 2 6683 0 0 2093 475 89 48 -15.9% Dom.
WM HSgFOBT 55-85, 2 7136 0 0 2182 481 90 49 -16.6% Dom.
WM HSgFOBT 50-75, 2 7629 0 0 2283 523 95 48 -11.2% Dom.
WM HSgFOBT 50-80, 2 8363 0 0 2438 540 99 52 -9.9% Dom.
WM HSgFOBT 50-85, 2 8660 0 0 2495 543 99 52 -9.9% Dom.
WM HSgFOBT 45-75, 2 9457 0 0 2609 575 102 51 -5.7% Dom.
WM HSgFOBT 45-80, 2 9942 0 0 2711 587 105 53 -4.9% Dom.
WM HSgFOBT 45-85, 2 10387 0 0 2797 592 105 55 -4.9% Dom.
WM HSgFOBT 55-75, 1 9034 0 0 2581 509 104 51 -16.3% Dom.
WM HSgFOBT 55-80, 1 9834 0 0 2722 519 107 53 -16.0% Dom.
WM HSgFOBT 55-85, 1 10306 0 0 2796 521 108 53 -16.3% Dom.
WM HSgFOBT 50-75, 1 11408 0 0 3008 575 114 54 -9.5% Dom.
WM HSgFOBT 50-80, 1 12203 0 0 3146 584 117 56 -8.5% Dom.
WM HSgFOBT 50-85, 1 12672 0 0 3219 587 117 56 -8.3% Dom.
WM HSgFOBT 45-75, 1 13946 0 0 3397 624 120 56 -2.8% Dom.
WM HSgFOBT 45-80, 1 14735 0 0 3533 633 123 58 -1.7% Dom.
WM HSgFOBT 45-85, 1 15201 0 0 3606 636 123 58 -1.5% Dom.
WM SIG 55-75, 10 0 2028 0 2134 459 102 47 0% 4.3
WM SIG 55-80, 10 0 2028 0 2134 459 102 47 0% 4.3
WM SIG 55-85, 10 0 2189 0 2222 462 103 48 -7.1% Dom.
WM SIG 50-75, 10 0 2281 0 2250 504 106 47 0% 2.6
WM SIG 50-80, 10 0 2562 0 2424 516 110 50 -3.1% Dom.
WM SIG 50-85, 10 0 2562 0 2424 516 110 50 -3.1% Dom.




SimCRC - Scenario 2: Increased CRC risk
WM SIG 45-80, 10 0 2903 0 2557 554 114 51 0% 6.2
WM SIG 45-85, 10 0 3063 0 2644 557 115 52 -0.8% 33.7*
WM SIG 55-75, 5 0 2850 0 2500 493 112 50 -9.5% Dom.
WM SIG 55-80, 5 0 3052 0 2592 497 114 51 -10.8% Dom.
WM SIG 55-85, 5 0 3165 0 2637 498 114 51 -11.3% Dom.
WM SIG 50-75, 5 0 3561 0 2817 555 120 53 -3.7% Dom.
WM SIG 50-80, 5 0 3761 0 2908 558 122 54 -4.3% Dom.
WM SIG 50-85, 5 0 3873 0 2952 559 122 54 -4.8% Dom.
WM SIG 45-75, 5 0 4319 0 3091 599 125 55 0% 11.9
WM SIG 45-80, 5 0 4518 0 3181 603 127 56 0% 23.3
WM SIG 45-85, 5 0 4630 0 3225 604 128 56 0% 55.9
WM CTC 55-75, 10 0 0 2006 2239 485 107 49 0% 4.3
WM CTC 55-80, 10 0 0 2006 2239 485 107 49 0% 4.3
WM CTC 55-85, 10 0 0 2158 2338 488 108 50 -8.3% Dom.
WM CTC 50-75, 10 0 0 2264 2335 532 110 50 0% 2.1
WM CTC 50-80, 10 0 0 2535 2528 544 115 53 -3.5% Dom.
WM CTC 50-85, 10 0 0 2535 2528 544 115 53 -3.5% Dom.
WM CTC 45-75, 10 0 0 2882 2648 583 118 54 0% 6.1
WM CTC 45-80, 10 0 0 2882 2648 583 118 54 0% 6.1
WM CTC 45-85, 10 0 0 3033 2746 586 119 54 -1.1% 37.0*
WM CTC 55-75, 5 0 0 2813 2596 521 117 52 -9.3% Dom.
WM CTC 55-80, 5 0 0 3005 2694 525 119 53 -10.6% Dom.
WM CTC 55-85, 5 0 0 3109 2740 526 119 54 -11.2% Dom.
WM CTC 50-75, 5 0 0 3530 2905 585 125 55 -3.7% Dom.
WM CTC 50-80, 5 0 0 3720 3001 589 127 56 -4.4% Dom.
WM CTC 50-85, 5 0 0 3824 3048 590 127 57 -5.0% Dom.
WM CTC 45-75, 5 0 0 4299 3164 632 130 57 0% 10.6
WM CTC 45-80, 5 0 0 4490 3260 636 132 58 0% 24.4
WM CTC 45-85, 5 0 0 4593 3307 637 132 58 0% 60.8
COL - colonoscopy; CRC - colorectal cancer; CTC - computed tomographic colonography; 
Dom. - dominated strategy; ER - efficiency ratio; FIT - fecal immunochemical test; FIT-DNA - 
multitarget stool DNA test; HSgFOBT - high-sensitivity guaiac-based fecal occult blood test; 
LYG - life-years gained; SIG - flexible sigmoidoscopy; WM - white male.
a Both models evaluated two scenarios for CRC risk: one in which age-specific risks were 
assumed to have remained stable since the early screening period in the U.S. (1975-1979 
for SimCRC; 1990-1994 for MISCAN), and one in which risks were assumed to have increased 
proportional to observed trends among adults under age 40 years. Strategies for each model 
and scenario are ordered successively by screening modality, interval ), end age ( ), and 
start age ( ).
b Total number of colonoscopies performed per 1000 40-year-olds, including diagnostic 
colonoscopies and potential surveillance colonoscopies after adenoma removal. The number 
of screening-related complications ranged from 4.9 to 33.5 per 1000 40-year-olds across 
models, scenarios, and strategies.
c Including deaths from complications of screening.
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d The difference in LYG compared to (combinations of ) adjacent strategies on the efficient 
frontier. Near-efficient strategies have a loss in LYG of less than 2% before rounding. For the 
least intensive screening strategy evaluated within each class of screening modality, the 
difference was zero by definition.
e Efficiency ratio = incremental number of colonoscopies/LYG with respect to the next less 
effective strategy on the efficient frontier, a burden-to-benefit ratio. Only calculated for 
efficient and near-efficient strategies (marked with an asterisk*), i.e. strategies within 2% from 
the efficient frontier among all evaluated strategies within a class of screening modalities 
(colonoscopy, stool-based, sigmoidoscopy, and CTC). 
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Supplementary Table A3.6: Lifetime number of colonoscopies and LYG for all evaluated 
screening strategies under two scenarios for CRC risk, by model, in black males a
































































































































MISCAN - Scenario 1: Stable CRC risk
BM No screening 0 0 0 62 0 0 0 - -
BM COL 55-75, 15 0 0 0 2812 210 33 21 0% 13.1
BM COL 55-80, 15 0 0 0 2812 210 33 21 0% 13.1
BM COL 55-85, 15 0 0 0 2975 211 33 21 -4.4% Dom.
BM COL 50-75, 15 0 0 0 3160 233 35 22 0% 15.7
BM COL 50-80, 15 0 0 0 3438 235 36 22 -1.7% 93.1*
BM COL 50-85, 15 0 0 0 3438 235 36 22 -1.7% 93.1*
BM COL 45-75, 15 0 0 0 3839 249 37 23 -0.3% 190.8*
BM COL 45-80, 15 0 0 0 3839 249 37 23 -0.3% 190.8*
BM COL 45-85, 15 0 0 0 3839 249 37 23 -0.3% 190.8*
BM COL 55-75, 10 0 0 0 3306 220 35 22 -6.7% Dom.
BM COL 55-80, 10 0 0 0 3306 220 35 22 -6.7% Dom.
BM COL 55-85, 10 0 0 0 3454 221 35 22 -8.1% Dom.
BM COL 50-75, 10 0 0 0 3791 248 38 23 0% 40.0
BM COL 50-80, 10 0 0 0 4040 250 38 23 -1.7% 157.8*
BM COL 50-85, 10 0 0 0 4040 250 38 23 -1.7% 157.8*
BM COL 45-75, 10 0 0 0 4561 266 40 24 0% 42.9
BM COL 45-80, 10 0 0 0 4561 266 40 24 0% 42.9
BM COL 45-85, 10 0 0 0 4710 267 40 24 -0.4% 526.0*
BM COL 55-75, 5 0 0 0 4335 231 37 23 -11.7% Dom.
BM COL 55-80, 5 0 0 0 4559 231 38 23 -13.2% Dom.
BM COL 55-85, 5 0 0 0 4697 231 38 23 -13.6% Dom.
BM COL 50-75, 5 0 0 0 5342 263 41 24 -4.0% Dom.
BM COL 50-80, 5 0 0 0 5566 263 41 24 -4.5% Dom.
BM COL 50-85, 5 0 0 0 5704 263 41 24 -5.0% Dom.
BM COL 45-75, 5 0 0 0 6375 284 43 25 0% 104.0
BM COL 45-80, 5 0 0 0 6599 284 43 25 0% 476.0
BM COL 45-85, 5 0 0 0 6737 284 43 25 0% 2032.9
BM FIT 55-75, 3 4690 0 0 792 152 14 15 0% 4.8
BM FIT 55-80, 3 5382 0 0 855 160 14 16 -0.7% 7.5*
BM FIT 55-85, 3 5801 0 0 888 162 14 17 -2.3% Dom.
BM FIT 50-75, 3 6157 0 0 958 177 16 16 0% 6.6
BM FIT 50-80, 3 6795 0 0 1014 183 17 18 0% 8.2
BM FIT 50-85, 3 7013 0 0 1030 185 16 18 -0.5% 14.8*
BM FIT 45-75, 3 7675 0 0 1102 194 18 18 -0.1% 8.5*
BM FIT 45-80, 3 8003 0 0 1129 197 18 18 0% 8.3
BM FIT 45-85, 3 8459 0 0 1164 200 18 19 -0.3% 13.1*
table continues
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MISCAN - Scenario 1: Stable CRC risk
BM FIT 55-75, 2 6739 0 0 1009 176 18 17 -3.7% Dom.
BM FIT 55-80, 2 7350 0 0 1055 181 19 18 -4.1% Dom.
BM FIT 55-85, 2 7951 0 0 1096 183 19 19 -5.3% Dom.
BM FIT 50-75, 2 8439 0 0 1190 201 21 19 -1.0% 17.2*
BM FIT 50-80, 2 9346 0 0 1256 208 21 20 -0.7% 12.3*
BM FIT 50-85, 2 9742 0 0 1282 209 21 20 -1.2% 13.1*
BM FIT 45-75, 2 10595 0 0 1375 220 23 20 -0.1% 10.9*
BM FIT 45-80, 2 11194 0 0 1418 224 23 20 0% 10.8
BM FIT 45-85, 2 11786 0 0 1457 226 23 21 0.0% 18.7*
BM FIT 55-75, 1 11061 0 0 1384 202 25 20 -8.5% Dom.
BM FIT 55-80, 1 12282 0 0 1456 207 26 21 -8.7% Dom.
BM FIT 55-85, 1 13078 0 0 1498 208 26 21 -9.1% Dom.
BM FIT 50-75, 1 14208 0 0 1662 232 28 21 -2.5% Dom.
BM FIT 50-80, 1 15415 0 0 1731 236 29 22 -2.3% Dom.
BM FIT 50-85, 1 16204 0 0 1772 237 29 22 -2.7% Dom.
BM FIT 45-75, 1 17548 0 0 1912 251 30 22 -0.2% 18.1*
BM FIT 45-80, 1 18746 0 0 1980 256 31 23 0% 17.8
BM FIT 45-85, 1 19532 0 0 2021 257 31 23 0% 34.8
BM FIT-DNA 55-75, 5 3159 0 0 1117 168 19 17 -14.1% Dom.
BM FIT-DNA 55-80, 5 3432 0 0 1166 172 19 17 -14.5% Dom.
BM FIT-DNA 55-85, 5 3599 0 0 1194 172 18 18 -15.2% Dom.
BM FIT-DNA 50-75, 5 3944 0 0 1324 192 21 18 -11.1% Dom.
BM FIT-DNA 50-80, 5 4214 0 0 1372 195 21 19 -11.4% Dom.
BM FIT-DNA 50-85, 5 4380 0 0 1399 196 21 19 -12.0% Dom.
BM FIT-DNA 45-75, 5 4769 0 0 1507 207 22 19 -9.5% Dom.
BM FIT-DNA 45-80, 5 5037 0 0 1554 211 22 20 -9.1% Dom.
BM FIT-DNA 45-85, 5 5202 0 0 1580 211 22 20 -9.4% Dom.
BM FIT-DNA 55-75, 3 4027 0 0 1334 187 23 18 -13.7% Dom.
BM FIT-DNA 55-80, 3 4567 0 0 1426 193 24 19 -14.1% Dom.
BM FIT-DNA 55-85, 3 4890 0 0 1474 195 24 20 -14.4% Dom.
BM FIT-DNA 50-75, 3 5231 0 0 1622 216 26 20 -8.4% Dom.
BM FIT-DNA 50-80, 3 5725 0 0 1702 221 26 21 -8.0% Dom.
BM FIT-DNA 50-85, 3 5893 0 0 1726 222 26 21 -8.2% Dom.
BM FIT-DNA 45-75, 3 6482 0 0 1879 234 28 21 -6.2% Dom.
BM FIT-DNA 45-80, 3 6736 0 0 1919 237 28 21 -6.1% Dom.
BM FIT-DNA 45-85, 3 7088 0 0 1971 239 28 22 -6.4% Dom.
BM FIT-DNA 55-75, 1 7811 0 0 2060 216 32 21 -15.9% Dom.
BM FIT-DNA 55-80, 1 8558 0 0 2158 219 32 22 -15.2% Dom.
BM FIT-DNA 55-85, 1 9055 0 0 2219 220 32 22 -15.2% Dom.
BM FIT-DNA 50-75, 1 9890 0 0 2483 247 35 23 -6.0% Dom.
BM FIT-DNA 50-80, 1 10646 0 0 2581 249 35 23 -5.4% Dom.
BM FIT-DNA 50-85, 1 11137 0 0 2641 250 35 23 -5.4% Dom.
BM FIT-DNA 45-75, 1 12136 0 0 2879 266 36 23 -0.5% 96.4*
BM FIT-DNA 45-80, 1 12883 0 0 2975 268 37 24 0% 83.5
BM FIT-DNA 45-85, 1 13372 0 0 3034 269 37 24 0% 96.8
BM HSgFOBT 55-75, 3 4408 0 0 982 149 15 15 -17.0% Dom.




MISCAN - Scenario 1: Stable CRC risk
BM HSgFOBT 55-85, 3 5409 0 0 1108 159 14 17 -18.4% Dom.
BM HSgFOBT 50-75, 3 5731 0 0 1219 175 17 16 -14.8% Dom.
BM HSgFOBT 50-80, 3 6303 0 0 1291 181 17 18 -14.5% Dom.
BM HSgFOBT 50-85, 3 6498 0 0 1313 183 17 18 -14.9% Dom.
BM HSgFOBT 45-75, 3 7092 0 0 1435 193 19 18 -14.3% Dom.
BM HSgFOBT 45-80, 3 7385 0 0 1471 196 19 18 -13.7% Dom.
BM HSgFOBT 45-85, 3 7790 0 0 1517 198 19 19 -13.6% Dom.
BM HSgFOBT 55-75, 2 6149 0 0 1269 174 19 17 -17.1% Dom.
BM HSgFOBT 55-80, 2 6675 0 0 1331 179 19 18 -17.3% Dom.
BM HSgFOBT 55-85, 2 7188 0 0 1386 181 19 19 -18.3% Dom.
BM HSgFOBT 50-75, 2 7625 0 0 1532 200 22 19 -13.2% Dom.
BM HSgFOBT 50-80, 2 8400 0 0 1620 206 22 20 -12.5% Dom.
BM HSgFOBT 50-85, 2 8736 0 0 1655 207 22 20 -12.7% Dom.
BM HSgFOBT 45-75, 2 9484 0 0 1811 220 24 20 -10.5% Dom.
BM HSgFOBT 45-80, 2 9994 0 0 1868 224 24 21 -10.1% Dom.
BM HSgFOBT 45-85, 2 10494 0 0 1920 226 24 21 -10.5% Dom.
BM HSgFOBT 55-75, 1 9232 0 0 1745 201 26 20 -16.9% Dom.
BM HSgFOBT 55-80, 1 10152 0 0 1838 205 27 21 -17.2% Dom.
BM HSgFOBT 55-85, 1 10751 0 0 1894 206 27 21 -17.8% Dom.
BM HSgFOBT 50-75, 1 11660 0 0 2128 231 29 21 -10.4% Dom.
BM HSgFOBT 50-80, 1 12572 0 0 2218 235 30 22 -9.4% Dom.
BM HSgFOBT 50-85, 1 13164 0 0 2273 236 30 22 -9.3% Dom.
BM HSgFOBT 45-75, 1 14234 0 0 2485 251 31 22 -4.4% Dom.
BM HSgFOBT 45-80, 1 15137 0 0 2574 254 32 23 -3.5% Dom.
BM HSgFOBT 45-85, 1 15726 0 0 2628 255 32 23 -3.4% Dom.
BM SIG 55-75, 10 0 1917 0 1540 175 28 18 0% 8.5
BM SIG 55-80, 10 0 1917 0 1540 175 28 18 0% 8.5
BM SIG 55-85, 10 0 2084 0 1577 175 28 18 -2.0% Dom.
BM SIG 50-75, 10 0 2171 0 1716 194 29 18 0% 9.0
BM SIG 50-80, 10 0 2441 0 1789 197 30 19 -0.9% 29.9*
BM SIG 50-85, 10 0 2441 0 1789 197 30 19 -0.9% 29.9*
BM SIG 45-75, 10 0 2778 0 1946 207 31 19 -0.1% 17.7*
BM SIG 45-80, 10 0 2778 0 1946 207 31 19 -0.1% 17.7*
BM SIG 45-85, 10 0 2943 0 1982 208 31 19 -0.9% 19.7*
BM SIG 55-75, 5 0 2748 0 1782 190 30 19 -4.2% Dom.
BM SIG 55-80, 5 0 2971 0 1828 191 31 19 -5.0% Dom.
BM SIG 55-85, 5 0 3108 0 1852 191 31 19 -5.5% Dom.
BM SIG 50-75, 5 0 3439 0 2084 215 33 20 -0.3% 17.8*
BM SIG 50-80, 5 0 3660 0 2129 216 33 21 -1.0% 19.1*
BM SIG 50-85, 5 0 3797 0 2153 216 33 21 -1.6% 20.0*
BM SIG 45-75, 5 0 4188 0 2343 230 34 21 0% 17.3
BM SIG 45-80, 5 0 4409 0 2388 231 35 21 0% 47.3
BM SIG 45-85, 5 0 4545 0 2412 231 35 21 0% 132.3
BM CTC 55-75, 10 0 0 2014 1155 170 23 17 -0.3% 6.4
BM CTC 55-80, 10 0 0 2014 1155 170 23 17 -0.3% 6.4
BM CTC 55-85, 10 0 0 2200 1199 172 23 18 -3.2% Dom.
BM CTC 50-75, 10 0 0 2277 1258 187 24 17 0% 6.2
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BM CTC 50-80, 10 0 0 2579 1336 193 25 19 -0.8% 12.7*
BM CTC 50-85, 10 0 0 2579 1336 193 25 19 -0.8% 12.7*
BM CTC 45-75, 10 0 0 2925 1434 201 26 19 -1.8% 12.9*
BM CTC 45-80, 10 0 0 2925 1434 201 26 19 -1.8% 12.9*
BM CTC 45-85, 10 0 0 3110 1477 202 26 19 -3.1% Dom.
BM CTC 55-75, 5 0 0 2976 1426 200 29 20 -1.8% 12.9*
BM CTC 55-80, 5 0 0 3227 1477 203 29 20 -2.9% Dom.
BM CTC 55-85, 5 0 0 3381 1506 203 29 20 -3.9% Dom.
BM CTC 50-75, 5 0 0 3733 1659 227 31 21 0% 10.1
BM CTC 50-80, 5 0 0 3983 1709 229 32 22 -0.7% 19.9*
BM CTC 50-85, 5 0 0 4135 1737 230 32 22 -1.4% 25.1*
BM CTC 45-75, 5 0 0 4538 1860 243 32 22 0% 12.0
BM CTC 45-80, 5 0 0 4786 1910 246 33 22 0% 19.6
BM CTC 45-85, 5 0 0 4938 1937 246 33 22 0% 48.3
MISCAN - Scenario 2: Increased CRC risk
BM No screening 0 0 0 88 0 0 0 - -
BM COL 55-75, 15 0 0 0 3256 298 48 30 0% 10.6
BM COL 55-80, 15 0 0 0 3256 298 48 30 0% 10.6
BM COL 55-85, 15 0 0 0 3372 299 48 30 -2.5% Dom.
BM COL 50-75, 15 0 0 0 3693 329 51 31 0% 13.9
BM COL 50-80, 15 0 0 0 3904 333 52 32 -1.2% 55.6*
BM COL 50-85, 15 0 0 0 3904 333 52 32 -1.2% 55.6*
BM COL 45-75, 15 0 0 0 4359 351 53 32 -0.7% 95.4*
BM COL 45-80, 15 0 0 0 4359 351 53 32 -0.7% 95.4*
BM COL 45-85, 15 0 0 0 4359 351 53 32 -0.7% 95.4*
BM COL 55-75, 10 0 0 0 3664 311 51 31 -5.0% Dom.
BM COL 55-80, 10 0 0 0 3664 311 51 31 -5.0% Dom.
BM COL 55-85, 10 0 0 0 3762 311 51 31 -6.3% Dom.
BM COL 50-75, 10 0 0 0 4243 350 55 33 0% 26.4
BM COL 50-80, 10 0 0 0 4419 352 55 33 -1.1% 92.8*
BM COL 50-85, 10 0 0 0 4419 352 55 33 -1.1% 92.8*
BM COL 45-75, 10 0 0 0 5010 375 57 34 0% 30.1
BM COL 45-80, 10 0 0 0 5010 375 57 34 0% 30.1
BM COL 45-85, 10 0 0 0 5108 376 57 34 -0.3% 297.7*
BM COL 55-75, 5 0 0 0 4459 324 54 32 -9.4% Dom.
BM COL 55-80, 5 0 0 0 4604 324 54 32 -10.4% Dom.
BM COL 55-85, 5 0 0 0 4691 324 54 32 -11.1% Dom.
BM COL 50-75, 5 0 0 0 5467 369 58 35 -3.5% Dom.
BM COL 50-80, 5 0 0 0 5612 370 59 35 -4.0% Dom.
BM COL 50-85, 5 0 0 0 5698 370 59 35 -4.3% Dom.
BM COL 45-75, 5 0 0 0 6499 399 61 36 0% 63.6
BM COL 45-80, 5 0 0 0 6645 399 61 36 0% 273.3
BM COL 45-85, 5 0 0 0 6731 400 61 36 0% 992.8
BM FIT 55-75, 3 4520 0 0 1040 209 21 21 0% 4.6
BM FIT 55-80, 3 5130 0 0 1115 220 21 23 -0.3% 6.5*
BM FIT 55-85, 3 5482 0 0 1152 223 21 24 -1.6% 7.7*




MISCAN - Scenario 2: Increased CRC risk
BM FIT 50-80, 3 6482 0 0 1314 252 24 25 0% 6.9
BM FIT 50-85, 3 6665 0 0 1333 253 24 25 -0.4% 11.9*
BM FIT 45-75, 3 7395 0 0 1428 267 26 25 -0.2% 7.6*
BM FIT 45-80, 3 7679 0 0 1459 272 26 25 0% 7.3
BM FIT 45-85, 3 8062 0 0 1498 275 26 26 -0.3% 10.7*
BM FIT 55-75, 2 6392 0 0 1307 243 27 24 -3.1% Dom.
BM FIT 55-80, 2 6910 0 0 1359 249 27 26 -3.3% Dom.
BM FIT 55-85, 2 7400 0 0 1401 252 27 26 -4.4% Dom.
BM FIT 50-75, 2 8032 0 0 1534 278 30 26 -0.7% 11.5*
BM FIT 50-80, 2 8796 0 0 1607 287 31 28 -0.4% 9.4*
BM FIT 50-85, 2 9117 0 0 1634 289 31 28 -0.8% 10.0*
BM FIT 45-75, 2 10094 0 0 1758 305 33 28 -0.2% 8.9*
BM FIT 45-80, 2 10597 0 0 1806 311 33 29 0% 8.8
BM FIT 45-85, 2 11076 0 0 1846 314 33 29 0.0% 14.5*
BM FIT 55-75, 1 10282 0 0 1748 281 37 28 -7.6% Dom.
BM FIT 55-80, 1 11268 0 0 1820 287 38 29 -7.9% Dom.
BM FIT 55-85, 1 11884 0 0 1860 289 38 30 -8.2% Dom.
BM FIT 50-75, 1 13244 0 0 2085 323 41 30 -2.3% Dom.
BM FIT 50-80, 1 14210 0 0 2153 329 42 31 -2.0% Dom.
BM FIT 50-85, 1 14816 0 0 2191 331 42 32 -2.3% Dom.
BM FIT 45-75, 1 16433 0 0 2380 351 44 31 -0.3% 14.4*
BM FIT 45-80, 1 17388 0 0 2446 357 45 32 0% 14.1
BM FIT 45-85, 1 17990 0 0 2483 358 45 33 0% 23.7
BM FIT-DNA 55-75, 5 3010 0 0 1420 233 27 24 -12.6% Dom.
BM FIT-DNA 55-80, 5 3239 0 0 1472 237 27 25 -13.0% Dom.
BM FIT-DNA 55-85, 5 3374 0 0 1499 239 27 25 -13.6% Dom.
BM FIT-DNA 50-75, 5 3759 0 0 1674 266 31 26 -10.2% Dom.
BM FIT-DNA 50-80, 5 3984 0 0 1724 270 31 27 -10.4% Dom.
BM FIT-DNA 50-85, 5 4116 0 0 1750 271 30 27 -10.9% Dom.
BM FIT-DNA 45-75, 5 4555 0 0 1892 287 33 27 -9.4% Dom.
BM FIT-DNA 45-80, 5 4777 0 0 1941 292 33 28 -9.0% Dom.
BM FIT-DNA 45-85, 5 4908 0 0 1967 293 33 28 -9.2% Dom.
BM FIT-DNA 55-75, 3 3819 0 0 1682 260 33 26 -12.3% Dom.
BM FIT-DNA 55-80, 3 4266 0 0 1775 269 35 27 -12.6% Dom.
BM FIT-DNA 55-85, 3 4519 0 0 1819 271 35 28 -13.3% Dom.
BM FIT-DNA 50-75, 3 4947 0 0 2026 300 38 28 -8.2% Dom.
BM FIT-DNA 50-80, 3 5348 0 0 2105 307 39 30 -7.8% Dom.
BM FIT-DNA 50-85, 3 5479 0 0 2128 308 39 30 -7.9% Dom.
BM FIT-DNA 45-75, 3 6134 0 0 2327 327 40 30 -6.1% Dom.
BM FIT-DNA 45-80, 3 6340 0 0 2366 330 41 30 -5.9% Dom.
BM FIT-DNA 45-85, 3 6615 0 0 2414 333 41 31 -6.1% Dom.
BM FIT-DNA 55-75, 1 7113 0 0 2475 304 46 30 -15.0% Dom.
BM FIT-DNA 55-80, 1 7674 0 0 2558 307 47 31 -14.5% Dom.
BM FIT-DNA 55-85, 1 8029 0 0 2605 308 47 31 -14.5% Dom.
BM FIT-DNA 50-75, 1 9026 0 0 2962 346 50 32 -5.6% Dom.
BM FIT-DNA 50-80, 1 9589 0 0 3043 350 51 33 -5.1% Dom.
BM FIT-DNA 50-85, 1 9937 0 0 3089 351 51 33 -5.1% Dom.
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BM FIT-DNA 45-75, 1 11132 0 0 3406 374 53 34 -0.4% 59.4*
BM FIT-DNA 45-80, 1 11687 0 0 3486 377 54 34 0% 53.7
BM FIT-DNA 45-85, 1 12034 0 0 3532 378 54 34 0% 61.3
BM HSgFOBT 55-75, 3 4269 0 0 1229 206 21 21 -14.0% Dom.
BM HSgFOBT 55-80, 3 4817 0 0 1318 216 22 23 -14.2% Dom.
BM HSgFOBT 55-85, 3 5131 0 0 1362 219 21 23 -15.2% Dom.
BM HSgFOBT 50-75, 3 5532 0 0 1517 241 25 23 -13.4% Dom.
BM HSgFOBT 50-80, 3 6024 0 0 1593 249 25 25 -13.1% Dom.
BM HSgFOBT 50-85, 3 6185 0 0 1615 251 25 25 -13.3% Dom.
BM HSgFOBT 45-75, 3 6836 0 0 1775 267 28 25 -13.2% Dom.
BM HSgFOBT 45-80, 3 7087 0 0 1812 271 28 26 -13.0% Dom.
BM HSgFOBT 45-85, 3 7424 0 0 1858 274 28 26 -12.8% Dom.
BM HSgFOBT 55-75, 2 5861 0 0 1565 241 28 24 -14.9% Dom.
BM HSgFOBT 55-80, 2 6302 0 0 1627 247 28 26 -15.1% Dom.
BM HSgFOBT 55-85, 2 6712 0 0 1678 250 28 26 -15.9% Dom.
BM HSgFOBT 50-75, 2 7271 0 0 1884 278 32 26 -12.2% Dom.
BM HSgFOBT 50-80, 2 7913 0 0 1971 286 33 28 -11.4% Dom.
BM HSgFOBT 50-85, 2 8179 0 0 2003 288 33 28 -11.5% Dom.
BM HSgFOBT 45-75, 2 9028 0 0 2209 307 35 28 -9.8% Dom.
BM HSgFOBT 45-80, 2 9447 0 0 2266 312 36 29 -9.4% Dom.
BM HSgFOBT 45-85, 2 9842 0 0 2313 314 35 30 -9.6% Dom.
BM HSgFOBT 55-75, 1 8639 0 0 2107 281 38 28 -15.5% Dom.
BM HSgFOBT 55-80, 1 9362 0 0 2191 286 39 29 -15.5% Dom.
BM HSgFOBT 55-85, 1 9809 0 0 2238 287 39 29 -15.9% Dom.
BM HSgFOBT 50-75, 1 10890 0 0 2555 323 43 30 -10.2% Dom.
BM HSgFOBT 50-80, 1 11597 0 0 2635 328 43 31 -9.3% Dom.
BM HSgFOBT 50-85, 1 12034 0 0 2680 329 44 32 -9.1% Dom.
BM HSgFOBT 45-75, 1 13309 0 0 2965 351 46 32 -4.4% Dom.
BM HSgFOBT 45-80, 1 14005 0 0 3042 355 47 33 -3.6% Dom.
BM HSgFOBT 45-85, 1 14438 0 0 3086 357 47 33 -3.5% Dom.
BM SIG 55-75, 10 0 1701 0 2327 276 45 28 0% 8.1
BM SIG 55-80, 10 0 1701 0 2327 276 45 28 0% 8.1
BM SIG 55-85, 10 0 1812 0 2359 276 45 28 -1.1% 61.5*
BM SIG 50-75, 10 0 1954 0 2607 308 48 29 0% 8.8
BM SIG 50-80, 10 0 2142 0 2679 311 48 30 -0.7% 26.2*
BM SIG 50-85, 10 0 2142 0 2679 311 48 30 -0.7% 26.2*
BM SIG 45-75, 10 0 2479 0 2915 328 50 31 0% 15.0
BM SIG 45-80, 10 0 2479 0 2915 328 50 31 0% 15.0
BM SIG 45-85, 10 0 2588 0 2947 329 50 31 -0.5% 62.2*
BM SIG 55-75, 5 0 2304 0 2554 292 48 30 -3.3% Dom.
BM SIG 55-80, 5 0 2451 0 2593 293 48 30 -4.4% Dom.
BM SIG 55-85, 5 0 2538 0 2612 293 48 30 -4.9% Dom.
BM SIG 50-75, 5 0 2895 0 2966 330 52 31 -0.6% 39.3*
BM SIG 50-80, 5 0 3040 0 3005 331 52 32 -1.0% 38.3*
BM SIG 50-85, 5 0 3127 0 3024 331 52 32 -1.3% 43.0*
BM SIG 45-75, 5 0 3565 0 3309 354 54 32 0% 15.4




MISCAN - Scenario 2: Increased CRC risk
BM SIG 45-85, 5 0 3797 0 3366 355 54 33 0% 97.7
BM CTC 55-75, 10 0 0 1914 1513 238 33 24 0% 6.0
BM CTC 55-80, 10 0 0 1914 1513 238 33 24 0% 6.0
BM CTC 55-85, 10 0 0 2064 1560 241 33 25 -2.2% Dom.
BM CTC 50-75, 10 0 0 2186 1649 261 35 25 0% 6.1
BM CTC 50-80, 10 0 0 2439 1734 269 36 26 -0.7% 10.0*
BM CTC 50-85, 10 0 0 2439 1734 269 36 26 -0.7% 10.0*
BM CTC 45-75, 10 0 0 2794 1856 281 37 26 -1.9% Dom.
BM CTC 45-80, 10 0 0 2794 1856 281 37 26 -1.9% Dom.
BM CTC 45-85, 10 0 0 2943 1901 283 37 27 -3.0% Dom.
BM CTC 55-75, 5 0 0 2770 1830 281 41 28 -0.7% 9.0*
BM CTC 55-80, 5 0 0 2971 1881 284 42 29 -1.6% 9.8*
BM CTC 55-85, 5 0 0 3089 1907 285 42 29 -2.5% Dom.
BM CTC 50-75, 5 0 0 3485 2113 318 45 30 0% 8.2
BM CTC 50-80, 5 0 0 3684 2163 321 46 31 -0.4% 14.1*
BM CTC 50-85, 5 0 0 3801 2189 322 46 31 -1.0% 17.7*
BM CTC 45-75, 5 0 0 4258 2351 341 47 31 0% 10.1
BM CTC 45-80, 5 0 0 4455 2400 345 48 32 0% 13.8
BM CTC 45-85, 5 0 0 4572 2426 345 48 32 0% 36.6
SimCRC - Scenario 1: Stable CRC risk
BM No screening 0 0 0 59 0 0 0 - -
BM COL 55-75, 15 0 0 0 2753 195 42 21 0% 13.8
BM COL 55-80, 15 0 0 0 2753 195 42 21 0% 13.8
BM COL 55-85, 15 0 0 0 2930 196 42 21 -8.8% Dom.
BM COL 50-75, 15 0 0 0 3027 222 44 22 0% 10.2
BM COL 50-80, 15 0 0 0 3351 226 46 22 -3.5% Dom.
BM COL 50-85, 15 0 0 0 3351 226 46 22 -3.5% Dom.
BM COL 45-75, 15 0 0 0 3748 248 48 23 0% 27.7
BM COL 45-80, 15 0 0 0 3748 248 48 23 0% 27.7
BM COL 45-85, 15 0 0 0 3748 248 48 23 0% 27.7
BM COL 55-75, 10 0 0 0 3302 204 44 22 -12.3% Dom.
BM COL 55-80, 10 0 0 0 3302 204 44 22 -12.3% Dom.
BM COL 55-85, 10 0 0 0 3448 204 44 22 -14.1% Dom.
BM COL 50-75, 10 0 0 0 3745 235 48 23 -5.4% Dom.
BM COL 50-80, 10 0 0 0 4011 236 48 23 -6.5% Dom.
BM COL 50-85, 10 0 0 0 4011 236 48 23 -6.5% Dom.
BM COL 45-75, 10 0 0 0 4519 262 51 24 0% 57.9
BM COL 45-80, 10 0 0 0 4519 262 51 24 0% 57.9
BM COL 45-85, 10 0 0 0 4665 262 51 25 -0.1% 434.1*
BM COL 55-75, 5 0 0 0 4404 210 46 22 -19.1% Dom.
BM COL 55-80, 5 0 0 0 4616 210 46 22 -19.7% Dom.
BM COL 55-85, 5 0 0 0 4735 211 46 22 -19.9% Dom.
BM COL 50-75, 5 0 0 0 5417 244 50 24 -8.2% Dom.
BM COL 50-80, 5 0 0 0 5629 245 51 24 -8.4% Dom.
BM COL 50-85, 5 0 0 0 5748 245 51 24 -8.5% Dom.
BM COL 45-75, 5 0 0 0 6456 271 53 25 0% 205.1
BM COL 45-80, 5 0 0 0 6668 272 53 25 0% 484.2
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BM COL 45-85, 5 0 0 0 6787 272 53 25 0% 1369.7
BM FIT 55-75, 3 4788 0 0 782 142 23 15 0% 5.1
BM FIT 55-80, 3 5489 0 0 867 150 24 16 -4.7% Dom.
BM FIT 55-85, 3 5865 0 0 910 152 24 17 -8.0% Dom.
BM FIT 50-75, 3 6294 0 0 946 172 27 17 0% 5.5
BM FIT 50-80, 3 6881 0 0 1017 178 27 18 -3.1% Dom.
BM FIT 50-85, 3 7152 0 0 1046 179 27 18 -4.8% Dom.
BM FIT 45-75, 3 7763 0 0 1085 195 29 18 0% 6.1
BM FIT 45-80, 3 8183 0 0 1131 199 30 19 0.0% 11.5*
BM FIT 45-85, 3 8623 0 0 1181 201 30 19 -0.9% 14.5*
BM FIT 55-75, 2 6797 0 0 1012 165 28 17 -9.8% Dom.
BM FIT 55-80, 2 7403 0 0 1076 169 29 18 -12.4% Dom.
BM FIT 55-85, 2 7981 0 0 1133 171 29 19 -13.7% Dom.
BM FIT 50-75, 2 8516 0 0 1180 194 32 19 -4.6% Dom.
BM FIT 50-80, 2 9417 0 0 1271 200 33 20 -5.3% Dom.
BM FIT 50-85, 2 9799 0 0 1308 201 33 20 -6.1% Dom.
BM FIT 45-75, 2 10684 0 0 1366 219 35 20 0% 11.4
BM FIT 45-80, 2 11281 0 0 1426 223 36 21 0% 15.3
BM FIT 45-85, 2 11852 0 0 1481 225 36 21 -0.3% 26.9*
BM FIT 55-75, 1 11113 0 0 1407 188 35 20 -15.4% Dom.
BM FIT 55-80, 1 12291 0 0 1502 192 36 20 -15.6% Dom.
BM FIT 55-85, 1 13027 0 0 1558 193 37 21 -16.1% Dom.
BM FIT 50-75, 1 14301 0 0 1671 221 40 21 -6.2% Dom.
BM FIT 50-80, 1 15470 0 0 1764 224 41 22 -6.4% Dom.
BM FIT 50-85, 1 16201 0 0 1819 225 41 22 -7.0% Dom.
BM FIT 45-75, 1 17665 0 0 1914 247 43 23 0% 20.8
BM FIT 45-80, 1 18830 0 0 2006 250 44 23 0% 26.2
BM FIT 45-85, 1 19559 0 0 2060 251 44 24 0% 52.0
BM FIT-DNA 55-75, 5 3198 0 0 1110 156 28 16 -20.8% Dom.
BM FIT-DNA 55-80, 5 3471 0 0 1176 159 28 17 -21.5% Dom.
BM FIT-DNA 55-85, 5 3633 0 0 1213 160 28 17 -22.3% Dom.
BM FIT-DNA 50-75, 5 3996 0 0 1305 183 32 18 -14.3% Dom.
BM FIT-DNA 50-80, 5 4267 0 0 1369 186 32 19 -15.1% Dom.
BM FIT-DNA 50-85, 5 4427 0 0 1405 187 32 19 -15.6% Dom.
BM FIT-DNA 45-75, 5 4828 0 0 1483 205 34 19 -9.2% Dom.
BM FIT-DNA 45-80, 5 5098 0 0 1546 208 35 20 -9.1% Dom.
BM FIT-DNA 45-85, 5 5258 0 0 1582 209 35 20 -9.4% Dom.
BM FIT-DNA 55-75, 3 4197 0 0 1346 176 33 18 -19.3% Dom.
BM FIT-DNA 55-80, 3 4731 0 0 1462 181 34 19 -19.6% Dom.
BM FIT-DNA 55-85, 3 4979 0 0 1513 182 34 20 -20.0% Dom.
BM FIT-DNA 50-75, 3 5457 0 0 1630 208 37 20 -10.7% Dom.
BM FIT-DNA 50-80, 3 5851 0 0 1714 212 38 21 -10.7% Dom.
BM FIT-DNA 50-85, 3 6117 0 0 1766 213 38 21 -11.2% Dom.
BM FIT-DNA 45-75, 3 6624 0 0 1860 232 40 21 -4.8% Dom.
BM FIT-DNA 45-80, 3 7045 0 0 1946 236 41 22 -4.8% Dom.
BM FIT-DNA 45-85, 3 7345 0 0 2007 237 41 23 -5.2% Dom.




SimCRC - Scenario 1: Stable CRC risk
BM FIT-DNA 55-80, 1 8588 0 0 2185 201 41 21 -20.3% Dom.
BM FIT-DNA 55-85, 1 9043 0 0 2256 202 42 21 -20.3% Dom.
BM FIT-DNA 50-75, 1 10012 0 0 2462 231 45 23 -9.3% Dom.
BM FIT-DNA 50-80, 1 10746 0 0 2582 234 46 23 -8.8% Dom.
BM FIT-DNA 50-85, 1 11196 0 0 2652 234 46 23 -8.8% Dom.
BM FIT-DNA 45-75, 1 12303 0 0 2843 258 48 24 -0.4% 121.1*
BM FIT-DNA 45-80, 1 13030 0 0 2961 260 48 24 0% 104.5
BM FIT-DNA 45-85, 1 13480 0 0 3031 260 49 24 0% 123.0
BM HSgFOBT 55-75, 3 4530 0 0 998 142 24 15 -21.2% Dom.
BM HSgFOBT 55-80, 3 5161 0 0 1099 149 25 16 -23.7% Dom.
BM HSgFOBT 55-85, 3 5473 0 0 1147 151 25 17 -24.4% Dom.
BM HSgFOBT 50-75, 3 5907 0 0 1229 173 28 17 -16.7% Dom.
BM HSgFOBT 50-80, 3 6394 0 0 1307 178 29 18 -17.0% Dom.
BM HSgFOBT 50-85, 3 6680 0 0 1347 179 29 18 -17.7% Dom.
BM HSgFOBT 45-75, 3 7191 0 0 1423 195 31 18 -12.4% Dom.
BM HSgFOBT 45-80, 3 7636 0 0 1489 199 31 19 -11.8% Dom.
BM HSgFOBT 45-85, 3 8010 0 0 1545 202 32 19 -11.9% Dom.
BM HSgFOBT 55-75, 2 6176 0 0 1285 165 29 17 -22.3% Dom.
BM HSgFOBT 55-80, 2 6699 0 0 1361 169 30 18 -22.9% Dom.
BM HSgFOBT 55-85, 2 7195 0 0 1429 171 30 19 -23.6% Dom.
BM HSgFOBT 50-75, 2 7679 0 0 1523 195 33 19 -14.6% Dom.
BM HSgFOBT 50-80, 2 8455 0 0 1634 200 34 20 -14.3% Dom.
BM HSgFOBT 50-85, 2 8781 0 0 1678 201 34 20 -14.5% Dom.
BM HSgFOBT 45-75, 2 9567 0 0 1791 220 36 21 -8.5% Dom.
BM HSgFOBT 45-80, 2 10080 0 0 1863 224 37 21 -8.4% Dom.
BM HSgFOBT 45-85, 2 10568 0 0 1929 226 37 22 -8.8% Dom.
BM HSgFOBT 55-75, 1 9260 0 0 1756 188 36 20 -21.4% Dom.
BM HSgFOBT 55-80, 1 10168 0 0 1869 191 37 20 -21.9% Dom.
BM HSgFOBT 55-85, 1 10734 0 0 1936 192 37 21 -22.4% Dom.
BM HSgFOBT 50-75, 1 11759 0 0 2111 220 41 22 -12.4% Dom.
BM HSgFOBT 50-80, 1 12665 0 0 2222 224 42 22 -11.6% Dom.
BM HSgFOBT 50-85, 1 13228 0 0 2288 224 42 22 -11.4% Dom.
BM HSgFOBT 45-75, 1 14396 0 0 2448 247 44 23 -3.2% Dom.
BM HSgFOBT 45-80, 1 15296 0 0 2559 250 45 23 -2.4% Dom.
BM HSgFOBT 45-85, 1 15856 0 0 2624 251 45 24 -2.3% Dom.
BM SIG 55-75, 10 0 2031 0 1214 149 32 16 0% 7.8
BM SIG 55-80, 10 0 2031 0 1214 149 32 16 0% 7.8
BM SIG 55-85, 10 0 2210 0 1275 150 32 16 -9.7% Dom.
BM SIG 50-75, 10 0 2295 0 1311 171 34 17 0% 4.4
BM SIG 50-80, 10 0 2593 0 1420 174 35 18 -4.4% Dom.
BM SIG 50-85, 10 0 2593 0 1420 174 35 18 -4.4% Dom.
BM SIG 45-75, 10 0 2938 0 1530 194 37 19 0% 9.4
BM SIG 45-80, 10 0 2938 0 1530 194 37 19 0% 9.4
BM SIG 45-85, 10 0 3116 0 1590 195 38 19 -1.2% 65.7*
BM SIG 55-75, 5 0 2969 0 1500 164 36 18 -13.9% Dom.
BM SIG 55-80, 5 0 3208 0 1568 166 36 18 -15.5% Dom.
BM SIG 55-85, 5 0 3348 0 1605 166 37 18 -16.1% Dom.
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BM SIG 50-75, 5 0 3721 0 1744 193 40 19 -5.8% Dom.
BM SIG 50-80, 5 0 3957 0 1811 195 40 20 -6.7% Dom.
BM SIG 50-85, 5 0 4096 0 1848 195 40 20 -7.4% Dom.
BM SIG 45-75, 5 0 4511 0 1966 217 42 21 0% 18.8
BM SIG 45-80, 5 0 4746 0 2032 219 43 21 0% 48.4
BM SIG 45-85, 5 0 4885 0 2069 219 43 21 0% 104.6
BM CTC 55-75, 10 0 0 2003 1345 179 38 19 0% 7.2
BM CTC 55-80, 10 0 0 2003 1345 179 38 19 0% 7.2
BM CTC 55-85, 10 0 0 2171 1414 180 38 19 -10.6% Dom.
BM CTC 50-75, 10 0 0 2271 1431 205 40 20 0% 3.5
BM CTC 50-80, 10 0 0 2557 1554 208 41 21 -4.4% Dom.
BM CTC 50-85, 10 0 0 2557 1554 208 41 21 -4.4% Dom.
BM CTC 45-75, 10 0 0 2907 1655 229 43 22 0% 9.0
BM CTC 45-80, 10 0 0 2907 1655 229 43 22 0% 9.0
BM CTC 45-85, 10 0 0 3075 1723 230 43 22 -1.1% 68.2*
BM CTC 55-75, 5 0 0 2917 1620 194 41 21 -14.0% Dom.
BM CTC 55-80, 5 0 0 3143 1691 195 42 21 -15.5% Dom.
BM CTC 55-85, 5 0 0 3274 1730 196 42 21 -16.1% Dom.
BM CTC 50-75, 5 0 0 3671 1857 226 45 22 -5.7% Dom.
BM CTC 50-80, 5 0 0 3896 1928 228 46 23 -6.6% Dom.
BM CTC 50-85, 5 0 0 4027 1966 228 46 23 -7.2% Dom.
BM CTC 45-75, 5 0 0 4469 2069 251 48 23 0% 19.0
BM CTC 45-80, 5 0 0 4694 2139 252 48 24 0% 49.4
BM CTC 45-85, 5 0 0 4824 2177 253 49 24 0% 119.8
SimCRC - Scenario 2: Increased CRC risk
BM No screening 0 0 0 92 0 0 0 - -
BM COL 55-75, 15 0 0 0 2870 314 63 32 0% 8.8
BM COL 55-80, 15 0 0 0 2870 314 63 32 0% 8.8
BM COL 55-85, 15 0 0 0 3033 316 63 32 -7.8% Dom.
BM COL 50-75, 15 0 0 0 3177 359 66 34 0% 6.8
BM COL 50-80, 15 0 0 0 3479 365 69 35 -3.2% Dom.
BM COL 50-85, 15 0 0 0 3479 365 69 35 -3.2% Dom.
BM COL 45-75, 15 0 0 0 3898 402 72 36 0% 17.0
BM COL 45-80, 15 0 0 0 3898 402 72 36 0% 17.0
BM COL 45-85, 15 0 0 0 3898 402 72 36 0% 17.0
BM COL 55-75, 10 0 0 0 3393 329 67 34 -11.5% Dom.
BM COL 55-80, 10 0 0 0 3393 329 67 34 -11.5% Dom.
BM COL 55-85, 10 0 0 0 3526 330 67 34 -13.2% Dom.
BM COL 50-75, 10 0 0 0 3869 381 72 36 -4.9% Dom.
BM COL 50-80, 10 0 0 0 4114 383 73 37 -6.2% Dom.
BM COL 50-85, 10 0 0 0 4114 383 73 37 -6.2% Dom.
BM COL 45-75, 10 0 0 0 4648 426 77 38 0% 31.0
BM COL 45-80, 10 0 0 0 4648 426 77 38 0% 31.0
BM COL 45-85, 10 0 0 0 4781 426 77 39 -0.1% 206.8*
BM COL 55-75, 5 0 0 0 4430 340 70 35 -18.8% Dom.
BM COL 55-80, 5 0 0 0 4623 341 70 35 -19.8% Dom.




SimCRC - Scenario 2: Increased CRC risk
BM COL 50-75, 5 0 0 0 5450 398 76 38 -8.2% Dom.
BM COL 50-80, 5 0 0 0 5643 399 77 38 -8.4% Dom.
BM COL 50-85, 5 0 0 0 5749 399 77 38 -8.6% Dom.
BM COL 45-75, 5 0 0 0 6496 443 81 40 0% 106.4
BM COL 45-80, 5 0 0 0 6689 444 81 40 0% 226.0
BM COL 45-85, 5 0 0 0 6795 444 81 40 0% 618.3
BM FIT 55-75, 3 4642 0 0 947 234 36 23 0% 3.7
BM FIT 55-80, 3 5288 0 0 1035 245 38 25 -4.3% Dom.
BM FIT 55-85, 3 5627 0 0 1078 248 38 26 -7.3% Dom.
BM FIT 50-75, 3 6107 0 0 1139 283 42 27 0% 3.9
BM FIT 50-80, 3 6645 0 0 1211 292 44 28 -2.9% Dom.
BM FIT 50-85, 3 6891 0 0 1241 294 44 29 -4.4% Dom.
BM FIT 45-75, 3 7548 0 0 1301 321 47 29 0% 4.2
BM FIT 45-80, 3 7934 0 0 1349 327 48 30 -0.1% 8.0*
BM FIT 45-85, 3 8331 0 0 1398 331 48 31 -1.0% 10.3*
BM FIT 55-75, 2 6534 0 0 1195 269 44 27 -9.2% Dom.
BM FIT 55-80, 2 7086 0 0 1260 275 45 28 -11.6% Dom.
BM FIT 55-85, 2 7604 0 0 1315 278 46 29 -13.9% Dom.
BM FIT 50-75, 2 8220 0 0 1390 317 50 30 -4.9% Dom.
BM FIT 50-80, 2 9040 0 0 1483 326 52 31 -5.7% Dom.
BM FIT 50-85, 2 9381 0 0 1519 328 52 32 -6.5% Dom.
BM FIT 45-75, 2 10333 0 0 1602 361 55 32 0% 7.6
BM FIT 45-80, 2 10876 0 0 1663 367 56 33 0% 10.5
BM FIT 45-85, 2 11388 0 0 1717 370 56 34 -0.3% 19.6*
BM FIT 55-75, 1 10581 0 0 1601 305 54 31 -15.6% Dom.
BM FIT 55-80, 1 11643 0 0 1694 310 56 32 -16.0% Dom.
BM FIT 55-85, 1 12296 0 0 1747 312 56 32 -16.5% Dom.
BM FIT 50-75, 1 13674 0 0 1895 359 61 34 -6.5% Dom.
BM FIT 50-80, 1 14728 0 0 1986 365 63 35 -6.8% Dom.
BM FIT 50-85, 1 15379 0 0 2038 366 63 35 -7.3% Dom.
BM FIT 45-75, 1 16963 0 0 2163 404 66 36 0% 13.5
BM FIT 45-80, 1 18013 0 0 2253 409 67 37 0% 17.3
BM FIT 45-85, 1 18661 0 0 2305 411 68 37 0% 35.2
BM FIT-DNA 55-75, 5 3096 0 0 1280 255 44 26 -19.3% Dom.
BM FIT-DNA 55-80, 5 3347 0 0 1345 260 45 27 -20.6% Dom.
BM FIT-DNA 55-85, 5 3492 0 0 1380 261 45 27 -21.3% Dom.
BM FIT-DNA 50-75, 5 3877 0 0 1501 301 50 29 -13.4% Dom.
BM FIT-DNA 50-80, 5 4125 0 0 1564 306 50 30 -14.2% Dom.
BM FIT-DNA 50-85, 5 4269 0 0 1599 307 50 30 -14.9% Dom.
BM FIT-DNA 45-75, 5 4695 0 0 1700 338 54 31 -8.5% Dom.
BM FIT-DNA 45-80, 5 4942 0 0 1762 343 54 32 -8.5% Dom.
BM FIT-DNA 45-85, 5 5085 0 0 1797 344 54 32 -8.8% Dom.
BM FIT-DNA 55-75, 3 4043 0 0 1526 286 51 29 -18.6% Dom.
BM FIT-DNA 55-80, 3 4529 0 0 1640 294 52 30 -19.5% Dom.
BM FIT-DNA 55-85, 3 4751 0 0 1688 295 53 31 -20.0% Dom.
BM FIT-DNA 50-75, 3 5263 0 0 1837 340 57 32 -10.6% Dom.
BM FIT-DNA 50-80, 3 5621 0 0 1920 345 59 33 -10.7% Dom.
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SimCRC - Scenario 2: Increased CRC risk
BM FIT-DNA 50-85, 3 5861 0 0 1969 346 59 33 -11.1% Dom.
BM FIT-DNA 45-75, 3 6410 0 0 2092 381 62 34 -4.4% Dom.
BM FIT-DNA 45-80, 3 6794 0 0 2176 387 63 35 -4.5% Dom.
BM FIT-DNA 45-85, 3 7063 0 0 2233 389 64 36 -4.8% Dom.
BM FIT-DNA 55-75, 1 7476 0 0 2233 322 62 33 -21.2% Dom.
BM FIT-DNA 55-80, 1 8126 0 0 2346 325 63 33 -20.9% Dom.
BM FIT-DNA 55-85, 1 8531 0 0 2411 326 63 34 -20.9% Dom.
BM FIT-DNA 50-75, 1 9559 0 0 2656 376 68 35 -9.6% Dom.
BM FIT-DNA 50-80, 1 10221 0 0 2770 380 69 36 -9.1% Dom.
BM FIT-DNA 50-85, 1 10622 0 0 2835 381 70 36 -9.1% Dom.
BM FIT-DNA 45-75, 1 11800 0 0 3059 420 73 37 -0.4% 77.9*
BM FIT-DNA 45-80, 1 12456 0 0 3172 424 74 38 0% 65.7
BM FIT-DNA 45-85, 1 12857 0 0 3236 425 74 38 0% 71.5
BM HSgFOBT 55-75, 3 4401 0 0 1146 233 38 24 -18.1% Dom.
BM HSgFOBT 55-80, 3 4984 0 0 1248 244 39 25 -21.0% Dom.
BM HSgFOBT 55-85, 3 5267 0 0 1295 247 40 26 -23.0% Dom.
BM HSgFOBT 50-75, 3 5743 0 0 1402 284 44 27 -15.3% Dom.
BM HSgFOBT 50-80, 3 6191 0 0 1480 291 45 28 -15.7% Dom.
BM HSgFOBT 50-85, 3 6450 0 0 1520 293 45 29 -16.4% Dom.
BM HSgFOBT 45-75, 3 7007 0 0 1618 321 48 29 -11.4% Dom.
BM HSgFOBT 45-80, 3 7417 0 0 1683 328 50 30 -11.1% Dom.
BM HSgFOBT 45-85, 3 7756 0 0 1738 331 50 31 -11.2% Dom.
BM HSgFOBT 55-75, 2 5958 0 0 1445 268 45 27 -21.1% Dom.
BM HSgFOBT 55-80, 2 6436 0 0 1519 274 47 28 -21.7% Dom.
BM HSgFOBT 55-85, 2 6882 0 0 1584 277 47 29 -22.9% Dom.
BM HSgFOBT 50-75, 2 7434 0 0 1709 317 52 30 -14.3% Dom.
BM HSgFOBT 50-80, 2 8143 0 0 1817 325 53 31 -14.1% Dom.
BM HSgFOBT 50-85, 2 8437 0 0 1859 327 53 32 -14.3% Dom.
BM HSgFOBT 45-75, 2 9278 0 0 1999 362 57 32 -7.7% Dom.
BM HSgFOBT 45-80, 2 9747 0 0 2070 367 58 33 -7.6% Dom.
BM HSgFOBT 45-85, 2 10187 0 0 2133 369 58 34 -8.1% Dom.
BM HSgFOBT 55-75, 1 8863 0 0 1919 304 55 31 -21.2% Dom.
BM HSgFOBT 55-80, 1 9686 0 0 2027 309 57 32 -21.6% Dom.
BM HSgFOBT 55-85, 1 10192 0 0 2089 310 57 32 -22.1% Dom.
BM HSgFOBT 50-75, 1 11295 0 0 2301 359 62 34 -12.7% Dom.
BM HSgFOBT 50-80, 1 12116 0 0 2408 363 63 35 -11.9% Dom.
BM HSgFOBT 50-85, 1 12619 0 0 2469 365 64 35 -11.8% Dom.
BM HSgFOBT 45-75, 1 13879 0 0 2660 403 67 36 -3.2% Dom.
BM HSgFOBT 45-80, 1 14695 0 0 2766 407 68 37 -2.5% Dom.
BM HSgFOBT 45-85, 1 15197 0 0 2826 409 69 37 -2.4% Dom.
BM SIG 55-75, 10 0 1955 0 1478 276 55 28 0% 5.0
BM SIG 55-80, 10 0 1955 0 1478 276 55 28 0% 5.0
BM SIG 55-85, 10 0 2113 0 1538 277 55 29 -8.1% Dom.
BM SIG 50-75, 10 0 2224 0 1608 317 58 30 0% 3.2
BM SIG 50-80, 10 0 2493 0 1718 322 60 31 -4.0% Dom.
BM SIG 50-85, 10 0 2493 0 1718 322 60 31 -4.0% Dom.




SimCRC - Scenario 2: Increased CRC risk
BM SIG 45-80, 10 0 2842 0 1855 358 63 33 0% 5.9
BM SIG 45-85, 10 0 2999 0 1914 360 64 33 -0.7% 42.5*
BM SIG 55-75, 5 0 2822 0 1751 295 59 30 -13.3% Dom.
BM SIG 55-80, 5 0 3035 0 1817 298 60 31 -15.5% Dom.
BM SIG 55-85, 5 0 3158 0 1852 298 61 31 -16.7% Dom.
BM SIG 50-75, 5 0 3550 0 2028 346 65 33 -6.6% Dom.
BM SIG 50-80, 5 0 3761 0 2092 348 66 34 -7.2% Dom.
BM SIG 50-85, 5 0 3883 0 2127 349 67 34 -7.6% Dom.
BM SIG 45-75, 5 0 4321 0 2277 388 70 35 0% 14.4
BM SIG 45-80, 5 0 4531 0 2341 390 71 35 0% 30.7
BM SIG 45-85, 5 0 4653 0 2376 390 71 36 0% 73.0
BM CTC 55-75, 10 0 0 1937 1563 294 58 30 0% 5.0
BM CTC 55-80, 10 0 0 1937 1563 294 58 30 0% 5.0
BM CTC 55-85, 10 0 0 2088 1629 295 58 31 -9.2% Dom.
BM CTC 50-75, 10 0 0 2209 1682 336 62 32 0% 2.8
BM CTC 50-80, 10 0 0 2469 1803 342 64 33 -4.0% Dom.
BM CTC 50-85, 10 0 0 2469 1803 342 64 33 -4.0% Dom.
BM CTC 45-75, 10 0 0 2823 1930 378 67 34 0% 6.0
BM CTC 45-80, 10 0 0 2823 1930 378 67 34 0% 6.0
BM CTC 45-85, 10 0 0 2973 1995 379 67 35 -1.0% 45.6*
BM CTC 55-75, 5 0 0 2787 1839 316 63 32 -12.8% Dom.
BM CTC 55-80, 5 0 0 2990 1907 319 64 33 -14.8% Dom.
BM CTC 55-85, 5 0 0 3106 1943 319 64 33 -15.8% Dom.
BM CTC 50-75, 5 0 0 3518 2110 370 69 35 -5.9% Dom.
BM CTC 50-80, 5 0 0 3720 2177 372 70 36 -6.7% Dom.
BM CTC 50-85, 5 0 0 3836 2213 372 70 36 -7.2% Dom.
BM CTC 45-75, 5 0 0 4298 2348 412 73 37 0% 12.1
BM CTC 45-80, 5 0 0 4500 2415 415 74 38 0% 31.0
BM CTC 45-85, 5 0 0 4615 2451 415 75 38 0% 70.7
BM - black male; COL - colonoscopy; CRC - colorectal cancer; CTC - computed tomographic 
colonography; Dom. - dominated strategy; ER - efficiency ratio; FIT - fecal immunochemical 
test; FIT-DNA - multitarget stool DNA test; HSgFOBT - high-sensitivity guaiac-based fecal 
occult blood test; LYG - life-years gained; SIG - flexible sigmoidoscopy.
a Both models evaluated two scenarios for CRC risk: one in which age-specific risks were 
assumed to have remained stable since the early screening period in the U.S. (1975-1979 
for SimCRC; 1990-1994 for MISCAN), and one in which risks were assumed to have increased 
proportional to observed trends among adults under age 40 years. Strategies for each model 
and scenario are ordered successively by screening modality, interval ( ), end age ( ), and 
start age ( ).
b Total number of colonoscopies performed per 1000 40-year-olds, including diagnostic 
colonoscopies and potential surveillance colonoscopies after adenoma removal. The number 
of screening-related complications ranged from 4.2 to 18.6 per 1000 40-year-olds across 
models, scenarios, and strategies.
c Including deaths from complications of screening.
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d The difference in LYG compared to (combinations of ) adjacent strategies on the efficient 
frontier. Near-efficient strategies have a loss in LYG of less than 2% before rounding. For the 
least intensive screening strategy evaluated within each class of screening modality, the 
difference was zero by definition.
e Efficiency ratio = incremental number of colonoscopies/LYG with respect to the next less 
effective strategy on the efficient frontier, a burden-to-benefit ratio. Only calculated for 
efficient and near-efficient strategies (marked with an asterisk*), i.e. strategies within 2% from 
the efficient frontier among all evaluated strategies within a class of screening modalities 
(colonoscopy, stool-based, sigmoidoscopy, and CTC). 
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Supplementary Table A3.7: Outcomes for CRC screening strategies with screening between 
similar ages as the selected benchmark colonoscopy strategy, under two scenarios for CRC 
risk, by model and demographic subgroup a 

















































































































































































MISCAN - Scenario 1: Stable CRC risk
WF Colonoscopy                        
COL 50-75, 10 0 0 0.0 4067 192 36 17 0% 43.2  - - Yes
Stool tests
FIT 50-75, 3 7173 0 0 880 134 15 11 0% 6.1 Yes No
FIT 50-75, 2 9907 0 0 1115 154 19 13 0% 11.9 Yes No
HSgFOBT 50-75, 3 6637 0 0 1199 134 17 11 -15.1% Dom. - No
FIT-DNA 50-75, 5 4652 0 0 1286 147 20 13 -9.3% Dom. - No
HSgFOBT 50-75, 2 8900 0 0 1530 155 21 13 -11.5% Dom. - No
FIT-DNA 50-75, 3 6138 0 0 1581 165 24 14 -6.9% Dom. - No
FIT 50-75, 1 16959 0 0 1620 179 26 15 0% 19.8 Yes Yes Yes
HSgFOBT 50-75, 1 13803 0 0 2179 180 28 15 -3.7% Dom. - Yes
FIT-DNA 50-75, 1 11871 0 0 2548 191 33 16 0% 76.4 No Yes
Sigmoidoscopy
SIG 50-75, 10 0 2537 0 1534 137 26 12 0% 10.8 Yes No
SIG 50-75, 5 0 4220 0 1978 158 30 14 0% 21.1 Yes No
CT colonography
CTC 50-75, 10 0 0 2614 1141 138 21 12 0% 7.8 Yes No
CTC 50-75, 5 0 0 4466 1592 174 29 15 0% 12.6 Yes Yes Yes
BF Colonoscopy
COL 45-75, 10 0 0 0 4894 285 40 23 0% 43.4  - - Yes
Stool tests
FIT 45-75, 3 8297 0 0 1136 205 19 16 0% 5.2 Yes No
FIT 45-75, 2 11477 0 0 1422 233 23 19 0% 10.2 Yes No
HSgFOBT 45-75, 3 7649 0 0 1502 205 20 17 -14.0% Dom. - No
FIT-DNA 45-75, 5 5168 0 0 1578 221 23 18 -8.8% Dom. - No
HSgFOBT 45-75, 2 10252 0 0 1899 234 25 19 -10.4% Dom. - No
FIT-DNA 45-75, 3 7012 0 0 1960 250 28 20 -5.8% Dom. - No
FIT 45-75, 1 19041 0 0 1988 267 30 21 0% 16.9 Yes Yes Yes
HSgFOBT 45-75, 1 15400 0 0 2611 266 32 21 -3.6% Dom. - Yes
FIT-DNA 45-75, 1 13174 0 0 3023 283 37 23 0% 63.7 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 3060 0 1905 208 30 18 0% 8.9 Yes No
SIG 45-75, 5 0 4650 0 2333 235 33 20 0% 15.9 Yes No
CT colonography
CTC 45-75, 10 0 0 3179 1490 215 26 18 0% 6.6 Yes No
CTC 45-75, 5 0 0 4935 1937 260 33 21 0% 10.1 Yes Yes Yes
WM Colonoscopy
COL 50-75, 10 0 0 0.0 4007 227 43 21 0% 38.6  - - Yes
Stool tests
FIT 50-75, 3 6689 0 0 947 162 18 15 0% 5.4 Yes No
FIT 50-75, 2 9204 0 0 1188 185 23 17 0% 10.5 Yes No
HSgFOBT 50-75, 3 6201 0 0 1248 161 20 15 -14.3% Dom. - No
FIT-DNA 50-75, 5 4308 0 0 1340 176 24 17 -9.1% Dom. - No
HSgFOBT 50-75, 2 8279 0 0 1580 185 25 17 -10.8% Dom. - No
FIT-DNA 50-75, 3 5701 0 0 1650 198 29 18 -6.5% Dom. - No
table continues
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MISCAN - Scenario 1: Stable CRC risk
FIT 50-75, 1 15619 0 0 1693 214 32 20 0% 17.0 Yes Yes Yes
HSgFOBT 50-75, 1 12737 0 0 2221 214 34 20 -3.5% Dom. - Yes
FIT-DNA 50-75, 1 10885 0 0 2589 227 40 21 0% 69.7 No Yes
Sigmoidoscopy
SIG 50-75, 10 0 2328 0 1822 183 35 18 0% 9.5 Yes No
SIG 50-75, 5 0 3737 0 2231 203 39 20 0% 20.6 Yes No
CT colonography
CTC 50-75, 10 0 0 2456 1223 166 26 15 0% 6.9 Yes No
CTC 50-75, 5 0 0 4110 1667 207 35 19 0% 10.8 Yes Yes Yes
BM Colonoscopy
COL 45-75, 10 0 0 0.0 4561 266 40 24 0% 42.9  - - Yes
Stool tests
FIT 45-75, 3 7675 0 0 1102 194 18 18 0% 5.4 Yes No
FIT 45-75, 2 10595 0 0 1375 220 23 20 0% 10.5 Yes No
HSgFOBT 45-75, 3 7092 0 0 1435 193 19 18 -13.6% Dom. - No
FIT-DNA 45-75, 5 4769 0 0 1507 207 22 19 -8.9% Dom. - No
HSgFOBT 45-75, 2 9484 0 0 1811 220 24 20 -10.2% Dom. - No
FIT-DNA 45-75, 3 6482 0 0 1879 234 28 21 -6.0% Dom. - No
FIT 45-75, 1 17548 0 0 1912 251 30 22 0% 17.0 Yes Yes Yes
HSgFOBT 45-75, 1 14234 0 0 2485 251 31 22 -3.5% Dom. - Yes
FIT-DNA 45-75, 1 12136 0 0 2879 266 36 23 0% 67.4 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 2778 0 1946 207 31 19 0% 9.1 Yes No
SIG 45-75, 5 0 4188 0 2343 230 34 21 0% 17.1 Yes No
CT colonography
CTC 45-75, 10 0 0 2925 1434 201 26 19 0% 6.8 Yes No
    CTC 45-75, 5 0 0 4538 1860 243 32 22 0% 10.0 Yes Yes Yes
MISCAN - Scenario 2: Increased CRC risk
WF Colonoscopy    
COL 45-75, 10 0 0 0.0 5823 398 74 35 0% 39.4  - - Yes
Stool tests
FIT 45-75, 3 8367 0 0 1583 281 32 24 0% 5.2 Yes No
FIT 45-75, 2 11456 0 0 1964 322 41 27 0% 9.3 Yes No
HSgFOBT 45-75, 3 7695 0 0 2019 283 36 24 -13.2% Dom. - No
FIT-DNA 45-75, 5 5161 0 0 2145 303 41 26 -9.3% Dom. - No
HSgFOBT 45-75, 2 10188 0 0 2526 325 45 28 -9.7% Dom. - No
FIT-DNA 45-75, 3 6941 0 0 2633 345 50 29 -6.2% Dom. - No
FIT 45-75, 1 18692 0 0 2690 371 54 31 0% 14.7 Yes Yes Yes
HSgFOBT 45-75, 1 15026 0 0 3402 372 58 31 -3.4% Dom. - Yes
FIT-DNA 45-75, 1 12627 0 0 3902 395 66 33 0% 50.6 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 2795 0 3466 350 65 31 0% 9.6 Yes No
SIG 45-75, 5 0 4005 0 3930 379 70 33 0% 16.1 Yes Yes Yes
CT colonography
CTC 45-75, 10 0 0 3178 2074 291 46 26 0% 6.7 Yes No
CTC 45-75, 5 0 0 4853 2652 358 58 31 0% 8.6 Yes Yes Yes
BF Colonoscopy
COL 45-75, 10 0 0 0 5231 366 52 30 0% 33.2  - - Yes
Stool tests
FIT 45-75, 3 8114 0 0 1363 261 24 21 0% 4.9 Yes No
FIT 45-75, 2 11148 0 0 1691 297 30 24 0% 9.1 Yes No
HSgFOBT 45-75, 3 7479 0 0 1745 261 26 21 -13.2% Dom. - No
FIT-DNA 45-75, 5 5024 0 0 1853 282 30 23 -8.8% Dom. - No
HSgFOBT 45-75, 2 9948 0 0 2185 300 32 24 -9.7% Dom. - No
FIT-DNA 45-75, 3 6780 0 0 2278 319 37 26 -5.6% Dom. - No
FIT 45-75, 1 18305 0 0 2319 341 39 27 0% 14.4 Yes Yes Yes
HSgFOBT 45-75, 1 14780 0 0 2957 342 41 28 -3.5% Dom. - Yes
FIT-DNA 45-75, 1 12503 0 0 3403 363 48 29 0% 49.4 No Yes
Sigmoidoscopy




MISCAN - Scenario 2: Increased CRC risk
SIG 45-75, 5 0 4134 0 3161 340 48 28 0% 16.0 Yes Yes Yes
CT colonography
CTC 45-75, 10 0 0 3090 1786 274 34 23 0% 6.2 Yes No
CTC 45-75, 5 0 0 4748 2284 333 42 27 0% 8.5 Yes Yes Yes
WM Colonoscopy
COL 45-75, 5 0 0 0.0 7182 554 102 51 0% 39.5  - - Yes
Stool tests
FIT 45-75, 3 7643 0 0 1853 378 45 35 0% 4.5 Yes No
FIT 45-75, 2 10343 0 0 2270 431 48 35 0% 7.8 Yes No
HSgFOBT 45-75, 3 7045 0 0 2260 379 56 39 -11.9% Dom. - No
FIT-DNA 45-75, 5 4674 0 0 2413 405 56 38 -8.7% Dom. - No
HSgFOBT 45-75, 2 9211 0 0 2792 434 60 40 -8.6% Dom. - No
FIT-DNA 45-75, 3 6240 0 0 2951 460 68 42 -5.8% Dom. - No
FIT 45-75, 1 16592 0 0 3033 495 74 45 0% 12.0 Yes No
HSgFOBT 45-75, 1 13359 0 0 3692 495 78 45 -2.9% Dom. - No
FIT-DNA 45-75, 1 11006 0 0 4210 522 89 47 0% 43.8 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 2451 0 3825 457 85 44 0% 8.0 Yes No
SIG 45-75, 5 0 3389 0 4302 494 91 46 0% 12.8 Yes No
CT colonography
CTC 45-75, 10 0 0 2875 2385 386 62 37 0% 5.8 Yes No
CTC 45-75, 5 0 0 4315 2999 474 78 44 0% 7.0 Yes No
BM Colonoscopy
COL 45-75, 10 0 0 0.0 5010 375 57 34 0% 30.1  - - Yes
Stool tests
FIT 45-75, 3 7395 0 0 1428 267 26 25 0% 5.0 Yes No
FIT 45-75, 2 10094 0 0 1758 305 33 28 0% 8.6 Yes No
HSgFOBT 45-75, 3 6836 0 0 1775 267 28 25 -12.9% Dom. - No
FIT-DNA 45-75, 5 4555 0 0 1892 287 33 27 -8.8% Dom. - No
HSgFOBT 45-75, 2 9028 0 0 2209 307 35 28 -9.4% Dom. - No
FIT-DNA 45-75, 3 6134 0 0 2327 327 40 30 -5.9% Dom. - No
FIT 45-75, 1 16433 0 0 2380 351 44 31 0% 13.6 Yes Yes Yes
HSgFOBT 45-75, 1 13309 0 0 2965 351 46 32 -3.5% Dom. - Yes
FIT-DNA 45-75, 1 11132 0 0 3406 374 53 34 0% 45.2 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 2479 0 2915 328 50 31 0% 8.6 Yes No
SIG 45-75, 5 0 3565 0 3309 354 54 32 0% 15.4 Yes Yes Yes
CT colonography
CTC 45-75, 10 0 0 2794 1856 281 37 26 0% 6.3 Yes No
    CTC 45-75, 5 0 0 4258 2351 341 47 31 0% 8.2 Yes Yes Yes
SimCRC - Scenario 1: Stable CRC risk
WF Colonoscopy                        
COL 45-75, 15 0 0 0.0 4062 283 55 23 0% 31.6  - - Yes
Stool tests
FIT 45-75, 3 8777 0 0 1046 232 31 18 0% 4.2 Yes No
FIT 45-75, 2 12158 0 0 1333 257 38 20 0% 11.6 Yes Yes
HSgFOBT 45-75, 3 8097 0 0 1434 233 33 18 -10.8% Dom. - No
FIT-DNA 45-75, 5 5489 0 0 1486 243 37 19 -7.6% Dom. - No
HSgFOBT 45-75, 2 10852 0 0 1824 258 40 20 -6.9% Dom. - Yes
FIT-DNA 45-75, 3 7510 0 0 1869 269 44 21 -3.7% Dom. - Yes
FIT 45-75, 1 20234 0 0 1911 281 47 22 0% 23.9 Yes Yes Yes
HSgFOBT 45-75, 1 16396 0 0 2530 282 49 22 -1.9% 1034.5* No Yes
FIT-DNA 45-75, 1 14124 0 0 2946 291 53 23 0% 100.7 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 3359 0 1510 214 41 17 0% 6.7 Yes No
SIG 45-75, 5 0 5179 0 1973 240 46 20 0% 17.8 Yes No
CT colonography
CTC 45-75, 10 0 0 3336 1608 261 48 21 0% 5.9 Yes Yes
CTC 45-75, 5 0 0 5163 2045 284 53 23 0% 19.0 Yes Yes Yes
table continues
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SimCRC - Scenario 1: Stable CRC risk
BF Colonoscopy
COL 45-75, 15 0 0 0 3845 317 53 26 0% 24.4  - - Yes
Stool tests
FIT 45-75, 3 8461 0 0 978 241 30 19 0% 3.8 Yes No
FIT 45-75, 2 11722 0 0 1249 274 36 22 0% 8.1 Yes No
HSgFOBT 45-75, 3 7815 0 0 1349 243 32 19 -13.5% Dom. - No
FIT-DNA 45-75, 5 5288 0 0 1392 255 36 21 -10.1% Dom. - No
HSgFOBT 45-75, 2 10472 0 0 1717 277 38 22 -9.4% Dom. - No
FIT-DNA 45-75, 3 7257 0 0 1759 292 42 23 -5.4% Dom. - Yes
FIT 45-75, 1 19536 0 0 1797 311 45 25 0% 14.9 Yes Yes Yes
HSgFOBT 45-75, 1 15850 0 0 2391 312 47 25 -2.7% Dom. - Yes
FIT-DNA 45-75, 1 13664 0 0 2789 327 52 26 0% 63.3 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 3231 0 1412 230 38 19 0% 5.9 Yes No
SIG 45-75, 5 0 4992 0 1852 261 44 22 0% 14.2 Yes No
CT colonography
CTC 45-75, 10 0 0 3211 1499 288 46 24 0% 5.0 Yes Yes
CTC 45-75, 5 0 0 4980 1916 317 52 26 0% 14.3 Yes Yes Yes
WM Colonoscopy
COL 45-75, 15 0 0 0.0 4098 307 64 27 0% 28.0  - - Yes
Stool tests
FIT 45-75, 3 8194 0 0 1213 256 40 22 0% 4.4 Yes No
FIT 45-75, 2 11274 0 0 1522 283 47 24 0% 11.5 Yes Yes
HSgFOBT 45-75, 3 7576 0 0 1578 256 42 22 -10.2% Dom. - No
FIT-DNA 45-75, 5 5102 0 0 1652 268 46 23 -7.2% Dom. - No
HSgFOBT 45-75, 2 10082 0 0 1979 283 49 25 -6.2% Dom. - Yes
FIT-DNA 45-75, 3 6966 0 0 2056 296 53 26 -3.2% Dom. - Yes
FIT 45-75, 1 18598 0 0 2119 308 57 27 0% 23.8 Yes Yes Yes
HSgFOBT 45-75, 1 15127 0 0 2689 308 58 27 -1.8% 8070.7* No Yes
FIT-DNA 45-75, 1 12911 0 0 3114 318 64 28 0% 99.4 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 3112 0 1711 248 51 22 0% 6.6 Yes No
SIG 45-75, 5 0 4760 0 2185 275 58 25 0% 17.7 Yes No
CT colonography
CTC 45-75, 10 0 0 3077 1854 287 58 26 0% 6.2 Yes Yes
CTC 45-75, 5 0 0 4713 2303 312 64 27 0% 18.2 Yes Yes Yes
BM Colonoscopy
COL 45-75, 15 0 0 0.0 3748 248 48 23 0% 27.7  - - Yes
Stool tests
FIT 45-75, 3 7763 0 0 1085 195 29 18 0% 5.3 Yes No
FIT 45-75, 2 10684 0 0 1366 219 35 20 0% 11.4 Yes No
HSgFOBT 45-75, 3 7191 0 0 1423 195 31 18 -12.1% Dom. - No
FIT-DNA 45-75, 5 4828 0 0 1483 205 34 19 -8.9% Dom. - No
HSgFOBT 45-75, 2 9567 0 0 1791 220 36 21 -8.4% Dom. - No
FIT-DNA 45-75, 3 6624 0 0 1860 232 40 21 -4.8% Dom. - Yes
FIT 45-75, 1 17665 0 0 1914 247 43 23 0% 20.0 Yes Yes Yes
HSgFOBT 45-75, 1 14396 0 0 2448 247 44 23 -2.4% Dom. - Yes
FIT-DNA 45-75, 1 12303 0 0 2843 258 48 24 0% 84.2 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 2938 0 1530 194 37 19 0% 7.6 Yes No
SIG 45-75, 5 0 4511 0 1966 217 42 21 0% 18.8 Yes No
CT colonography
CTC 45-75, 10 0 0 2907 1655 229 43 22 0% 7.0 Yes Yes
    CTC 45-75, 5 0 0 4469 2069 251 48 23 0% 19.0 Yes Yes Yes
SimCRC - Scenario 2: Increased CRC risk
WF Colonoscopy                        
COL 45-75, 10 0 0 0.0 5138 473 99 41 0% 29.4  - - Yes
Stool tests
FIT 45-75, 3 8732 0 0 1155 348 48 28 0% 3.0 Yes No




SimCRC - Scenario 2: Increased CRC risk
HSgFOBT 45-75, 3 8066 0 0 1539 350 52 28 -12.3% Dom. - No
FIT-DNA 45-75, 5 5466 0 0 1607 368 59 30 -8.9% Dom. - No
HSgFOBT 45-75, 2 10808 0 0 1945 396 63 32 -7.9% Dom. - No
FIT-DNA 45-75, 3 7484 0 0 2003 414 70 34 -4.7% Dom. - No
FIT 45-75, 1 20115 0 0 2064 439 76 36 0% 13.3 Yes Yes Yes
HSgFOBT 45-75, 1 16337 0 0 2676 440 79 36 -2.4% Dom. - Yes
FIT-DNA 45-75, 1 14057 0 0 3120 460 88 38 0% 49.4 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 3257 0 2103 416 85 36 0% 4.8 Yes No
SIG 45-75, 5 0 4937 0 2567 446 92 38 0% 15.5 Yes Yes Yes
CT colonography
CTC 45-75, 10 0 0 3325 1780 405 79 35 0% 4.1 Yes No
CTC 45-75, 5 0 0 5134 2248 449 89 38 0% 10.4 Yes Yes Yes
BF Colonoscopy
COL 45-75, 10 0 0 0 4623 416 67 33 0% 34.8  - - Yes
Stool tests
FIT 45-75, 3 8465 0 0 949 294 34 23 0% 3.0 Yes No
FIT 45-75, 2 11747 0 0 1207 336 42 26 0% 6.1 Yes No
HSgFOBT 45-75, 3 7822 0 0 1311 297 37 23 -14.0% Dom. - No
FIT-DNA 45-75, 5 5301 0 0 1347 312 41 25 -10.6% Dom. - No
HSgFOBT 45-75, 2 10500 0 0 1666 340 44 27 -10.1% Dom. - No
FIT-DNA 45-75, 3 7288 0 0 1700 359 49 28 -5.8% Dom. - No
FIT 45-75, 1 19641 0 0 1735 384 53 30 0% 10.9 Yes Yes Yes
HSgFOBT 45-75, 1 15942 0 0 2322 386 55 30 -2.9% Dom. - Yes
FIT-DNA 45-75, 1 13792 0 0 2709 406 61 32 0% 45.6 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 3174 0 1657 351 56 29 0% 4.5 Yes No
SIG 45-75, 5 0 4862 0 2068 379 61 31 0% 14.6 Yes Yes Yes
CT colonography
CTC 45-75, 10 0 0 3228 1425 354 54 28 0% 3.8 Yes No
CTC 45-75, 5 0 0 5024 1829 394 62 31 0% 10.0 Yes Yes Yes
WM Colonoscopy
COL 45-75, 10 0 0 0.0 5513 650 137 59 0% 23.5  - - Yes
Stool tests
FIT 45-75, 3 7768 0 0 1784 522 84 46 0% 3.1 Yes No
HSgFOBT 45-75, 3 7199 0 0 2136 521 87 46 -8.7% Dom. - No
FIT 45-75, 2 10548 0 0 2172 575 99 51 0% 7.3 Yes No
FIT-DNA 45-75, 5 4814 0 0 2272 544 96 49 -6.5% Dom. - No
HSgFOBT 45-75, 2 9457 0 0 2609 575 102 51 -5.1% Dom. - No
FIT-DNA 45-75, 3 6500 0 0 2753 599 111 53 -2.9% Dom. - Yes
FIT 45-75, 1 17055 0 0 2867 625 118 56 0% 13.9 Yes Yes Yes
HSgFOBT 45-75, 1 13946 0 0 3397 624 120 56 -1.6% Dom. - Yes
FIT-DNA 45-75, 1 11686 0 0 3874 644 129 58 0% 54.2 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 2903 0 2557 554 114 51 0% 4.3 Yes No
SIG 45-75, 5 0 4319 0 3091 599 125 55 0% 11.9 Yes Yes Yes
CT colonography
CTC 45-75, 10 0 0 2882 2648 583 118 54 0% 4.3 Yes No
CTC 45-75, 5 0 0 4299 3164 632 130 57 0% 10.6 Yes Yes Yes
BM Colonoscopy
COL 45-75, 10 0 0 0.0 4648 426 77 38 0% 31.0  - - Yes
Stool tests
FIT 45-75, 3 7548 0 0 1301 321 47 29 0% 3.8 Yes No
FIT 45-75, 2 10333 0 0 1602 361 55 32 0% 7.6 Yes No
HSgFOBT 45-75, 3 7007 0 0 1618 321 48 29 -11.3% Dom. - No
FIT-DNA 45-75, 5 4695 0 0 1700 338 54 31 -8.2% Dom. - No
HSgFOBT 45-75, 2 9278 0 0 1999 362 57 32 -7.6% Dom. - No
FIT-DNA 45-75, 3 6410 0 0 2092 381 62 34 -4.4% Dom. - No
FIT 45-75, 1 16963 0 0 2163 404 66 36 0% 13.1 Yes Yes Yes
HSgFOBT 45-75, 1 13879 0 0 2660 403 67 36 -2.5% Dom. - Yes
table continues
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SimCRC - Scenario 2: Increased CRC risk
FIT-DNA 45-75, 1 11800 0 0 3059 420 73 37 0% 54.9 No Yes
Sigmoidoscopy
SIG 45-75, 10 0 2842 0 1855 358 63 33 0% 4.9 Yes No
SIG 45-75, 5 0 4321 0 2277 388 70 35 0% 14.4 Yes Yes Yes
CT colonography
CTC 45-75, 10 0 0 2823 1930 378 67 34 0% 4.9 Yes No
    CTC 45-75, 5 0 0 4298 2348 412 73 37 0% 12.1 Yes Yes Yes
BF - black female; BM - black male; COL - colonoscopy; CRC - colorectal cancer; CTC - computed 
tomographic colonography; Dom. - dominated strategy; ER - efficiency ratio (incremental 
burden-to-benefit ratio); FIT - fecal immunochemical test; FIT-DNA - multitarget stool DNA 
test; HSgFOBT - high-sensitivity guaiac-based fecal occult blood test; LYG - life-years gained; 
SIG - flexible sigmoidoscopy; WF - white female; WM - white male.
a Both models evaluated two scenarios for CRC risk: one in which age-specific risks were 
assumed to have remained stable since the early screening period in the U.S. (1975-1979 
for SimCRC; 1990-1994 for MISCAN), and one in which age-specific risks were assumed 
to have increased proportional to observed trends among adults under age 40 years. 
b Including deaths from complications of screening.
c The difference in LYG compared to a combination of efficient strategies with similar 
number of required colonoscopies; measure of inefficiency. Values for strategies other than 
colonoscopy screening differ from those in Supplementary Tables A3.3-A3.6, as efficiency 
was reassessed including only strategies with similar start and stop ages as the benchmark 
(model-recommendable) colonoscopy strategy.
d Efficiency ratio = incremental number of colononoscopies/LYG compared to the next 
less effective strategy on the efficient frontier; an incremental burden-to-benefit ratio. 
Values for strategies other than colonoscopy screening differ from those in Supplementary 
Tables A3.3-A3.6, as efficiency was reassessed including only efficient and near-efficient* 
options among the strategies with similar start and stop ages as the benchmark (model-
recommendable) colonoscopy strategy.
e Efficient or near-efficient strategy with an efficiency ratio lower than the benchmark (model-
recommendable) colonoscopy strategy. 
f Efficient or near-efficient strategy with a lower burden-to-benefit ratio and at least 90% of 
the LYG compared to the benchmark (model-recommendable) colonoscopy strategy. 
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Supplementary Table A3.8: Model-recommendable strategies under two scenarios of CRC 
risk, with best-case test performance assumptions a










 Scenario 1: Stable CRC risk b
MISCAN COL  50-75, 10  45-75, 10  50-75, 10  45-75, 10
Stool FIT 50-75, 1 FIT 45-75, 1 FIT 50-75, 1 FIT 45-75, 1
SIG - -  50-75, 5 -
CTC  50-75, 5  45-75, 5  50-75, 5  45-75, 5
SimCRC COL  45-75, 15  45-75, 15  45-75, 15  45-75, 15
Stool FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 2 FIT 45-75, 1
SIG - -  45-75, 5 -
  CTC  45-75, 5  45-75, 5  45-75, 5  45-75, 5
 Scenario 2: Increased CRC risk c
MISCAN  45-75, 10  45-75, 10  45-75, 5  45-75, 10
FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1
 X X - X
 45-75, 5 45-75, 5 -  45-75, 5
SimCRC  45-75, 10  45-75, 10  45-75, 10  45-75, 10
FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1
 45-75, 5  45-75, 5  45-75, 5  45-75, 5
   45-75, 5  45-75, 5  45-75, 5  45-75, 5
- = no model-recommendable strategy within this class; COL - colonoscopy; CRC - colorectal 
cancer; CTC - computed tomographic colonography; FIT - fecal immunochemical test; SIG - 
flexible sigmoidoscopy; X - class of screening modality was no longer recommended in the 
sensitivity analysis.
a Numbers in each field of the table successively represent recommended age to start 
screening, age to stop, and interval, all in years. For the class of stool-based screening 
modalities, the model-recommendable modality is also included, i.e. FIT. Changes from the 
base-case are designated in bold-faced letters. Best-case test performance assumptions are 
provided in Table 3.1.
b Risk within each age-, race-, and sex-specific demographic subgroup was assumed to have 
remained stable over time since the early screening period in the U.S (1975-1979 for SimCRC; 
1990-1994 for MISCAN). 
c CRC risk was increased proportional to observed trends in CRC incidence among adults 
under 40 years old. Estimated incidence rate ratios were 1.80-1.90 for white females (range 
across models), 1.24-1.27 for black females, 2.07-2.13 for white males, and 1.41-1.56 for black 
males.
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Supplementary Table A3.9: Model-recommendable strategies under two scenarios of CRC 
risk, with worst-case test performance assumptions a










 Scenario 1: Stable CRC risk b
MISCAN COL  50-75, 10  45-75, 10  50-75, 10  45-75, 10
Stool X FIT 45-75, 1 FIT 50-75, 1 FIT 45-75, 1
SIG - - - -
CTC X X X X
SimCRC COL  45-75, 15  45-75, 10  45-75, 10  45-75, 15
Stool FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1
SIG - - - -
  CTC  45-75, 5  45-75, 5  45-75, 5  45-75, 5
 Scenario 2: Increased CRC risk c
MISCAN COL  45-75, 10  45-75, 10  45-75, 5  45-75, 10
Stool FIT 45-75, 1 FIT 45-75, 1 FIT-DNA 
45-75, 1
FIT 45-75, 1
SIG X X - X
CTC X X - X
SimCRC COL  45-75, 10  45-75, 10  45-75, 10  45-75, 10
Stool X FIT-DNA  
45-75, 1
FIT 45-75, 1 FIT 45-75, 1
SIG  45-75, 5  45-75, 5  45-75, 5  45-75, 5
  CTC  45-75, 5  45-75, 5  45-75, 5  45-75, 5
- = no model-recommendable strategy within this class; COL - colonoscopy; CRC - colorectal 
cancer; CTC - computed tomographic colonography; FIT - fecal immunochemical test; FIT-
DNA - multitarget stool DNA test; SIG - flexible sigmoidoscopy; X - class of screening modality 
was no longer recommended in the sensitivity analysis.
a Numbers in each field of the table successively represent recommended age to start screening, 
age to stop, and interval, all in years. For the class of stool-based screening modalities, the 
model-recommendable modality is also included, i.e. FIT or FIT-DNA. Changes from the base-
case are designated in bold-faced letters. Worst-case test performance assumptions are 
provided in Table 3.1.
b Risk within each age-, race-, and sex-specific demographic subgroup was assumed to have 
remained stable over time since the early screening period in the U.S (1975-1979 for SimCRC; 
1990-1994 for MISCAN). 
c CRC risk was increased proportional to observed trends in CRC incidence among adults 
under 40 years old. Estimated incidence rate ratios were 1.80-1.90 for white females (range 




Supplementary Table A3.10: Model-recommendable strategies under two scenarios of CRC 
risk, applying a lower acceptance threshold for LYG relative to the benchmark colonoscopy 
strategy a










 Scenario 1: Stable CRC risk b
MISCAN COL  50-75, 10  45-75, 10  50-75, 10  45-75, 10
Stool FIT 50-75, 1 FIT 45-75, 1 FIT 50-75, 1 FIT 45-75, 1
SIG  50-75, 5  45-75, 5  50-75, 5  45-75, 5
CTC  50-75, 5  45-75, 5  50-75, 5  45-75, 5
SimCRC COL  45-75, 15  45-75, 15  45-75, 15  45-75, 15
Stool FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1
SIG  45-75, 5  45-75, 5  45-75, 5  45-75, 5
  CTC  45-75, 5  45-75, 5  45-75, 5  45-75, 5
 Scenario 2: Increased CRC risk c
MISCAN COL  45-75, 10  45-75, 10  45-75, 5  45-75, 10
Stool FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1
SIG  45-75, 5  45-75, 5  45-75, 5  45-75, 5
CTC  45-75, 5  45-75, 5  45-75, 5  45-75, 5
SimCRC COL  45-75, 10  45-75, 10  45-75, 10  45-75, 10
Stool FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1
SIG  45-75, 5  45-75, 5  45-75, 5  45-75, 5
  CTC  45-75, 5  45-75, 5  45-75, 5  45-75, 5
COL - colonoscopy; CRC - colorectal cancer; CTC - computed tomographic colonography; FIT 
- fecal immunochemical test; SIG - flexible sigmoidoscopy.
a Model-recommendable strategies were required to provide at least 75% (rather than 90% in 
the base-case) of the predicted LYG for the model-recommendable colonoscopy screening 
strategy. Numbers in each field of the table successively represent recommended age to 
start screening, age to stop, and interval, all in years. For the class of stool-based screening 
modalities, the model-recommendable modality is also included, i.e. FIT. Changes from the 
base-case are designated in bold-faced letters. 
b Risk within each age-, race-, and sex-specific demographic subgroup was assumed to have 
remained stable over time since the early screening period in the U.S (1975-1979 for SimCRC; 
1990-1994 for MISCAN). 
c CRC risk was increased proportional to observed trends in CRC incidence among adults 
under 40 years old. Estimated incidence rate ratios were 1.80-1.90 for white females (range 
across models), 1.24-1.27 for black females, 2.07-2.13 for white males, and 1.41-1.56 for black 
males.
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Supplementary Table A3.11: Model-recommendable strategies under two scenarios of CRC 
risk, applying a more stringent acceptance threshold for required number of colonoscopies 
per LYG a










 Scenario 1: Stable CRC risk b
MISCAN COL  50-75, 10 d  50-75, 10  50-75, 10  50-75, 10
Stool FIT 50-75, 1 FIT 50-75, 1 FIT 50-75, 1 FIT 50-75, 1
SIG - - - -
CTC  50-75, 5  50-75, 5  50-75, 5  50-75, 5
SimCRC COL  45-75, 15  45-75, 15  45-75, 15  45-75, 15
Stool FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1
SIG - - - -
  CTC  45-75, 5  45-75, 5  45-75, 5  45-75, 5
 Scenario 2: Increased CRC risk c
MISCAN COL  45-75, 10  45-75, 10  45-75, 5  45-75, 10
Stool FIT 45-75, 1 FIT 45-75, 1 - FIT 45-75, 1
SIG  45-75, 5  45-75, 5 -  45-75, 5
CTC  45-75, 5  45-75, 5 -  45-75, 5
SimCRC COL  45-75, 10  45-75, 10  45-75, 10  45-75, 10
Stool FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1
SIG  45-75, 5  45-75, 5  45-75, 5  45-75, 5
  CTC  45-75, 5  45-75, 5  45-75, 5  45-75, 5
- = no model-recommendable strategy within this class; COL - colonoscopy; CRC - colorectal 
cancer; CTC - computed tomographic colonography; FIT - fecal immunochemical test; SIG - 
flexible sigmoidoscopy.
a Model-recommendable strategies could require no more than 40 additional colonoscopies 
per LYG (rather than 50 in the base-case) compared to the next less effective strategy on the 
efficient frontier. Numbers in each field of the table successively represent recommended age 
to start screening, age to stop, and interval, all in years. For the class of stool-based screening 
modalities, the model-recommendable modality is also included, i.e. FIT. Changes from the 
base-case are designated in bold-faced letters. 
b Risk within each age-, race-, and sex-specific demographic subgroup was assumed to have 
remained stable over time since the early screening period in the U.S (1975-1979 for SimCRC; 
1990-1994 for MISCAN). 
c CRC risk was increased proportional to observed trends in CRC incidence among adults 
under 40 years old. Estimated incidence rate ratios were 1.80-1.90 for white females (range 
across models), 1.24-1.27 for black females, 2.07-2.13 for white males, and 1.41-1.56 for black 
males.
d For white females, MISCAN-Colon recommended colonoscopy every 10 years between age 
50 and 75 years despite failure to meet the applied burden-to-benefit ratio criterion. Less 
intensive strategies did not meet the prioritized benefit criterion.
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Financial barriers to colorectal cancer screening persist despite the Affordable Care 
Act (ACA). Medicare beneficiaries may face 20 percent coinsurance for a screening 
colonoscopy when the procedure includes the removal of polyps or follows a positive 
fecal screening test. Using an established microsimulation model, we estimated that 
waiving this coinsurance would result in 1.7 fewer colorectal cancer deaths (a decrease 
of 13 percent) and $17,000 higher colorectal cancer–related costs (an increase of 0.6 
percent) for the Centers for Medicare and Medicaid Services per 1,000 sixty-five-
year-olds, assuming a 10-percentage-point increase in the rates of first colonoscopy 
screening, follow-up, and surveillance. If the rates did not change, waiving coinsurance 
would increase total costs by $51,000 (1.9 percent) per 1,000 sixty-five-year-olds. 
Estimated screening benefits were comparable when fecal testing was assumed to be 
the primary screening method. Moreover, waiving coinsurance would be cost-effective 
if the screening rate increased by 0.6 percentage points, assuming a willingness-to-pay 
threshold of $50,000 per quality-adjusted life-year gained. Thus, the waiver is likely to 
have a favorable balance of health and cost impact. 




Colorectal cancer is the second leading cause of cancer death in the United States (US). 
It is estimated that in 2017, over 135,000 new cases will be diagnosed, and more than 
50,000 deaths due to the disease will occur.187 Screening may prevent such deaths and 
is therefore recommended for people ages 50-75 years by the US Preventive Services 
Task Force.76 Despite the overwhelming evidence for the effectiveness of screening,51 
in 2015 only 61.1 percent of eligible people reported having received colorectal cancer 
testing consistent with current guidelines (Stacey Fedewa, director of screening and 
risk factor surveillance, American Cancer Society, personal communication, February 
1, 2017). Removing financial barriers is an effective way to increase participation in 
colorectal cancer screening.188,189 Provisions of the Affordable Care Act (ACA) aimed to 
improve health care access and affordability of preventive services for all Americans190 
and eliminated cost sharing for services such as colorectal cancer screening that are 
recommended with by the task force a grade A or B.191-195 Financial barriers for receipt 
of colorectal cancer screening persist despite the ACA. For Medicare beneficiaries, the 
group with the highest age-related disease risk, negative screening colonoscopy and fecal 
test such as fecal immunochemical test (FIT) are full covered–that is, the beneficiary has 
no deductible or coinsurance. However, beneficiaries without supplemental insurance 
face out-of-pocket spending when a polyp is detected and removed during the course 
of a screening colonoscopy, as the service is then classified by Medicare as diagnostic 
rather than preventive and is subject to a 20 percent coinsurance.196 Beneficiaries are also 
responsible for both the part B deductible and the 20 percent coinsurance payment for 
colonoscopy when it is performed after a positive fecal test, regardless of the outcome. 
Since the 2011-2012 session of Congress, bills have been introduced to amend title XVIII 
of the Social Security Act to waive colonoscopy screening coinsurance for Medicare 
beneficiaries, regardless of the findings of the procedure. On the basis of Medicare claims, 
it has been estimated that the amendment increase Medicare spending on colonoscopies 
by US $48 million annually.196 Because of the lack of studies on the potential impact of 
waiving the coinsurance on screening rates and the corresponding savings in colorectal 
cancer treatment, none of the introduced legislation has become law. To help inform 
future Medicare reimbursement policy, we estimated the potential impact of waiving 
Medicare coinsurance for screening colonoscopies with polyp removal and for diagnostic 
colonoscopies performed after a positive FIT. Using a well-established microsimulation 
model, we evaluated several scenarios for the effect of such a waiver on take-up of screening 
to determine whether, and under what circumstances, it could prove cost-effective. 
Study data and methods
The Microsimulation Screening Analysis-Colon model
We used the Microsimulation Screening Analysis-Colon model to estimate the cost-
effectiveness of waiving coinsurance for every component of colorectal cancer screening 
from the prospective of the Centers for Medicare and Medicaid Services (CMS). The model 
was developed by the Department of Public Health in the Erasmus University Medical 
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Center, and it has been described extensively elsewhere (Model Appendix).102,103 It is 
part of the National Cancer Institute’s Cancer intervention and Surveillance Modeling 
Network 197 and has been used to inform screening recommendations of the US 
Preventive Services Task Force.96,97 In brief, the model generates, with random variation, 
the life histories of people in a large cohort to simulate the US population in terms of life 
expectancy and cancer risk. Each simulated person ages over time and may develop one 
or more adenomas that can progress from small (no more than 5 mm), to medium (6-9 
mm) to large size (10 mm or more). Some adenomas develop into preclinical cancer, which 
may progress through stages I to IV. At each disease transition point, colorectal cancer 
may be diagnosed because of symptoms. Survival after clinical diagnosis is determined 
by the stage at diagnosis, the location of the cancer, and the person’s age. Some simulated 
life histories are altered by the effect of detecting and removing adenomas or diagnosing 
colorectal cancer at an earlier stage, which results in a better prognosis. Screening 
also results in overdiagnosis and overtreatment and may have several complications, 
which are considered in the modelling. The Microsimulation Screening Analysis-Colon 
model quantifies the effectiveness and associated costs of the screening by comparing 
outcomes with and without a specific screening intervention. Further details about the 
model and its natural history assumptions are presented in the Model Appendix.
Analysis 
We simulated an average-risk Medicare-eligible US population cohort of sixty-five-year-
olds, 60 percent of whom were then up-to-date with screening according to guidelines 
of the US Preventive Services Task Force (which recommend colonoscopy screening at 
ages fifty and sixty or annual FIT screening from age fifty to age sixty-four). We then 
simulated potential increases in screening rates and benefits and costs due to waiving 
the Medicare coinsurance from age sixty-five over the patient’s lifetime. We simulated 
screening until age seventy-five, following the task force’s guidelines. 
Patients with a positive FIT result were referred to diagnostic colonoscopy. Detected 
adenomas were removed and followed by colonoscopy surveillance every three to five 
years, depending on the number and the size of adenomas detected, as recommended 
by current guidelines.107 Test characteristics were based on a study by Amy Knudsen and 
coauthors.96 We assumed a Medicare reimbursement of $21.65 per FIT.198 Estimates of 
the costs of colonoscopy screening, follow-up, and surveillance without polyp removal 
and of colonoscopies with polyp removal were obtained from an analysis of 2014 
Medicare claims data from the Chronic Conditions Data Warehouse and updated to 
2015 US dollars using the Consumer Price Index (CPI). Costs of colorectal cancer care 
were obtained from an analysis of data for the period 1998–2003 that linked information 
from the Surveillance, Epidemiology, and End Results (SEER) database with data 
from Medicare claims,199 updated to 2015 US dollars using the CPI. Detailed model 
assumptions regarding test characteristics, utility losses in terms of quality-adjusted life-
years (QALYs), and costs are in Supplementary Table A5.1. 
Five scenarios were simulated that differed with regard to coinsurance and screening 
rate— which were evaluated separately for FIT- and colonoscopy-based screening 
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strategies. The first scenario was the current state, in which 70 percent of the total 
population ages 50–75 had received at least one screening, 60 percent adhered to 
screening recommendations,113,176,200 80 percent adhered to potential diagnostic and 
surveillance colonoscopy recommendations,55,87 and there was a 20 percent coinsurance 
for screening colonoscopy with polypectomy and colonoscopy after a positive FIT result 
(no supplemental insurance was taken into account) (for more details on adherence 
assumptions as applicable to each round, see Supplementary Table A5.1). 
In the second scenario, coinsurance for all participants was waived, with no assumed 
effect on screening rates. In the third scenario, waiving coinsurance was assumed to lead 
to a 5-percentage-point increase in the rate of completion of a diagnostic colonoscopy 
and surveillance after a positive FIT result.
In the fourth scenario, waiving coinsurance produced a 5-percentage-point increase 
in the initial screening rate and in diagnostic follow-up and surveillance rates. In this 
scenario, the percentage of people up-to-date with screening and ever having been 
screened increased to 65 percent and 73.75 percent, respectively (for similar relative 
reductions in the number not current with screening and never screened). In the fifth 
scenario, we simulated a 10-percentage-point increase in the initial screening rate and 
diagnostic follow-up and surveillance rates, which resulted in 70 percent and 77.5 
percent of people being up-to-date with screening and ever having been screened, 
respectively (see Supplementary Table A5.1). The levels of increased screening 
participation simulated in the fourth and the fifth scenarios match the effect seen with 
the elimination of coinsurance for screening colonoscopies.191,192,201 
For all coinsurance and screening-rate scenarios, and for both the FIT- and colonoscopy-
based screening regimens, our main outcomes were numbers of colorectal cancer cases 
and deaths, number of colonoscopies potentially subject to coinsurance, life-years 
and QALYs gained compared to no screening, and associated costs. We applied the 
conventional 3 percent annual discount rate to all outcomes except for the numbers of 
colorectal cancer cases and deaths and of colonoscopies with coinsurance requirements. 
In addition, because the true effect on screening participation of waiving coinsurance 
is unknown, we determined the threshold increase in screening rate at which full 
coverage of colonoscopy by CMS is cost-effective compared to the current state based 
on willingness-to-pay thresholds of $100,000 and $50,000 per QALY gained.202 
Sensitivity analyses
In sensitivity analyses, we used the following seven alternative assumptions to evaluate 
the robustness of our results: 60 percent of the cohort of sixty-five-year-olds had been 
screened once at age fifty-five using colonoscopy and received colonoscopy screening 
at ages sixty-five and seventy-five; none of the cohort of sixty-five-year-olds received 
screening before that age; the costs for colonoscopy were 10–75 percent higher (see 
Supplementary Table A5.1); treatment costs for the initial phases of stage III and IV 
and the terminal phase of colorectal cancer care (at all stages) were 10–75 percent higher 
(see Supplementary Table A5.1); the population that participated in screening 
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only if coinsurance was waived (socioeconomically disadvantaged people without 
supplemental insurance) and the population that never participated had a 1.2-fold 
higher incidence of colorectal cancer than the population that participated in screening 
regardless of the cost (based on a study by Raymond Oliphant and coauthors);203 test 
sensitivities of FIT and colonoscopy were lower (worst case) or higher (best case) than 
our base-case analyses (see Supplementary Table A5.1); and potential increases in 
screening rates, benefits, and costs were simulated from age fifty on. 
Limitations 
Our study had a few limitations. First, the effect of waiving coinsurance on participation 
is not well known because of the paucity of published studies. We therefore evaluated 
several scenarios based on estimates of the effect of the coinsurance waiver for screening 
colonoscopies, and we determined a threshold of increased screening at which waiving 
the coinsurance was cost-effective. Second, the costs of colorectal cancer treatment 
derived from SEER-Medicare linked data for 1998–2003 might be underestimates, 
as therapy with monoclonal antibodies received approval by the Food and Drug 
Administration after that period. Therefore, we underestimated cost savings due to 
averted treatment expenses for cancer cases in our base-case analyses, and we explored 
the impact of higher treatment costs in our sensitivity analyses. Third, no up-to-date 
information was available on the proportion of Medicare beneficiaries with supplemental 
insurance. Supplemental coverage may vary across packages and states. We assumed a 
20 percent increase in costs for CMS for all colonoscopies with polypectomy and those 
performed after a positive FIT after waiving the coinsurance. Since for people with 
Medicare Advantage, the private plans that receive premiums from CMS may already 
cover expenses, this likely overestimated the increase in cost from CMS’s perspective and 
therefore the cost-effectiveness threshold of waiving coinsurance. Likewise, the health 
impact of waiving coinsurance might mainly occur among people without supplemental 
coverage (an estimated 14 percent of Medicare beneficiaries in 2010),204 given that those 
with additional insurance might not benefit financially from the coinsurance change.
Study results
Potential benefits and costs of waiving coinsurance
We estimated that in the current state, using the colonoscopy regimen with coinsurance, 
12.8 colorectal cancer deaths occurred and 124.1 QALYs were gained per 1,000 sixty-
five-year-olds (Table 5.1). The total number of procedures per 1,000 Medicare 
beneficiaries was 1,132, of which 410 (36 percent) were potentially subject to coinsurance 
requirements. We estimated the total lifetime costs for CMS, which included colorectal 
cancer screening, surveillance, and treatment, with coinsurance, to be $2.675 million 
per 1,000 sixty-five-year-olds (Table 5.1 and Supplementary Table A5.2). 
The benefits of waiving coinsurance for a screening colonoscopy in which a polyp 
is removed varied with the assumed increase in participation. For the colonoscopy 
strategy, if there was no change in screening rate as a result of waiving the coinsurance, 
Waiving Coinsurance for CRC Screening
209
5
the benefits of screening would not change, but the total costs of screening and treatment 
would increase to $2.726 million (an increase of $51,000, or 1.9 percent) per 1,000 sixty-
five-year-olds (Table 5.1). In contrast, an assumed 5-percentagepoint increase in the 
rates of first colonoscopy screening and surveillance decreased the number of colorectal 
cancer deaths by 0.9 (6.4 percent), accompanied by an increase of $33,000 (1.2 percent) 
in total costs, with a cost per QALY gained (or cost-effectiveness ratio) of $4,086. A 
10-percentage-point increase instead decreased deaths by 1.7 (13 percent) and increased 
costs by only $17,000 (0.6 percent), resulting in a cost- effectiveness ratio of $1,035. 
The potential benefits and costs of waiving all coinsurance for colorectal cancer 
screening were comparable using a FIT-based strategy (Table 5.1). Of special interest is 
the scenario in which a 5-percentage-point increase in adherence to diagnostic follow-
up and surveillance was assumed to be a consequence of waiving coinsurance. This 
resulted in a cost-effectiveness ratio of $48,606 compared to the current state, which 
suggests that even if only adherence to diagnostic follow-up and surveillance increased 
by this amount—with no increase in adherence to primary FIT screening—waiving the 
coinsurance would be cost-effective.
In the colonoscopy strategy, costs were higher at ages seventy, seventy-five, and 
eighty because of the increased costs for screening and surveillance colonoscopies, 
but costs were lower at the other ages if the waiver increased the screening rate (see 
Supplementary Figure A5.1). In the FIT strategy, waiving coinsurance was estimated 
to initially increase costs but to lead to cost savings after a decade because of averted 
cases of colorectal cancer. The estimated increase in per person costs was slightly higher 
for the colonoscopy strategy compared to the FIT strategy (see Supplementary 
Figure A5.1).
Cost-effectiveness threshold determination
Assuming a willingness-to-pay threshold of $100,000 per QALY gained, we estimated 
that waiving all coinsurance would be cost-effective if it increased screening participation 
by 0.4 percentage points (from 60.0 percent to 60.4 percent) in a colonoscopy-based 
screening protocol and by 0.3 percentage points (from 60.0 percent to 60.3 percent) in 
a FIT-based screening protocol (Figure 5.1). When a willingness-to-pay threshold of 
$50,000 was applied, we estimated that in both protocols the screening rate would need 




Table 5.1: Colorectal cancer (CRC) outcomes per 1,000 sixty-five-year-old Medicare 














































































































No screening 60.1 26.6 60.1 0.0 0.0 3.276 - c
Colonoscopy 
With coinsurance 
Current state 34.2 12.8 410d 104.1 124.1 2.675 - c
Without coinsurance, 
assuming:
No impact on adherence 34.2 12.8 410 104.1 124.1 2.726 - c
5 percentage point increase  
in diagnostic follow-up and 
surveillance.
34.1 12.7 411 104.1 124.1 2.728 $1,142,885
5 percentage point increase 
in first screening, diagnostic 
follow-up, and surveillance.
32.9 11.9 439 111.0 132.2 2.708 4,086
10 percentage point 
increase in first screening, 
diagnostic follow-up, and 
surveillance.
31.6 11.1 470 117.9 140.4 2.692 1,035
Fecal immunochemical test
With coinsurance 
Current state 39.5 14.0 357 99.4 115.9 2.743 - c
Without coinsurance, 
assuming:
No impact on adherence 39.5 14.0 357 99.4 115.9 2.785 - c
5 percentage point increase 
in diagnostic follow-up and 
surveillance.
39.2 13.9 368 100.1 116.7 2.783 48,606
5 percentage point increase 
in first screening, diagnostic 
follow-up and surveillance.
38.5 13.2 391 106.2 123.7 2.772 3,747
10 percentage point 
increase in first screening, 
diagnostic follow-up and 
surveillance.
37.3 12.4 427 112.9 131.6 2.758 974
Increases are compared to the current state (a 60 percent screening rate and 80 percent 
adherence rates to diagnostic follow-up and surveillance after a positive FIT). QALYs are 
quality-adjusted life-years.  
a Not discounted.  
b Discounted at the conventional 3 percent annual rate.  
c Not applicable.  
d Out of a total 1,132 colonoscopies.
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Figure 5.1: Predicted increases in costs per quality-adjusted life-year (QALY) gained if 
coinsurance for colorectal cancer screening were waived, by percentage-point increase 
in adherence to screening, diagnostic follow-up, and surveillance. Increases in costs and 
adherence are compared to the current state for sixty-five-year-old Medicare beneficiaries 
(who have a screening rate of 60 percent and an 80 percent adherence rate to diagnostic 
follow-up and surveillance), and are 3 percent discounted to the age of 65. With a willingness-
to-pay threshold of $50,000 or even $100,000 per QALY gained, waiving coinsurance is cost-
effective with even small increases in adherence. FIT is fecal immunochemical test.
 
Sensitivity analyses 
Several sensitivity analyses affected the percentage-point increase in screening rate 
required for waiving coinsurance to be cost-effective. First, in the sensitivity analysis 
that assumed one previous colonoscopy screening at age fifty-five or no screening 
before age sixty-five increased the thresholds at which waiving coinsurance was cost-
effective from 0.6 to 0.9 and 1.8 percentage points, respectively, using a willingness-
to-pay threshold of $50,000 per QALY gained (Table 5.2). Second, in the sensitivity 
analysis that assumed higher colonoscopy costs, the threshold increased up to 1.3 
percentage points. Third, if we simulated potential increases in screening rates, benefits, 
and costs starting at age fifty rather than age sixty-five, the threshold more than doubled 
(increasing to 1.8 percentage points). Sensitivity analyses that evaluated the effect of 
alternative assumptions for treatment costs, higher colorectal cancer risk in additional 
participants, and test sensitivities demonstrated that these assumptions minimally 
affected the percentage-point increase in screening rate needed to make waiving 
coinsurance cost-effective. The needed increase in screening rate did not exceeded 1.8 
percentage points in any of the sensitivity analyses.
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Table 5.2: Percentage-point increases in screening rate for colorectal cancer (CRC), diagnostic 
follow-up, and surveillance needed for waiving coinsurance for Medicare beneficiaries to be 
cost-effective, by selected assumptions.
Assumption Colonoscopy, by 
willingness  
to pay per QALY 
gained
FIT, by willingness  
to pay per QALY 
gained
$100,000 $50,000 $100,000 $50,000
Base-Case 0.4 0.6 0.3 0.6
One previous screening at age 55a 0.5 0.9 -b -b
With no screening before age 65a 0.8 1.8 0.4 0.8
Higher Colonoscopy costs of:
  10% 0.4 0.7 0.3 0.6
  25% 0.4 0.8 0.4 0.7
  50% 0.5 1.0 0.5 0.9
  75% 0.6 1.3 0.5 1.0
Higher Treatment costsc of:
  10% 0.4 0.6 0.3 0.6
  25% 0.3 0.6 0.3 0.6
  50% 0.3 0.6 0.3 0.5
  75% 0.3 0.6 0.3 0.5
Higher CRC risk in additional participants 0.3 0.5 0.3 0.5
Worst-case test sensitivity 0.4 0.6 0.3 0.6
Best-case test sensitivity 0.3 0.6 0.3 0.6
50-year-olds 0.8 1.8 0.5 1.0
Increases are compared to the current state among sixty-five-year-old beneficiaries (a 
60 percent screening rate and 80 percent adherence rates to diagnostic follow-up and 
surveillance after a positive fecal immunochemical test [FIT]). All costs were discounted at the 
conventional 3 percent annual rate. QALYs - quality-adjusted life-years. 
a Screenings at ages sixty-five and seventy-five. 
b Not applicable. 
c For initial phase stages III and IV and for terminal phase (all stages) CRC care.
Costs per QALY gained compared to the current state remained below $25,000 in 
every scenario if waiving coinsurance resulted in an increase in the screening rate (see 
Supplementary Figure A5.2). Strikingly, in the sensitivity analysis that assumed at 
least 25 percent higher costs of colorectal cancer care, the increase in costs of waiving 
coinsurance was totally offset by savings in the colorectal cancer care costs if the waiver 
resulted in a 10-percentage-point increase in the screening rate, which means that in 
this scenario, waiving coinsurance would be cost-saving (see Supplementary Figure 
A5.2 and Supplementary Table A5.3).




Colorectal cancer screening is an effective prevention method, and removing financial 
barriers has been identified as a promising intervention for enhancing participation 
in the screening.188,189 While we did not estimate the effect on participation of waiving 
coinsurance for screening colonoscopies with polyp removal or for colonoscopies 
performed after a positive FIT, we showed that the policy would be cost-effective if it 
increased the screening rate from 60.0 percent to 60.6 percent in Medicare beneficiaries, 
using a willingness-to-pay threshold of $50,000 per QALY gained. Even if waiving all 
coinsurance for colorectal cancer screening did not result in an increase in the screening 
rate, total costs for Medicare would increase by only 1.9 percent for the colonoscopy 
strategy and 1.5 percent for the FIT strategy (assuming that costs were discounted at 
the conventional 3 percent annual rate). Our sensitivity analyses demonstrated that if 
the actual costs were at least 25 percent higher than the current state for initial phases 
of care for stages III and IV colorectal cancer, and for terminal phases of care for all 
stages, waiving coinsurance would be cost-saving if it increased screening rates from 60 
percent to 70 percent. 
Literature on cost and health impacts of waiving coinsurance 
We are aware of one previous study that examined the potential budget impact of 
waiving coinsurance for all screening related colonoscopies. David Howard and co-
authors reported a 10 percent increase in total colonoscopy costs after coinsurance 
was waived for a diagnostic colonoscopy after a positive FIT and for a positive 
screening colonoscopy.196 The increases in total colonoscopy costs in our analyses 
were 7.3 percent (the costs of screening, diagnostic follow-up, surveillance, and 
associated complications) in the colonoscopy strategy and 11.8 percent (the costs of 
diagnostic follow-up, surveillance, and associated complications) for the FIT strategy, 
if waiving coinsurance did not increase screening rate. However, the study by Howard 
and coauthors focused only on colonoscopy costs and did not consider cost savings 
from averted cases of colorectal cancer.196 The strength of our study is that we also 
considered the potential impact of waiving coinsurance on screening behavior and 
estimated costs of the entire colorectal cancer screening process—including screening, 
diagnosis, surveillance, complications, and care—thereby placing the increase in costs 
from waiving coinsurance in a more complete context. To our knowledge, ours is the 
first study to explore the potential benefits of waiving coinsurance for a colonoscopy 
with polypectomy and for a follow-up colonoscopy after a positive FIT. The predicted 
health benefits of the waiver depend on its assumed impact on the screening rate. As a 
potential source of information for the expected impact, several studies have looked at 
the effect of similar legislation changes in which coinsurance was removed for screening 
colonoscopies. Shabnam Khatami and colleagues reported that waiving coinsurance for 
a negative screening colonoscopy resulted in an annual increase in colonoscopy use of 
8.0–9.5 percent among employees of the University of Texas System,201 an increase of 18 
percent. Mary Hamman and Kandice Kapinos found a 4-percentage-point increase in 
annual colonoscopy rates in men ages 66–75 within one year of the ACA’s enactment. 
They found even larger increases among socioeconomically disadvantaged men.192 
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Stacey Fedewa and coauthors compared data from the National Health Interview 
Survey for 2013 and 2008 and found a 9.8-percentage-point increase in colorectal 
cancer screening prevalence among Medicare beneficiaries after mandates on coverage 
of preventive care from the ACA took effect.191 However, it is important to note that 
the ACA affected more factors than cost sharing that could have influenced screening 
participation, such as providing a free annual wellness visit and a temporary primary 
care bonus for physicians. In contrast, some studies found no effect of the elimination 
of cost sharing for screening colonoscopies on rates of colorectal cancer screening,205-207 
despite the fact that financial concerns constitute one of the most reported barriers 
to the screening. Substantial financial barriers may persist despite ACA provisions 
(for example, coinsurance requirements remain for an estimated 36 percent of the 
procedures), which reflects the complexity of the current reimbursement policy for both 
patients and providers. Other factors such as the need to take time off from work, family 
responsibilities, transportation, and fear of or other perceptions about the screening test 
also affect screening participation.208,209 
Policy implications 
We showed that waiving coinsurance would be cost-effective even with a modest 
increase of 0.6 percentage points in the screening rate, assuming a current rate of 60 
percent. If all colonoscopies used in screening were fully reimbursed regardless of their 
findings or indications, a clear and consistent message could be communicated—which 
in itself might be a stimulus for screening participation in addition to reducing financial 
barriers. In general, FIT screening was associated with a lower number of procedures 
subject to coinsurance. If FIT screening becomes more popular in the United States, 
following trends observed in several settings,158,210 the costs of waiving the coinsurance 
would be even lower. It is likely that waiving coinsurance would primarily affect the out-
of-pocket spending of Medicare beneficiaries of low socioeconomic status, who more 
often than other beneficiaries lack Medigap and supplemental insurance.204 Beneficiaries 
of very low socioeconomic status are eligible for Medicaid and may be protected from 
coinsurance in the thirty-one states that, along with the District of Columbia, expanded 
eligibility for Medicaid under the ACA.204 However, in the remaining nineteen states, 
people of low socioeconomic status neither are eligible for Medicaid as well as Medicare 
nor can afford supplemental insurance. This means that waiving coinsurance might also 
contribute to reducing disparities in colorectal cancer in the United States.74 Health 
disparities are larger in the United States than in many other Western countries,211 and 
reducing them is an important objective of Healthy People 2020.212 
Conclusion
The results of our study can inform the public debate and policy related to the balance 
of costs and benefits of waiving Medicare beneficiaries’ coinsurance for colonoscopy 
screening in instances where a polyp is removed or the procedure is a follow-up to a 
positive FIT result. We estimated that waiving coinsurance would be cost-effective if 
screening rates increased from 60.0 percent to 60.6 percent, assuming a willingness- to-
pay threshold of $50,000 per QALY gained—which suggests that the waiver would likely 
have a very favorable balance of health and cost impact.









 [Worst-case –Best-case]c 
    Adenoma 1-5 mm 75% [70.0-79.0%] 0.00% [0.00-0.00%]d
    Adenoma 6-9 mm 85% [80.0-92.0%] 11.4% [8.30-15.2%] 
    Adenoma 10+ mm 95% [93.1-99.5%] 15.9% [13.7-18.3%] 
    Colorectal cancer
Reach
95% [93.1-99.5%]
95% reaches the cecum
62.565/88.6% [48/81.1-75.3/93.4%]e 













with polypectomy  814.12 [895.53-1221.18]/ 
982.40 [1080.64-1473.60]f
diagnosis of CRC by 
symptoms
814.12 [895.53-1221.18]
Utility loss (QALYs) 0.002 (1.5 day at 0.5 utility) 0
COLORECTAL CANCER CARE
Costs per LY 









    Stage I CRC 29,135 2,319 52,228 [57,451-91,399] 12,868
    Stage II CRC 40,207 2,161 52,081 [57,289-91,141] 11,255
    Stage III CRC 49,023 [53,925 – 85,790] 3,089 54,877 [60,365-96,035] 14,891
    Stage IV CRC 64,015 [70,416 – 112,026] 9,573 73,649 [81,014-128,886] 39,980
Utility losses 
per LY with CRC 
careh
    Stage I CRC 0.12 0.05 0.70 0.05
    Stage II CRC 0.18 0.05 0.70 0.05
    Stage III CRC 0.24 0.24 0.70 0.24





Costs (2015 US$) Utility losses
Serious gastrointestinal 
eventi
6,665 0.0055 (4 days at 0.5 utility)
Other Gastrointestinal 
eventj
4,749 0.0027 (2 days at 0.5 utility)






















FU q & surv.
Adh.
-----------Stratum 1 and Stratum 2 ----------- Stratum3
Current 
adherence
70% 0% 30% 85.71%r 90.00% 60.00% 80.00% 0
+5 %point FU 
and Surv.
70% 0% 30% 85.71% 90.00% 60.00% 85.00% 0
+5%point 1st 
Scr. FU and 
Surv.
70% 3.75% 26.25% 88.14% 91.25% 65.00% 85.00% 0
+10%point 
1st Scr. FU and 
Surv
70% 7.5% 22.5% 90.32% 92.50% 70.00% 90.00% 0
CRC - colorectal cancer; Str. – Stratum; Adh =-Adherence; Scr. – Screening; prev. – previously; 
FU - diagnostic follow-up; Surv. - Surveillance. 
a The lack of specificity with endoscopy reflects the detection of non-adenomatous lesions, 
where the non-adenomatous lesions are removed and therefore induce polypectomy and 
biopsy.
b The sensitivity of colonoscopy for the detection of adenomas and CRC within the reach of 
the endoscope was obtained from a systematic review on miss rates observed in tandem 
colonoscopy studies 213 .We assumed the same test characteristics for diagnostic colonoscopy 
as for screening colonoscopy.
c In the worst- and best-case test sensitivity FIT scenarios, the corresponding worst- and best-
case values for colonoscopy were used.
d We assumed that small adenomas do not bleed, and therefore cannot cause a positive stool test. 
e “Long” before clinical diagnosis / “Short” before clinical diagnosis.
f CMS costs in the current state with coinsurance/ CMS costs if coinsurance is waived 
g CRC care costs were obtained from an analysis of 1998-2003 SEER-Medicare linked data 199 
and updated to 2015 US dollars using the Consumer Price Index. CRC care was divided in 
three clinically relevant phases. The initial care phase was defined as the first 12 months after 
diagnosis, the terminal care phase as the final 12 months of life, and the continuing care phase 
as all months in between. For patients surviving less than 24 months, the last 12 months were 
allocated to the terminal care phase and the remaining months were allocated to the initial 
care phase. As these costs are derived from 2003 data, these costs exclude the potential use 
of expensive monoclonal antibodies cetuximab and bevacizumab as these received FDA 
approval for treatment of colorectal cancer in 2004. Therefore, we assumed 10%, 25%, 50% 
and 75% 
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higher treatment costs for initial phase stage III and IV, and terminal care CRC death all stages. 
h Utility losses for LYs with initial care were derived from a study by Ness et al. 171. For LYs with 
continuing care for stage I and II CRC, we assumed a utility loss of 0.05 QALYs; for LYs with 
continuing care for stage III and IV CRC, we assumed the corresponding utility losses for LYs 
with initial care. For LYs with terminal care for another cause, we assumed the corresponding 
utility losses for LYs with continuing care. 
I Serious gastrointestinal events are perforations, gastrointestinal bleeding, or transfusions. 
The rate depends on age, formula 1/[exp(9.27953 – 0.06105 x Age) + 1] – 1/[exp(10.78719 – 
0.06105 x Age) + 1].
j Other gastrointestinal events are paralytic ileus, nausea and vomiting, dehydration, or 
abdominal pain. The rate depends on age, formula 1/[exp(8.81404 – 0.05903 x Age) + 1] – 1/
[exp(9.61197 – 0.05903 x Age) + 1].
k Cardiovascular events are myocardial infarction or angina, arrhythmias, congestive heart 
failure, cardiac or respiratory arrest, syncope, hypotension, or shock. The rate depends on 
age, formula 1/[exp(9.09053 – 0.07056 x Age) + 1] – 1/[exp(9.38297 – 0.07056 x Age) + 1]. 
lTo reflect observed screening rates in the United States, the population of 10 million men and 
women was divided in three strata: stratum 1 (70%) contained current participants 175,176,185, 
stratum 2 (0-7.5%) contained additional participants, stratum 3 (30-22.5%) never attended 
screening.
m In sensitivity analyses 5, we assumed that stratum 2 and stratum 3 have a relative risk of 
getting CRC of 1.2 compared to the population that attends irrespectively of costs, based on 
the study of Oliphant et al. 203.
n We decreased the population that is never screened with the same proportion as the 
population that is currently not up to date with CRC screening by increasing the proportion 
of the population in stratum 2. 
o We assumed 90% adherence next screening if previously adherent 185,186. We decreased the 
population that not adheres to the next screening round if previously adherent by the same 
proportion as the population that is currently not up to date with CRC screening.
p Calculated that overall adherence in next screening round remains the same. 
q Represents the adherence to a diagnostic colonoscopy after a positive FIT test.




















































































No screening 0.000 0.034 0.000 0.005 3.236 3.276
Colonoscopy
With coinsurance 
Current state 0.238 0.016 0.412 0.032 1.978 2.675
Without coinsurance
No impact on adherence 0.252 0.016 0.449 0.032 1.978 2.726
With 5 percentage point increase in 
adherence diagnostic follow-up and 
surveillance.
0.252 0.016 0.452 0.032 1.977 2.728
With 5 percentage point increase in 
adherence first screening, diagnostic follow-
up and surveillance.
0.283 0.014 0.468 0.034 1.910 2.708
With 10 percentage point increase in 
adherence first screening, diagnostic follow-
up and surveillance.
0.314 0.013 0.488 0.036 1.840 2.692
FIT
With coinsurance 
Current state 0.077 0.111 0.224 0.022 2.309 2.743
Without coinsurance
No impact on adherence 0.077 0.131 0.246 0.022 2.309 2.785
With 5 percentage point increase in 
adherence diagnostic follow-up and 
surveillance.
0.076 0.136 0.253 0.023 2.296 2.783
With 5 percentage point increase in 
adherence first screening, diagnostic follow-
up and surveillance.
0.083 0.148 0.263 0.024 2.255 2.772
With 10 percentage point increase in 
adherence first screening, diagnostic follow-
up and surveillance.
0.089 0.166 0.281 0.025 2.196 2.758
a In the current state, we assumed a 60% adherence in first screening, an 80% adherence to 
diagnostic follow-up after a positive FIT, and an 80% adherence to surveillance. In the second 
scenario, coinsurance is waived without an effect on adherence. In the third scenario, waiving 
coinsurance is assumed to lead to a 5 percentage point increase in adherence to diagnostic 
follow-up and surveillance. In the fourth and the fifth scenario, we simulated a 5 percentage 
point and 10 percentage point increase in adherence to screening, diagnostic follow-up and 
surveillance as a consequence of coinsurance removal, respectively.
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+ 5 percentage point adherence Diagnostic Follow -up and Surveillance
+ 5 percentage point adherence Screening, Diagnostic Follow -up and Surveillance
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+ 10 percentage point adherence Screening, Diagnostic Follow -up and Surveillance
Supplementary Figure A5.1: Annual incremental costs of waiving coinsurance from a 
CMS perspective (including costs of screening, diagnostic follow-up, and surveillance and 
savings of treatment, 3% discounted) compared to a situation without coinsurance removal 
by screening strategy and screening rate scenario. Most of the increase in costs would occur 
immediately upon waiving all coinsurance, while after a decade costs start to stabilize and 
decline due to costs savings in CRC treatment costs. In the graph of the colonoscopy strategy, 
the peaks reflect the screening and surveillance years. 
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Incremental Costs/QALYG compared to the current state
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Supplementary Figure A5.2: Cost-effectiveness of waiving coinsurance for every component 
of CRC screening with alternative model assumptions if this coinsurance waiver would lead 
to a 5 percentage point increase in adherence diagnostic follow-up and Surveillance (top) or 
a 5 percentage point (middle) or a 10 percentage point (bottom) increase in adherence to 
screening, diagnostic follow-up and surveillance. The costs and QALY gained were compared 
to the current state, in which we assumed a 60% adherence in screening, an 80% adherence 
to diagnostic follow-up after a positive FIT, and an 80% adherence to surveillance. In the first 
sensitivity analysis, 60% of the cohort had one previous colonoscopy screening at the age 
of 55. We then simulated potential increases in screening uptake, benefits and costs due to 
waiving the Medicare coinsurance from age 65 years onward, implementing screening rounds 
at age 65 and 75. In the second sensitivity analyses, no screening before the age of 65 was 
assumed. In the third sensitivity analyses, we assumed 10-75% higher colonoscopy costs. The 
different shades of grey represent the cost-effectiveness of a 10%, 25%, 50% and 75% higher 
colonoscopy costs, respectively, where the results of assuming a 10% higher colonoscopy 
costs are shown in the lightest color, and the results of assuming a 75% higher colonoscopy 
costs are shown in black. In the fourth sensitivity analyses, 10-75% higher treatment cost for 
initial phase stage III and IV and for Terminal phase CRC care (all stages) were simulated. The 
different shades of grey represent the cost-effectiveness of a 75%, 50%, 25% and 10% higher 
treatment costs, respectively, where the results of assuming a 75% higher treatment costs 
is shown in the lightest color, and the results of assuming a 10% higher treatment costs are 
shown in black. In the fifth sensitivity analysis, we assumed that the population that only 
attends if coinsurance of every CRC screening component are fully waived and the population 
that never attends have a relative risk of getting CRC of 1.2 compared to the population that 
attends irrespectively of costs. In the sixth sensitivity analyses, we assumed Best-Case (light 
grey) and Worst-Case (dark grey) test sensitivities. In the seventh sensitivity analysis, we 
simulated potential increases in screening rate, benefits and costs from age 50 onward.
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Supplementary Table A5.3: Results sensitivity analyses: Quality-adjusted life-years gained 
and Total costs from a CMS perspective per 1,000 65-year-old Medicare Beneficiaries, by 
screening category, coinsurance requirement and screening rate scenario (3% discounted). 
Category 
Scenarioa
Base-case One previous 









































































No screening 0.0 3.276 0 3.211 0 2.832
Colonoscopy
With coinsurance 
Current state 124.1 2.675 112.7 2.929 69.1 3.020
Without coinsurance
No impact on adherence 124.1 2.726 112.7 2.996 69.1 3.105
With 5 percentage point 
increase in adherence 
diagnostic follow-up and 
surveillance.
124.1 2.728 112.9 3.000 69.7 3.114
With 5 percentage point 
increase in adherence first 
screening, diagnostic follow-
up and surveillance.
132.2 2.708 120.6 3.012 75.2 3.138
With 10 percentage point 
increase in adherence first 
screening, diagnostic follow-
up and surveillance.
140.4 2.692 128.6 3.028 81.4 3.172
FIT
With coinsurance 
Current state 115.9 2.743 - - 57.5 2.867
Without coinsurance
No impact on adherence 115.9 2.785 - - 57.5 2.913
With 5 percentage point 
increase in adherence 
diagnostic follow-up and 
surveillance.
116.7 2.783 - - 59.2 2.909
With 5 percentage point 
increase in adherence first 
screening, diagnostic follow-
up and surveillance.
123.7 2.772 - - 63.2 2.912
With 10 percentage point 
increase in adherence first 
screening, diagnostic follow-
up and surveillance.
131.6 2.758 - - 68.9 2.912
table continues




















































































No screening 0.0 3.420 – 4.358 0.0 3.420 – 4.358 0 3.276
Colonoscopy
With coinsurance 
Current state 124.1 2.745 – 3.201 124.1 2.745 – 3.201 116.8 2.731
Without coinsurance
No impact on adherence 124.1 2.796 – 3.252 124.1 2.796 – 3.252 116.8 2.780
With 5 percentage point 
increase in adherence 
diagnostic follow-up and 
surveillance.
124.1 2.798 – 3.254 124.1 2.798 – 3.254 116.9 2.782
With 5 percentage 
point increase in 
adherence first screening, 
diagnostic follow-up and 
surveillance.
132.2 2.774 – 3.202 132.2 2.774 – 3.202 125.9 2.755
With 10 percentage 
point increase in 
adherence first screening, 
diagnostic follow-up and 
surveillance.
140.4 2.754 – 3.157 140.4 2.754 – 3.157 135.0 2.730
FIT
With coinsurance 
Current state 115.9 2.817 – 3.301 115.9 2.817 – 3.301 109.5 2.779
Without coinsurance
No impact on adherence 115.9 2.859 – 3.344 115.9 2.859 – 3.344 109.5 2.819
With 5 percentage point 
increase in adherence 
diagnostic follow-up and 
surveillance.
116.7 2.857 – 3.336 116.7 2.857 – 3.336 110.3 2.818
With 5 percentage 
point increase in 
adherence first screening, 
diagnostic follow-up and 
surveillance.
123.7 2.842 – 3.301 123.7 2.842 – 3.301 118.2 2.804
With 10 percentage 
point increase in 
adherence first screening, 
diagnostic follow-up and 
surveillance.

























































No screening 0 3.276 0 2.433
Colonoscopy
With coinsurance 
Current state 120.8 ; 128.3 2.719 ; 2.628 75.4 2.835
Without coinsurance
No impact on adherence 120.8 ; 128.3 2.770 ; 2.679 75.4 2.927
With 5 percentage point increase 
in adherence diagnostic follow-up 
and surveillance.
120.8 ; 128.3 2.772 ; 2.681 76.4 2.935
With 5 percentage point increase 
in adherence first screening, 
diagnostic follow-up and 
surveillance.
128.8 ; 136.5 2.753 ; 2.660 82.1 2.980
With 10 percentage point increase 
in adherence first screening, 
diagnostic follow-up and 
surveillance.
136.9 ; 144.8 2.737 ; 2.642 88.7 3.035
FIT
With coinsurance 
Current state 106.5 ; 125.4 2.830 ; 2.644 70.8 2.491
Without coinsurance
No impact on adherence 106.5 ; 125.4 2.871 ; 2.687 70.8 2.554
With 5 percentage point increase 
in adherence diagnostic follow-up 
and surveillance.
107.3 ; 126.1 2.871 ; 2.685 72.8 2.554
With 5 percentage point increase 
in adherence first screening, 
diagnostic follow-up and 
surveillance.
114.1 ; 133.5 2.862 ; 2.670 77.3 2.563
With 10 percentage point increase 
in adherence first screening, 
diagnostic follow-up and 
surveillance.
121.7 ; 141.7 2.852 ; 2.651 83.8 2.574
QALY - quality-adjusted life-years gained compared to no screening; CRC - colorectal cancer
a In the current state, we assumed a 60% adherence in first screening, an 80% adherence to 
diagnostic follow-up after a positive FIT, and an 80% adherence to surveillance. In the second 
scenario, coinsurance is waived without an effect on adherence. In the third scenario, waiving 
coinsurance is assumed to lead to a 5 percentage point increase in adherence to diagnostic 
follow-up and surveillance. In the fourth and the fifth scenario, we simulated a 5 percentage 
point and 10 percentage point increase in adherence, diagnostic follow-up and surveillance 
as a consequence of coinsurance removal, respectively.
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b In the fourth sensitivity analysis, we assumed a 10%, 25%, 50% and 75% higher treatment 
cost for initial phase stage III and IV and for Terminal phase CRC care (all stages) as the 
costs of CRC care were obtained from an analysis of 1998-2003 SEER-Medicare linked data 
which excludes costs for potential use of expensive monoclonal antibodies cetuximab and 
bevacizumab as these received FDA approval for treatment of colorectal cancer in 2004. 
c In the fifth sensitivity analysis, we assumed that the population that only attends if 
coinsurance of every CRC screening component is fully waived and the population that never 
attends have a relative risk of getting CRC of 1.2 compared to the population that attends 
irrespectively of costs.
d We tested worst-case and best-case test sensitivity of FIT and colonoscopy. In the worst- 
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Colorectal cancer (CRC) screening with colonoscopy and the fecal immunochemical 
test (FIT) is underutilized. Innovative tests could increase screening acceptance. This 




The previously-validated MISCAN-Colon model was used to evaluate the cost-
effectiveness of screening with capsule endoscopy every 5 or 10 years, computed 
tomographic colonography (CTC) every 5 years, the multi-target stool DNA (mtSDNA) 
test every 1 or 3 years, and the methylated SEPT9 DNA plasma assay (mSEPT9) every 1 
or 2 years. We also compared these strategies to annual FIT screening and colonoscopy 
screening every 10 years. Quality-adjusted life-years gained (QALYG), number of 
colonoscopies, and incremental cost-effectiveness ratios (ICERs) were projected. We 
assumed a willingness-to-pay threshold of $100,000 per QALYG.
Results
Among the alternative tests, CTC every 5 years, annual mSEPT9 and annual mtSDNA 
screening had ICERs of $1,092, $63,253 and $214,974 per QALYG, respectively. Other 
screening strategies were more costly and less effective than (a combination of) these 
three. Under the assumption of perfect adherence, annual mSEPT9 screening resulted 
in more QALYG, CRC cases averted and CRC deaths averted than annual FIT screening, 
but led to a high rate of colonoscopy referral (51% after 3 years, 69% after 5 years). The 
alternative tests were not cost-effective compared to FIT and colonoscopy.
Conclusion
This study suggests that for individuals not willing to participate in FIT or colonoscopy 
screening, mSEPT9 is the test of choice if the high colonoscopy referral rate is acceptable 
to them.
 




Colorectal cancer (CRC) is a leading cause of cancer death in the United States (US), 
with an estimated 53,000 associated deaths in 2020.214 CRC screening can prevent 
CRC death through earlier detection or through removal of premalignant polyps,51,64 
and is recommended from age 50 to 75 years by the US Preventive Services Task Force 
(USPSTF)76 and from age 45 to 75 years by the American Cancer Society (ACS).78 
Despite the effectiveness of screening, almost 40% of 50 to 75-year-olds reported not 
having received guideline-consistent CRC screening. Important barriers for screening 
include fear and disgust of the screening test.208,209 Therefore, new tests that circumvent 
these barriers are needed to increase screening participation.
Fecal occult blood testing and colonoscopy were already proposed as CRC screening 
tests in the late 1960s.215,216 More recently developed FDA-approved tests are capsule 
endoscopy, specifically the PillCam COLON 2 (PillCam), the computed tomographic 
colonography (CTC), the multitarget stool DNA test (mtSDNA), also known as 
Cologuard® (Exact Sciences Corporation), and the methylated SEPT9 DNA plasma assay 
(mSEPT9), also known as the Epi proColon® (Epigenomics AG). All these tests require 
colonoscopy follow-up of individuals with a positive test result. Several studies have 
suggested that these alternative tests are not cost-effective compared to colonoscopy or 
fecal immunochemical test (FIT) screening.172,217-222 However, these tests have potential 
to attract the population not currently participating in screening. The mSEPT9 requires 
a blood sample, which may be preferred for some patients over collecting a stool sample 
or a more invasive test. The CTC, PillCam and mtSDNA all have better test sensitivities 
than FIT while being less invasive than colonoscopy. Therefore it is important to 
evaluate which of these alternative tests should be offered to individuals who are not 
willing to participate in FIT or colonoscopy screening. No study has compared all of 
these alternative screening tests in terms of cost-effectiveness. Therefore, in this study, 
the Microsimulation Screening Analysis-Colon (MISCAN-Colon) model was used to 




The MISCAN-Colon model was developed by the Department of Public Health 
within Erasmus University Medical Center, Rotterdam, the Netherlands, and has been 
described in detail elsewhere (Model Appendix).102,103 It is part of the US National 
Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET) 
144 and has been used to inform screening recommendations.96,98,99 In brief, the model 
generates, with random variation, a large population similar to the US population in 
terms of life expectancy and CRC risk. As each simulated person ages, one or more 
adenomas may develop, which can progress in size and can develop into preclinical 
cancer (stages I to IV). During each stage CRC may be diagnosed because of symptoms. 
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Screening can alter some simulated life histories, as CRC can be prevented or diagnosed 
at an earlier stage. Screening may also result in complications, over-diagnosis and over-
treatment, which are also taken into account by the model. 
Screening strategies
We simulated screening from age 50 through 75 years in an-average risk population, with 
perfect adherence to screening, diagnostic follow-up and surveillance recommendations 
76,107. We used the same model assumptions as for the 2018 ACS guidelines, which 
accounts for recent trends in CRC incidence.16,99 The screening strategies evaluated were 
CTC every 5 years, mtSDNA testing every 1 or 3 years,76 PillCam every 5 or 10 years, 
and annual or biennial mSEPT9 testing. These alternative screening strategies were 
compared to colonoscopy every 10 years and annual FIT. Positive non-colonoscopy 
tests were followed by a diagnostic colonoscopy, and individuals in whom adenomas 
were detected and removed received colonoscopy surveillance through age 85 years.107
To compare the different screening strategies, an incremental cost-effectiveness analysis 
was performed, ranking strategies based on costs. Strategies that were more costly and 
less effective than a (combination of) other strategies were considered dominated. 
Remaining strategies provided good value for money (i.e. were efficient). For the 
efficient strategies, the incremental cost-effectiveness ratios (ICERs) were obtained 
by dividing the additional costs by the additional quality-adjusted life-years gained 
(QALYG) compared with the next less costly alternative strategy. In this analysis, we 
assumed a willingness-to-pay threshold of $100,000 per QALYG.109,174 
Test characteristics
mSEPT9 performance characteristics were based on Potter et al. 223(Table 6.1 and 
Supplementary Table A6.1), which was used for the FDA approval of mSEPT9. 224 
In this study, 1544 samples were retrospectively selected from the PRESEPT trial.225 A 
CRC sensitivity and specificity of 68.2% and 78.8%, were reported, respectively, with a 
sensitivity for advanced adenoma of 21.6%. PillCam characteristics were based on the 
study of Rex et al., in which 695 asymptomatic individuals were successfully screened 
using the PillCam, followed by colonoscopy several weeks later.226 This study reported a 
sensitivity of 92% and 91% for adenomas larger than 10mm and 6mm, respectively, with 
a specificity of 83%.226 Colonoscopy, FIT, CTC and mtSDNA characteristics were similar 
to previous analyses from our group (Table 6.1).96,99 All test characteristics were varied 
in probabilistic sensitivity analyses (see below).
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Table 6.1: Test characteristics































Colonoscopyd 75 85 95 95 100e van Rijn et al. 2006 213
CTC 12f 57 84 84g 88h Johnson et al. 2008 227
PillCam 17f 91i 92 92g 83 Rex et al. 2015 226
Stool-based
FIT 7.6j 23.8k 73.8 96.4 Imperiale et al. 2014 72
mtSDNA 17.2j 42.4k 92.3 89.8 Imperiale et al. 2014 72
Blood-based
 mSEPT9 21.2f 21.2f 21.6k 68.2 78.8 Potter et al. 2014 223
CTC - computed tomographic colonography; PillCam - PillCam COLON 2; FIT - fecal 
immunochemical test; mtSDNA - multitarget stool DNA; mSEPT9 - methylated SEPT9 DNA 
plasma assay 
a The sensitivities of CTC and colonoscopy are presented per lesion; the sensitivities of the 
other tests are presented per person which were calibrated to per lesion test sensitivities that 
were used as MISCAN-Colon model input. 
b Specificity is defined as the probability of having a negative test result for individuals without 
lesions (including adenomas and CRC), unless otherwise noted.
c Additional details about these studies (designs, sample sizes, periods and regions) can be 
found in Supplementary Table A6.1.
d We assumed that 95% of colonoscopies reach the cecum.
e We accounted for the detection of nonadenomatous polyps, which is 14% based on Schroy 
et al. 2013 228. 
f Sensitivity equals the false-positivity rate. It is 1 – specificity. 
g The same sensitivity for CRC as for adenomas ≥ 10 mm was assumed. 
h The lack of specificity of a CTC reflects the detection of > 5 mm nonadenomatous lesions, 
artifacts, stool and adenomas smaller than the 6-mm threshold for referral to colonoscopy 
that are measured as > 5 mm.
i Value of all adenomas ≥ 6 mm
j Sensitivity for persons with nonadvanced adenomas. For persons with 1-5 mm, it was 
assumed that the sensitivity is equal to the positivity in persons without adenomas. The 
sensitivity for adenomas 6-9 mm was chosen such that the weighted average sensitivity is 
equal to that for nonadvanced adenomas.
k Sensitivity for persons with advanced adenomas. In MISCAN-Colon, advanced adenomas are 




Costs of screening, screening-related complications, and cancer care were computed 
from a societal perspective, obtained from various sources, and included (as relevant), 
payments, co-insurance, cathartic bowel preparation agents, and patient- and escort 
time costs (Table 6.2; Supplementary Tables A6.2-A6.6). Costs were updated to 
2017 US dollars using the Personal Health Care Deflator Price Index. Estimated test 
disutilities included those associated with the test itself, and those related to fear or 
anxiety while waiting for the test result or a follow-up colonoscopy after a positive result 
(Supplementary Table A6.4). Complication and CRC care disutilities were in line 
with previous analyses.154,172













































































Colonoscopy screening w/o 
polypectomy
0.000496 $794 $51 $434 $1,279 
Colonoscopy follow-up w/o 
polypectomy
0.000496 $847 $51 $434 $1,332
Colonoscopy surveillance w/o 
polypectomy
0.000496 $796 $51 $434 $1,281 
Colonoscopy with polypectomy 0.001401 $1,172 $51 $434 $1,656 
CTC 0.001559 / 0.000292a $236 $51 $206 $493 
PillCam 0.001692 / 0.000425a $939 $104 $310 $1,352
FIT 0.001330 / 0.000063a $22 - $18 $40
mtSDNA 0.001394 / 0.000127a $512 - $18 $531 
mSEPT9 0.001330 / 0.000063a $192 - $18 $210 
CMS - Centers for Medicare and Medicaid Services; CTC - computed tomographic colonography; 
PillCam - PillCam COLON 2; FIT - fecal immunochemical test; mtSDNA - multitarget stool DNA; 
mSEPT9 - methylated SEPT9 DNA plasma assay 
a Assumed disutility per event if test is positive / assumed disutility per event if test is negative. 
 
Scenario analyses
We repeated analyses under several alternative scenarios. In the first scenario, we 
evaluated CRC screening from age 45 years instead of 50 years, in line with the most 
recent ACS screening guideline.78 In the second scenario, we used the version of the 
MISCAN-model which informed the 2016 USPSTF CRC screening recommendations, 
with CRC incidence based on 1975-1979 data 96 instead of more recent data. In the 
third scenario, we accounted for suboptimal adherence to diagnostic and surveillance 
colonoscopy and for decreasing adherence over multiple screening rounds.229 For this 
scenario, we assumed a 100% adherence at the first screening and that 90% of the people 
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screened at a given age would participate again at the next recommended age.185,230 In 
line with current CRC participation rates,231 we assumed screening adherence would 
not drop below 60% at any age by assuming that 15% of the people who previously did 
not participate would participate at the next recommended age. We further assumed 
80% adherence to diagnostic and surveillance colonoscopy.55,114 Finally, we evaluated a 
scenario in which 12% of the advanced adenomas and 18% of CRCs were systematically 
missed by the mSEPT9, due to no methylation of the SEPT9 gene promoter.232 
Probabilistic sensitivity analyses
To evaluate the model parameter uncertainty, a probabilistic sensitivity analysis was 
performed, varying the characteristics, costs and disutilities of all screening tests as 
well as the costs and disutilities of CRC treatment and colonoscopy complications 
(Supplementary Tables A6.7-A6.8). For every evaluated screening strategy, 
we performed 1000 simulation runs of 10 million persons, in which we sampled 
parameters values from distributions that reflect the parameter’s current level of 
evidence (Supplementary Tables A6.7-A6.8). The results of the probabilistic 
sensitivity analysis were displayed with cost-effectiveness acceptability curves and a 
frontier representing the proportion that each strategy is cost-effective, and the strategy 
with the highest expected net monetary benefit at each cost-effectiveness threshold, 




Without screening, the model predicted 108 CRC cases and 45 CRC deaths per 1000 
50-year-olds (Figure 6.1). The number of CRC cases and deaths ranged from 37 to 59 
and from 8 to 15, respectively, for the different screening strategies. The strategy that 
prevented most CRC deaths was colonoscopy screening every 10 years, while screening 
with the PillCam every 10 years prevented the fewest. 
In the absence of screening, the model predicted life-time CRC-related costs of $7.286 
million per 1000 50-year-olds (Table 6.3). None of the alternative screening strategies 
were cost-saving compared with no screening. Of the alternative strategies, CTC 
screening every 5 years had the lowest costs ($7.479 million), whereas annual mtSDNA 
screening was the most expensive ($10.798 million). The number of QALYG compared 
to no screening ranged from 165 for PillCam screening every 10 years to 205 for annual 
mtSDNA screening; the number of total colonoscopies required ranged from 1,824 per 




Figure 6.1: Colorectal cancer cases and deaths with the different screening strategies. 
CRC - colorectal cancer; mSEPT9 - methylated SEPT9 DNA plasma assay; PillCam - PillCam 
COLON 2; mtSDNA - multitarget stool DNA; CTC - computed tomographic colonography; FIT 
- fecal immunochemical test
Cost-effectiveness analysis
For individuals who are not willing to undergo FIT or colonoscopy screening (i.e. those 
for whom FIT and colonoscopy are not considered acceptable alternatives), CTC every 
5 years and annual mSEPT9 were efficient strategies, with ICERs of $1,092 and $63,253 
per QALYG, respectively (Figure 6.2, Table 6.3). Annual screening with the mSEPT9 
resulted in a high number of individuals referred to colonoscopy: 51% after 3 years 
and 69% after 5 years. PillCam strategies were dominated by other strategies, while 
annual mtSDNA screening had an ICER of $214,974 per QALYG which is above the 
willingness-to-pay threshold. 
When considering all screening strategies including FIT and colonoscopy, colonoscopy 
every 10 years resulted in an ICER of $48,155 per QALYG compared to annual FIT 
screening and was therefore the cost-effective strategy in this analysis (Table 6.3, 
Figure 6.2). Annual FIT screening was cost saving compared to no screening. All 
alternative strategies were dominated by FIT and colonoscopy screening. The number 
of QALYG, CRC cases prevented and CRC deaths prevented for annual mSEPT9 were 
higher than for annual FIT screening (Figure 6.1, Table 6.3). However, the test burden 
in terms of number of diagnostic colonoscopies was 63% higher, and the total costs were 
26% higher compared to annual screening with FIT (Table 6.3).
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Total no. of 
colonoscopies
No screening - 0 108 0 108
FIT 1 15,044 791 1,558 2,349
CTC 5 4,292 628 1,196 1,824
Colonoscopy 10 1,995 15 2,725 4,735
mSEPT9 2 5,802 1,269 1,932 3,201
mSEPT9 1 7,159 1,548 2,279 3,827
mtSDNA 3 5,583 785 1,494 2,279
PillCam 10 2,383 671 1,502 2,173
PillCam 5 3,710 899 1,837 2,736
mtSDNA 1 10,185 1,233 2,101 3,334









ICER ($ per 
QALYG) 
without FIT and 
colonoscopy
No screening - 0 0 7.286 - -
FIT 1 162 189 6.793 Cost Saving -
CTC 5 151 177 7.479 D 1,092
Colonoscopy 10 174 209 7.751 48,155 -
mSEPT9 2 151 175 8.298 D D
mSEPT9 1 165 194 8.574 D 63,253
mtSDNA 3 151 175 8.887 D D
PillCam 10 141 165 8.951 D D
PillCam 5 166 196 9.940 D D
mtSDNA 1 173 205 10.798 D 214,974
ICER - incremental cost-effectiveness ratio; mSEPT9 - methylated SEPT9 DNA plasma assay; 
CTC - computed tomographic colonography; mtSDNA - multitarget stool DNA; PillCam - 
PillCam COLON 2; D - dominated
a Includes both diagnostic follow-up colonoscopies and colonoscopies for clinical detection of 
colorectal cancer. LYG = life-years gained, QALYG = quality-adjusted life-years gained, 
Scenario analyses
In all our scenario analyses, the same three strategies were efficient for individuals not 
willing to undergo FIT or colonoscopy screening - CTC screening every 5 years, annual 
mSEPT9 and annual mtSDNA. Our results were robust for alternative assumptions 
regarding start age of screening, screening adherence and systematically missing 
adenomas or cancers, which resulted in ICERs for annual mSEPT9 of $66,372, $41,041 
and $68,682 per QALYG compared with the next-best alternative, respectively (Table 
6.4 and Supplementary Table A6.9). However, when we simulated a lower CRC 
incidence, annual mSEPT9 resulted in an ICER of $119,336 per QALYG. Hence, CTC 
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screening every 5 years was the cost-effective strategy for these individuals with an 
ICER of $9,397 per QALYG (Supplementary Table A6.9). Although efficient, annual 
mtSDNA screening was never cost-effective using a willingness-to-pay threshold of 
$100,000 per QALYG. When FIT and colonoscopy were also considered, colonoscopy 
screening every 10 years was the cost-effective strategy in all our scenario analyses 
(Supplementary Table A6.9).
Figure 6.2: Efficient Frontier. Lifetime costs and quality-adjusted life-years of the evaluated 
screening strategies.
QALYG - quality-adjusted life-years gained; FIT - fecal immunochemical test; mSEPT9 - 
methylated SEPT9 DNA plasma assay; CTC - computed tomographic colonography; mtSDNA 
- multitarget stool DNA; PillCam - PillCam COLON 2.
Probabilistic sensitivity analyses
For individuals who are not willing to undergo FIT or colonoscopy screening, annual 
screening with mSEPT9 was the cost-effective strategy in 54% of the 1,000 simulations 
evaluated in the probabilistic sensitivity analyses at a willingness-to-pay threshold of 
$100,000 per QALYG (Figure 6.3). In 20% and 17% of the simulations, annual mtSDNA 
screening and CTC screening every 5 years were cost-effective strategies, respectively. 
At higher willingness-to-pay thresholds, the probability that annual mtSDNA screening 
was the cost-effective strategy increased, while the probability that CTC screening every 
5 years was cost-effective decreased. At a willingness-to-pay threshold of $200,000 per 
QALYG, the probabilities were 48%, 47% and 1% for mtSDNA, mSEPT9 and CTC, 
respectively (Figure 6.3). 
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Table 6.4: Most effective strategy with an ICER below $100,000 per quality-adjusted life-year 
gained, by scenario analysis and inclusion of FIT and colonoscopy.
Analysis Most effective 
strategy excluding FIT 
and colonoscopy
Most effective strategy 
including FIT and 
colonoscopy
Base case Annual mSEPT9 Colonoscopy every 10 years
Screening from age 45 Annual mSEPT9 Colonoscopy every 10 years
USPSTF model; lower CRC 
incidence
CTC every 5 yearsa Colonoscopy every 10 years
Adjusted adherence Annual mSEPT9 Colonoscopy every 10 years
Systematic false-negativity mSEPT9 Annual mSEPT9 Colonoscopy every 10 years
ICER - incremental cost-effectiveness ratio; FIT - fecal immunochemical test; USPSTF - United 
States Preventative Services Task Force; mSEPT9 - methylated SEPT9 DNA plasma assay; CRC 
- colorectal cancer; CTC - computed tomographic colonography; QALYG - quality-adjusted 
life-years gained
a In this scenario, the ICER for annual mSEPT9 was $119,336 per QALYG, just above the 
willingness-to-pay threshold. 
 
Figure 6.3: Cost-Effectiveness Acceptability Curve and Frontier. 
mSEPT9 - methylated SEPT9 DNA plasma assay; PillCam - PillCam COLON 2; mtSDNA - 
multitarget stool DNA; CTC - computed tomographic colonography; QALYG - quality-adjusted 
life-years gained;-
* The cost-effectiveness acceptability frontier (CEAF) plots the probability that the optimal 




New strategies are needed to increase CRC screening participation in the US, given 
rates reached a plateau of approximately 60%.231 By comparing the incremental cost-
effectiveness of CTC, PillCam, mtSDNA and mSEPT9 from a societal perspective, this 
study revealed that of these alternatives annual screening with mSEPT9 is cost-effective. 
Annual screening with the mSEPT9 had an ICER of $63,253 per QALYG. Other efficient 
strategies were CTC screening every 5 years (ICER: $1,092 per QALYG) and annual 
mtSDNA screening (ICER: $214,974 per QALYG), which were not optimal given the 
willingness-to-pay threshold ($100,000 per QALYG).
The uncertainty of our conclusion is reflected in our probabilistic sensitivity analyses, in 
which the mSEPT9 was the cost-effective strategy in 54% of our analyses. Test accuracy 
of the mSEPT9 is not as well established as for some of the other test evaluated in 
this study. In line with requirements of the FDA, a prospective trail including 4,500 
participants is currently being performed which will provide essential additional 
information about test characteristics of the mSEPT9, and adherence to multiple rounds 
of testing and follow-up.236
Among the tests evaluated in this analysis, the mSEPT9 has the lowest sensitivity for both 
adenomas and CRC. Therefore, an important driver of its cost-effectiveness compared to 
CTC, PillCam and mtSDNA is the substantially lower cost of the test. Similar as for FIT 
screening, the effectiveness of the mSEPT9 depends on annual repetition of the test, and 
similar to any other non-colonoscopy-based screening strategy, receipt of diagnostic 
follow-up colonoscopy. Due to the relatively low specificity of the mSEPT9 (79%) 
compared with the other tests, a high number of individuals are referred to a diagnostic 
follow-up colonoscopy regardless of disease status (51% after 3 years and 69% after 5 
years with annual repetition of the test). Consequently, 21% of simulated individuals 
with a non-advanced adenoma received a colonoscopy when screened with mSEPT9, in 
contrast to 7.6% when screened with FIT. Although non-advanced adenomas generally 
confer low risk, they are more common than advanced adenomas and some may have 
aggressive biology. The detection of non-advanced adenomas in these colonoscopies 
contributed to the slightly higher QALYG, CRC cases averted and CRC deaths averted 
for mSEPT9 screening vs. FIT screening despite its lower test sensitivity for advanced 
adenomas and cancers.
To our knowledge, this is the first study that simultaneously evaluated the PillCam, 
CTC, mSEPT9 and mtSDNA in a single cost-effectiveness analysis. In addition, it is the 
first cost-effectiveness analysis of these tests that uses updated test characteristics, CRC 
treatment costs and CRC incidence. As expected, updated test characteristics, costs, and 
incidence levels have a substantial impact on cost-effectiveness outcomes. One cost-
effectiveness analysis reported that mSEPT9 is less effective and more costly than FIT 
screening,221 with costs of $8,400 to $11,500 per QALYG compared to no screening. 
This study based the test characteristics of the mSEPT9 on the study by Church et al.,225 
which used an earlier version of the test. Changes that were made to the mSEPT9 as 
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part of the development process for its premarket approval by the FDA resulted in 
the version used for the Potter et al. study, 223 which has an increased sensitivity but a 
decreased specificity compared with the version used by Church et al.237 Our analyses 
suggest that with the current version of the mSEPT9, annual mSEPT9 screening 
is not less effective than annual FIT screening, but is still more costly and requires 
considerably more colonoscopies. One previous study found a cost-effectiveness ratio 
of $29,244 per QALYG of 10-yearly PillCam screening vs. no screening,222 compared 
to approximately $10,000 in our study with updated assumptions. Previous analyses 
that evaluated the cost-effectiveness of mtSDNA described that the mtSDNA is too 
expensive to be cost-effective compared to FIT and colonoscopy screening.172,217,218 This 
study suggests that even when FIT and colonoscopy screening are not considered, the 
costs of mtSDNA screening are still too high compared to other alternative tests. Finally, 
our group’s previous analyses on CTC suggested that CTC is not an efficient strategy 
when compared to FIT and colonoscopy.219,220 This study suggest that for individuals 
that are not willing to do FIT and colonoscopy, CTC is an efficient strategy. However, 
annual screening with the mSEPT9 had an ICER of $63,253 per QALYG compared to 
5-yearly CTC, and is therefore preferred from a cost-effectiveness perspective.
Several limitations of our study are noteworthy. First, we assumed that no adenomas 
and cancers were systematically missed over time by a particular screening test. This 
assumption may not hold for the stool-based tests, because bleeding of a lesion is not 
necessarily a random event.238 Furthermore, it may not hold for the mSEPT9 because 
approximately 18% of the tumors do not have methylation of the SEPT9 gene promoter 
232 and will remain undetected at every subsequent mSEPT9 screening until their SEPT9 
gene promoter is methylated. The systematic miss rates for the different screening tests 
are unknown. We performed a scenario analysis in which we assumed that 12% of 
advanced adenomas and 18% of CRCs are systematically missed by the mSEPT9, which 
minimally impacted our results. This is in line with a previous study, which suggested 
that incorporating systematically missing adenomas with stool-based test has minimal 
impact on effectiveness of FIT screening.238 
Second, we assumed perfect adherence to screening, diagnostic follow-up and 
surveillance in our base case analysis. This implies that the model predicted the 
maximum achievable benefit for all screening tests. Unfortunately, there is limited data 
on test-specific adherence to every step in the screening process (getting screening, 
diagnostic follow-up, treatment and/or surveillance) over multiple rounds of screening 
(e.g. from ages 50 to 75 years), making it impossible to inform our analyses with 
empirical evidence. We performed a scenario analysis that accounted for suboptimal 
adherence to follow-up and surveillance colonoscopies and for decreasing adherence 
over multiple screening rounds. Although the effectiveness of all screening modalities 
decreased with a lower adherence, the impact on ICERs was limited. 
Third, the current lifetime risk of developing CRC in the absence of screening is 
uncertain. Our assumed CRC incidence is in line with previous analyses for the ACS 
and the observation that the increased CRC incidence in young adults is a cohort 
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effect.16,99 We explored the effect of a lower CRC incidence in a scenario analysis, which 
suggested that when CRC incidence resembles 1975-1979 data, CTC screening every 5 
years is the cost-effective strategy as the ICER of annual screening with the mSEPT9 is 
approximately $120,000, just above the willingness-to-pay threshold.
Our study can be used to inform clinicians, as it ranks the different CRC screening tests 
from a cost-effectiveness perspective. Individuals who are not willing to be screened 
with FIT or colonoscopy should be advised to undergo mSEPT9 screening if the high 
colonoscopy referral rate is acceptable to them. CTC should be the next test of choice. 
Ultimately, the best test is the “one that gets done”. Although lack of participation may 
have various reasons, such as lack of resources in rural areas or more general reluctance 
against screening, previous studies suggest that the mSEPT9 has the potential to attract 
the population that currently does not participate in screening.239,240 A recent study found 
substantially higher uptake of a blood-based test compared to a FIT in individuals who 
were overdue for screening,239 and another study found that among people who declined 
stool-based tests, there was a 25% uptake of a blood-based test.240 This suggests that the 
mSEPT9 might be a suitable test to increase current CRC screening participation.
In conclusion, a well-established microsimulation model demonstrates that for 
people who are unwilling to be screened with FIT or colonoscopy, annual screening 
with the mSEPT9 is the test of choice given its cost-effectiveness profile compared to 
CTC, PillCam and mtSDNA. The number of CRC cases and deaths averted, and the 
number QALYG from annual mSEPT9 screening are even higher than from annual 
FIT screening. However, the number of colonoscopies required for the mSEPT9 is 63% 
higher, and the total costs are 26% higher compared to annual FIT screening. Therefore, 
physicians should first offer individuals to participate in CRC screening using FIT or 
colonoscopy. 




Supplementary Table A6.1: Study designs, sample sizes, periods and regions of the studies 




Source Design Sample 
size
Period Region
Colonoscopy van Rijn et al. 2006 213 Systematic 
review
465 1991-2004 Multiple
CTC Johnson et al. 2008 227 Prospective trial 2600 2005-2006 US
PillCam Rex et al. 2015 226 Prospective trial 695 2011-2012 US & Israel
FIT Imperiale et al. 2014 72 Prospective trial 9989 2011-2012 US & 
Canada
mtSDNA Imperiale et al. 2014 72 Prospective trial 9989 2011-2012 US & 
Canada
mSEPT9 Potter et al. 2014 223 Retrospective 
triala
1544 2008-2010 US & 
Germany
CTC - computed tomographic colonography; PillCam - PillCam COLON 2; FIT - fecal 
immunochemical test, mtSDNA - multitarget stool DNA; mSEPT9 - methylated SEPT9 DNA 
plasma assay
a Subjects for this study were selected retrospectively from the Prospective Evaluation of 

















  COL CTC PillCam a COL COL
Bowel 
preparation
16.7 16.7 16.7 0 16.7 Same for all procedures
Travel to 0.42 0.42 0.42 0.42 0.83 Same for all procedures
Waiting/
preparing
1.4 1.4 1.4 1.4 2.8 Same for all procedures
Sedation 0.2 0 0 0.2 0.4 Sedation is only used for COL




PillCam: 76% of the patients 




0.78 0 0 0.78 1.57 CTC & PillCam: no on-site 
recovery
Travel home 0.58 0.58 0.58 0.58 1.17 Same for all procedures
Recovery to 
routine
15.8 0 0 0 15.8 CTC & PillCam: immediately 
back to routine
Sleep -16 -8 -8 0 -16
Total 20.22 11.35 17.1 3.72 23.93
COL – colonoscopy; CTC - computed tomographic colonography; PillCam - PillCam COLON 2
a  We assume that the methylated SEPT9 DNA plasma assay and the stool-based tests take 1 
hour.  
b  We assume that no escort was needed for screening with the CTC and the PillCam as these 
procedures do not require sedation.
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74261 CTCf $236.15 NA NA $236.15 $51.09 $205.66 $492.90 2017 Phy-
sician Fee 
Schedule






FIT $21.82 NA NA $21.82 NA $18.12 $39.94 2017 CLFS
81528 mtSDNA $512.43 NA NA $512.43 NA $18.12 $530.55 2017 CLFS
81327 mSEPT9 $192 NA NA $192 NA $18.12 $210.12 2019 CLFSi
COL – colonoscopy; CTC - computed tomographic colonography; PillCam - PillCam COLON 2; 
FIT - fecal immunochemical test; mtSDNA - multitarget stool DNA; mSEPT9 - methylated SEPT9 
DNA plasma assay; CLFS - clinical laboratory fee schedule
a Includes propofol and facility payments, when appropriate. 
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b Costs for bowel preparation agents for colonoscopy, CTC and PillCam were based on the 
section “Colon Cleansing Medications” on GoodRX.com.
c We assume that the value of an hour of patient/escort time is equal to the median wage rate 
in the US in 2017. The 2017 median hourly wage rate ($18.12) comes from the U.S. Bureau 
of Labor Statistics (BLS) May 2017 National Occupational Employment and Wage Estimates. 
d All costs are expressed in 2017 US dollars. Costs from other years are inflated to 2017 dollars 
using the Personal Health Care Deflator price index (https://www.cms.gov/Research-Statistics-
Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/
Tables.zip). 
e Colonoscopy costs were based on an analysis of 2014 Medicare claims data from the 
Chronic Conditions Data Warehouse performed by the Centers for Medicare and Medicaid 
Services (CMS).15 There is no national average payment for CTC because it is not a covered 
procedure. We based our estimate on the payment for a diagnostic CTC w/o IV contrast. 
f As there is no estimate of the PillCam COLON 2 (0355T), we used the price of the PillCam™ SB 
3 system (91110) that is used for visualization of the small bowel.
g As explained in the study by Rex et al. 226, the PillCam requires an additional 6 oz of an 
oral sulfate solution (e.g., SUPREP) to boost the PillCam through the small intestine and 
to add fluid to the colon, which is why additional costs for SUPREP were included in 
the estimate for PillCam. The price for 2 bottles SUPREP on GoodRX.com is $106 dollars. 
Therefore, we assumed an additional $53 dollars for the bowel preparation of PillCam. 
h The 2019 Clinical Laboratory Fee Schedule was used for the mSEPT9 as previous years 
are not representative of current reimbursement rates (reimbursement went from $84 in 
2017 to $192 in 2019, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/
ClinicalLabFeeSched).
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Supplementary Table A6.4: Assumptions for utility losses associated with the screening 
tests.
Utility loss of the test itself




Colonoscopy 0.12 Swan et al. 168 36.22 0.000496
CTC 0.12 Same as colonoscopy 19.35 0.000265
PillCam 0.12 Same as colonoscopy 25.1 0.000344
FIT 0 Expert opinion 1 0
mtSDNA 0 Expert opinion 1 0
mSEPT9 0 Expert opinion 1 0
Utility loss of waiting for the test result







0 Immediate results 0 0
Colonoscopy with 
polypectomy
0.033036 Expert opinion, same as 
waiting for a diagnostic 
follow-up after a positive FIT
10 0.000905
CTC 0.003304 Expert opinion, 10% of 
waiting for a diagnostic 






Utility loss of waiting for a diagnostic follow-up colonoscopy




CTC 0.033036 12.5% are very worried 
169. Assuming they 
experience half of the utility 
decrement as for a positive 















CTC - computed tomographic colonography; PillCam - PillCam COLON 2; FIT - fecal 
immunochemical test; mtSDNA - multitarget stool DNA; mSEPT9 - methylated SEPT9 DNA 
plasma assay
a See Supplementary Table A6.2 on how these were derived, without subtracting time for 
sleeping.
b These time estimates are based on expert opinion.
Chapter 6
246
Supplementary Table A6.5: Assumptions for colorectal cancer care.
Phase of cancer carea Time costs
Hours Annual costs (2017 $) Source
Initial phase 243.5 $4,412 Yabroff et al. 241
Continuing phase 19.56 $354 Yabroff et al. 242
Terminal phase, death CRC 282.8 $5,124 Yabroff et al. 241
Terminal phase, death other causes 282.8 $5,124 Yabroff et al. 241
Phase of cancer carea Annual societal costs (2017 $)b
Stage I Stage II Stage III Stage IV
Initial phase $42,763 $58,796 $83,427 $121,828
Continuing phase $4,301 $4,944 $7,456 $34,017
Terminal phase, death CRC $82,519 $92,366 $96,461 $119,979
Terminal phase, death other causes $25,450 $26,997 $35,026 $77,051
Phase of cancer carea Utility lossesc
Stage I Stage II Stage III Stage IV
Initial phase 0.12 0.18 0.24 0.70
Continuing phase 0.05 0.05 0.24 0.70
Terminal phase, death CRC 0.70 0.70 0.70 0.70
Terminal phase, death other causes 0.05 0.05 0.24 0.70
CRC - colorectal cancer
a The terminal phase takes precedence over the initial and continuing phase. The terminal 
phase reflects the last 12 months of life. The initial phase reflects the 12 months following 
diagnosis for persons who survival for more than 12 months (if survive for ≤12 months, 
person only experiences the terminal phase). The continuing phase is the time between 
the initial phase and the terminal phase for persons who survive for more than 24 months. 
b Source: Patient time costs + 2007-2013 SEER-Medicare linked data (update prior analysis 161, 
personal communication, Angela Mariotto, PhD)
c Source: Adapted from Ness et al.171
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Supplementary Table A6.6: Assumptions for complications.
Complications Rate per colonoscopy
Positive colonoscopy (with adenoma polypectomy)
Serious gastrointestinal 
eventa
1/[exp(9.27953 − 0.06105 × Age) + 1] − 1/[exp(10.78719 − 
0.06105 × Age) + 1]
Other gastrointestinal 
eventb
1/[exp(8.81404 − 0.05903 × Age) + 1] − 1/[exp(9.61197 − 0.05903 
× Age) + 1]
Cardiovascular eventc 1/[exp(9.09053 − 0.07056 × Age) + 1] − 1/[exp(9.38297 − 0.07056 
× Age) +1]
Negative colonoscopy (without adenoma polypectomy)
0
Complications Time spent with complications from colonoscopy





8 7 240 Expert opinion
Other gastrointestinal 
eventb
4 2 96 Expert opinion
Cardiovascular eventc 5 7 192 Expert opinion
Complications Costsd













6,847 1,238 4,349 12,434 2013 CMS costs
Other gastrointestinal 
eventb
4,878 1,238 1,740 7,855 2013 CMS costs
Cardiovascular eventc 5,347 1,238 3,479 10,063 2013 CMS costs
Complications Utility losses
Utility loss Rationale [expert opinion]
Serious gastointestinal 
eventa
0.0055 4 days at 0.5 utility
Other gastrointestinal 
eventb
0.0027 2 days at 0.5 utility
Cardiovascular eventc 0.0048 3.5 days at 0.5 utility
CMS - Centers for Medicare and Medicaid Services
a Serious gastrointestinal events are fatal complications, perforations, gastrointestinal 
bleeding or transfusions.
b Other gastrointestinal events are paralytic ileus, nausea and vomiting, dehydration, 
abdominal pain.
c Cardiovascular events are myocardial infarction or angina, arrhythmias, congestive heart 
failure, cardiac or respiratory arrest, syncope, hypotension, or shock.
d All costs are expressed in 2017 US dollars. Costs from other years are inflated to 2017 dollars 





Supplementary Table A6.7. Test characteristics varied in the probabilistic sensitivity analysis.
Test characteristicab Mean Source 95% CIc Source
Colonoscopy
Sensitivity for adenomas 
≤5 mm, %
75 van Rijn et al. 2006 213 [70, 79] Zauber et al. 2008 97
Sensitivity for adenomas 
6-9 mm, %
85 van Rijn et al. 2006 213 [80, 92] Zauber et al. 2008 97
Sensitivity for adenomas 
≥10 mm, %
95 van Rijn et al. 2006 213 [93.1, 99.5] Johnson et al. 2008 227
Sensitivity for colorectal 
cancer, %d
95 by assumption [93.1, 99.5] by assumption
Specificity, % 100 Not varied
CTC
Sensitivity for adenomas 
≤5 mm, %
0f Not varied
Sensitivity for adenomas 
6-9 mm, %
57 Johnson et al. 2008 227 [48.9, 71.6] Johnson et al. 2008 227
Sensitivity for adenomas 
≥10 mm, %
84 Johnson et al. 2008 227 [75.6, 92.4] Johnson et al. 2008 227
Sensitivity for colorectal 
cancer, %d
84 Johnson et al. 2008 227 [75.6, 92.4] Johnson et al. 2008 227
Specificity, % 88 Johnson et al. 2008 227 [84, 92] Johnson et al. 2008 227
PillCam
Sensitivity for adenomas 
≤5 mm, %
0f Not varied
Sensitivity for adenomas 
6-9 mm, %
86.5 Rex et al. 2015 226 [78.4, 92.1] Rex et al. 2015 226
Sensitivity for adenomas 
≥10 mm, %
87.5 Rex et al. 2015 226 [75.4, 96.0] Rex et al. 2015 226
Sensitivity for colorectal 
cancer, %d
87.5 Rex et al. 2015 226 [75.4, 96.0] Rex et al. 2015 226
Specificity, % 83 Rex et al. 2015 226 [80, 86] Rex et al. 2015 226
FIT
Sensitivity for adenomas 
≤5 mm, %
0f Not varied
Sensitivity for adenomas 
6-9 mm, %
11.4 Imperiale et al. 2014 72 [8.2, 15.2] Imperiale et al. 2014 72
Sensitivity for adenomas 
≥10 mm, %
15.9 Imperiale et al. 2014 72 [13.7, 18.3] Imperiale et al. 2014 72






Imperiale et al. 2014 72 [48, 75.3]/ 
[81, 93.4]
Imperiale et al. 2014 72
Specificity, % 96.4 Imperiale et al. 2014 72 [95.8, 96.9] Imperiale et al. 2014 72
mtSDNA
Sensitivity for adenomas 
≤5 mm, %
0f Not varied
Sensitivity for adenomas 
6-9 mm, %
22 Imperiale et al. 2014 72 [17, 27.9] Imperiale et al. 2014 72
table continues
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Test characteristicab Mean Source 95% CIc Source
Sensitivity for adenomas 
≥10 mm, %
28.4 Imperiale et al. 2014 72 [25.2, 31.6] Imperiale et al. 2014 72






Imperiale et al. 2014 72 [73.5, 94.7]/ 
[92.8, 98.8]
Imperiale et al. 2014 72
Specificity, % 89.8 Imperiale et al. 2014 72 [88.9, 90.7] Imperiale et al. 2014 72
mSEPT9
Sensitivity for adenomas 
≤5 mm, %
0f Not varied
Sensitivity for adenomas 
6-9 mm, %
0f Not varied
Sensitivity for adenomas 
≥10 mm, %
0.28 Potter et al. 2014 223 [0, 3] Potter et al. 2014 223
Sensitivity for colorectal 
cancer, %
59.4 Potter et al. 2014 223 [40, 74.3] Potter et al. 2014 223
Specificity, % 78.8 Potter et al. 2014 223 [77, 81] Potter et al. 2014 223
CI - confidence interval; CTC - computed tomographic colonography; PillCam - PillCam COLON 
2; FIT = fecal immunochemical test; mtSDNA= multitarget stool DNA; mSEPT9 = methylated 
SEPT9 DNA plasma assay
a All test sensitivities in this table are per lesion. For the PillCam, FIT, mtSDNA, and mSEPT9 the 
per lesion sensitivities that are used as inputs for MISCAN-Colon were calibrated to per person 
estimates derived from literature.
b For all test, we assumed that test sensitivities for smaller lesions could not exceed test 
sensitivities for bigger lesions. To do this, we used the preference order algorithm developed 
by Goldhaber-Fiebert and Jalal. 243, with epsilon = 0.05, delta = 0.01.
c We assumed beta distributions for the test characteristics and derived their parameters using 
method of moments.
Standard deviations were generated from 95% confindence intervals using 
With s= standard deviation, UB=upperbound, LB= lowerbound, -1(0.976) ≈ 1.96.
The means and standard deviations were used to generate shape parameters for the beta 
distributions using  and .
d We assumed the same sensitivity for colorectal cancer and for advanced adenomas. Therefore, 
the same value that was drawn from the distibution was used for for both.
e For stool-based tests, we used different sensitivities for colorectal cancers that are either long 
or short before clinical diagnosis based on Lansdorp-Vogelaar et al. 184 .





Supplementary Table A6.8: Costs and disutilities varied in the probabilistic sensitivity 
analysis.
















95% CI disutiliy 
when negativeb
Colonoscopy
Screeninga 1,279 [640, 2,558] - - 0.0005c [0.00025, 0.00099]c
Diagnostica 1,332 [666, 2,664] - - 0.0005c [0.00025, 0.00099]c
Surveillancea 1,281 [640, 2,561] - - 0.0005c [0.00025, 0.00099]c
With  
polypectomy
1,656 [828, 3,313] 0.001401 [0.0007, 0.0028] - -
CTC 493 [246, 986] 0.00156 [0.00078, 0.00321] 0.00029 [0.00015, 0.00058]
PillCam 1,352 [676, 2,705] 0.00169 [0.00085, 0.00338] 0.00043 [0.00021, 0.00085]
FIT 40 [20, 80] 0.00133 [0.00067, 0.00266] 0.00006 [0.0003, 0.000013]
mtSDNA 531 [265, 1,061] 0.00139 [0.0007, 0.00279] 0.00013 [0.00006, 0.00025]
Treatment costs ($) 
Phase of cancer 
cared
Value Stage I Stage II Stage III Stage IV
Initial phase Mean 42,763 58,796 83,427 121,828 
CIe [21,381, 85,526] [29,398, 117,592] [41,716, 166,854] [60,914, 243,656]
Continuing 
phase
Mean 4,301 4,944 7,456 34,017 




Mean 82,519 92,366 96,461 119,979 





Mean 25,450 26,997 35,026 77,051 
CIe [12,725, 50,900] [13,499, 53,994] [17,513, 70,052] [38,526, 154,102]
Treatment disutilities 
Phase of cancer 
cared,f,g
Value Stage I Stage II Stage III Stage IV
Initial phase Mean 0.12 0.18 0.24 0.70
CIh [0.0605, 0.1795] [0.1205, 0.2395] [0.1805, 0.2995] [0.6405, 0.7595]
Continuing 
phase
Mean 0.05i 0.05i 0.24 0.70 




Mean 0.70j 0.70j 0.70j 0.70e





Mean 0.05k 0.05k 0.24 0.70 
CIh [0, 0.1095] [0, 0.1095] [0.1805, 0.2995] [0.6405, 0.7595]
table continues
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Complication costs and disutilities
Complications Mean 
costs ($)
95% CI costs ($)b Mean 
disutility
95% CI disutiliyb
Serious gastrointestinal event 12,434 [6,271, 24,868] 0.0055 [0.00274, 0.010959]
Other gastrointestinal event 7,855 [3,928, 15,710] 0.0027 [0.001378, 0.005479]
Cardiovascular event 10,063 [5,032, 20,126] 0.0048 [0.00240, 0.009589]
CI - confidence interval; CRC - colorectal cancer; CTC - computed tomographic colonography; 
PillCam - PillCam COLON 2; FIT - fecal immunochemical test; mtSDNA - multitarget stool DNA; 
mSEPT9 - methylated SEPT9 DNA plasma assay
a These are costs for procedures without polypectomy.
b We used gamma distributions for all cost and disutility values. CIs were derived by halving 
and doubling the mean value. The CIs were used to derive the mean and standard deviation, 
μ and σ, respectively, that were used to obtain shape parameter k and scale parameter θ using 
method of moments by   and θ .
c We assumed disutility for any type of colonoscopy without polypectomy, so the same value 
that was drawn from the distibution was used for all three different types.
d The terminal phase takes precedence over the initial and continuing phase. The terminal 
phase reflects the last 12 months of life. The initial phase reflects the 12 months following 
diagnosis for persons who survival for more than 12 months (if survive for ≤ 12 months, 
person only experiences the terminal phase). The continuing phase is the time between the 
initial phase and the terminal phase for persons who survive for more than 24 months.
e We used gamma distributions for all treatment costs. CIs were derived by halving and 
doubling the mean value. The CIs were used to derive the mean and standard deviation, μ 
and σ, respectively, that were used to obtain shape parameter k and scale parameter θ using 
method of moments by   and θ .
f We used gamma distributions for all disutility values. 
g For all, we assumed that disutilities for lower stages could not exceed disutilities for higher 
stages. To do this, we used the preference order algorithm developed by Goldhaber-Fiebert 
and Jalal. 243, with epsilon = 0.05, delta = 0.01.
h CIs were based on Ness et al. 171, using ±0.05/0.84 as bounds. The CIs were used to 
derive the mean and standard deviation, μ and σ, respectively, that were used to obtain 
shape parameter k and scale parameter θ using method of moments by   and θ . 
I For the continuing phase of care, the value drawn from the distribution was used for both 
Stage I and Stage II CRC.
j For the terminal phase of care, the value drawn from the distrubtion was used for for all 
stages.
k For the terminal phase of care with death from other causes, the value drawn from the 
distrubtion was used for both Stage I and Stage II CRC.
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Supplementary Table A6.9: Results of the scenario analysis. Outcomes are per 1000 50-year-
olds, unless otherwise specified.

















No screening - 0 110 0 110
FIT 1 18,278 898 1,735 2,633
CTC 5 5,144 705 1,261 1,966
Colonoscopy 10 2,497 13 2,992 5,002
mSEPT9 2 6,946 1,510 2,190 3,700
mSEPT9 1 8,467 1,824 2,534 4,358
mtSDNA 3 6,804 904 1,672 2,576
PillCam 10 3,026 790 1,649 2,439
PillCam 5 4,439 1,012 1,998 3,010









ICER ($ per QALYG) without 
FIT and Colonoscopy
-------------------------------------- 3% Discounted ---------------------------------------
No screening - 0 0 6.630 - -
FIT 1 153 179 6.404 Cost Saving -
CTC 5 140 165 7.241 D 3,705
Colonoscopy 10 162 195 7.697 78,669 -
mSEPT9 2 143 167 8.049 D D
mSEPT9 1 156 183 8.469 D 66,372
mtSDNA 3 142 166 8.754 D D
PillCam 10 131 154 8.899 D D
PillCam 5 154 183 10.085 D D
mtSDNA 1 162 192 11.125 D 303,378
table continues
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Scenario analysis 2, using the model version that was used to inform the 2016 USPSTF 













Total no. of 
colonoscopies
-------------------------------------Undiscounted --------------------------------------
No screening - 0 67 0 67
FIT 1 16,378 748 985 1,733
CTC 5 4,526 608 746 1,354
Colonoscopy 10 2,278 10 1,753 4,041
mSEPT9 2 6,244 1,349 1,233 2,582
mSEPT9 1 7,902 1,695 1,458 3,153
mtSDNA 3 5,973 746 945 1,691
PillCam 10 2,528 598 948 1,546
PillCam 5 4,085 866 1,166 2,032









ICER ($ per QALYG) without 
FIT and Colonoscopy
--------------------------------------- 3% Discounted ---------------------------------------
No screening - 0 0 4.560 - -
FIT 1 101 117 4.757 1,683 -
CTC 5 94 110 5.593 D 9,397
Colonoscopy 10 108 130 6.004 99,296 -
mSEPT9 2 94 108 6.251 D D
mSEPT9 1 103 120 6.744 D 119,336
mtSDNA 3 94 108 6.849 D D
PillCam 10 88 102 6.922 D D
PillCam 5 103 121 8.337 D D




Scenario analysis 3, assuming that 90% of the people that participated in a previous 
round would participate in a subsequent round, and 15% of the people that did not 
participate in the previous round would participate in the subsequent round. An 80% 













Total no. of 
colonoscopies
-------------------------------------Undiscounted --------------------------------------
No screening - 0 108 0 108
FIT 1 11,612 658 1,311 1,969
CTC 5 3,767 574 1,103 1,677
Colonoscopy 10 1,869 18 2,634 4,521
mSEPT9 2 5,203 1,148 1,757 2,905
mSEPT9 1 6,625 1,439 2,143 3,582
mtSDNA 3 4,809 696 1,331 2,027
PillCam 10 2,246 639 1,439 2,078
PillCam 5 3,346 829 1,726 2,555









ICER ($ per QALYG) without 
FIT and Colonoscopy
------------------------------------- 3% Discounted -----------------------------------------
No screening - 0 0 7.286 - -
FIT 1 143 165 6.919 Cost Saving -
CTC 5 138 161 7.503 D 1,346
Colonoscopy 10 169 203 7.707 20,495 -
mSEPT9 2 139 161 8.229 D D 
mSEPT9 1 158 185 8.482 D 41,041
mtSDNA 3 136 157 8.723 D D
PillCam 10 134 158 8.892 D D
PillCam 5 156 185 9.731 D D
mtSDNA 1 164 192 10.238 D 239,907
table continues
Innovative CRC Screening Tests
255
6
Scenario analysis 4, assuming 12% of advanced adenomas and 18% of colorectal 













Total no. of 
colonoscopies
-------------------------------------Undiscounted --------------------------------------
No screening - 0 108 0 108
FIT 1 15,044 791 1,558 2,349
CTC 5 4,292 628 1,196 1,824
Colonoscopy 10 1,995 15 2,725 4,735
mSEPT9 2 5,804 1,269 1,932 3,201
mSEPT9 1 7,162 1,548 2,279 3,827
mtSDNA 3 5,583 785 1,494 2,279
PillCam 10 2,383 671 1,502 2,173
PillCam 5 3,710 899 1,837 2,736









ICER ($ per QALYG) without 
FIT and Colonoscopy
------------------------------------- 3% Discounted -----------------------------------------
No screening - 0 0 7.286 - -
FIT 1 162 189 6.793 Cost Saving -
CTC 5 151 177 7.479 D 1,092
Colonoscopy 10 174 209 7.751 48,155 -
mSEPT9 2 149 173 8.281 D D
mSEPT9 1 164 193 8.567 D 68,682
mtSDNA 3 151 175 8.887 D D
PillCam 10 141 165 8.951 D D
PillCam 5 166 196 9.940 D D
mtSDNA 1 173 205 10.798 D 188,729
LYG - life-years gained; QALYG - quality-adjusted life-years gained; ICER - incremental cost-
effectiveness ratio; FIT - fecal immunochemical test; mSEPT9 - methylated SEPT9 DNA plasma 
assay; CTC - computed tomographic colonography; mtSDNA - multitarget stool DNA; PillCam 
- PillCam COLON 2; D – dominated
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The province of Ontario, Canada is considering immunohistochemical followed by 
cascade analyses of all patients who received a diagnosis of colorectal cancer (CRC) at 
an age younger than 70 years to identify individuals with Lynch syndrome. We evaluated 
the costs and benefits of testing for Lynch syndrome and determined the optimal 
surveillance interval for first-degree relatives (FDRs) found to have Lynch syndrome.
Methods
We developed a patient flow diagram to determine costs and yield of immunohistochemical 
testing for Lynch syndrome in CRC cases and, for those found to have Lynch syndrome, 
their FDRs, accounting for realistic uptake. Subsequently, we used the MISCAN-colon 
model to compare costs and benefits of annual, biennial, and triennial surveillance in 
FDRs identified with Lynch syndrome vs colonoscopy screening every 10 years (usual 
care for individuals without a diagnosis of Lynch syndrome).
Results
Testing 1000 CRC cases was estimated to identify 20 CRC index cases and 29 FDRs 
with Lynch syndrome at a cost of $310,274. Despite the high cost of Lynch syndrome 
tests, offering the FDRs with Lynch syndrome biennial colonoscopy surveillance was 
cost-effective at $8785 per life-year gained compared with usual care because of a 
substantial increase in life-years gained (+122%) and cost savings in CRC care. Triennial 
surveillance was more costly and less effective, and annual surveillance showed limited 
additional benefit compared with biennial surveillance.
Conclusions
Immunohistochemical testing for Lynch syndrome in persons younger than 70 years 
who received a diagnosis of CRC and then testing FDRs of those found to have Lynch 
syndrome provide a good balance between costs and long-term benefits. Colonoscopy 
surveillance every 2 years is the optimal surveillance interval for patients with Lynch 
syndrome. 




Lynch syndrome (LS) is an autosomal dominant genetic disorder caused by a germline 
mutation in one of the DNA mismatch repair genes (MLH1, MSH2, MSH6, or PMS2) 
or by last exomes deletions of EPCAM. LS is the most common cause of hereditary 
colorectal cancer (CRC) and accounts for approximately 3% of all CRC cases.36 
Individuals with LS have a 15%–66% probability of developing CRC before the age of 70 
years, depending on sex and type of mutation.37,334-338The average age of CRC diagnosis 
in LS cases is 45 years,37 which is substantially younger than the general population 
in which the majority of CRC cases are diagnosed in individuals aged 65 or older.15 
Intensive colonoscopy surveillance in LS cases that have not developed CRC yet has been 
shown to lead to a substantial reduction in CRC incidence and mortality.339 However, 
to qualify for such intensive surveillance, individuals first need to be identified with LS. 
Historically, identification of individuals with LS has been based on the Amsterdam 
or revised Bethesda criteria.340 However, sensitivity and specificity of these criteria 
are limited, and because both sets of criteria rely on accurate family history, their 
implementation in routine clinical practice has been poor.340
More recently, laboratory-based testing of CRC cases through immunohistochemistry 
(IHC) has been suggested as a more effective pathway for identifying individuals with 
LS.340 First-degree relatives (FDRs) of LS-positive cases can undergo cascade testing: 
genetic counseling and testing for a known germline mutation in a mismatch repair 
gene. Those with LS can then be offered intensified colonoscopy surveillance to enable 
timely detection of CRC. Compared with currently used criteria, programmatic IHC 
testing is likely to increase the number of LS identifications. Therefore, the province 
of Ontario, Canada is currently considering introducing reflex testing of all CRC cases 
younger than age 70 years.341 In this study, we (1) evaluated the costs and life-years 
gained (LYG) of IHC testing for LS followed by cascade testing in CRC cases younger 
than age 70 and (2) determined the optimal colonoscopy surveillance interval in LS-
identified first-degree relatives (FDRs).
Methods
A pathway from CRC diagnosis to the identification of FDRs with LS, including the 
associated probabilities and costs, was developed on the basis of experience at the 
Familial Gastrointestinal Cancer Registry, Mount Sinai Hospital, Toronto, Ontario, 
supplemented with literature. Subsequently, we used the Microsimulation Screening 
Analysis (MISCAN)–Colon decision model to estimate costs and LYG of triennial, 
biennial, and annual colonoscopy in identified FDRs with LS. We compared results 
with those of colonoscopy screening every 10 years, the recommended strategy 
for individuals without an increased risk of CRC. Costs and LYG in both steps were 




Development of patient flow diagram
Figure 9.1 and Supplementary Table A9.1 describe the flow of CRC patients and 
their FDRs through IHC testing for LS. The patient flow diagram does not reflect cases 
that are missed because of a lack of test sensitivity. First, all CRC patients diagnosed 
younger than age 70 years are tested for expression deficiencies of MLH1, MSH2/6, 
and PMS2. Patients with MSH2/6 or PMS2 deficiencies are directly referred to a patient 
navigator, who informs them about the possibility of undergoing germline testing. 
The genomic DNA of tumors that lack MLH1 expression is first tested for the BRAF 
V600E mutation. If the tumor is BRAF wild-type, methylation of the MLH1 promoter is 
determined. Patients with MLH1-negative tumors are only referred to a patient navigator 
if they are BRAF wild-type and do not have hypermethylation of the MLH1 promoter 
(Figure 9.1). CRC patients who have a germline mutation receive post-test genetic 
counseling in which FDRs are traced. We assumed an average of 5.96 FDRs per CRC 
patient diagnosed with LS.342 These FDRs are offered genetic counseling, subsequent 
germline testing, and, if positive for LS, post-test genetic counseling (Figure 9.1).
Microsimulation Screening Analysis–Colon model
MISCAN-Colon is a well-established microsimulation model for CRC that was 
developed at the Department of Public Health of the Erasmus MC, University Medical 
Center (Rotterdam, the Netherlands). The model’s structure, underlying assumptions, 
and calibration for the Canadian setting have been described elsewhere (Model 
Appendix).343 In brief, MISCAN-Colon simulates the life histories of a large population 
of persons from birth to death, with adenoma prevalence and CRC incidence as 
observed in the Canadian population. By comparing all life histories with and without 
screening and surveillance, MISCAN-Colon quantifies the effectiveness of screening 
and surveillance as well as the associated costs.
Model adjustments for the Lynch syndrome population
We adjusted the MISCAN-Colon model built for the general Canadian population to 
reflect the LS population by assuming that, on average, adenomas progress 10 times 
faster (Supplementary Table A9.2). Adenoma onset was then calibrated to the age-
specific cumulative CRC risk described by Bonadona et al,343 assuming an average CRC 
risk of 42% at age 80 for both sexes. We assumed the same difference in relative risk 
between men and women as modeled for the general population (Supplementary 
Figure A9.1). Because LS cases have a better overall CRC survival, we adjusted survival 
in the MISCAN-Colon model by using a hazard ratio of overall survival of 0.65 compared 
with the general population. 344 We assumed no differences in CRC stage distribution or 
other-cause mortality between LS patients and the average-risk population.
Simulated population
For each screening and surveillance strategy, we simulated a cohort of 10 million individuals 
identified with LS in 2015 to generate stable model results. Their median age was 42 years, 
with an interquartile range of 31–55 years in accordance with the age distribution of LS-
identified FDRs in a Dutch study.342 Distribution by sex was based on the percentage of 
women in the 2015 Ontario population, accounting for the age distribution of the FDRs.345
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Figure 9.1: Patient flow diagram of CRC index cases and cascade testing. 




Lynch syndrome testing and colonoscopy surveillance strategies
We simulated 5 LS testing and colonoscopy strategies for LS-positive FDRs:
1. No LS testing and no colonoscopy screening.
2. No LS testing. FDRs are offered colonoscopy screening every 10 years at ages 50–80 
years (ie, usual care).
3. LS testing. FDRs with LS are offered triennial colonoscopy surveillance at ages 25–
59 years, extending the surveillance interval to 5 years at ages 60–80 if no adenomas 
are detected.346
4. LS testing. Similar to strategy 3, except that LS-positive FDRs are offered biennial 
surveillance rather than triennial surveillance.
5. LS testing. Similar to strategy 3, except that LS-positive FDRs are offered annual 
surveillance rather than triennial surveillance.
We assumed a 60% screening participation for the usual care strategy (strategy 2).347 For 
strategies 3–5, we assumed an 80% surveillance adherence for LS-positive FDRs, 340,348-350 
irrespective of the surveillance interval.
The analysis was conducted from a third-party health care payer perspective. All costs 
were expressed in 2018 Canadian dollars (Figure 9.1, Supplementary Table A9.3). 
Colonoscopy test characteristics have been published previously (Supplementary 
Table A9.4).343 For 10-yearly colonoscopy screening, individuals with adenomas 
detected and removed at screening at any age enter a surveillance regimen, for which 
we assumed 100% adherence. This entails a subsequent colonoscopy in 3 years in case of 
high-risk findings (ie, 1 adenoma ≥10 mm or ≥3 adenomas <10 mm) and in 5 years in 
case of low-risk findings (ie, ≤2 adenomas <10 mm). For any of the simulated strategies, 
individuals with adenomas detected at their last scheduled colonoscopy will undergo 
such surveillance beyond age 80 until no adenomas are detected.
Outcomes
For all strategies, we evaluated the number of CRC cases and deaths, the costs of 
diagnosing CRC cases through symptoms, and the costs of CRC treatment. For strategy 
2 (usual care), the LYG and associated costs from colonoscopy screening compared 
with strategy 1 (no screening) were also evaluated. For strategies 3–5 with intensified 
colonoscopy surveillance for LS-positive FDRs, we estimated costs for LS testing of 
the index cases and their FDRs, if applicable, and downstream LYG and costs of CRC 
surveillance of LS-positive FDRs. We used these to calculate the average cost-effectiveness 
ratio (compared with usual care) of LS testing followed by intensified colonoscopy 
surveillance for LS-positive FDRs, assuming a willingness-to-pay threshold of $100,000 
per LYG. Furthermore, the incremental cost-effectiveness ratios (ICERs) of the different 
strategies were evaluated. Costs and LYG were discounted at an annual rate of 3% to the 
year in which the index case was diagnosed with CRC. The results section starts with 
costs of LS testing per 1000 CRC cases, but they are then converted to costs per 1000 
FDRs identified with LS, and all subsequent outcomes of colonoscopy screening and 
surveillance are presented per 1000 FDRs with identified LS.




To evaluate the robustness of our results, we varied all parameters in one-way 
sensitivity analyses (Supplementary Table A9.1, Supplementary Table A9.2, 
Supplementary Table A9.3), in addition to evaluating a scenario in which 5-yearly 
colonoscopy instead of 10-yearly colonoscopy is the usual care, and a scenario in which 
the surveillance interval between ages 60 and 80 is not extended when no adenomas are 
detected. Because the progression rate of CRC in LS is uncertain, we evaluated ×0, ×2, 
×5, ×10, and ×20 faster adenoma progression than the general population. For these 5 
progression rates, adenoma onset was recalibrated to obtain a uniform age-specific CRC 
incidence.37 Furthermore, a probabilistic sensitivity analysis was performed to evaluate 
the uncertainty of our estimates (Supplementary Table A9.1, Supplementary 
Table A9.2, Supplementary Table A9.3). Each of the progression assumptions was 
used in 20% of the runs. For the probability parameters, 1000 values were drawn from 
beta distributions; gamma distribution was used for all other parameters.
Results
Lynch Syndrome Testing in Index Colorectal Cancer Cases and First-Degree Relatives
Testing 1000 index CRC cases for LS through IHC and subsequent germline testing 
identified 20 LS cases (Figure 9.1) with an associated cost of $278,558 (Supplementary 
Table A9.5). The costs of cascade testing of the 119 family members of those 20 LS 
cases were estimated at an additional $31,716 and resulted in the identification of 29 
FDRs with LS. Overall, tumor testing of 1000 index CRC cases for LS would thus cost 
$310,274 to identify 29 FDRs with LS, which corresponds to $10.462 million per 1000 
LS-positive FDRs (Table 9.1).
CRC surveillance in first-degree relatives with Lynch syndrome
In the absence of CRC screening, MISCAN-Colon predicted 359 CRC cases and 165 
CRC deaths per 1000 LS-positive FDRs of CRC patients diagnosed younger than the 
age of 70 from their LS diagnosis until death (Table 9.1). Associated costs of CRC 
diagnosis and care were estimated at $67.465 million. In the strategy without LS testing 
but with 10-yearly colonoscopy screening at 60% participation (usual care), the number 
of CRC cases and deaths was reduced to 308 (–14%) and 112 (–33%) per 1000 LS-
positive FDRs, respectively. This strategy gained 334 life-years per 1000 LS-positive 
FDRs compared with no screening. Total costs of usual care were $63.992 million per 
1000 FDRs; therefore, usual care was cost saving compared with no CRC screening.
LS testing was very cost-effective compared with no LS testing. The benefits of LS testing 
depend on the subsequent colonoscopy surveillance that is offered to the FDRs who are 
identified with LS. Compared with the care these FDRs would receive if they had not 
been diagnosed with LS, universal LS testing through IHC and subsequent intensified 
colonoscopy surveillance resulted in 722 (+116%), 741 (+122%), and 753 (+126%) LYG 
per 1000 FDRs with LS and increased CRC screening and surveillance costs to $4.237 
million (+291%), $5.669 million (+423%), and $9.932 million (+816%) for triennial, 
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biennial, and annual surveillance from age 25, respectively (Table 9.1). The shorter the 
surveillance interval, the more CRC cases are averted, and therefore CRC care costs are 
lower. Strikingly, the total costs of LS testing, CRC surveillance, and CRC care of offering 
biennial surveillance to LS cases were lower than those of triennial surveillance. The 
number of LYG per 1000 LS-positive FDRs was 741 for biennial surveillance, resulting 
in ICER of $8785 compared with usual care. Offering LS cases annual colonoscopy 
surveillance minimally increased the number of LYG (753, +1.6%) and increased total 
costs by approximately $2.565 million (+3.8%) per 1000 LS-positive FDRs, resulting 
in an unfavorable ICER of $218,647 per LYG compared with biennial colonoscopy 
surveillance (Table 9.1).































































































































No LS testing or CRC 
screening
359 165 0.227 67.237 67.465 - - -
No LS testing  
 10-yearly colonoscopy 308 112 1.084 62.908 63.992 334 -
Cost-
Saving
LS testing  
   3-yearly colonoscopy 244 67 10.462 4.237 53.048 67.747 722 9,670 D
   2-yearly colonoscopy 235 66 10.462 5.669 51.441 67.573 741 8,785 8,785
   1-yearly colonoscopy 228 66 10.462 9.932 49.743 70.138 753 14,655 218,647
CRC - Colorectal Cancer; LS - Lynch Syndrome; LYG - Life-Years Gained; ACER - Average Cost-
Effectiveness Ratio, ICER - Incremental Cost-Effectiveness Ratio; D - Dominated.
a CRC cases and deaths include those from LS diagnosis until death.
b Results were discounted at an annual rate of 3%.
c Include total costs of screening CRC index cases and their FDRs, including LS negative and 
non-participants.
d Include costs of CRC screening, diagnosis and surveillance.
e Compared to no LS screening.
Sensitivity analyses
The ICER of reflex tumor testing for all patients with CRC younger than age 70 followed 
by biennial colonoscopy compared with 10-yearly colonoscopy for FDRs identified 
with LS varied between being Cost Saving and $34,230 in our one-way sensitivity 
analyses (Supplementary Figure A9.2, Supplementary Table A9.6). The ICER 
of universal tumor testing followed by annual colonoscopy of FDRs with LS exceeded 
the threshold of $100,000 per LYG in all sensitivity and scenario analyses, except in 
the scenario where a cumulative CRC risk of 60% at age 80 was assumed for LS cases 
(Supplementary Table A9.6) and the scenario in which it assumed that the adenoma 
progression of LS cases is ×20 faster than the general population, which resulted in 
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ICERs of $95,197 and $93,835. Finally, at a willingness-to-pay threshold of $100,000, LS 
testing with subsequent biennial colonoscopy surveillance was the optimal strategy in 
77.2% of our probabilistic sensitivity analyses (Figure 9.2).
Figure 9.2: Cost-effectiveness acceptability curve of the probabilistic sensitivity analyses. 
CRC - colorectal cancer; LS - Lynch syndrome.
Discussion
The results of this study suggest that programmatic testing for LS with IHC in patients 
with CRC diagnosed younger than age 70 years followed by cascade testing is very 
cost-effective, and that biennial colonoscopy surveillance of identified FDRs with LS 
is optimal. Testing tumors of 1000 CRC patients for LS was estimated to result in the 
identification of 29 FDRs with LS at a cost of $310,274. Despite the high cost of LS 
testing, offering these FDRs with LS biennial versus 10-yearly colonoscopy screening 
resulted in a favorable ICER of $8785 because of a substantial increase in LYG (+122%) 
and cost savings in CRC care. Strikingly, because of cost savings in CRC care, the total 
costs of biennial surveillance were lower than those of triennial surveillance. Annual 
colonoscopy surveillance provided little benefit compared with biennial surveillance at 
a much higher cost, resulting in ICER of $218,647. LS testing with biennial colonoscopy 
surveillance was the optimal strategy in 77.2% of our probabilistic sensitivity analyses 




With LS testing costs of more than $10,000 per LS-positive FDR identified, investigating 
the presence of LS in all CRC index cases <70 years and their FDRs is expensive. To 
identify 1 FDR with LS, 35 tumor samples of CRC index cases have to be analyzed 
by IHC, and 3 germline tests have to be performed. This emphasizes the costs of IHC 
testing being an important driver for the cost-effectiveness of LS testing and subsequent 
colonoscopy surveillance, which we also observed in our sensitivity analyses. The 
additional costs of offering an LS case biennial CRC surveillance were $4585 compared 
with 10-yearly colonoscopy. Because LS cases are at very high risk of developing CRC, 
substantial downstream cost savings in CRC treatment ($11,467) occur by preventing 
CRC cases and by diagnosing CRC cases in an earlier stage. Overall, LS testing in CRC 
patients younger than age 70 and subsequent biennial colonoscopy surveillance require 
an upfront investment that is largely offset by future savings in CRC treatment.
A recent study compared CRC incidence in LS cases between 3 countries with different 
colonoscopy surveillance policies (1-, 2-, and 3-year intervals) and found no difference 
in cumulative CRC incidence among countries.351 Because we found only minor 
differences in the number of CRC cases (244–228 CRC cases per 1000 LS cases), those 
results are consistent with our findings. Nevertheless, because the additional costs are 
also small, our results demonstrate that surveillance every 2 years rather than every 3 
years is worthwhile, whereas surveillance every year is not.
Our study has some limitations. First, we did not include any strategies in which we 
evaluated other methods for LS testing. Other studies have compared different strategies 
for LS testing and determined that screening with IHC is the most cost-effective 
strategy.342,352-355 Second, not all steps in the patient flow diagram could be based on 
Canadian data. We varied all estimates in our sensitivity analyses and demonstrated 
that they did not influence our recommendation of offering biennial colonoscopy 
surveillance to LS cases. Third, the CRC risk for LS cases is uncertain; estimates vary 
greatly among studies.37,334-338 We calibrated our model to the largest study that accounted 
for ascertainment bias.37,356  Fourth, we did not evaluate gene-specific colonoscopy 
surveillance because of its high uncertainty in CRC risk and natural history. To address 
these third and fourth limitations, we performed sensitivity analyses with 30% and 
60% CRC risk at age 80, which revealed that more intense colonoscopy surveillance 
might be optimal for LS cases with high-risk mutations, which should therefore be 
explored in future studies. Fifth, the natural history of CRC in LS is uncertain. We 
covered this uncertainty by evaluating 5 different progression assumptions. Only if we 
assumed that the progression of adenomas in LS is ×20 faster than the progression in the 
general population, the ICER of annual surveillance was below the willingness-to-pay 
threshold, which was $93,835 per LYG compared with biennial surveillance. Sixth, the 
assumptions regarding the costs for LS testing used in our study are not reflective for 
settings where genetic testing is performed by using multiple-gene panels. Furthermore, 
we did not take into account that patients with stage II CRC with adverse features may 
undergo IHC testing to guide chemotherapy. Lower costs for LS testing would make 
programmatic testing for LS even more cost-effective, and it would not influence the 
optimal surveillance interval. Seventh, we used LYG rather than quality-adjusted life 
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years gained. An important determinant of the quality of life of LS cases is the distress LS 
patients experience from knowing they have LS. To our knowledge, no data are available 
that quantify this disutility, which is why we could not incorporate it in our analyses. Last, 
we did not consider other LS-related cancers such as the increased risk for endometrial 
cancer and ovarian cancer; we assumed that apart from an increased CRC risk, LS cases 
have a normal life expectancy. This potentially resulted in an overestimation of LYG per 
CRC deaths prevented. However, an asymptomatic individual identified with LS has the 
additional benefit of potential earlier detection or prevention of other cancer types, and 
this additional benefit is also not captured in the current analysis.
Despite these limitations, our study may be of great value to policy makers and fellow 
researchers. This cost-effectiveness analysis evaluates different colonoscopy surveillance 
intervals in LS cases identified by IHC testing. The optimal colonoscopy surveillance 
interval for LS cases is a topic of intense debate 351; therefore, this study provides insights 
that can be used to inform surveillance guidelines internationally. In line with previous 
studies, LS testing with more intensive colonoscopy surveillance was very cost-effective 
compared with usual care.352-355  However, we revealed that biennial colonoscopy 
surveillance was cost saving compared with triennial surveillance, and that annual 
colonoscopy was not cost-effective compared with biennial colonoscopy. Another 
major strength of our study is that both the costs to identify LS in CRC cases and the 
subsequent costs of cascade testing and colonoscopy surveillance of at-risk relatives 
were included in our analyses. Furthermore, we used a well-established microsimulation 
model that has been used to inform CRC screening guidelines in several countries, 
among which is the United States.96,99 This study also evaluates universal LS testing in 
CRC index cases (in this case limited to patients <70 years) and subsequent cascade 
screening and colonoscopy surveillance in at-risk relatives for the Canadian setting. 
Important barriers that have been identified for implementation of a population-based 
program for LS screening in Canada are the education of stakeholders and concerns 
regarding sustaining various resources.341 The results of this study provide data that are 
essential to overcome these barriers. For other countries with universal LS screening, 
the results of this study can be used to optimize existing programs, because it provides 
insight in which elements of the patient flow diagram are important drivers for the 
(cost-)effectiveness of LS screening.
 
In conclusion, we estimated that programmatic IHC testing for LS in patients with 
CRC diagnosed <70 years that is followed by cascade testing and subsequent biennial 
colonoscopy surveillance of identified FDRs is very cost-effective in Canada. These 





Supplementary Figure A9.1: Cumulative CRC risk assumed by MISCAN-Colon was calibrated 
to Bonadona et al. 37 
CRC - Colorectal cancer


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table A9.1: Assumptions regarding the participation of CRC Index cases and 
their FDRs in every step of the patient flow diagram, and the positivity rates of the genetic 
tests.
Parameter Value (rangea) Source
LS testing of index CRC cases




Proportion of index CRC cases with an MLH1 deficiency, 
subsequently tested for BRAF V600E
13.3%
Proportion of MLH1 deficient tumors with wildtype BRAF, 
subsequently tested for MLH1 promoter hypermethylation
64%
Proportion of MLH1 deficient BRAF wildtype tumors 
without MLH1 promoter hypermethylation, referred to 
genetic counseling
33%
Proportion of index CRC cases with an MSH2/6 or PMS2 
deficiency, subsequently referred to genetic counseling
1.7%
Index case genetic pathway














Average number of FDRs of identified LS case 5.96  
(2.98-8.94)
342
Proportion of FDRs that accept genetic counseling 52%  
(26-78%)
340









Colonoscopy screening participation not diagnosed with LS 60%  
(40-80%)d
347
Colonoscopy surveillance participation diagnosed with LS 80%  
(70-90%)d
340,348-350 
CRC - Colorectal cancer; FDR -first-degree relative; LS - Lynch Syndrome
a Alternative values evaluated in sensitivity analyses. Ranges evaluated were mean*0.5 –
mean*1.5.
b Estimates were based on experience at the Familial Gastrointestinal Cancer Registry, Mount 
Sinai Hospital, Toronto, Ontario
c In the Probabilistic Sensitivity Analysis, the participation when not being diagnosed with 
LS was never lower than the participation when being diagnosed with LS, using preference 
ordering.243
d As we are more certain of these estimated, smaller ranges were evaluated.
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Supplementary Table A9.2: Natural History adjustments for the Lynch Syndrome population. 
Parameter Value (rangea) Source
Probability of having developed colorectal cancer before 
age 80
42% (30-60%) 37
Dwelling times, faster progression compared to the 
general population
10x (0x/2x/5x/20x)b Assumption
Hazard Ratio overall survival of CRC in LS cases versus 
CRC in the general population
0.65 (0.59-0.71) 344
CRC - Colorectal cancer; LS - Lynch Syndrome
a Alternative values evaluated in sensitivity analyses. 
b In the Probabilistic Sensitivity Analysis, 0x, 2x, 5x, 10x and 20x faster dwelling times were 
evenly incorporated. 
Supplementary Table A9.3: Assumptions regarding costs. All costs are in 2018 Canadian 
Dollars.
 
Procedure Costs (rangea) Sourceb
Related to genetic testing
Combined costs of lab testing in index CRC case 224 (112-336) Ontario Estimate
          IHC MLH1, MSH2/6, PMS2 150
          BRAF V600E mutation 300
          Methylation of MLH1 promoter 400
Cost of patient navigator per individual  
referred to genetic counseling
108 (54-162) Ontario Estimatec
Costs of pre-test genetic counseling in CRC index 
case
255 (128-383) Ontario Estimated
Avg. cost of germline test in index CRC case 1,099 (549- 1,648) Ontario Estimatee
          MSH2/6, PMS2 1,200
          MLH1 1,040
Post-test genetic counseling and tracing FDRs for LS 
positive cases & Costs of pre-test genetic counseling 
of FDRs (per index CRC case with LS) & Post-test 
genetic counseling FDR
90  (45-135) Ontario Estimatef
Somatic testing for LS negative cases 500 (250-750) Ontario Estimate
Costs of germline testing for LS in a FDR 
with a known mutation
400 (200-600) Ontario Estimate
Related to colonoscopiesg
Colonoscopy without polypectomy 947 (474-1,421) 158
Colonoscopy with polypectomy & 
Colonoscopy for diagnosis of CRC by symptoms







Stage I Stage II Stage III Stage IV











































































CRC - Colorectal cancer; LS - Lynch syndrome; FDR - first-degree relative; OC - other causes.
a Alternative values evaluated in sensitivity analyses. Ranges evaluated were mean*0.5 –
mean*1.5.
b Ontario Estimate: costs are based on experience at the Familial Gastrointestinal Cancer 
Registry, Mount Sinai Hospital, Toronto, Ontario
c Annual salary of a navigator ($70,000) was divided by the estimated number of cases per 
year (650).
d Includes 1 hour Salary for Genetic Counseler ($90) and Ontario Health Insurance Plan (OHIP) 
Fee Schedule code A225 ($165).
e 62% of individuals were tested for MLH1.
f Includes 1 hour Salary for Genetic Counseler ($90). 
g Costs of colonoscopy were obtained from the 2013 Ontario Health Insurance Plan (OHIP) 
Schedule of Benefits and Fees,158 and updated to 2018 Canadian dollars using the consumer 
price index (CPI; All-items).364 These were varied together in the one-way sensitivity analysis. 
h CRC care was divided in three clinically relevant phases. The initial care phase was defined 
as the first 12 months after diagnosis, the terminal care phase as the final 12 months of life, 
and the continuing care phase as all months in between. For patients surviving less than 24 
months, the last 12 months were allocated to the terminal care phase and the remaining 
months were allocated to the initial care phase. 
The costs attributable to CRC care by sex, CRC stage, and phase of care (initial, continuing, and 
terminal care) included outpatient visits, hospitalizations, treatment, home care, long-term 
care, and rehabilitation. The costs were estimated using health care administrative data in a 
matched cohort study, which compared the health care costs of CRC patients with their age- 
and sex-matched controls, and updated to 2018 Canadian dollars using the CPI.364 
I Based on the 2015 Ontario Population, accounting for the age distribution of the FDRs.
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Supplementary Table A9.4: Colonoscopy test characteristics
Sensitivity
     Adenoma 1-5 mm 75%
     Adenoma 6-9 mm 85%
     Adenoma 10+ mm 95%
     Colorectal Cancer 95%
Specificity 86%a
Reach (until cecum) 95%
Fatal complication riskb 1/14,000 
a The lack of specificity with endoscopy reflects the detection of non-adenomatous lesions, 
where the non-adenomatous lesions are removed and therefore induce polypectomy and 
biopsy.
b The fatal complication risk was only included for colonoscopies with polypectomy, and was 
based on Rabeneck et al. 365
Supplementary Table A9.5: Number of individuals and associated costs per 1000 CRC index 
cases in every step of the patient flow diagram.
Step in patient flow diagram No. of individuals Costs ($)a
LS testing of index CRC cases
Immunohistochemistry MLH1, MSH2/6, PMS2 1000 150,000
BRAF V600E mutation 133 39,900
Methylation MLH1 promoter 85 34,000
Total 223,900
Index case genetic pathway
Patient navigator 45 4,848
Pre-germline testing counseling 38 9,639
Germline testing 30 33,234
Positive cases: post-germline testing counseling 20 1,796
Negative cases: somatic testing 10 5,141
Total 54,658
First-degree relatives pathway
FDRs of LS positive CRC index cases 119
Pre-germline testing counseling 62 5,567
Germline testing 59 23,505
Post-germline testing counseling 29 2,644
Total 31,716
Total 310,274
CRC - Colorectal cancer; FDR - First-degree relatives; LS - Lynch syndrome
a Costs are in 2018 Canadian Dollars.
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Supplementary Table A9.6: Results of one-way sensitivity analyses per 1,000 LS positive 
first-degree relatives of CRC index cases.





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   5-yearly colonoscopy 293 105 1.514
LS testing 
   3-yearly colonoscopy 244 67 10.462 4.237
   2-yearly colonoscopy 235 66 10.462 5.669
   1-yearly colonoscopy 228 66 10.462 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 229 63 10.462 4.798
   2-yearly colonoscopy 207 59 10.462 6.970
   1-yearly colonoscopy 176 55 10.462 13.557





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
354 157 0.221
No LS testing 
   10-yearly colonoscopy 245 93 1.380
LS testing 
   3-yearly colonoscopy 150 50 10.462 4.613
   2-yearly colonoscopy 140 49 10.462 6.131






Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
363 166 0.229
No LS testing 
   10-yearly colonoscopy 271 102 1.275
LS testing 
   3-yearly colonoscopy 179 57 10.462 4.500
   2-yearly colonoscopy 167 55 10.462 5.995
   1-yearly colonoscopy 155 54 10.462 10.306
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67.237 67.465 - - -
61.690 63.204 362 - Cost-Saving
53.048 67.747 722 12,617 D
51.441 67.573 741 11,516 11,516
49.743 70.138 753 17,728 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
51.845 67.105 739 7,672 D
49.078 66.510 772 5,741 5,741
45.493 69.513 802 11,785 100,826








64.196 64.417 - - -
55.624 57.005 363 - Cost-Saving
43.341 58.417 727 3,880 3,880
41.932 58.525 742 4,010 7,111
40.627 61.572 753 11,716 284,648








67.431 67.66 - - -
59.987 61.262 371 - Cost-Saving
47.678 62.639 766 3,486 D
45.926 62.383 785 2,705 2,705









Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
362 166 0.228
No LS testing 
   10-yearly colonoscopy 293 108 1.155
LS testing 
   3-yearly colonoscopy 215 63 10.462 4.349
   2-yearly colonoscopy 205 61 10.462 5.809
   1-yearly colonoscopy 196 61 10.462 10.098





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
364 167 0.229
No LS testing 
   10-yearly colonoscopy 335 118 1.047
LS testing 
   3-yearly colonoscopy 287 74 10.462 4.157
   2-yearly colonoscopy 279 73 10.462 5.572
   1-yearly colonoscopy 268 73 10.462 9.809





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
255 117 0.161
No LS testing 
   10-yearly colonoscopy 218 79 1.046
LS testing 
   3-yearly colonoscopy 172 48 10.462 4.284
   2-yearly colonoscopy 166 47 10.462 5.718
   1-yearly colonoscopy 161 47 10.462 10.010





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
510 240 0.327
No LS testing 
   10-yearly colonoscopy 444 163 1.121
LS testing 
   3-yearly colonoscopy 356 99 10.462 4.135
   2-yearly colonoscopy 344 97 10.462 5.562
   1-yearly colonoscopy 333 98 10.462 9.768
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67.227 67.455 - - -
61.431 62.586 353 - Cost-Saving
50.331 65.143 747 6,491 D
48.627 64.898 766 5,599 5,599
46.972 67.532 778 11,621 208,305








67.428 67.657 - - -
65.172 66.219 305 - Cost-Saving
56.789 71.408 694 13,348 D
54.881 70.915 719 11,345 11,345
52.444 72.716 739 15,000 93,835








47.555 47.715 - - -
44.488 45.534 233 - Cost-Saving
37.525 52.271 509 24,387 D
36.380 52.560 523 24,227 24,227
35.183 55.655 531 33,911 366,988








99.024 99.352 - - -
93.110 94.231 494 - D
78.906 93.503 1072 Cost-Saving D
76.476 92.501 1100 Cost-Saving Cost-Saving









Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 158 0.227
No LS testing 
   10-yearly colonoscopy 308 106 1.082
LS testing 
   3-yearly colonoscopy 243 64 10.462 4.228
   2-yearly colonoscopy 235 63 10.462 5.657
   1-yearly colonoscopy 228 63 10.462 9.910





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
360 173 0.228
No LS testing 
   10-yearly colonoscopy 309 117 1.086
LS testing 
   3-yearly colonoscopy 244 71 10.462 4.246
   2-yearly colonoscopy 236 70 10.462 5.681
   1-yearly colonoscopy 228 70 10.462 9.952





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 18.007 4.237
   2-yearly colonoscopy 235 66 18.007 5.669
   1-yearly colonoscopy 228 66 18.007 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 7.948 4.237
   2-yearly colonoscopy 235 66 7.948 5.669
   1-yearly colonoscopy 228 66 7.948 9.932
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69.302 69.529 - - -
64.677 65.758 321 - Cost-Saving
54.406 69.096 692 9,009 D
52.778 68.898 710 8,080 8,080
51.071 71.443 721 14,236 235,800








65.423 65.65 - - -
61.341 62.427 344 - Cost-Saving
51.848 66.556 749 10,203 D
50.259 66.402 770 9,345 9,345
48.566 68.980 782 14,958 203,055








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 75.292 722 29,097 D
51.441 75.117 741 27,292 27,292
49.743 77.682 753 32,645 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 65.233 722 3,194 D
51.441 65.058 741 2,615 2,615









Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 18.17 4.237
   2-yearly colonoscopy 235 66 18.17 5.669
   1-yearly colonoscopy 228 66 18.17 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 9.229 4.237
   2-yearly colonoscopy 235 66 9.229 5.669
   1-yearly colonoscopy 228 66 9.229 9.932
Index case genetic pathway: proportion of patients that once seen by genetic counselor will 





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 18.495 4.237
   2-yearly colonoscopy 235 66 18.495 5.669
   1-yearly colonoscopy 228 66 18.495 9.932
Index case genetic pathway: proportion of patients that once seen by genetic counselor will 





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 8.856 4.237
   2-yearly colonoscopy 235 66 8.856 5.669
   1-yearly colonoscopy 228 66 8.856 9.932
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67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 75.455 722 29,518 D
51.441 75.281 741 27,693 27,693
49.743 77.845 753 33,034 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 66.514 722 6,494 D
51.441 66.340 741 5,759 5,759
49.743 68.905 753 11,714 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 75.780 722 30,354 D
51.441 75.606 741 28,490 28,490
49.743 78.170 753 33,809 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 66.141 722 5,533 D
51.441 65.967 741 4,844 4,844




Index case genetic pathway: proportion of patients undergoing genetic testing that are positive 





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 20.124 4.237
   2-yearly colonoscopy 235 66 20.124 5.669
   1-yearly colonoscopy 228 66 20.124 9.932
Index case genetic pathway: proportion of patients undergoing genetic testing that are positive 





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 7.242 4.237
   2-yearly colonoscopy 235 66 7.242 5.669
   1-yearly colonoscopy 228 66 7.242 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 19.845 4.237
   2-yearly colonoscopy 235 66 19.845 5.669
   1-yearly colonoscopy 228 66 19.845 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 7.335 4.237
   2-yearly colonoscopy 235 66 7.335 5.669
   1-yearly colonoscopy 228 66 7.335 9.932
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67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 77.409 722 34,549 D
51.441 77.234 741 32,486 32,486
49.743 79.799 753 37,693 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 64.527 722 1,377 D
51.441 64.353 741 884 884
49.743 66.917 753 6,975 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 77.130 722 33,831 D
51.441 76.956 741 31,803 31,803
49.743 79.521 753 37,029 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 64.620 722 1,616 D
51.441 64.445 741 1,112 1,112









Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 19.845 4.237
   2-yearly colonoscopy 235 66 19.845 5.669
   1-yearly colonoscopy 228 66 19.845 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 7.335 4.237
   2-yearly colonoscopy 235 66 7.335 5.669
   1-yearly colonoscopy 228 66 7.335 9.932






Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 20.035 4.237
   2-yearly colonoscopy 235 66 20.035 5.669
   1-yearly colonoscopy 228 66 20.035 9.932






Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 9.984 4.237
   2-yearly colonoscopy 235 66 9.984 5.669
   1-yearly colonoscopy 228 66 9.984 9.932
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67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 77.130 722 33,831 D
51.441 76.956 741 31,803 31,803
49.743 79.521 753 37,029 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 64.620 722 1,616 D
51.441 64.445 741 1,112 1,112
49.743 67.010 753 7,197 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 77.320 722 34,319 D
51.441 77.145 741 32,268 32,268
49.743 79.710 753 37,481 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.269 722 8,437 D
51.441 67.094 741 7,610 7,610









Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 20.835 4.237
   2-yearly colonoscopy 235 66 20.835 5.669
   1-yearly colonoscopy 228 66 20.835 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 7.005 4.237
   2-yearly colonoscopy 235 66 7.005 5.669
   1-yearly colonoscopy 228 66 7.005 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 325 130 0.799
LS testing 
   3-yearly colonoscopy 244 67 10.462 4.237
   2-yearly colonoscopy 235 66 10.462 5.669
   1-yearly colonoscopy 228 66 10.462 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 291 94 1.370
LS testing 
   3-yearly colonoscopy 244 67 10.462 4.237
   2-yearly colonoscopy 235 66 10.462 5.669
   1-yearly colonoscopy 228 66 10.462 9.932
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67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 78.120 722 36,379 D
51.441 77.945 741 34,230 34,230
49.743 80.510 753 39,389 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 64.290 722 767 D
51.441 64.116 741 303 303
49.743 66.680 753 6,410 218,647








67.237 67.465 - - -
64.351 65.150 222 - Cost-Saving
53.048 67.747 722 5,200 D
51.441 67.573 741 4,671 4,671
49.743 70.138 753 9,401 218,647








67.237 67.465 - - -
61.465 62.835 445 - Cost-Saving
53.048 67.747 722 17,727 D
51.441 67.573 741 15,985 15,985









Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 258 80 10.462 3.736
   2-yearly colonoscopy 251 79 10.462 4.989
   1-yearly colonoscopy 244 79 10.462 8.719





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 229 55 10.462 4.738
   2-yearly colonoscopy 220 54 10.462 6.350
   1-yearly colonoscopy 212 54 10.462 11.145





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 6.69 4.237
   2-yearly colonoscopy 235 66 6.69 5.669
   1-yearly colonoscopy 228 66 6.69 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 14.235 4.237
   2-yearly colonoscopy 235 66 14.235 5.669
   1-yearly colonoscopy 228 66 14.235 9.932
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67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
54.822 69.020 632 16,866 D
53.416 68.867 649 15,478 15,478
51.930 71.111 659 21,890 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
51.274 66.475 812 5,188 D
49.467 66.279 834 4,571 4,571
47.557 69.164 847 10,072 218,647








67.237 67.465 - - -
62.908 63.992 334 - D
53.048 63.975 722 Cost-Saving D
51.441 63.801 741 Cost-Saving Cost-Saving
49.743 66.366 753 5,660 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 71.520 722 19,383 D
51.441 71.345 741 18,039 18,039










Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.381 4.237
   2-yearly colonoscopy 235 66 10.381 5.669
   1-yearly colonoscopy 228 66 10.381 9.932






Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.544 4.237
   2-yearly colonoscopy 235 66 10.544 5.669
   1-yearly colonoscopy 228 66 10.544 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.3 4.237
   2-yearly colonoscopy 235 66 10.3 5.669
   1-yearly colonoscopy 228 66 10.3 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.625 4.237
   2-yearly colonoscopy 235 66 10.625 5.669
   1-yearly colonoscopy 228 66 10.625 9.932
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67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.666 722 9,459 D
51.441 67.491 741 8,584 8,584
49.743 70.056 753 14,460 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.829 722 9,880 D
51.441 67.655 741 8,985 8,985
49.743 70.219 753 14,849 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.585 722 9,252 D
51.441 67.411 741 8,386 8,386
49.743 69.975 753 14,267 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.910 722 10,088 D
51.441 67.735 741 9,183 9,183









Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 9.903 4.237
   2-yearly colonoscopy 235 66 9.903 5.669
   1-yearly colonoscopy 228 66 9.903 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 11.022 4.237
   2-yearly colonoscopy 235 66 11.022 5.669
   1-yearly colonoscopy 228 66 11.022 9.932






Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.292 4.237
   2-yearly colonoscopy 235 66 10.292 5.669
   1-yearly colonoscopy 228 66 10.292 9.932






Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.633 4.237
   2-yearly colonoscopy 235 66 10.633 5.669
   1-yearly colonoscopy 228 66 10.633 9.932
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67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.188 722 8,228 D
51.441 67.013 741 7,411 7,411
49.743 69.578 753 13,320 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 68.307 722 11,111 D
51.441 68.133 741 10,158 10,158
49.743 70.698 753 15,989 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.577 722 9,231 D
51.441 67.403 741 8,367 8,367
49.743 69.968 753 14,249 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.918 722 10,108 D
51.441 67.743 741 9,202 9,202









Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.377 4.237
   2-yearly colonoscopy 235 66 10.377 5.669
   1-yearly colonoscopy 228 66 10.377 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.547 4.237
   2-yearly colonoscopy 235 66 10.547 5.669
   1-yearly colonoscopy 228 66 10.547 9.932






Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.062 4.237
   2-yearly colonoscopy 235 66 10.062 5.669
   1-yearly colonoscopy 228 66 10.062 9.932






Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.862 4.237
   2-yearly colonoscopy 235 66 10.862 5.669
   1-yearly colonoscopy 228 66 10.862 9.932
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67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.662 722 9,451 D
51.441 67.488 741 8,576 8,576
49.743 70.053 753 14,452 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.832 722 9,888 D
51.441 67.658 741 8,993 8,993
49.743 70.223 753 14,857 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 67.347 722 8,640 D
51.441 67.173 741 7,803 7,803
49.743 69.738 753 13,701 218,647








67.237 67.465 - - -
62.908 63.992 334 - Cost-Saving
53.048 68.147 722 10,700 D
51.441 67.973 741 9,766 9,766









Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.114
No LS testing 
   10-yearly colonoscopy 308 112 0.542
LS testing 
   3-yearly colonoscopy 244 67 10.462 2.119
   2-yearly colonoscopy 235 66 10.462 2.835
   1-yearly colonoscopy 228 66 10.462 4.966





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.341
No LS testing 
   10-yearly colonoscopy 308 112 1.626
LS testing 
   3-yearly colonoscopy 244 67 10.462 6.356
   2-yearly colonoscopy 235 66 10.462 8.504
   1-yearly colonoscopy 228 66 10.462 14.898





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.462 4.237
   2-yearly colonoscopy 235 66 10.462 5.669
   1-yearly colonoscopy 228 66 10.462 9.932





Costs LS testingb,c  
(million$)
Costs CRC screeningb,d 
(million$)
No LS testing or CRC 
screening
359 165 0.227
No LS testing 
   10-yearly colonoscopy 308 112 1.084
LS testing 
   3-yearly colonoscopy 244 67 10.462 4.237
   2-yearly colonoscopy 235 66 10.462 5.669
   1-yearly colonoscopy 228 66 10.462 9.932
CRC - Colorectal Cancer; LS - Lynch Syndrome; LYG - Life-Years Gained; ACER - Average Cost-
Effectiveness Ratio; ICER - Incremental Cost-Effectiveness Ratio; D - Dominated.
a CRC cases and deaths include those from LS diagnosis until death.
b Costs and life-years gained were discounted at an annual rate of 3%.
c Include total costs of screening CRC index cases and their FDRs, including LS negative and 
non-participants.
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67.237 67.351 - - -
62.908 63.450 334 - Cost-Saving
53.048 65.629 722 5,610 D
51.441 64.738 741 3,160 3,160
49.743 65.172 753 4,105 36,951








67.237 67.578 - - -
62.908 64.534 334 - Cost-Saving
53.048 69.866 722 13,729 D
51.441 70.408 741 14,409 28,093
49.743 75.104 753 25,204 400,343








33.619 33.846 - - -
31.454 32.538 334 - Cost-Saving
26.524 41.223 722 22,365 D
25.721 41.852 741 22,850 32,610
24.872 45.266 753 30,351 291,020








100.856 101.083 - - -
94.362 95.446 334 - D
79.572 94.271 722 Cost-Saving D
77.162 93.294 741 Cost-Saving Cost-Saving
74.615 95.010 753 Cost-Saving 146,275
d Include costs of CRC screening, diagnosis and surveillance.
e Compared to no LS screening.
f Costs used for colonoscopies without polypectomy/with polypectomy.
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Colorectal cancer screening has the potential to prevent many colorectal cancer cases 
and deaths. In this thesis, we aimed to guide colorectal cancer screening policies using 
microsimulation modeling. Our analyses attempted to optimize colorectal cancer 
screening guidelines (Part I, Chapters 2-4), evaluate the cost-effectiveness of interventions 
that potentially increase screening participation (Part II, Chapters 5-8) and improve 
the detection and clinical management of Lynch syndrome patients (Part III, Chapter 
9-10). The main findings from the studies presented in this thesis are summarized 
below. Subsequently, methodological considerations, practical implications and future 
perspectives are discussed. This Chapter ends with conclusions and recommendations 




Colorectal cancer screening has been recommended by expert panels in the US for more 
than two decades.115 Recommendation panels regularly re-evaluate their guidelines 
due to epidemiological trends, newly developed tests and new evidence regarding 
the effectiveness or screening. Although overall colorectal cancer incidence has been 
declining for several decades, the incidence of colorectal cancer has been increasing since 
the mid-1980s in individuals below the age of 50 years.16 This fueled debate regarding 
the age to start screening. In 2018, the American Cancer Society (ACS) re-evaluated 
their colorectal cancer screening guidelines in light of the increasing incidence in the 
prescreening ages, for which they commissioned decision-analytic modeling from our 
group. 
Does the optimal screening strategy for the general population change when 
incorporating contemporary trends in colorectal cancer incidence?
 
In Chapter 2, we evaluated the optimal age to start screening, age to stop screening 
and the screening interval incorporating contemporary trends in young adults. The 
original version of the Microsimulation Screening Analysis-Colon (MISCAN-Colon) 
model, which was calibrated to 1975-1979 data, was adjusted by incorporating an 
incidence multiplier of 1.59 across all ages. This multiplier was based on the comparison 
of colorectal cancer incidence in the 1935 birth cohort (40-year-olds in 1975) and the 
1975 birth cohort (40-year-olds in 2015). We evaluated 132 screening strategies, which 
differed with respect to test modality, ages to start screening (40/45/50 years), ages 
to stop screening (75/80/85 years) and screening intervals (depending on screening 
modality). We used the number of colonoscopies as a proxy for resource utilization, and 
efficiency ratios (Δ colonoscopies / Δ life-years gained) to select model-recommended 
screening strategies. Our analyses demonstrated that because of the higher incidence, 
the benefits of screening for colorectal cancer increased, and consequently the balance 
of burden (colonoscopies) to benefit (life-years gained) improved. With the updated 
model, the efficiency ratio of 10-yearly colonoscopy screening from ages 45 to 75 years 




efficiency ratio thresholds. For the current 40-year-olds, the model-recommendable 
strategies were screening every 10 years with colonoscopy, every year with the Fecal 
Immunochemical Test (FIT), every 5 years with sigmoidoscopy or every 5 years with 
computed tomographic colonography (CTC) from ages 45 to 75 years. Therefore, 
the optimal screening strategies for the general population changed by incorporating 
contemporary trends in colorectal cancer incidence, now favoring colorectal cancer 
screening initiation at age 45 years rather than 50 years. 
What is the potential benefit and burden from earlier screening for black men and 
women versus whites? 
 
As colorectal cancer risk varies by race and sex, the influence of race and sex on optimal 
colorectal cancer screening strategies was explored in Chapter 3 using the MISCAN-
Colon model and the SimCRC model, developed by the University of Minnesota and 
Massachusetts General Hospital. As there was controversy around the mechanism for the 
increase in colorectal cancer incidence, two risk scenarios were evaluated: one based on 
the original race- and sex-specific models and one incorporating race- and sex-specific 
incidence rate ratios. Using a similar selection algorithm as used in Chapter 2, model-
recommendable screening strategies for white females, black females, white males and 
black males were evaluated. When using the original models, colonoscopy screening 
every 10 years from ages 50 to 75 years for whites and ages 45 to 75 years for blacks 
was optimal with MISCAN-Colon based on the efficiency ratio. However, colonoscopy 
screening from ages 45 to 75 years every 15 years was recommended by SimCRC for 
all population subgroups. Both models recommended annual FIT screening and CTC 
screening every 5 years as alternatives to colonoscopy screening. In the scenario where 
the increased risk was incorporated, both models recommended screening between 
age 45 and 75 years for all four demographic subgroups. Recommended screening 
modalities for all demographic subgroups were colonoscopy every 10 years, FIT every 
year, sigmoidoscopy every 5 years, and CTC every 5 years, except for white males, 
in whom MISCAN-Colon recommended colonoscopy every 5 years. Therefore, our 
analyses suggested that there is not a very strong rationale for an earlier start age of 
colorectal cancer screening in blacks than in whites, particularly if lifetime risks 
have increased similar to observed trends under age 40 years. For blacks and whites, 
recommendable strategies generally did not differ for men and women.
How do the rising colorectal cancer incidence and the increasing colorectal cancer 
treatment costs impact the optimal screening strategy from a cost-effectiveness 
perspective?
 
Cost-effectiveness analyses are commonly used to compare screening strategies, 
in which the incremental cost-effectiveness ratio (ICER) is used to evaluate which 
screening strategy is deemed optimal given the willingness-to-pay threshold. For all 
efficient strategies, the ICER represent the additional costs of saving one additional 
(healthy) life year compared to the next less effective efficient strategy. Costs were 
not included in the analyses presented in Chapters 2 and 3, as the ACS chose not to 
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apply cost as a decision-making criterion. Therefore, in Chapter 4, we evaluated the 
impact of the rising colorectal cancer incidence and the increasing colorectal cancer 
treatment costs on the cost-effectiveness of colorectal cancer screening. Four scenarios 
were evaluated, differing with respect to colorectal cancer incidence (with or without 
the incidence multiplier described above) and treatment costs (2007-2013 or 1998-
2003 Centers for Medicare and Medicaid Services(CMS) costs). Costs were evaluated 
from a healthcare sector perspective, with commercial cost estimates for individuals 
below age 65 years and CMS cost estimates for individuals ages 65 years and above. Our 
results demonstrated that the total costs of colorectal cancer in the absence of screening 
increased from $2.57 million to $5.87 million per 1,000 40-year-olds, an increase of 
128% compared to 1975-1979 incidence and 1998-2003 cost estimates. All strategies 
which used primary FIT screening are now cost-saving compared to no screening, as 
well as the large majority of guaiac fecal occult blood test strategies, 3 sigmoidoscopy 
screening strategies with an interval of 10 years, and colonoscopy screening from ages 
50 to 75 years every 15 years. Annual FIT screening from ages 40 to 85 years resulted in 
the highest benefit at acceptable incremental costs, with an ICER of $26,777 per quality-
adjusted life-year gained (QALYG). When the cost-effectiveness of colonoscopy-based 
screening strategies was compared, the cost-effectiveness of screening from ages 45 to 
75 years every 10 years was $38,695 per QALYG with the incidence multiplier and new 
treatment costs, which is lower than the estimate of $61,702 for colonoscopy screening 
every 10 years from ages 50 to 75 years without the incidence multiplier and old 
treatment costs. Therefore, as a result of the increasing incidence and treatment costs, 
the cost-effectiveness of colorectal cancer screening greatly improved, which further 
supports screening initiation at age 45 years rather than age 50 years in the US.
Interventions to improve adherence
In addition to having optimal screening guidelines, the effectiveness of any screening 
program greatly depends on the willingness of the target population to adhere to the 
guidelines. Previous analyses from our group estimated that approximately 58% of 
colorectal cancer deaths that will occur in 2020 can be attributed to the nonuse of 
screening.401 Therefore, many studies in the past decade tested interventions intended 
to increase colorectal cancer screening completion. In the second part of this thesis, we 
evaluated the cost-effectiveness of four potential interventions.
Under what circumstances is waiving all coinsurance for colorectal cancer screening in 
Medicare beneficiaries cost-effective?
 
The 2010 provisions of the Affordable Care Act require health plans to cover 
recommended preventive services without charging a deductible, copayment or 
coinsurance. However, due to a “loophole” in this legislation, financial barriers for 
colorectal cancer screening persist. Colonoscopies in which lesions are removed and 
colonoscopies that are performed as a diagnostic follow-up after a positive stool-based 
test are coded as “diagnostic” rather than “preventive”, and are therefore subject to a 
20% coinsurance. In Chapter 5, we evaluated the cost-effectiveness of waiving these 




FIT setting. Our results suggested that if waiving the coinsurance increases colonoscopy 
screening participation by 5 percentage-points, the number of colorectal cancer 
deaths would decrease by 6.4% while the total costs would increase by 1.2%. Given the 
uncertainty regarding the effect of this waiver on participation, we also determined the 
threshold increase in participation needed for this waiver to be cost-effective. Waiving 
all coinsurance would be cost-effective if it increased screening participation from 60% 
to 60.4% for a colonoscopy setting and from 60% to 60.3% in a setting where FIT is 
used as a primary screening modality. Therefore, the health benefits of the waiver would 
likely outweigh the additional costs.
For individuals who are unwilling to undergo FIT or colonoscopy screening, which 
screening strategy is a cost-effective alternative?
 
Other possible barriers for individuals to participate in screening are fear and disgust 
of the screening test. Therefore, new tests that try to circumvent these barriers have 
the potential to increase screening acceptance. In Chapter 6, we determined which 
currently available alternative screening test to FIT and colonoscopy is most promising 
from a cost-effectiveness perspective. The cost-effectiveness of screening with capsule 
endoscopy every 5 or 10 years, CTC screening every 5 years, the multi-target stool 
DNA (mtSDNA) test every 1 or 3 years, and the methylated SEPT9 DNA plasma assay 
(mSEPT9) every 1 or 2 years was compared from a societal perspective. None of these 
alternative tests were cost-effective compared to FIT or colonoscopy screening. When 
colonoscopy and FIT were not considered, CTC every 5 years, annual mSEPT9 and 
annual mtSDNA were efficient strategies with ICERs of $1,092, $63,253 and $214,974 
per QALYG, respectively. Under the assumption of perfect adherence, annual screening 
with the mSEPT9 resulted in higher benefits but 63% more colonoscopies and 26% 
higher costs than annual FIT screening. Therefore, our results suggested that for 
individuals that are unwilling to be screened with FIT or colonoscopy, annual screening 
with the mSEPT9 is the test of choice given its cost-effectiveness profile compared to the 
other alternative tests.
What are the optimal screening strategies for women willing to obtain some, but not all, 
US Preventive Services Task Force (USPSTF)-recommended screenings? 
 
For women above the age of 50 years in the US, not only screening for colorectal 
cancer is recommended, but also for cervical cancer, breast cancer and, for those with 
heavy smoking histories, lung cancer. Only one in three women obtain all guideline-
recommended cancer screening. Women might be time-limited or overwhelmed. 
Therefore, in Chapter 7, we sought to quantify optimal cancer screening strategies for 
women who were unwilling or unable to obtain all guideline-recommended screenings. 
For this study, we utilized the MISCAN models developed for breast cancer, cervical 
cancer, colorectal cancer and lung cancer.246,270,272 We stratified women based on their 
eligibility for lung cancer screening, and evaluated 45 different screening strategies 
combining breast, cervical, colorectal and/or lung cancer screenings, restricted to 1, 2, 
3, or 4 screenings per year. Our results suggested that it is possible to reduce screening 
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intensity to one test per year in women ineligible for lung cancer screening and to 
two tests per year in women eligible for lung cancer screening while maintaining 94% 
and 97% of life-years gained, respectively, compared to full compliance to all USPSTF 
cancer screening guidelines. Screening for a variety of cancers, but less often than 
recommended, was more effective than to screen only for specific cancers. For women 
eligible for lung cancer screening, lung cancer screening should be the top priority, as 
strategies omitting it provided ≤25% life-years gained compared to full compliance to 
all USPSTF cancer screening guidelines.
Would it be cost-effective to include the FIT kit in the screening invitation letter in 
France?
 
US studies suggest that mailing stool-based tests to individuals eligible for colorectal 
cancer screening is the most effective way to increase screening participation.312 
Several countries with organized screening programs, such as the Netherlands, already 
disseminate FIT kits using this method. However, in France, a letter is sent by mail that 
invites individuals to collect the FIT kit at their general practitioner’s office. In 2016, 
only 29% of French individuals invited for colorectal cancer screening participated, 
which is much lower than participation in surrounding countries/regions such as the 
Netherlands (73%), Basque country (72%) and Flanders (55%).402 In Chapter 8, we 
estimated the potential benefits and costs of including the FIT in the invitation letter in 
France. We simulated the French population ages 35 to 75 years in 2018, incorporating 
historical screening, and followed them for a life time. If participation increased to 60% 
as a result of the change in invitation method, there were 11% fewer colorectal cancer 
deaths, 6% fewer cases, 42% more QALYG and a 2.2% increase in costs, resulting in an 
ICER of €1,510 per QALYG. Mailing out the FIT needs to increase participation by only 
0.5 percentage point for it to be cost-effective (willingness-to-pay threshold of €30,000 
per QALYG). Therefore, including the FIT in the invitation letter is likely a very cost-
effective intervention to increase participation in colorectal cancer screening in France.
Screening and subsequent steps for Lynch syndrome patients
Approximately 3% of all colorectal cancer patients have a germline mutation in one of 
the mismatch repair genes (MLH1, MSH2, MSH6, PMS2 or EPCAM). These individuals 
have Lynch syndrome, which is the most common familial colorectal cancer syndrome. 
By sequencing the DNA of first-degree relatives of Lynch syndrome patients (= 
cascade testing), individuals that carry these mutations can be identified before clinical 
manifestation. These asymptomatic first-degree relatives with Lynch syndrome have an 
increased risk to develop several cancers, among them colorectal cancer (42% before age 
80 years), and, for women, endometrial cancer (35% before age 80 years).37 Identifying 
mutation carriers before they develop symptoms gives them the opportunity to take 




Is it cost-effective to screen colorectal cancer cases for Lynch syndrome, and what is 
the optimal surveillance interval for first-degree relatives identified through cascade 
testing?
 
The province of Ontario, Canada, was considering to implement Lynch syndrome 
testing for all colorectal cancer cases under age 70 years using immunohistochemistry. 
In Chapter 9, we developed a patient flow diagram to determine costs and yield of 
immunohistochemical testing for Lynch syndrome in colorectal cases and, for those 
found to have Lynch syndrome, their first-degree relatives, accounting for realistic 
uptake. Subsequently, we compared costs and benefits of annual, biennial, and triennial 
surveillance in asymptomatic Lynch syndrome cases. We estimated that testing 1,000 
colorectal cancer cases would result in identifying 20 colorectal cancer cases and 29 
asymptomatic first-degree relatives with Lynch syndrome at a cost of CA$310,274. The 
benefit of identifying these asymptomatic mutation carriers depends on the colonoscopy 
surveillance interval offered to these individuals. Offering these first-degree relatives 
biennial colonoscopy surveillance was optimal from a cost-effectiveness perspective, 
as it resulted in a favorable ICER of CA$8,785 per life-year gained due to a substantial 
increase in life-years gained (+122%). The total costs of biennial surveillance were lower 
than those of triennial surveillance due to cost savings in colorectal cancer care. Annual 
colonoscopy surveillance provided little benefit compared to biennial surveillance at a 
much higher cost, resulting in an ICER of CA$218,647 per life-year gained. Therefore, 
the results of our study suggested that immunohistochemical testing for Lynch syndrome 
in colorectal cancer cases followed by cascade testing is very cost-effective, and that 
biennial colonoscopy surveillance is optimal for asymptomatic Lynch syndrome cases.
What are the optimal age thresholds for offering prophylactic hysterectomy to 
asymptomatic women identified with Lynch syndrome from a cost-effectiveness 
perspective?
 
Another preventive measure that can be taken by women with Lynch syndrome is 
prophylactic hysterectomy. In Chapter 10, we evaluated the costs and benefits of 
this preventive measure. The MISCAN Endometrial model was developed, which 
incorporated the natural history for the development of hyperplasia with and without 
atypia into endometrial cancer. We simulated women identified with Lynch syndrome 
through the steps described in Chapter 9. We estimated costs and benefits of offering 
this cohort prophylactic hysterectomy, accounting for a reduced quality of life after 
prophylactic hysterectomy due to premature menopause, and for having endometrial 
cancer. Three minimum ages (30/35/40 years) and three maximum ages (70/75/80 years) 
were compared. When adjusting for quality of life, only strategies with a minimum age 
of 40 years were efficient. Lower minimum ages increased the total costs and resulted in 
fewer QALYG in women with Lynch syndrome. Prophylactic hysterectomy for women 
aged 40-70 years, 40-75 years and 40-80 years resulted in ICERs of $22,017, $57,869 and 
$86,105 per QALYG, respectively. Therefore, prophylactic hysterectomy for women with 
Lynch syndrome aged 40 to 80 years is optimal from a cost-effectiveness perspective. 
However, women may consider performing prophylactic hysterectomy at age 35 years, as 
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the optimal age range was heavily depended on the impact of prophylactic hysterectomy 
on quality of life, which differs vastly between patients
Methodological considerations
All studies presented in this thesis used the MISCAN-colon model to simulate the 
effects of colorectal cancer screening policy changes. In addition, the study described in 
Chapter 7 used three other MISCAN cancer models. The value of these models has been 
internationally recognized as policy makers from around the globe request analyses 
with these MISCAN models to inform their cancer screening programs. The MISCAN-
colon model has been used to guide public health research and policies for over two 
decades. However, the findings presented in this thesis should be interpreted in light of 
several limitations. 
Limitations in the model structure of MISCAN-colon
There are two major limitations regarding the structure of the MISCAN-colon model. 
First, the natural history module of MISCAN-colon only includes the adenoma-
carcinoma sequence as a carcinogenic pathway. The serrated pathway, which may 
account for up to one-third of all colorectal cancers, has not been incorporated. There 
is great uncertainty regarding the progression risk, detectability and recurrence risk 
of sessile serrated lesions, which is why incorporating this pathway is challenging 
and would require making several assumptions. Nevertheless, not incorporating this 
pathway might have impacted the results presented in this thesis. In Chapters 2, 3, 4 
and 6 of this thesis, different screening modalities were compared. These tests might 
have different test sensitivities for the lesions in the serrated pathway. In particular, it 
has been described that the multi-target stool DNA test has an increased sensitivity for 
sessile serrated lesions compared to the FIT,72,403 which was not captured in our analyses. 
This potentially underestimates the cost-effectiveness of the multi-target stool DNA 
test compared to the other evaluated screening modalities. Second, the progression 
rates of adenomas do not vary by location in MISCAN-colon. This implies that the 
distribution of adenomas and cancers by location are identical. However, from autopsy 
studies, we know that the fraction of distal adenomas (approximately 40%) is smaller 
than the fraction of distal cancers (63%), suggestion a faster adenoma progression rate 
for distal compared to proximal adenomas. As we simulate a relatively high proportion 
of adenoma in the distal colon or rectum, our estimates of the (cost-)effectiveness of 
sigmoidoscopy screening in Chapters 2-4 might be too optimistic. 
Uncertainty in model parameters
As for any type of modeling analysis, the accuracy of our predictions depends on the 
accuracy of the data used to inform our model. Unfortunately, not all parameters in the 
model can be directly informed by empirical data. For those parameters, we have to 
make assumptions. Six assumptions that potentially impact the results from our analyses 
are noteworthy. First, the current background risk of colorectal cancer in the general 




In response to the increasing incidence observed in the prescreening ages, which has 
been identified as a cohort effect,16 we assumed a 59% increase in background colorectal 
cancer incidence compared to 1975-1979 data across all ages in Chapters 2, 3, 4 and 
6; the analyses presented in Chapter 5 were finalized before the landmark publication 
of the increasing incidence. The assumed background colorectal cancer incidence 
is an important driver of the cost-effectiveness of screening. In retrospect, we likely 
underestimated the benefits of the coinsurance waiver in Chapter 5. The true magnitude 
of the increase in colorectal cancer incidence above the age of 50 years is uncertain, and 
will be difficult to assess due to the high uptake of screening in these ages. Second, the 
risk of developing colorectal cancer and endometrial cancer for Lynch syndrome patients 
is uncertain, and varies greatly between studies. In Chapters 9 and 10, we calibrated our 
models to the largest study that accounted for ascertainment bias.37 However, results 
of Chapters 9 and 10 indicate that the assumed risks impact the cost-effectiveness of 
screening and subsequence steps for Lynch syndrome patients. Third, the version of 
the MISCAN-colon model used in the Chapter 3 assumed a difference in background 
colorectal cancer risk between whites and blacks. However, a recent comprehensive 
review of the literature from our collaborators concluded that the primary driver of 
differences in colorectal cancer incidence and mortality by race is access to screening 
and subsequent care, rather than biological differences in natural history.404 This further 
questions differential screening recommendations by race even without assumed 
increases in risk since the 1990s. Fourth, studies suggest that test performance in repeat 
stool-based screening is not independent like we assumed in all analyses presented in 
this thesis.238,405 If adenomas do not bleed over several years, they will cause systematic 
false-negative FIT results. A previous analysis from our group showed that the impact of 
assuming correlation of outcomes in repeat FIT screening rounds is likely to be modest.238 
However, systematic false-negativity might not be restricted to stool-based screening 
tests. The proportion of adenomas and cancers that are systematically missed by the 
different screening modalities might impact their relative (cost-)effectiveness. Fifth, no 
studies provide information on long-term adherence patterns required to accurately 
model realistic adherence. Given the limited evidence to inform long-term adherence 
patterns and the variability in estimates of short-term adherence rates, simulating the 
impact of imperfect adherence required numerous assumptions. Reflecting the goal of 
estimating the impact of screening among average risk persons who are willing to be 
screened for colorectal cancer, we assumed perfect adherence in the studies described 
in Chapter 2, 3, 4 and 6. This implies that the estimated effects of colorectal cancer 
screening are unrealistic. Lastly, important drivers of the cost-effectiveness of colorectal 
cancer screening are the costs of the screening tests and the costs of treatment. Not all 
cost parameters could be based on national US estimates. For example, we assumed 
costs from a CMS perspective in Chapters 5 and 6. Those costs are substantially lower 
than those for individuals with private insurance. We tried to account for this in the 
analyses presented in Chapter 4 by using a multiplier for individuals below age 65 years. 
However, this multiplier is based on costs of screening tests only, not treatment. 
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Considerations with outcome metrics used
The optimal measures to compare the effects of colorectal cancer screening policies 
are somewhat arbitrary. First, the optimal measure of benefit is debatable. According 
to panel recommendations,109 the QALYG is the optimal measure of benefit. However, 
in Chapters 2, 3, 7 and 9, we did not account for quality of life, and used life-years 
gained as a measure of benefit. Accounting for quality of life requires making several 
subjective assumptions about, for example, the burden of a particular screening test, 
as these are often unknown. Using (quality-adjusted) life-years gained as the primary 
measure of benefit accounts for a larger gain in life expectancy from, for example, 
preventing a colorectal cancer death in a 53-year-old individual compared to a 73-year-
old individual. However, it also implies that, when assuming an average life expectancy 
of 83, saving three 73-year-olds gets the same weight as saving one 53-year-old. This 
may be ethically questionable. Using cases and deaths prevented gives the same value 
to every life saved, might be easier to interpret for clinicians and patients, and these 
were also provided as secondary outcomes for most analyses. Second, the measure 
of cost or burden varied between the different studies presented in this thesis. Panel 
recommendations suggest reporting costs both from a health care sector perspective 
and from a societal perspective.109 In practice, performing analyses from a societal 
perspective can be challenging and requires a lot of assumptions. We attempted 
obtaining cost estimates from a societal perspective for Chapter 6, but only analyzed 
a health care sector perspective in Chapters 4, 5, 8, 9 and 10. As per the request of the 
ACS, the number of required colonoscopies was used as the measure of the burden of 
screening in Chapters 2 and 3. This was chosen because colonoscopy is the only burden 
shared by all modalities. However, this does not assign any burden to a non-colonoscopy 
screening test, making comparisons across different modalities impossible. Especially 
when individuals need to undergo bowel preparation for their primary screening test 
(as with sigmoidoscopy and CTC) this burden is not negligible. Lastly, the incremental 
burden-to-benefit ratios used in this thesis have limitations. In Chapters 2 and 3, the 
efficiency ratio ((Δ colonoscopies / Δ life-years gained) was used. This ratio does not 
have a commonly accepted threshold. The ICER, used in other Chapters of this thesis, 
also has limitations. The so-called willingness-to-pay threshold is not set in stone. 
Furthermore, ICERs are influenced by the other strategies evaluated in a study. This 
is illustrated by comparing results in Chapters 4 and 6, where 10-yearly colonoscopy 
screening was cost-effective compared to FIT in the latter, but not in the former due to 
the limited number of strategies evaluated in Chapter 6. 
 
Practical implications
Despite the limitations described in the section above, the studies presented in this 
thesis may be of great value to policy makers.
Start colorectal cancer screening at age 45 years in the US
The studies presented in Chapters 2 and 3 of this thesis were instrumental for the 2018 




modeling analyses, the increased disease burden in individuals below age 50 years 
and the reasonable expectation that screening will perform similarly in individuals 
aged 45-49 as in those above age 50, the ACS included a qualified recommendation to 
start screening at age 45 years.78 It has been estimated that if the current age-specific 
screening rates shift to 5 years earlier, this change in legislation will prevent 29,400 
colorectal cancer cases and 11,100 colorectal cancer deaths over the next 5 years.152 
The recommendation to start screening at age 45 years in the US has sparked intense 
debate. Despite the substantial health benefits, opponents argue that it may divert 
limited resources away from higher-priority areas, such as unscreened elderly patients.406 
Although colonoscopy constraints may not be a problem for the US as a whole,407 they 
most likely are for some areas or individuals. Furthermore, colorectal cancer health 
disparities might increase. As the colonoscopy demand of the commercially insured 
45 to 49-year-olds expands, adults with Medicaid or Medicare insurance may be given 
lower priority as those reimbursements rates are lower.408 Insurers are currently not 
required to cover colorectal cancer screening below age 50 years, which means that 
the 45-year-olds that currently get screened are likely those with a high socioeconomic 
status. A potential solution for areas with a limited colonoscopy capacity would be to 
use FIT as a primary screening test rather than colonoscopy. This is supported by our 
analyses presented in Chapter 4, which demonstrate that annual FIT screening from 
ages 45 to 80 years results in a higher number of (QA)LYG than colonoscopy screening 
every 10 years from ages 50 to 75 at a lower cost and colonoscopy demand. 
Despite the fact that the ACS is the only organization that recommends colorectal 
cancer screening initiation at age 45 years for average-risk individuals, CRC test use 
among 45 to 49-year-olds has been increasing. According to data from the National 
Health Interview Survey (NHIS), utilization rates in this age group increased from 
4.8% in the first quarter to 11.7% in the last quarter of 2018, coinciding with the release 
of the ACS guidelines.183 The USPSTF is currently updating their colorectal cancer 
screening guidelines.409 A potential change in their guidelines will probably have an 
even larger impact on screening rates due to the mandate for insurers to cover USPSTF 
recommendations graded A or B. Similar to their previous updates in 2008 and 2016, 
the USPSTF requested analyses from all three CISNET modeling groups to help inform 
their updated guidelines. 
Remove financial barriers for screening participation
In most countries, there is some financial barrier for screening participation, either in 
the form of copays or deductibles. In the Netherlands, the deductible applies to the 
diagnostic follow-up colonoscopy after a positive FIT. Individuals in the Netherlands 
have deductibles between €385 to €885 depending on their health care plan, suggesting 
a potential financial barrier for individuals to get a follow-up colonoscopy. In the US, 
due to a “loophole” in the law, screening colonoscopies with polyp removal or follow-up 
for another test can be coded as “diagnostic” rather than “screening” and are therefore 




Our analyses in Chapter 5 demonstrate that removing this coinsurance requirement 
in the US is most likely a cost-effective way to increase screening participation. Given 
the waiver may primarily affect the out-of-pocket costs of Medicare beneficiaries from 
low socioeconomic status background, who more often lack supplemental insurance, it 
may also contribute to reducing colorectal cancer health disparities in the US. Results of 
our study have been used by advocates to convince members of congress to change this 
legislation. Flyers describing the main findings of our study were distributed at the 11th 
call-on congress, an annual event organized by Fight Colorectal Cancer. Bills have been 
introduced since the 2011-12 sessions of Congress to address this loophole. The current 
bills (H.R.1570 and S.668) were introduced in March 2019 in the house and the senate, 
respectively, but haven’t moved forward as of today. 
Send out the FIT by mail to those eligible for screening
Our analyses in Chapter 8 suggest that including the FIT kit in the invitation letter in 
France is very likely a cost-effective way to increase screening participation. Our study 
is not only informative for France, but also for other countries facing similar screening 
barriers. Mailing the FIT kits has been suggested as a way to improve colorectal cancer 
screening worldwide.410 In the US, where there is largely opportunistic screening, sending 
out the FIT by mail to those eligible has been identified as the most effective way to 
increase screening participation.312 Furthermore, participation among beneficiaries of 
the Kaiser Permanente Northern California health plan increased from 40% in 2006 to 
83% in 2015 following a switch towards programmatic screening using mailed-out FITs.411 
Extending programmatic screening using FIT outreach would also imply an increased 
uptake of FIT screening compared to other screening modalities, which is supported by 
our results in Chapter 4 favoring FIT screening from a cost-effectiveness perspective. 
Discuss alternative screening options for those not willing to participate
Chapter 6 suggests that for individuals that are not willing to be screened with 
colonoscopy or FIT, screening with the mSEPT9 is a cost-effective alternative. This 
implies that colorectal cancer screening guidelines should be reevaluated, as from a 
cost-effectiveness perspective, there is no rationale to recommend the CTC, capsule 
endoscopy and mtSDNA while not recommending the mSEPT9 as an alternative to FIT 
or colonoscopy. The mSEPT9 has the potential to attract the population that currently 
does not want to participate in screening. It just requires a blood sample, and might be 
administered during primary care visits. Some individuals might prefer this test over 
collecting a stool sample or a more invasive test. A previous study identified an increased 
uptake of a blood-based test compared to a stool-based test among individuals overdue 
for screening,239 and another study found that among people who declined stool-based 
tests, there was a 25% uptake of a blood-based test,240 demonstrating its potential. 
However, the mSEPT9 might not be the best alternative in every setting. For example, 
due to its relatively low specificity, it requires a high number of follow-up colonoscopies, 
which might not be warranted in settings with a limited capacity.
One potential reason for women not to participate in colorectal cancer screening might 




results from Chapter 7 suggest that less frequent screening than recommended can 
still result in the majority of the benefits if 1) those who are eligible participate in lung 
cancer screening and 2) women select screening for a variety of cancers although less 
frequently than recommended rather than screening only for some cancers. According 
to 2015 NHIS data, current percentages up to date are 4% for lung (in those eligible), 
57% for colorectal, 87% for cervical and 71% for breast cancer screening in those above 
age 50 years, which does not align with predicted benefits. Lung cancer screening has the 
highest benefits for those eligible, and the benefits of colorectal cancer screening exceed 
those of breast cancer screening and cervical cancer screening. Therefore, physicians 
should be discussing priorities and less-intensive cancer screening schedules for women 
if this helps increasing their likelihood of participating in those cancer screenings that, 
given their screening history, result in the highest expected benefit.
Implement Lynch syndrome testing for all colorectal cancer cases below age 
70 years
Our analyses presented in Chapter 9 suggest that implementing Lynch syndrome 
testing for colorectal cancer cases below age 70 years using immunohistochemistry and 
subsequently testing first-degree relatives if positive for Lynch syndrome is very cost-
effective. Our study used data from Ontario, Canada, as they considered implementing 
screening for Lynch syndrome. Important barriers that have been identified for the 
implementation in Canada are the education of stakeholders and concerns regarding 
resources such as laboratory costs and workload for pathologists.341 Our study provides 
data that may help overcome these barriers.
Although implementation of a population-based program for Lynch syndrome 
screening is recommended by expert panels,340 it is still not universally implemented 
in many countries worldwide. A recent survey performed among institutions in the 
US, Canada, Europe and Australia suggest an encouraging 86% uptake, of which 76% 
used primary immunohistochemistry.412 Results of our study urge policymakers and 
clinicians worldwide to increase the implementation of universal Lynch syndrome 
testing using primary immunohistochemistry. 
Offer Lynch syndrome cases biennial colonoscopy surveillance and 
prophylactic hysterectomy
Chapters 9 and 10 suggest that Lynch syndrome patients should undergo biennial 
colonoscopy surveillance and prophylactic hysterectomy from a cost-effectiveness 
perspective. These preventive measures greatly reduce colorectal and endometrial cancer 
mortality in Lynch syndrome patients. The study presented in Chapter 9 was the first 
cost-effectiveness analysis that evaluated different colonoscopy surveillance intervals 
in Lynch syndrome cases identified by primary immunohistochemical testing. No 
randomized-controlled trials have been performed that compare different surveillance 
intervals, and it is difficult to compare interval cancer rates between observational studies 
due to different methodologies.368 Therefore, the optimal colonoscopy surveillance 
interval for Lynch syndrome patients is a topic of intense debate.351 Our modeling study 
provides insights that can be used to inform surveillance guidelines internationally.
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Current guidelines recommend to offer prophylactic hysterectomy to women with Lynch 
syndrome from age 40 or when childbearing has completed.368 This is in line with the 
results from our study presented in Chapter 10, suggesting prophylactic hysterectomy 
for women aged 40 to 80 years is cost-effective. Our study further underlines the 
importance of implementing universal Lynch syndrome screening of colorectal cancer 
patients and subsequent cascade testing to improve future prospects of these patients 
in terms of life expectancy and quality of life. Furthermore, our results can inform 
physicians and women with Lynch syndrome regarding the decision whether or not 
to perform prophylactic hysterectomy and from which age, which is especially helpful 
given the preference-sensitive nature of the decisions these patients are facing.
Future perspectives
Colorectal cancer screening is a rapidly evolving field. Four areas are of particular 
interest with respect to the studies presented in this thesis. The character of the 
increase in colorectal cancer incidence in prescreening ages has only been recognized 
a few years ago, fueling many ongoing studies. Our understanding of the role of the 
serrated polyp pathway in colorectal cancer is rapidly increasing. Furthermore, our 
knowledge about (genetic) risk factors for colorectal cancer has substantially increased 
in recent years, potentially opening the door for personalized screening. Lastly, with 
the increased implementation of routine screening for Lynch syndrome, we better 
understand the cancer risks associated with the different mismatch repair mutations. 
These research areas, their expectations for the near future and potential contributions 
of microsimulation modeling are described below.
The driver(s) of the increasing colorectal cancer incidence observed in the 
prescreening ages
While most experts agree that the trends in colorectal cancer incidence are concerning 
and warrant investigation, there is disagreement on the underlying causes. Several 
studies mention the increase in obesity, a known risk factor, as a possible explanation, 
but there is contrasting evidence about this hypothesis. A large prospective female US 
cohort study found an association between obesity and early-onset colorectal cancer.413 
However, two recent retrospective studies did not confirm this association and pointed 
towards an important role for non-modifiable risk factors,414 alcohol consumption 
and specific dietary components.415 Furthermore, a recent analysis looking at US state 
variation demonstrated no correlation between obesity and heavy alcohol consumption 
trends and early-onset colorectal cancer trends.416 Importantly, the increase in colorectal 
cancer incidence is stronger in whites than in blacks,16 whereas obesity prevalence 
has risen more rapidly in blacks than in whites.417 A limitation of these studies is that 
risk factor trends are assessed in isolation, while a more comprehensive approach is 
needed.99 A complicating factor is that in the US, the increase is stronger in rectal cancer 
compared to distal colon cancers and proximal colon cancers,16 while in Europe it is the 




Microsimulation modeling provides a window into unobserved data, and is a useful 
tool to inform ongoing debates. For example, our models can be used to evaluate if 
background colorectal risk is also increasing in individuals above age 50 years by 
adjusting for the increased uptake of screening in those ages. Furthermore, we can 
estimate what fraction of the increasing incidence can be explained by specific risk factors 
by incorporating those into our model, accounting for their prevalence over time and 
relative risk estimates. Understanding the etiology of the increasing incidence is critical 
for accurate assessment of the benefits, harms and costs of colorectal cancer screening. 
The sessile serrated polyp pathway for colorectal cancer
The sessile serrated polyp pathway to colorectal cancer was postulated more than two 
decades ago. It accounts for up to 30% of all colorectal cancers.418 However, unlike 
adenomatous polyps (their more common counterparts), we have only recently been 
able to gather data about their outcomes and natural history. Researchers in our group 
recently conducted a systematic review to determine the prevalence, clinical features, 
and progression risk of sessile serrated polyps.419 Interestingly, sessile serrated polyps 
are more likely to be located in the proximal colon compared to typical adenomas. 
Furthermore, among individuals with a sessile serrated polyp, a smaller proportion is 
diagnosed with multiple sessile serrated polyps compared to individuals with a typical 
adenoma. However, approximately half of individuals with a sessile serrated polyp 
also have conventional adenomas. Another interesting finding is the apparent lack of 
a relationship between age and sessile serrated polyp prevalence, which is in sharp 
contrast to the strong positive correlation between age and adenoma prevalence.
Despite the remaining uncertainty, we have now gained sufficient knowledge about the 
sessile serrated polyp pathway to start including it into our microsimulation model. 
The inclusion of this carcinogenic pathway in our model will help unravel its natural 
history. For example, it can be used to explore to what extent the apparent faster 
disease progression of sessile serrated polyps stems from poorer visibility, and how 
the progression risk relates to its size and multiplicity. Including this pathway in our 
model may have important implications for our estimates on the (cost-)effectiveness of 
colorectal cancer screening, and on the relative performance of different screening tests.
Personalizing colorectal cancer screening based on risk factors
The majority of individuals who participate in screening (approximately 94%) 
will never develop colorectal cancer, but do experience the burden and potential 
harms. Ideally, we would be able to identify those individuals that will benefit from 
resource-demanding colorectal cancer screening strategies. The most comprehensive 
risk prediction model today has been developed by the Fred Hutchinson Cancer 
Research Center, Seattle, WA, US. This colorectal cancer risk prediction model was 
generated using data from 40,000 colorectal cancer patients and 46,000 controls, 
and includes family history, 63 genetic, and 19 environmental (including lifestyle) 
factors.420 In addition, it has been validated against a community-based cohort of 
>100,000 participants (manuscript in preparation), and has a current discriminative 
accuracy of 0.652. As the optimal age to start and stop screening, screening interval 
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and screening test are influenced by individual risk, this risk prediction model can 
be utilized to personalize screening recommendations. For example, in an individual 
with an unhealthy lifestyle and many high-risk alleles in his DNA, the screening 
recommendation might be a colonoscopy every 5 years from ages 40 to 80, while an 
individual with a healthy lifestyle and few high-risk alleles, screening every 2 years 
from ages 60 to 70 with a stool-based test might provide the best benefit-to-harm ratio. 
The translation of genetic- and environmental risk factors to risk-tailored screening 
recommendations can be performed using microsimulation modeling.118 Interestingly, 
previous exploratory analyses from our group suggested that with an AUC of 0.65 
based on genetics only, risk-stratified colorectal cancer screening can be cost-effective 
when the costs of a polygenic test are below $291.421 Risk-differentiation based on both 
environmental and genetic risk information can likely achieve even better results. In an 
ongoing collaboration with the Fred Hutchinson Cancer Research Center, we combine 
the strengths of their unparalleled risk prediction model and our microsimulation model. 
This collaboration has the potential to accelerate the translation of contemporary genetic 
and epidemiologic research into changes in clinical practice and advances in public health.
Another option for personalizing screening recommendations in FIT-based programs, 
is by using absolute hemoglobin levels as risk predictors. Results from the Dutch 
program (cut-off = 47 μg/g feces) revealed that individuals with a hemoglobin level 
between 15 and 47 μg/g feces in the first round were 23 times more likely to have an 
advanced neoplasia detected in the second round compared to those with 0 μg.230 This 
demonstrates that the amount of hemoglobin detected in the stool is a strong predictor 
for future cancer risk. While using hemoglobin levels does not allow for personalization 
of the start age of screening, it has the advantage that this information is already 
present in registries and does not require additional resources. Our group will develop 
a risk prediction model based on age, sex, geographical location and fecal hemoglobin 
concentration and identify optimal risk-based screening strategies using our 
microsimulation model. Subsequently, a randomized controlled trial will be performed 
within the Dutch colorectal cancer screening program to demonstrate feasibility, 
acceptability and superiority of risk-tailored screening compared to uniform screening. 
Mutation-specific surveillance of Lynch syndrome patients
The risks of developing colorectal cancer, endometrial cancers and various other cancers 
for Lynch syndrome patients depend on which mismatch repair gene is mutated.369 The 
lifetime risk to develop colorectal cancer is estimated between 30% and 74% for MLH1 
and MSH2 gene mutation carriers, between 10% and 22% for MSH6 gene mutation 
carriers, and between 15% and 20% in PMS2 mutation carriers. Furthermore, risk in 
males is higher than in females. How carcinogenic pathways differ by mutation is poorly 
understood. A recent study identified that CTNNB1 is frequently mutated in tumors of 
MLH1 mutation carriers, whereas APC is more frequently mutated in tumors of MSH2 
mutation carriers.422 Interestingly, in this study that included 2747 Lynch syndrome 
patients, MSH2 mutation carriers had an increased risk of developing (advanced) 




risk was the same.422 Based on these findings, the authors hypothesized that MSH2-
associated cancers may have developed from an accelerated adenoma-carcinoma 
sequence, whereas a substantial proportion of MLH1-associated cancers may have 
derived without prior polyp formation through an immediate invasive pathway 
arising from mismatch-repair deficient crypts.423 This implies that the effectiveness of 
colonoscopy surveillance might depend on which mismatch repair gene is mutated.
Apart from the recent UK guidelines that recommend colonoscopy surveillance from 
age 25 years for MLH1 and MSH2 mutation carriers and from age 35 years for MSH6 and 
PMS2 mutation carriers,424 surveillance guidelines in general are not mutation-specific. 
Offering colonoscopy surveillance every two years to MSH6 and PMS2 mutation carriers 
while offering colonoscopy surveillance every five years to individuals with a family 
history in whom no driver mutation has been identified (lifetime risk between 14% 
and 30%) seems illogical, as their lifetime risk is comparable. Microsimulation models 
can be a useful tool to translate the most recent knowledge about gene-specific cancer 
risk and natural history to personalize surveillance start ages, stop ages and intervals 
in Lynch syndrome patients. In the analyses presented in Chapter 9, we evaluated a 
range of 30%-60% risk of developing colorectal cancer before age 80, and revealed that 
an individual’s optimal surveillance interval is strongly influenced by an individual’s 
lifetime risk. We anticipate that gene-specific surveillance recommendations will be 
implemented in the future.
Conclusions
Considering all of the above, the following conclusions can be drawn based on the 
studies presented in this thesis:
As a result of the increase in colorectal cancer incidence observed in young adults, 
screening initiation at age 45 years rather than age 50 years in the US has a favorable 
balance between screening benefits, burden and costs.
The optimal screening ages for individuals in the US are not influenced by race and 
sex under assumed increases in background risk.
The increase in colorectal cancer incidence in young adults and the increase in 
colorectal cancer treatment costs greatly improved the cost-effectiveness of 
colorectal cancer screening.
Only colorectal cancer screening strategies that use FIT as a primary screening test 
are cost-effective.
Waiving the coinsurance for all colonoscopy procedures has a favorable balance of 
health and cost impact.
For individuals that are not willing to participate in colorectal cancer screening 
using FIT and colonoscopy, annual screening with the mSEPT9 is the test of choice 
given its cost-effectiveness profile compared to the other alternative tests.
Women unable or unwilling to obtain all guideline-recommended cancer 
screenings may be able to reduce screening intensity with limited impact on overall 
benefits, but should go for lung cancer screening if eligible.
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Lung cancer screening in eligible women has greater benefit than colorectal, 
cervical and breast cancer screening.
It is more valuable for women to obtain a variety of cancer screenings even if less-
often than recommended, than to screen for some cancers but skip others entirely.
Including the FIT in the invitation letter is a very cost-effective intervention to 
increase colorectal cancer screening participation.
Immunohistochemical testing for Lynch syndrome in persons younger than 70 
years with a colorectal cancer diagnosis, and then testing first-degree relatives of 
those found to have Lynch syndrome, provides a good balance between costs and 
long-term benefits.
Colonoscopy surveillance every 2 years is the optimal surveillance interval for 
patients with Lynch syndrome.
Prophylactic hysterectomy in Lynch syndrome women aged between 40 and 80 
years is cost-effective from a population perspective.
The earliest age to recommend prophylactic hysterectomy in women with Lynch 
















































































Since colorectal cancer incidence in the prescreening ages is increasing, one should 
consider recommending screening from ages 45 to 75 years.
Colorectal cancer screening guidelines need not to be differentiated by race and 
sex.
Average-risk individuals should be encouraged to use the FIT for colorectal cancer 
screening for an optimal balance between resources and benefits.
Health insurance programs should consider removing all coinsurance 
requirements for colorectal cancer screening, as this will likely have a very 
favorable balance between health and cost impact.
Physicians should offer annual screening with the mSEPT9 to individuals not 
willing to undergo FIT or colonoscopy.
General practitioners need to discuss alternative, less intensive, screening 
strategies if women are not willing to perform all guideline-recommended 
cancer screenings, and help them decide on an appropriate strategy.
The French government should consider mailing the FIT to the population eligible 
for colorectal cancer screening, rather than inviting them to collect the test at the 
general practitioner.
In settings with sufficient resources, all colorectal cancer cases below the age of 70 
years should be tested for Lynch syndrome using immunohistochemistry.
Lynch syndrome patients should be advised to undergo biennial colonoscopy 
surveillance.
Prophylactic hysterectomy should be offered to women with Lynch syndrome aged 






MISCAN-Colon is a stochastic, semi-Markov, microsimulation model for colorectal 
cancer (CRC) programmed in Delphi (Borland Software Corporation, Scotts Valley, 
California, United States). It can be used to explain and predict trends in CRC incidence 
and mortality and to quantify the effects and costs of primary prevention of CRC, 
screening for CRC, and surveillance after polypectomy. The term ‘microsimulation’ 
implies that the individuals are moved through the model one at a time, rather than as 
proportions of a cohort. The term ‘semi-Markov’ implies that MISCAN-Colon, unlike 
traditional Markov models, does not assume annual state transitions; instead it generates 
durations in states, allowing future state transitions to depend on past transitions, and 
thereby increases model flexibility and computational performance. The term ‘stochastic’ 
implies that the model determines the states and corresponding durations by drawing 
from probability distributions, rather than using fixed values. Hence, the results of the 
model are subject to random variation. MISCAN-Colon consists of three modules: a 
demography module, natural history module, and screening module.
Demography module
Using birth- and life-tables representative for the population under consideration, 
MISCAN-Colon draws a date of birth and a date of non-CRC death for each individual 
simulated. The maximum age an individual can achieve is assumed to be 100 years.
Natural history module
Transitions
As each simulated person ages, one or more adenomas may develop (Figure 1). These 
adenomas can be either progressive or non-progressive. Both progressive and non-
progressive adenomas can grow in size from small (≤5mm), to medium (6-9mm), 
to large (≥10mm); however, only progressive adenomas can develop into preclinical 
cancer. A preclinical cancer may progress through stages I to IV without symptoms, 
or be diagnosed during each stage CRC because of symptoms. After clinical diagnosis, 
CRC survival is simulated using age-, stage-, and localization-specific survival estimates 
for clinically diagnosed CRC. These survival estimates are country-specific,134,318 
although US survival estimates are used for the Canadian model due to the lack of data. 
For individuals with synchronous CRCs at time of diagnosis, the survival of the most 
advanced cancer is used. The date of death for individuals with CRC is set to the earliest 
simulated death due either to CRC or another cause (‘Demography module’). 
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Figure 1: The stages of disease in the semi-Markov model.
a Cancer stages were based on the 5th edition Cancer Staging Manual from the American Joint 
Committee on Cancer425
Transition rates and durations 
An individual’s risk of developing adenomas depends on the individual’s age and a 
personal Gamma-distributed risk index (non-homogeneous Poisson process). As a 
result of the latter most individuals develop no adenomas, whilst some develop many. 
We assumed that the distribution of adenomas over the colon and rectum equals the 
distribution of cancers as observed in the population under consideration before the 
introduction of screening.37,426,427 The age-specific onset of adenomas and the dispersion 
of the personal risk index were calibrated to data on the prevalence and multiplicity 
distribution of adenomas as observed in autopsy studies (Figure 2).123-132 In chapters 
2, 3, 4, and 6, adenoma onset across all ages was multiplied to account for the increase 
in CRC incidence observed in young adults in the US, as indicated. The age-specific 
probability of adenoma-progressivity and the age- and localization-specific transition 
probabilities between preclinical cancer stages and between preclinical and clinical 
cancer stages were simultaneously calibrated to country-specific data on the age-, 
stage-, and localization-specific incidence of CRC as observed before the introduction 
of screening (Figures 3 & 4).426-429
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Figure 2: Simulated versus observed adenoma prevalence in selected autopsy studies (with 
95% confidence intervals).a
a Observed results are only shown for the two largest studies on which the model has been 
calibrated. MISCAN-Colon  has additionally been calibrated to 8 other autopsy studies.
 
Figure 3: Simulated versus observed colorectal cancer incidence in the US, based on  1975-





Figure 4: Stage-specific simulated versus observed colorectal cancer incidence in the US, 
based on  1975-1979 Surveillance Epidemiology and End Results program data.
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The average durations between the preclinical cancer stages were calibrated to the 
rates of screen-detected and interval cancers observed in randomized controlled trials 
evaluating screening using guaiac fecal occult blood tests.53,430,431 This exercise has been 
described extensively elsewhere.184 The average duration from the emergence of an 
adenoma until progression into preclinical cancer (i.e. the adenoma dwell-time) was 
calibrated to the rates of interval cancers (including surveillance detected cancers) 
observed in a randomized controlled trial evaluating once-only sigmoidoscopy screening 
(Figure 5),184 and validated against the NORCCAP trial (Figure 6).432 We assumed an 
equal overall dwell-time for adenomas developing into CRC from a medium size (30% 
of all CRCs) and from a large size (70% of all CRCs). All durations in the adenoma 
and preclinical cancer phase were drawn from Exponential distributions. Durations 
of the disease stages within the adenoma and preclinical cancer phase, respectively, 
were assumed to be perfectly correlated (i.e. if a small adenoma grows into a medium-
sized adenoma rapidly, it will also grow into a large adenoma or develop into CRC 
rapidly). However, durations in the adenoma phase were assumed to be uncorrelated 
with durations in the preclinical cancer phase (i.e. a rapidly growing adenoma does not 
necessarily develop into a rapidly progressing cancer). The proportion of medium sized, 
non-progressive adenomas growing large and the average duration in the medium size, 
non-progressive adenoma state were calibrated to size-specific adenoma detection rates 
observed in a Dutch randomized controlled trial on colonoscopy screening (not shown). 
All calibrations were performed using the Nelder-Mead search algorithm to minimize 
deviances from observed values based on log-likelihood functions (Poisson likelihood 
for incidence, Binomial likelihood for adenoma prevalence, and Multinomial likelihood 
for cancer stages).
 
Figure 5: Simulated versus observed distal colorectal cancer incidence in the intervention 




Figure 6: Simulated versus observed colorectal cancer incidence and mortality separately for 





Screening will alter some of the simulated life histories: some cancers will be prevented 
by the detection and removal of adenomas, while other cancers will be detected in an 
earlier stage with a more favorable survival. As the stage-specific survival of screen-
detected CRC as observed in randomized controlled trials on guaiac fecal occult blood 
testing was substantially more favorable than that of clinically detected CRC, even after 
correcting for lead-time bias,184 we assigned those screen-detected cancers that would 
have been clinically detected in the same stage the survival corresponding to a one stage 
less progressive cancer. Hence, a cancer screen-detected in stage II, that would also have 
been clinically diagnosed in stage II, is assigned the survival of a clinically diagnosed 
stage I cancer. The only exceptions were screen-detected stage IV cancers. These cancers 
were always assigned the survival of a clinically diagnosed stage IV cancer. 
Besides positive health effects of screening, the model also allows for the evaluation of 
colonoscopy-related complications and over-diagnosis and over-treatment of CRC (i.e. 




The demography module generates a date of birth and a date of non-CRC death for 
each individual simulated, creating a life-history without adenomas or CRC. Then, in 
Patient A in Figure 7, the natural history module generates an adenoma. This adenoma 
progresses into preclinical cancer, which, in the absence of screening, is diagnosed 
because of symptoms in stage II and results in CRC death before non-CRC death 
would have occurred. In the screening module a screening examination is simulated, 
indicated by the blue arrow. During this examination the adenoma is detected, and as 
a result both CRC and CRC death are prevented. Hence, integrating all 3 modules for 
Patient A, screening prolongs life by the amount indicated by the green arrow. Patient 
B also develops an adenoma, and although this adenoma does progress into preclinical 
cancer, Patient B would never have been diagnosed with CRC in a scenario without 
screening (see Life history 2). However, during the screening examination simulated in 
the screening module, indicated by the blue arrow, CRC is screen-detected in stage I. 
Hence, in this patient screening results in over-diagnosis of CRC: it detects a cancer that 
would never have been diagnosed in a scenario without screening. Hence, integrating 
all 3 modules in this patient, screening does not prolong life but results in additional LYs 
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Colorectal cancer is one of the leading causes of cancer death, and is an increasing public 
health concern for many countries worldwide. Screening can prevent colorectal cancer 
death through removal of premalignant lesions or through early detection of colorectal 
cancer. The aim of this thesis was to estimate population-level effects (including benefits, 
harms and costs) of colorectal cancer screening policy changes or interventions. These 
studies can aid in optimizing colorectal cancer screening programs. 
All nine studies presented in this thesis made use of the microsimulation screening 
analysis model for colorectal cancer (MISCAN-Colon). This model is based on 
simulation and mathematical techniques within a logical framework to integrate and 
synthesize known biological, epidemiological, clinical, behavioral and/or economic 
information. Its value has been internationally recognized, and policy makers from 
multiple countries requested analyses using MISCAN-Colon to address their colorectal 
cancer screening policy questions.
 
Informing screening guidelines
The first part of this thesis is comprised of studies that were commissioned by the 
American Cancer Society for their 2018 colorectal cancer screening guideline. These 
studies compare the benefits, harms and burden of over one hundred screening 
strategies, differing in terms of the screening test used, age to start screening, age to 
stop screening and the screening interval. The key difference between these analyses 
and those performed previously by our group was the incorporation of the most recent 
trends in colorectal cancer incidence - an alarming increase was observed in colorectal 
cancer diagnoses before the age of 50 years. Chapter 2 demonstrated that as a result 
of these epidemiological trends, the balance between the benefits and the burden of 
screening improved, now favoring initiation of screening at age 45 years rather than age 
50 years. Model-recommendable strategies for average-risk individuals were screening 
every 10 years with colonoscopy, every year with the fecal immunochemical test (FIT), 
every 5 years with sigmoidoscopy and every 5 years with computed tomographic 
colonography until age 75 years. Chapter 3 built upon the analyses performed in 
Chapter 2 by exploring the influence of race and sex on the optimal colorectal cancer 
screening strategies. These analyses were not only performed using the MISCAN-Colon 
model, but also by using the simulation model of colorectal cancer (SimCRC). Two 
different scenarios regarding colorectal cancer risk were evaluated: one in which age-, 
race-, and sex-specific risks were assumed to remain stable over time and another in 
which risks increased proportionally to trends observed in young-onset cases. Results 
from this modeling study suggest that if lifetime risk increases proportionally to trends 
observed in younger ages, screening should be recommended from the age of 45 years 
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for all population subgroups. Under the assumption of stable risk, models agreed about 
the age to start screening in black Americans (age 45 years) but disagreed about the 
age to start screening in white Americans (age 50 vs 45 years). Based on the results 
from the modeling analyses presented in Chapters 2 & 3, the increased disease burden 
in individuals below age 50 years and the reasonable expectation that screening will 
perform similarly in individuals aged 45-49 as in those above age 50, the American 
Cancer Society included a qualified recommendation to start screening at age 45 years. 
This change in the US colorectal cancer screening guideline has the potential to save 
thousands of lives each year in the US. 
In the analyses performed in Chapters 2 & 3, costs were not taking into account as 
the American Cancer Society does not apply cost as a decision-making criterion for 
their recommendations. In Chapter 4, we explored how the increasing incidence as 
well as increasing treatment costs of colorectal cancer impacted the cost-effectiveness of 
screening. We demonstrated that the benefits of starting screening at age 45 years rather 
than age 50 years outweigh the additional costs. As a results of the increased treatment 
costs, several colorectal cancer screening strategies were cost-saving compared to 
no screening. Only FIT and colonoscopy were efficient screening modalities, but the 
additional costs of gaining one additional quality-adjusted life-year of colonoscopy 
screening compared to FIT screening exceeded the willingness-to-pay threshold. Annual 
screening from ages 40 to 85 years with FIT would be optimal from a cost-effectiveness 
perspective. These results favor FIT rather than colonoscopy as a primary screening test. 
Interventions to improve adherence
The benefits of screening cannot only be improved by optimization of the guidelines, but 
also by improving adherence to the guidelines. Among individuals ages 50 to 75 years, 
current colorectal cancer screening participation reached a plateau of approximately 
60% in the US. Therefore, the second part of this thesis explored the cost-effectiveness 
of several interventions that have the potential to increase colorectal cancer screening 
participation rates. 
In Chapter 5, we addressed a financial barrier for colorectal cancer screening in the US. 
There is a so-called “loophole” in the current legislation that allows insurers to charge a 
20% coinsurance for follow-up colonoscopy performed after a positive non-colonoscopy 
test and for screening colonoscopies in which polyps are removed. We estimated that 
waiving coinsurance would be cost-effective from a Medicare perspective if it would 
increase screening rates from 60.0% to 60.4%. Therefore, the waiver would likely have a 
very favorable balance of health and cost impact. This study is used by colorectal cancer 
screening advocates to influence politicians and change legislation. 
In Chapter 6 the cost-effectiveness of newly developed colorectal cancer screening tests 
was compared. These tests have the potential of attracting individuals who do not want 
to participate in colorectal cancer screening using FIT or colonoscopy. We evaluated 
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capsule endoscopy, computed tomographic colonography, the multi-target stool DNA 
test and the methylated SEPT9 DNA plasma assay (mSEPT9), and compared their 
effectiveness to colonoscopy and FIT screening. Our study revealed that among these 
innovative alternative strategies, annual screening with mSEPT9, a blood-based test, 
is cost-effective. Other efficient strategies were computed tomographic colonography 
screening every 5 years and annual multi-target stool DNA screening, which were not 
optimal given the willingness-to-pay threshold. mSEPT9 had similar benefits as FIT 
screening, but resulted in 63% more colonoscopies and 26% higher costs. Therefore, 
screening with the mSEPT9 should only be recommended if an individual is not willing 
to undergo FIT or colonoscopy screening.
In Chapter 7, we considered a holistic framework of cancer screening. For women in the 
US, screening is not only recommended for colorectal cancer, but also for breast, cervical, 
and, for those with heavy smoking histories, lung cancer. However, only one out of three 
women participates in all guideline-recommended cancer screenings. Therefore, we 
aimed to evaluate optimal screening strategies in women willing to obtain some, but not 
all, recommended screenings by combining results from MISCAN models of these four 
cancer types. We demonstrated that it is possible to reduce screening intensity to one or 
two cancer screenings per year for women ineligible or eligible for lung cancer screening, 
respectively, while maintaining ≥94% of the benefits. Screening for a variety of cancers, 
although less frequent than recommended, was more effective than screening for specific 
cancers but omitting others. For eligible women, lung cancer screening was essential; 
strategies omitting it provided ≤25% of maximum benefits. Our study suggests that 
women who prefer to reduce cancer screening intensity may be able to do so with a small 
loss in benefits, provided they choose an optimal less-intensive strategy. Offering women 
the option to lower screening intensity has the potential to increase their participation.
Chapter 8 focused on the French colorectal cancer screening program. Interestingly, its 
current participation rate is below 35%, which is much lower than participation rates in 
neighboring European countries. A potential explanation for this low participation rate 
is the need for participants to visit their general practitioner to collect a FIT. In other 
countries, such as the Netherlands, the FIT is mailed directly to the homes of those eligible 
for colorectal cancer screening. Therefore, we estimated the potential benefits and costs 
of including the FIT in the invitation letter in France. Our results suggest that including 
the FIT in the invitation letter is cost-effective if it increases screening participation by 0.5 
percentage point. It can be expected that the impact of this intervention on participation 
is considerably higher than this threshold, suggesting that including the FIT in the 
invitation letter in France would have a favorable balance between its benefits and costs.
 
Screening and subsequent steps for Lynch syndrome patients
The last part of this thesis focused on Lynch syndrome patients. Approximately 42% 
of individuals with Lynch syndrome develop colorectal cancer before the age of 80 
years, and approximately 35% of women develop endometrial cancer. Therefore, it is 
Summary
432
important to identify asymptomatic individuals with Lynch syndrome as preventative 
measures can be taken to reduce cancer incidence and mortality. 
In Chapter 9, we evaluated the benefits and costs of screening all colorectal cancer 
patients below the age of 70 years for Lynch syndrome using immunohistochemistry in a 
Canadian setting. Screening colorectal cancer patients for Lynch syndrome can ultimately 
identify asymptomatic relatives who benefit from intensive colonoscopy surveillance. 
Our study predicted that testing 1,000 colorectal cancer patients would result in the 
identification of 29 asymptomatic relatives with Lynch syndrome. Offering these relatives 
biennial colonoscopy surveillance instead of usual care (had they not been diagnosed 
with Lynch syndrome) decreased their probability to die from colorectal cancer by 40%. 
The long-term benefits of identifying these relatives outweigh the additional cost of 
Lynch syndrome screening. Furthermore, our study revealed that biennial colonoscopy 
surveillance for individuals with Lynch syndrome is optimal; the optimal surveillance 
interval has been a topic of intense debate. These results were especially informative for 
policy makers in the province of Ontario, Canada, who were considering introducing 
Lynch syndrome screening for all colorectal cancer cases below the age of 70 years.
Chapter 10 builds upon the analyses performed in Chapter 9, by estimating the benefits 
and costs of offering prophylactic hysterectomy to the asymptomatic female relatives 
identified with Lynch syndrome. The MISCAN Endometrial model was developed to 
compare different age ranges of prophylactic hysterectomy. From a cost-effectiveness 
perspective, prophylactic hysterectomy should be offered to women with Lynch syndrome 
aged 40-80 years. However, the optimal age range depended on an individual’s quality 
of life after a prophylactic hysterectomy. The impact of a prophylactic hysterectomy on 
a woman’s quality of life varies from woman to woman. Therefore, women with Lynch 
syndrome may consider performing prophylactic hysterectomy at age 35 years. Results 
of this study can inform physicians and women with Lynch syndrome regarding the 




The following conclusions can be drawn based on the studies presented in this thesis:
As a result of the increase in colorectal cancer incidence observed in young adults, 
screening initiation at age 45 years rather than age 50 years in the US has a favorable 
balance between screening benefits, burden and costs.
The optimal screening ages for individuals in the US are not influenced by race and 
sex under assumed increases in background risk.
The increase in colorectal cancer incidence in young adults and the increase in 
colorectal cancer treatment costs greatly improved the cost-effectiveness of 
colorectal cancer screening.
Only colorectal cancer screening strategies that use FIT as a primary screening test 
are cost-effective.
Waiving the coinsurance for all colonoscopy procedures has a favorable balance of 
health and cost impact.
For individuals that are not willing to participate in colorectal cancer screening 
using FIT and colonoscopy, annual screening with the mSEPT9 is the test of choice 
given its cost-effectiveness profile compared to the other alternative tests.
Women unable or unwilling to obtain all guideline-recommended cancer 
screenings may be able to reduce screening intensity with limited impact on overall 
benefits, but should go for lung cancer screening if eligible.
Lung cancer screening in eligible women has greater benefit than colorectal, 
cervical and breast cancer screening.
It is more valuable for women to obtain a variety of cancer screenings even if less-
often than recommended, than to screen for some cancers but skip others entirely.
Including the FIT in the invitation letter is a very cost-effective intervention to 
increase colorectal cancer screening participation.
Immunohistochemical testing for Lynch syndrome in persons younger than 70 
years with a colorectal cancer diagnosis, and then testing first-degree relatives of 
those found to have Lynch syndrome, provides a good balance between costs and 
long-term benefits.
Colonoscopy surveillance every 2 years is the optimal surveillance interval for 
patients with Lynch syndrome.
Prophylactic hysterectomy in Lynch syndrome women aged between 40 and 80 
years is cost-effective from a population perspective.
The earliest age to recommend prophylactic hysterectomy in women with Lynch 
































































































Since colorectal cancer incidence in the prescreening ages is increasing, one should 
consider recommending screening from ages 45 to 75 years.
Colorectal cancer screening guidelines need not to be differentiated by race and 
sex.
Average-risk individuals should be encouraged to use the FIT for colorectal cancer 
screening for an optimal balance between resources and benefits.
Health insurance programs should consider removing all coinsurance 
requirements for colorectal cancer screening, as this will likely have a very 
favorable balance between health and cost impact.
Physicians should offer annual screening with the mSEPT9 to individuals not 
willing to undergo FIT or colonoscopy.
General practitioners need to discuss alternative, less intensive, screening 
strategies if women are not willing to perform all guideline-recommended 
cancer screenings, and help them decide on an appropriate strategy.
The French government should consider mailing the FIT to the population eligible 
for colorectal cancer screening, rather than inviting them to collect the test at the 
general practitioner.
In settings with sufficient resources, all colorectal cancer cases below the age of 70 
years should be tested for Lynch syndrome using immunohistochemistry.
Lynch syndrome patients should be advised to undergo biennial colonoscopy 
surveillance.
Prophylactic hysterectomy should be offered to women with Lynch syndrome aged 
between 40 and 80 years.
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Nederlandse samenvatting 
Darmkanker is een van de voornaamste doodsoorzaken aan kanker en vormt een 
toenemende bedreiging voor de volksgezondheid. Darmkankersterfte kan worden 
voorkomen door screening, doordat screening goedaardige voorlopers van darmkanker 
kan opsporen en screening de ziekte in een vroeg stadium kan detecteren. Het doel 
van dit proefschrift was het schatten van de effecten op populatieniveau (voordelen, 
nadelen, kosten) van beleidswijzigingen en interventies rondom darmkankerscreening. 
De studies beschreven in dit proefschrift zijn gericht op het optimaliseren van 
darmkankerscreeningprogramma’s. 
In alle studies beschreven in dit proefschrift is gebruik gemaakt van het rekenmodel 
MISCAN-Colon. Dit model is gebaseerd op simulaties en wiskundige technieken, en 
is gebaseerd op de meest recente biologische, epidemiologie, klinische, gedragsmatige 
en economische inzichten die betrekking hebben op darmkankerscreening. Dit model 
is wereldwijd bekend onder onderzoekers in het veld, en beleidsmakers van vele landen 
vragen om analyses met MISCAN-Colon voor het implementeren en/of optimaliseren 
van hun bevolkingsonderzoeken. 
 
Richtlijnen van darmkankerscreening informeren
Het eerste gedeelte van dit proefschrift bestaat uit studies die gedaan zijn in opdracht van 
de American Cancer Society, die in 2018 nieuwe richtlijnen voor darmkankerscreening 
opgesteld heeft. Deze studies vergelijken de voor- en nadelen van meer dan honderd 
verschillende screeningsstrategieën, die verschillen in de screeningstest die gebruikt 
wordt en de leeftijden waarop gescreend wordt (startleeftijd, stopleeftijd en interval). Het 
belangrijkste verschil tussen deze analyses en analyses die eerder door onze groep gedaan 
zijn, is dat in deze analyses de meest recente trends in darmkankerincidentie meegenomen 
worden – er is namelijk een alarmerende toename in het aantal darmkankerdiagnoses 
onder leeftijd 50. In Hoofdstuk 2 laten we zien dat door deze epidemiologische trends, 
de balans tussen de voor- en nadelen van screening verbetert, waardoor het nu gunstig 
is om op leeftijd 45 te beginnen met screening in plaats van op leeftijd 50. 10-jaarlijkse 
coloscopiescreening, jaarlijkse screening met de faeces-immunochemische test op 
occult bloed (FIT), 5-jaarlijkse screening met sigmoïdoscopie en 5-jaarlijkse screening 
met de CT-colografie, allen tot leeftijd 75, zijn volgens het model de beste strategieën 
om te implementeren. Hoofdstuk 3 bouwt verder op deze analyses door de invloed 
van geslacht en etniciteit op de optimale darmkankerscreeningsstrategieën te evalueren. 
Deze analyses werden niet alleen met behulp van MISCAN-Colon gedaan, maar ook 
met het rekenmodel SimCRC. Twee verschillende scenario’s met betrekking tot de 
incidentie van darmkanker werden doorgerekend: één waarbij het aangenomen werd 
dat leeftijd- etniciteit- en geslachtsspecifieke darmkankerincidentie stabiel blijft over de 
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tijd, en één waarbij het risico op darmkanker toeneemt in lijn met trends geobserveerd 
in jongvolwassenen. Resultaten van deze modelstudie suggereren dat als het risico op 
darmkanker inderdaad toeneemt, screening vanaf leeftijd 45 aangeboden moet worden 
aan de gehele bevolking, onafhankelijk van etniciteit en geslacht. In het scenario 
waarin aangenomen werd dat het risico op darmkanker stabiel blijft, identificeerde de 
twee modellen dezelfde optimale startleeftijd voor Afro-Amerikanen (45 jaar), maar 
een verschillende optimale startleeftijd voor Euro-Amerikanen (50/45 jaar). Mede 
gebaseerd op de analyses van hoofdstukken 2 en 3 heeft de American Cancer Society een 
aanbeveling gedaan om individuen met gemiddeld risico vanaf leeftijd 45 te screenen. 
Deze verandering in de richtlijnen kan mogelijk duizenden sterfgevallen als gevolg van 
darmkanker per jaar voorkomen in de Verenigde Staten.
In de analyses van hoofdstukken 2 en 3 werden kosten niet meegenomen omdat de 
American Cancer Society deze buiten beschouwing wil laten bij het opstellen van de 
screeningsrichtlijnen. In Hoofdstuk 4 kijken we naar de effecten van de toenemende 
incidentie en behandelkosten op de kosteneffectiviteit van darmkankerscreening. Deze 
analyses wijzen uit dat de gezondheidswinst van het aanbieden van darmkankerscreening 
vanaf leeftijd 45 in plaats van vanaf leeftijd 50 opweegt tegen de additionele kosten. 
Doordat de behandelkosten van darmkanker toe zijn genomen, zijn er meerdere 
screeningsstrategieën kostenbesparend ten opzichte van geen screening. Zowel FIT en 
coloscopiescreening bleken efficiënte screeningstesten, maar de kosten om een extra 
levensjaar te winnen met coloscopiescreening ten opzichte van FIT-screening waren 
hoger dan de drempelwaarde voor kosteneffectiviteit. Op basis van kosteneffectiviteit 
zou jaarlijkse screening met FIT van leeftijd 40 tot 85 jaar optimaal zijn. Deze resultaten 
pleiten voor het gebruik van FIT-screening in plaats van coloscopiescreening.
 
Interventies voor het verhogen van deelname
De gezondheidswinst van darmkankerscreening kan niet alleen verbeterd worden door 
richtlijnen te optimaliseren, maar ook door de deelname aan screening te verbeteren. 
In Amerika neemt ongeveer 60% van de individuen tussen leeftijd 50 en 75 deel aan 
darmkankerscreening. Daarom focust het tweede gedeelte van de proefschrift op 
de kosteneffectiviteit van verschillende interventies die mogelijk de deelname aan 
darmkankerscreening kunnen verhogen.
Hoofdstuk 5 heeft betrekking op een financiële barrière voor participatie aan screening. 
In principe is screening voor Amerikanen gratis, maar door een maas in de wet kunnen 
zorgverzekeraars een eigen bijdragen van 20% in rekening brengen voor coloscopieën 
die gedaan worden na een positieve ontlastingstest, en voor screeningscoloscopieën 
waarbij een poliep verwijderd wordt. Resultaten van onze studie suggereren dat, 
vanuit het perspectief van Medicare, het verwijderen van de 20% eigen bijdrage al 
kosteneffectief zou zijn als dit de deelname aan screening zou verhogen van 60.0% naar 
60.4%. Daarom is het zeer aannemelijk dat de gezondheidswinst van het opheffen van 
de eigen bijdrage opweegt tegen de kosten. Deze studie wordt door voorstanders van 
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darmkankerscreening gebruikt om politici te overtuigen om de wetgeving aan te passen.
Nieuwe screeningstesten hebben de potentie om mensen die niet gescreend willen 
worden met FIT of coloscopie alsnog deel te laten nemen aan het Amerikaanse 
bevolkingsonderzoek. In Hoofdstuk 6 werd de kosteneffectiviteit van nieuwe 
darmkankerscreeningstesten vergeleken. De nieuwe testen die we mee hebben genomen 
in deze studie zijn de videocapsule-endoscopie, de CT-colografie, de multi-target fecale 
DNA-test en de gemethyleerde Septin-9 test (mSEPT9). De kosteneffectiviteit van 
deze nieuwe testen werd ook vergeleken met die van FIT en coloscopie. Onze studie 
liet zien dat van deze nieuwe testen, jaarlijkse screening met de mSEPT9, een test die 
zoekt naar kankermarkers in het bloed, het meest veelbelovend is. Andere efficiënte 
screeningsopties waren screening elke 5 jaar met CT-colografie en jaarlijkse screening 
met de multi-target fecale DNA-test, maar de extra kosten van deze strategieën wogen 
niet op tegen de extra opbrengsten en ze worden daarom niet kosteneffectief geacht. 
De voordelen van jaarlijkse screening met de mSEPT9 zijn vergelijkbaar met die van 
jaarlijkse FIT-screening, maar deze strategie resulteerde wel in 63% meer coloscopieën 
en 26% hogere kosten. Daarom moet screening met de mSEPT9 alleen aangeboden 
worden aan individuen die niet gescreend willen worden met FIT of coloscopie.
In Hoofdstuk 7 hebben we een meer holistisch benadering van kankerscreening 
meegenomen. Aan vrouwen in de Verenigde Staten wordt naast screening op darmkanker 
ook screening op borstkanker, baarmoederhalskanker en, aan vrouwen die erg veel 
roken/gerookt hebben, longkanker aangeboden. Slechts één op de drie vrouwen neemt 
deel aan al deze bevolkingsonderzoeken. Daarom hebben wij in deze studie gekeken 
wat optimale screeningsstrategieën zijn voor vrouwen die wel wat screening, maar niet 
alle aanbevolen screenings willen ondergaan. We hebben dit gedaan door resultaten 
van vier verschillende MISCAN modellen te combineren. De resultaten van deze 
studie demonstreren dat het aantal screenings gereduceerd kan worden tot maximaal 
2 of 1 per jaar, respectievelijk voor vrouwen die wel of niet in aanmerking komen voor 
longkankerscreening, terwijl ≥94% van de gezondheidswinst behouden kan blijven. 
Screenen voor verschillende kankers, ook al wordt het screeningsinterval hierdoor langer, 
levert meer gezondheidswinst op dan het volledig deelnemen aan sommige maar niet alle 
bevolkingsonderzoeken. Voor vrouwen die in aanmerking komen is longkankerscreening 
essentieel: strategieën zonder longkankerscreening behaalden ≤25% van de 
gezondheidswinst. Samenvattend toont onze studie aan dat het mogelijk is voor vrouwen 
om hun screeningsintensiteit te verlagen met maar een beperkt gezondheidsverlies, mits 
zij een optimaal afwisselend schema kiezen. Door vrouwen de optie te geven minder 
vaak gescreend te worden zijn er mogelijk meer vrouwen bereid om deel te nemen. 
Hoofdstuk 8 heeft betrekking op het bevolkingsonderzoek darmkanker in Frankrijk. De 
huidige deelname aan dit bevolkingsonderzoek is onder de 35%, wat veel lager is dan de 
deelname in omliggende Europese landen. Een mogelijke verklaring hiervoor is dat in 
Frankrijk de bevolking opgeroepen wordt een FIT op te halen bij de huisarts, terwijl in 
andere landen, waaronder Nederland, een FIT met de post naar het huisadres verstuurd 
wordt. Daarom hebben we de mogelijke gezondheidswinst en bijkomende kosten van 
het per post versturen van de FIT in Frankrijk geschat. Onze resultaten suggereren 
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dat het per post versturen van de FIT kosteneffectief is als het de deelname aan het 
bevolkingsonderzoek met 0,5 procentpunt verhoogd. Het ligt in lijn der verwachting 
dat het effect van deze maatregel op participatie vele malen groter is, en daarom heeft 
deze maatregel waarschijnlijk een gunstige kosten-batenbalans. 
Screening en vervolgstappen voor Lynch syndroom patiënten
Het laatste gedeelte van dit proefschrift richt zich op patiënten met Lynch-syndroom. 
Individuen gediagnostiseerd met Lynch-syndroom hebben ongeveer 42% kans op het 
ontwikkelen van darmkanker voor leeftijd 80. Daarnaast hebben vrouwen ongeveer 35% 
kans op het krijgen van endometriumkanker. Het is daarom van belang om individuen 
met Lynch-syndroom te identificeren voordat zij kanker ontwikkelen zodat preventieve 
maatregelen genomen kunnen worden. 
In Hoofdstuk 9 wordt voor de Canadese setting de kosteneffectiviteit berekend van 
het screenen op Lynch-syndroom van alle darmkankerpatiënten jonger dan 70 jaar 
door middel van immunohistochemie. Het screenen van darmkankerpatiënten kan 
uiteindelijk leiden tot het identificeren van asymptomatische familieleden, die baat hebben 
bij intensieve coloscopiesurveillance. Onze studie voorspelde dat het testen van 1000 
darmkankerpatiënten leidt tot het identificeren van 29 asymptomatische familieleden 
met Lynch-syndroom. Door deze familieleden elke twee jaar coloscopiesurveillance 
aan te bieden in plaats van de normale darmkankerscreening, verlaagde de kans van 
deze familieleden om te sterven aan darmkanker met 40%. De langetermijneffecten van 
het identificeren van deze familieleden wegen op tegen de kosten van het screenen op 
Lynch-syndroom van alle darmkankerpatiënten onder leeftijd 70. Daarnaast toonde 
onze studie aan dat het optimale surveillance-interval twee jaar is; in het veld wordt 
momenteel uitvoerig gediscussieerd over het optimale surveillance-interval. Onze 
resultaten waren met name informatief voor beleidsmakers in Ontario, Canada, waar 
overwogen werd deze vorm van screening op het Lynch-syndroom in te voeren. 
Hoofdstuk 10 bouwt voort op de analyses van hoofdstuk 9 door de gezondheidswinst 
en kosten te schatten van het aanbieden van profylactische hysterectomie aan asympto-
matische vrouwelijke familieleden van darmkankerpatiënten die gediagnostiseerd zijn 
met Lynch-syndroom. Het MISCAN-endometriummodel werd ontwikkeld om de op-
timale leeftijdsgroep voor profylactische hysterectomie te bepalen. 
Vanuit het oogpunt van kosteneffectiviteit is het optimaal om vrouwen met Lynch-
syndroom tussen de 40 en 80 jaar profylactische hysterectomie aan te bieden. Echter, 
de optimale leeftijdsgroep hangt sterk af van de kwaliteit van leven van een individu 
nadat het profylactische hysterectomie heeft ondergaan; vrouwen kunnen overwegen 
al profylactische hysterectomie te ondergaan op leeftijd 35 als ze de negatieve effecten 
van het vervroegd in de overgang raken acceptabel vinden. Resultaten van deze studie 
informeren artsen en vrouwen met Lynch-syndroom over de beslissing over het al dan 
niet ondergaan van profylactische hysterectomie, en op welke leeftijd. 
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Conclusies en aanbevelingen
De volgende conclusies kunnen getrokken worden op basis van de studies in dit 
proefschrift:
Doordat de darmkankerincidentie toeneemt in Amerikaanse jongvolwassenen 
weegt de gezondheidswinst van het starten met screening op leeftijd 45 in plaats 
van leeftijd 50 op tegen de lasten en de kosten.
De optimale screeningsstrategie voor Amerikanen is onafhankelijk van etniciteit 
en geslacht als de darmkankerincidentie toeneemt. 
De toenemende darmkankerincidentie en behandelkosten zorgen voor een 
verbeterde kosteneffectiviteit van darmkankerscreening. 
Van alle testen voor darmkankerscreening biedt FIT de meest gunstige verhouding 
tussen kosten en opbrengsten
Het opheffen van de eigen bijdrage voor alle coloscopieën in de setting van 
darmkankerscreening heeft een gunstige balans tussen gezondheidswinst en 
kosten. 
Voor individuen die niet deel willen nemen aan FIT of coloscopiescreening 
is jaarlijkse screening met de mSEPT9 op basis van kosteneffectiviteit het beste 
alternatief. 
Vrouwen die niet aan alle kankerscreenings kunnen of willen deelnemen, 
kunnen hun screeningsintensiteit verlagen met beperkte impact op de totale 
gezondheidswinst van kankerscreening, mits vrouwen die daarvoor in aanmerking 
komen longkankerscreening ondergaan.
Longkankerscreening levert voor vrouwen die daarvoor in aanmerking komen 
meer gezondheidswinst op dan screening op darmkanker, borstkanker of 
baarmoederhalskanker.
Het screenen op meerdere kankers, zelfs als dit minder frequent is dan aanbevolen 
wordt, levert meer gezondheidswinst op dan het screenen op specifieke kankers 
maar niet op alle kankers. 
Het per post versturen van de FIT is een zeer kosteneffectieve interventie om de 
deelname aan darmkankerscreening te verbeteren. 
Het testen op Lynch-syndroom van alle darmkankerpatiënten onder leeftijd 70, 
en, wanneer positief, het testen van familieleden, heeft een gunstige balans tussen 
gezondheidswinst en kosten.
Twee jaar is het optimale coloscopiesurveillance-interval voor patiënten met 
Lynch-syndroom. 
Het aanbieden van profylactische hysterectomie aan vrouwen met Lynch-
syndroom tussen leeftijd 40 en 80 is kosteneffectief op populatieniveau. 
Vanaf welke leeftijd profylactische hysterectomie aangeboden zou moeten worden, 
hangt af van de impact van profylactische hysterectomie op de kwaliteit van leven 
van de betreffende vrouw.
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Omdat de darmkankerincidentie omhoog gaat zou overwogen moeten worden om 
op darmkanker te screenen van leeftijd 45 tot 75.
Darmkankerscreeningsaanbevelingen hoeven geen onderscheid te maken op 
basis van etniciteit en geslacht.
Individuen met een gemiddeld risico zouden, voor een optimale balans tussen 
gezondheidswinst en middelen, gestimuleerd moeten worden om gescreend te 
worden met FIT.
Zorgverzekeraars zouden alle eigen bijdrages voor darmkankerscreening moeten 
opheffen omdat deze maatregel zeer waarschijnlijk een gunstige balans heeft 
tussen gezondheidswinst en kosten.
Artsen zouden individuen die niet gescreend willen worden met FIT of 
coloscopie jaarlijkse screenen met de mSEPT9 aan moeten bieden.
Huisartsen zouden alternatieve, minder intensieve, screeningsstrategieën 
voor moeten leggen aan vrouwen die niet aan alle kankerscreenings deel 
willen nemen, en hen helpen met het kiezen van de optimale strategie. 
De Franse overheid moet overwegen om de FIT per post te gaan versturen naar de 
populatie die in aanmerking komt voor darmkankerscreening, in plaats van hen te 
vragen een FIT op te halen bij de huisarts. 
Indien er voldoende testcapaciteit is, zouden alle darmkankerpatiënten onder de 70 
jaar getest moeten worden op Lynch-syndroom door middel van 
immunohistochemie.
Patiënten met Lynch-syndroom zouden elke twee jaar coloscopiesurveillance 
aangeboden moeten krijgen.
Aan vrouwen met Lynch-syndroom tussen leeftijd 40 en 80 zou profylactische 
hysterectomie aangeboden moeten worden. 
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